var images_info;if (!images_info) images_info =[]; images_info["62"]={"62001":{"type":"graphic_figure","displayName":"Norepinephrine in HF","title":"Plasma norepinephrine and survival in HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma norepinephrine and survival in HF</div><div class=\"cntnt\"><img style=\"width:396px; height:224px;\" src=\"images/CARD/62001_Norepinephrine_in_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percent probability of survival in patients with advanced heart failure according to the plasma norepinephrine concentration. Survival was inversely related to the degree of norepinephrine activation, a presumed reflection of worsening cardiac function. The time to 50 percent survival was approximately 30 months in patients with normal norepinephrine levels (200 pg/mL) but only about 10 months in those with marked hypersecretion (1200 pg/mL).</div><div class=\"graphic_reference\">Data from: Cohn JN, Levine TB, Olivaro MT, et al. N Engl J Med 1984; 311:819.</div><div id=\"graphicVersion\">Graphic 62001 Version 2.0</div></div></div>"},"62003":{"type":"graphic_picture","displayName":"Tracheal stenosis Endosc","title":"Tracheal stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheal stenosis</div><div class=\"cntnt\"><img style=\"width:328px; height:312px;\" src=\"images/PULM/62003_Tracheal_stenosis_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchosopy shows severe, web-like tracheal stenosis following prolonged intubation.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 62003 Version 1.0</div></div></div>"},"62004":{"type":"graphic_form","displayName":"HAE wallet card","title":"Hereditary angioedema (HAE) emergency care wallet card","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Hereditary angioedema (HAE) emergency care wallet card</div><div class=\"cntnt\"><img style=\"width:541px; height:392px;\" src=\"images/ALLRG/62004_HAE_wallet_card_edt3.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62004 Version 9.0</div></div></div>"},"62005":{"type":"graphic_figure","displayName":"BP by postconceptual age","title":"Blood pressure based on postconceptual age","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Blood pressure based on postconceptual age</div><div class=\"cntnt\"><img style=\"width:474px; height:578px;\" src=\"images/PEDS/62005_BP_postconcep_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear regression of mean systolic (top) and diastolic (bottom) blood pressures by postconceptual age in weeks, with 95% confidence intervals (upper and lower dashed lines).</div><div class=\"graphic_footnotes\">BP: blood pressure.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol 1995; 15:470. Copyright Â© 1995.</div><div id=\"graphicVersion\">Graphic 62005 Version 5.0</div></div></div>"},"62006":{"type":"graphic_figure","displayName":"Survival after liver TPL in PBC","title":"Improved survival with liver transplantation in primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Improved survival with liver transplantation in primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:483px; height:242px;\" src=\"images/GAST/62006_Survival_after_liver_TPL_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival probabilities in 161 patients with primary biliary cholangitis treated with liver transplantation compared with the simulated survival in a \"control\" group calculated from the Mayo model. After six months, survival with transplantation exceeded that predicted with medical therapy alone.</div><div class=\"graphic_reference\">Data from Markus, BH, Dickson, ER, Grambsch, PM, et al, N Engl J Med 1989; 320:1709.</div><div id=\"graphicVersion\">Graphic 62006 Version 3.0</div></div></div>"},"62007":{"type":"graphic_table","displayName":"Comorbidities and pneumonia","title":"Comorbidities associated with delayed resolution of pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comorbidities associated with delayed resolution of pneumonia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Condition\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Effects\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chronic obstructive pulmonary disease</td>\r\n  \r\n   <td>Impaired cough and mucociliary clearance</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Alcoholism</td>\r\n  \r\n   <td>Aspiration, malnutrition, impaired neutrophil function</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Neurologic disease</td>\r\n  \r\n   <td>Aspiration, impaired clearance of secretions and cough</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Heart failure</td>\r\n  \r\n   <td>Edema fluid, impaired lymphatic drainage</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chronic kidney disease</td>\r\n  \r\n   <td>Hypocomplementemia, impaired macrophage and neutrophil function, reduced humoral immunity</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Malignancy</td>\r\n  \r\n   <td>Impaired immune function, altered colonization, effects of chemotherapy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Human immunodeficiency virus</td>\r\n  \r\n   <td>Impaired cell-mediated and humoral immunity</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Diabetes mellitus</td>\r\n  \r\n   <td>Impaired neutrophil function and cell-mediated immunity</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 62007 Version 1.0</div></div></div>"},"62009":{"type":"graphic_diagnosticimage","displayName":"Abdominal radiograph of renal stones","title":"Abdominal radiograph of renal stones","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Abdominal radiograph of renal stones</div><div class=\"cntnt\"><img style=\"width:541px; height:756px;\" src=\"images/RADIOL/62009_Staghorn_calculi_KUB_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nephrolithiasis. Abdominal radiograph anteroposterior projection shows a staghorn calculus in the right renal pelvis and smaller stones (arrows) in the left kidney.</div><div id=\"graphicVersion\">Graphic 62009 Version 5.0</div></div></div>"},"62010":{"type":"graphic_figure","displayName":"Oculomotor circuitry","title":"Oculomotor circuitry for horizontal eye movements","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Oculomotor circuitry for horizontal eye movements</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/NEURO/62010_Oculomotorcircuitry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During horizontal saccades, the paramedian pontine reticular formation (PPRF) burst cells innervate the abducens nucleus, which contains two distinctive sets of neurons. Axons from the abducens motor neurons innervate the ipsilateral lateral rectus muscle, while the axons of the abducens interneurons cross the midline to become the medial longitudinal fasciculus (MLF) and subsequently innervate the medial rectus subnucleus of the oculomotor complex (cranial nerve nucleus III).<br />Internuclear ophthalmoplegia (INO) is characterized by slowing and/or limitation of the adducting eye during horizontal saccades and is the result of damage to the MLF within the dorsomedial pontine or midbrain tegmentum, adjacent to the fourth ventricle and cerebral aqueduct, respectively.</div><div class=\"graphic_reference\">Modified from: Blumenfeld H. Neuroanatomy through Clinical Cases, figure 13.13 p.549. Sinauer Associates, MA 2002.</div><div id=\"graphicVersion\">Graphic 62010 Version 7.0</div></div></div>"},"62011":{"type":"graphic_diagnosticimage","displayName":"Duodenal atresia","title":"Duodenal atresia with \"double bubble sign\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duodenal atresia with &quot;double bubble sign&quot;</div><div class=\"cntnt\"><img style=\"width:276px; height:254px;\" src=\"images/OBGYN/62011_Duodenal_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial image of the fetal abdomen of a third trimester fetus. The &quot;double bubble sign&quot; is present representing a dilated stomach and proximal duodenum. Polyhydramnios is present. The connection between the stomach and duodenum is identified in this image, confirming the diagnosis of duodenal atresia.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 62011 Version 2.0</div></div></div>"},"62012":{"type":"graphic_figure","displayName":"Fibrin polymerization","title":"Model of fibrin polymerization","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Model of fibrin polymerization</div><div class=\"cntnt\"><img style=\"width:524px; height:520px;\" src=\"images/HEME/62012_Fibrin_polymerization.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thrombin (factor IIa) binds to fibrinogen and cleaves FPA and FPB to generate fibrin monomers consisting of one E region (open circle) and two D regions (closed circles). Adjacent monomers self-assemble to form protofibrils through interaction of complementary sites between the D and E regions (D-E contact). FPB release exposes additional determinants complementary with binding sites on the D region, resulting in lateral growth and thickening of the protofibrils. Factor XIIIa induces formation of covalent bonds between adjacent D regions (D-D contact, shown here as double lines) to stabilize the fibrin polymer. The exact spatial orientation of D-D cross-linking remains unresolved. There is evidence supporting both longitudinal as well as transverse cross-linking between adjacent D regions.</div><div class=\"graphic_footnotes\">FPA: fibrinopeptide A; FPB: fibrinopeptide B.</div><div id=\"graphicVersion\">Graphic 62012 Version 3.0</div></div></div>"},"62013":{"type":"graphic_diagnosticimage","displayName":"Thalamic lesion lymphoma","title":"Secondary thalamic lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Secondary thalamic lymphoma</div><div class=\"cntnt\"><img style=\"width:368px; height:390px;\" src=\"images/HEME/62013_Thalamic_lesion_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This axial FLAIR MRI shows a large right thalamic mass (red arrow) with extensive edema and mass effect on the lateral ventricle, with an associated midline shift (yellow arrow). This mass lesion was shown to be a parenchymal metastasis to the brain in a patient with systemic diffuse large B-cell non-Hodgkin's lymphoma.</div><div id=\"graphicVersion\">Graphic 62013 Version 2.0</div></div></div>"},"62015":{"type":"graphic_table","displayName":"Causes of acute pediatric upper airway obstruction","title":"Causes of acute upper airway obstruction that are potentially life-threatening","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute upper airway obstruction that are potentially life-threatening</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <p>Infectious</p> <ul> <li>Epiglottitis </li> <li>Croup </li> <li>Bacterial tracheitis </li> <li>Retropharyngeal abscess (rare) </li> <li>Peritonsillar abscess (rare) </li> <li>Infectious mononucleosis </li> </ul> </td> </tr> <tr> <td>Foreign body</td> </tr> <tr> <td> <p>Trauma</p> <ul> <li>Blunt or penetrating airway injury </li> <li>Upper airway burns (thermal and chemical [eg, caustic ingestion]) </li> </ul> </td> </tr> <tr> <td>Anaphylaxis</td> </tr> <tr> <td>Decreased oropharyngeal muscle tone</td> </tr> <tr> <td>Hereditary angioedema</td> </tr> <tr> <td>Laryngospasm (vocal cord irritation or hypocalcemia)</td> </tr> <tr> <td>Vocal cord dysfunction (eg, paradoxical vocal cord movement, brainstem abnormality [eg, Arnold Chiari malformation]&nbsp;or recurrent laryngeal nerve injury)</td> </tr> <tr> <td>Acute on chronic conditions (eg, viral laryngotracheitis in a child with laryngomalacia, bleeding into adjacent tumor)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62015 Version 5.0</div></div></div>"},"62016":{"type":"graphic_picture","displayName":"Normal shoulder ligaments anterior view","title":"Normal shoulder ligaments: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Normal shoulder ligaments: Anterior view</div><div class=\"cntnt\"><img style=\"width:539px; height:408px;\" src=\"images/EM/62016_Normal_shoulder_lig.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62016 Version 7.0</div></div></div>"},"62019":{"type":"graphic_figure","displayName":"Sigmoid pull through colostomy","title":"Sigmoid pull through colostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sigmoid pull through colostomy</div><div class=\"cntnt\"><img style=\"width:202px; height:249px;\" src=\"images/OBGYN/62019_Sigmoid_pull_through_colost.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A loop of sigmoid colon is pulled through the incision.</div><div id=\"graphicVersion\">Graphic 62019 Version 2.0</div></div></div>"},"62020":{"type":"graphic_figure","displayName":"Pleural liquid turnover","title":"Pathways of pleural liquid turnover","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Pathways of pleural liquid turnover</div><div class=\"cntnt\"><img style=\"width:463px; height:308px;\" src=\"images/PULM/62020_Pleural_liquid_turnover.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the pathways of normal pleural liquid turnover. Pleural liquid appears to originate from the systemic vessels of both the parietal and visceral pleural membranes (dashed arrows). The parietal vessels (intercostal microvessels) are thought to be of primary importance because they are closer to the pleural space and have a higher filtration pressure than the bronchial microvessels of the visceral pleura. Pleural liquid is initially partially reabsorbed by the microvessels; the remaining fluid exits the pleural space via the lymphatic stomata in the parietal pleura (solid arrow).</div><div id=\"graphicVersion\">Graphic 62020 Version 2.0</div></div></div>"},"62022":{"type":"graphic_table","displayName":"Criteria for Takayasu arteritis","title":"American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Criterion</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td>Age at disease &#8804;40 years</td> <td>Development of symptoms or findings related to Takayasu arteritis at age &#8804;40 years</td> </tr> <tr> <td>Claudication of extremities</td> <td>Development and worsening of fatigue and discomfort in muscles of one or more extremities while in use, especially the upper extremities</td> </tr> <tr> <td>Decreased brachial artery pressure</td> <td>Decreased pulsation of one or both brachial arteries</td> </tr> <tr> <td>Blood pressure difference &#62;10 mmHg</td> <td>Difference of &#62;10 mmHg in systolic blood pressure between arms</td> </tr> <tr> <td>Bruit over subclavian arteries or aorta</td> <td>Bruit audible on auscultation over one or both subclavian arteries or abdominal aorta</td> </tr> <tr> <td>Arteriogram abnormality</td> <td>Arteriographic narrowing or occlusion of the entire aorta, its primary branches, or large arteries in the proximal upper or lower extremities, not due to arteriosclerosis, fibromuscular dysplasia, or similar causes; changes usually foci or segmental</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For purposes of classification, a patient shall be said to have Takayasu arteritis if at least three of these six criteria are present. The presence of any three or more criteria yields a sensitivity of 90.5 percent and a specificity of 97.8 percent.</div><div class=\"graphic_reference\">Adapted from Arend, WP, Michel, BA, Block, DA, et al, Arthritis Rheum 1990; 33:1129.</div><div id=\"graphicVersion\">Graphic 62022 Version 2.0</div></div></div>"},"62023":{"type":"graphic_table","displayName":"Psychiatric DXs in fibromyalgia","title":"Percentage of fibromyalgia (FM) patients, FM nonpatients, and healthy controls with lifetime psychiatric diagnoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percentage of fibromyalgia (FM) patients, FM nonpatients, and healthy controls with lifetime psychiatric diagnoses</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Diagnosis</td>\n<td class=\"subtitle1\">FM Patients n=64</td>\n<td class=\"subtitle1\">FM Nonpatients n=28</td>\n<td class=\"subtitle1\">Healthy controls n-23</td>\n<td class=\"subtitle1\">P</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Anxiety disorders</td>\n<td class=\"sublist_other_start\">60</td>\n<td class=\"sublist_other_start\">36</td>\n<td class=\"sublist_other_start\">26</td>\n<td class=\"sublist_other_start\">0.008*</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Simple phobia</td>\n<td class=\"sublist_other\">38</td>\n<td class=\"sublist_other\">18</td>\n<td class=\"sublist_other\">4</td>\n<td class=\"sublist_other\">0.001</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Panic disorder with agoraphobia</td>\n<td class=\"sublist_other\">11</td>\n<td class=\"sublist_other\">0</td>\n<td class=\"sublist_other\">0</td>\n<td class=\"sublist_other\">0.050</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Mood disorders</td>\n<td class=\"sublist_other_start\">52</td>\n<td class=\"sublist_other_start\">18</td>\n<td class=\"sublist_other_start\">22</td>\n<td class=\"sublist_other_start\">0.002*</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Major depressive episode</td>\n<td class=\"sublist_other\">39</td>\n<td class=\"sublist_other\">11</td>\n<td class=\"sublist_other\">9</td>\n<td class=\"sublist_other\">0.001</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Major depression-recurrent episode</td>\n<td class=\"sublist_other\">25</td>\n<td class=\"sublist_other\">7</td>\n<td class=\"sublist_other\">4</td>\n<td class=\"sublist_other\">0.014</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Dysthymic disorder</td>\n<td class=\"sublist_other\">22</td>\n<td class=\"sublist_other\">7</td>\n<td class=\"sublist_other\">0</td>\n<td class=\"sublist_other\">0.004</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Bipolar disorder</td>\n<td class=\"sublist_other\">13</td>\n<td class=\"sublist_other\">4</td>\n<td class=\"sublist_other\">0</td>\n<td class=\"sublist_other\">0.043</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Body image disorders</td>\n<td class=\"sublist_other_start\">34</td>\n<td class=\"sublist_other_start\">14</td>\n<td class=\"sublist_other_start\">4</td>\n<td class=\"sublist_other_start\">0.002*</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Somatization disorder</td>\n<td class=\"sublist_other\">23</td>\n<td class=\"sublist_other\">10</td>\n<td class=\"sublist_other\">0</td>\n<td class=\"sublist_other\">0.004</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Behavior/character</td>\n<td>27</td>\n<td>14</td>\n<td>13</td>\n<td>0.23</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">Probability of meeting criteria for at least one diagnosis in this category: P&lt;0.01 after Bonferroni correction, FM patients vs. controls; P&lt;0.05, FM nonpatients vs controls.</div><div class=\"graphic_reference\">Adapted from: Aaron, LA, Bradley, LA, Alarc&#8212;n, GS, et al, Arthritis Rheum 1996; 39:436.</div><div id=\"graphicVersion\">Graphic 62023 Version 1.0</div></div></div>"},"62024":{"type":"graphic_figure","displayName":"Rubin maneuver","title":"Rubin maneuver","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Rubin maneuver</div><div class=\"cntnt\"><img style=\"width:484px; height:653px;\" src=\"images/OBGYN/62024_Rubin manuever.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The clinician places one hand in the vagina behind the posterior fetal shoulder and then rotates it anteriorly (towards the fetal face). If the fetal spine is on the maternal left, the operator's right hand is used. Alternatively, the Rubin maneuver can be attempted by placing a hand behind the anterior shoulder, if it is more accessible.</div><div id=\"graphicVersion\">Graphic 62024 Version 3.0</div></div></div>"},"62027":{"type":"graphic_picture","displayName":"Lingual mandibular incisors","title":"Lingual position of permanent incisors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lingual position of permanent incisors</div><div class=\"cntnt\"><img style=\"width:402px; height:255px;\" src=\"images/PEDS/62027_Lingual_mandibular_incisors.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eruption of the permanent mandibular incisors behind the primary incisors is not infrequent due to the lingual position of the developing permanent incisor to the mandibular incisor tooth root.</div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:975. Copyright WB Saunders 2000.</div><div id=\"graphicVersion\">Graphic 62027 Version 3.0</div></div></div>"},"62028":{"type":"graphic_diagnosticimage","displayName":"Polyostotic fibrous dysplas","title":"Polyostotic fibrous dysplasia (tibia and fibula)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polyostotic fibrous dysplasia (tibia and fibula)</div><div class=\"cntnt\"><img style=\"width:400px; height:516px;\" src=\"images/PEDS/62028_Polyostotic_fibrous_dysplas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Observe the significant expansion of the middiaphysis of the tibia and fibula, with the characteristic ground-glass appearance to the matrix of the fibrous dysplastic lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62028 Version 2.0</div></div></div>"},"62029":{"type":"graphic_diagnosticimage","displayName":"Thoracolumbar scoliosis","title":"Thoracolumbar scoliosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracolumbar scoliosis</div><div class=\"cntnt\"><img style=\"width:274px; height:396px;\" src=\"images/PEDS/62029_Thoracolumbar_scoliosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior radiograph demonstrating right thoracolumbar scoliosis. The air-fluid level in the stomach confirms that the radiograph was taken with the patient standing.&nbsp;Scoliosis radiographs are&nbsp;viewed with the patient's heart on the examiner's left (as if the examiner is standing behind the patient).</div><div class=\"graphic_reference\">Courtesy of Susan A Scherl, MD.</div><div id=\"graphicVersion\">Graphic 62029 Version 6.0</div></div></div>"},"62030":{"type":"graphic_picture","displayName":"Chalazion 2","title":"Chalazion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chalazion</div><div class=\"cntnt\"><img style=\"width:432px; height:274px;\" src=\"images/PC/62030_Chalazion_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic meibomian gland plugging leads to granulomatous inflammation seen as a yellow-white bump on the inner aspect of the mid-lower lid.</div><div id=\"graphicVersion\">Graphic 62030 Version 2.0</div></div></div>"},"62031":{"type":"graphic_picture","displayName":"Traumatic hyphema","title":"Hyphema associated with trauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyphema associated with trauma</div><div class=\"cntnt\"><img style=\"width:340px; height:248px;\" src=\"images/PC/62031_Hyphema2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A layer of blood at the bottom of the anterior chamber.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe JD, Hackel RE. Field Guide to the Eyes. Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright Â© 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62031 Version 11.0</div></div></div>"},"62032":{"type":"graphic_table","displayName":"Analysis of ascitic fluid","title":"Tests performed on ascitic fluid","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tests performed on ascitic fluid</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Routine tests</td> </tr> <tr> <td class=\"indent1\">Cell count and differential</td> </tr> <tr> <td class=\"indent1\">Albumin concentration</td> </tr> <tr> <td class=\"indent1\">Total protein concentration</td> </tr> <tr> <td class=\"subtitle1_single\">Optional tests</td> </tr> <tr> <td class=\"indent1\">Culture in blood culture bottles</td> </tr> <tr> <td class=\"indent1\">Glucose concentration</td> </tr> <tr> <td class=\"indent1\">Lactate dehydrogenase concentration</td> </tr> <tr> <td class=\"indent1\">Gram stain</td> </tr> <tr> <td class=\"indent1\">Amylase concentration</td> </tr> <tr> <td class=\"subtitle1_single\">Unusual tests</td> </tr> <tr> <td class=\"indent1\">Tuberculosis smear and culture</td> </tr> <tr> <td class=\"indent1\">Adenosine deaminase activity</td> </tr> <tr> <td class=\"indent1\">Cytology</td> </tr> <tr> <td class=\"indent1\">Triglyceride concentration</td> </tr> <tr> <td class=\"indent1\">Bilirubin concentration</td> </tr> <tr> <td class=\"indent1\">Serum pro-brain natriuretic peptide</td> </tr> <tr> <td class=\"indent1\">Carcinoembryonic antigen (CEA) concentration</td> </tr> <tr> <td class=\"indent1\">Alkaline phosphatase concentration</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62032 Version 5.0</div></div></div>"},"62033":{"type":"graphic_picture","displayName":"Coronavirus EM","title":"Coronavirus electron micrograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronavirus electron micrograph</div><div class=\"cntnt\"><img style=\"width:360px; height:353px;\" src=\"images/ID/62033_Coronavirus_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Group of coronavirus particles, negatively stained with phosphotungstic acid (PTA). Some variation in size is seen, but shape is relatively uniform. Magnification 144,000x.</div><div class=\"graphic_reference\">Reproduced with permission from: McIntosh K, Dees JH, Becker WB, et al. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA. 1967; 57:933. Copyright Â© 1967 Kenneth McIntosh, MD.</div><div id=\"graphicVersion\">Graphic 62033 Version 3.0</div></div></div>"},"62034":{"type":"graphic_figure","displayName":"Pathway of NRTI induced MT","title":"Simplified mechanism to show the pathway of NRTI induced mitochondrial toxicity","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Simplified mechanism to show the pathway of NRTI induced mitochondrial toxicity</div><div class=\"cntnt\"><img style=\"width:531px; height:403px;\" src=\"images/ID/62034_Pathway_of_NRTI_induced_MT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When NRTIs inhibit DNA polymerase gamma, all mtDNA encoded proteins will ultimately be missing in the new generation of mitochondria, which then will only contain nDNA encoded proteins.</div><div class=\"graphic_reference\">Courtesy of Kees Brinkman, MD.</div><div id=\"graphicVersion\">Graphic 62034 Version 1.0</div></div></div>"},"62036":{"type":"graphic_picture","displayName":"Extrusion injury","title":"Extrusion injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extrusion injury</div><div class=\"cntnt\"><img style=\"width:340px; height:238px;\" src=\"images/PEDS/62036_Extrusion_Injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extrusion of the primary central incisors. The teeth are centrally dislocated from the socket, and the periodontal ligament is lacerated and inflamed.</div><div class=\"graphic_reference\">Reproduced with permission from McTigue, DJ. Managing traumatic injuries in the young permanent dentition. Courtesy of Dennis J McTigue, MD.</div><div id=\"graphicVersion\">Graphic 62036 Version 3.0</div></div></div>"},"62037":{"type":"graphic_diagnosticimage","displayName":"Periosteal chondroma","title":"Periosteal chondroma of the hand and humerus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Periosteal chondroma of the hand and humerus</div><div class=\"cntnt\"><img style=\"width:444px; height:372px;\" src=\"images/PEDS/62037_Periosteal_chondroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Hand. Observe the juxtacortical radiolucency present within the metaphysis of the proximal phalanx (arrow). There is a cortical indentation, with scalloping or a saucerized depression of the outer cortex and a well-defined inner margin. <BR>B) Humerus. Note the rather large cortical indentation with scalloped inner margins present on the medial aspect of the metaphysis of the proximal humerus. The classic cortical saucerized depression at the outer cortex, with a well-defined inner margin, is visualized at the caudal aspect of this lesion. This is a characteristic appearance for a periosteal chondroma (juxtacortical chondroma).</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62037 Version 2.0</div></div></div>"},"62038":{"type":"graphic_table","displayName":"Classification of candidal vaginitis","title":"Classification of candidal vaginitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of candidal vaginitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Uncomplicated disease*</td> <td class=\"subtitle1\">Complicated disease<sup>&#182;</sup></td> </tr> <tr> <td>Symptom severity</td> <td>Mild or moderate</td> <td>Severe</td> </tr> <tr> <td>Frequency </td> <td>Sporadic</td> <td>Recurrent</td> </tr> <tr> <td>Organism</td> <td><em>Candida albicans</em></td> <td>Nonalbicans species</td> </tr> <tr> <td>Host</td> <td>Normal</td> <td>Abnormal (eg, uncontrolled diabetes mellitus, recurrent infections, immunosuppression, pregnancy)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patients must have ALL of these features.<br />Â¶ Patients may have ANY of these features.</div><div id=\"graphicVersion\">Graphic 62038 Version 6.0</div></div></div>"},"62040":{"type":"graphic_waveform","displayName":"ECG Mobitz type I AV block and inferior MI","title":"Electrocardiogram (ECG) showing concurrent Mobitz type I (Wenckebach) atrioventricular (AV) block and inferior myocardial infarction (MI)","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing concurrent Mobitz type I (Wenckebach) atrioventricular (AV) block and inferior myocardial infarction (MI)</div><div class=\"cntnt\"><img style=\"width:540px; height:87px;\" src=\"images/CARD/62040_Mobitz_type_I_and_IMI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This rhythm strip shows a Mobitz type I (Wenckebach) atrioventricular block with 4:3 and 3:2 conduction and progressive prolongation of the PR intervals of conducted beats. The marked ST segment elevation suggests acute inferior wall ischemia or infarction that may be responsible for the arrhythmia.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 62040 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"62041":{"type":"graphic_picture","displayName":"Skin biopsy MCTD II","title":"Skin lesion in mixed connective tissue disease (MCTD)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin lesion in mixed connective tissue disease (MCTD)</div><div class=\"cntnt\"><img style=\"width:359px; height:236px;\" src=\"images/RHEUM/62041_Skin_biopsy_MCTD_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of an interface dermatitis with prominent suprabasilar lymphocytosis and dyskeratosis in mixed connective tissue disease.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 62041 Version 2.0</div></div></div>"},"62042":{"type":"graphic_picture","displayName":"TDP43 in IBM myofibers","title":"TDP-43 in IBM myofibers","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">TDP-43 in IBM myofibers</div><div class=\"cntnt\"><img style=\"width:511px; height:575px;\" src=\"images/RHEUM/62042_TDP43_redistribution_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TDP-43 sarcoplasmic accumulations shown with paired hematoxylin and eosin (H&amp;E) staining to demonstrate these are occuring in non-necrotic myofibers.</div><div class=\"graphic_reference\">Salajegheh, M, Pinkus, JL, Taylor, JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle &amp; Nerve 2009; 40:19. Copyright Â© 2009. This material was reproduced with permission of John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 62042 Version 3.0</div></div></div>"},"62043":{"type":"graphic_figure","displayName":"SFEMG recording","title":"Single fiber electromyography recording","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Single fiber electromyography recording</div><div class=\"cntnt\"><img style=\"width:537px; height:445px;\" src=\"images/NEURO/62043_SFEMG_recording.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single fiber eletromyography (SFEMG) recording. The recording position of the SFEMG electrode (e) is depicted between two adjacent single muscle fibers (1 and 2) from the same motor unit.</div><div id=\"graphicVersion\">Graphic 62043 Version 2.0</div></div></div>"},"62044":{"type":"graphic_figure","displayName":"Resumption of the steady state in primary aldosteronism","title":"Resumption of the steady state in primary aldosteronism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Resumption of the steady state in primary aldosteronism</div><div class=\"cntnt\"><img style=\"width:441px; height:341px;\" src=\"images/NEPH/62044_Aldosterone_escape_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The combination of aldosterone administration and the ingestion of a high Na+ diet leads initially to Na+ retention, volume expansion, and a rise in systemic blood pressure. After several days, however, there is a spontaneous diuresis, resulting in the return of Na+ balance toward normal but persistent hypertension.</div><div class=\"graphic_footnotes\">Na: sodium.</div><div class=\"graphic_reference\">From Hall JE, Granger JP, Smith MJ Jr, Premen AJ, Hypertension 1983; 6(2 Pt 2):I-183. By permission of the American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 62044 Version 4.0</div></div></div>"},"62045":{"type":"graphic_diagnosticimage","displayName":"Pericardial melioidosis","title":"Computed tomography of pericardial melioidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of pericardial melioidosis</div><div class=\"cntnt\"><img style=\"width:367px; height:277px;\" src=\"images/ID/62045_Pericardial_melioidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melioidosis involving the pericardium visible by CT scan.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Bart Currie, FRACP.</div><div id=\"graphicVersion\">Graphic 62045 Version 5.0</div></div></div>"},"62046":{"type":"graphic_diagnosticimage","displayName":"Ultrasonography of acute pyelonephritis","title":"Ultrasonography of acute pyelonephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasonography of acute pyelonephritis</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/NEPH/62046_Acute_pyelonephritis_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal ultrasonography in a patient with acute pyelonephritis showing a hypodense mass with internal echoes (outlined by the arrows).</div><div class=\"graphic_reference\">Courtesy of Alain Meyrier, MD.</div><div id=\"graphicVersion\">Graphic 62046 Version 4.0</div></div></div>"},"62048":{"type":"graphic_diagnosticimage","displayName":"Cloacal malformation","title":"Cloacal malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cloacal malformation</div><div class=\"cntnt\"><img style=\"width:360px; height:344px;\" src=\"images/OBGYN/62048_Cloacal_malformation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse view of fetal abdomen at gestational age of 21 weeks shows a distended loop of bowel (arrows) with echogenic debris, some of which is calcified. A loop of bowel containing calcifications and located in the midabdomen/pelvis is a marker for cloacal malformation.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 62048 Version 2.0</div></div></div>"},"62051":{"type":"graphic_table","displayName":"Ultrarush VIT","title":"Example of ultrarush venom immunotherapy schedule","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of ultrarush venom immunotherapy schedule</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time (minutes)</td> <td class=\"subtitle1\">Dose (micrograms)</td> </tr> <tr> <td>0</td> <td>0.1</td> </tr> <tr> <td>30</td> <td>1</td> </tr> <tr> <td>60</td> <td>10</td> </tr> <tr> <td>90</td> <td>20</td> </tr> <tr> <td>120</td> <td>30</td> </tr> <tr> <td>150</td> <td>40</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients are observed for at least two hours after completion of the initial series of injections. The maintenance dose of 100 micrograms was then given on day 15 and once per month thereafter.</div><div class=\"graphic_reference\">Reproduced from: Schiavino D, Nucera E, Pollastrini E, et al. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol 2004; 92:409. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 62051 Version 2.0</div></div></div>"},"62052":{"type":"graphic_picture","displayName":"Lentigo maligna eyebrow","title":"Lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lentigo maligna</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/62052_Lentigomalignaeyebrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62052 Version 2.0</div></div></div>"},"62054":{"type":"graphic_picture","displayName":"Laryngoscope lifting","title":"Laryngoscope lifting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laryngoscope lifting</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/62054_Laryngoscopelifting.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the proper direction of forces applied for direct laryngoscopy. Note the assistant providing cricoid pressure (optional maneuver) and the proper shape of the endotracheal tube: straight to the cuff and with no greater than 35 degrees of angulation at the top of the cuff.</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62054 Version 10.0</div></div></div>"},"62055":{"type":"graphic_picture","displayName":"Acetic acid mag Endosc1","title":"Magnification endoscopy in a patient with Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnification endoscopy in a patient with Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:441px; height:232px;\" src=\"images/GAST/62055_Acetic_acid_mag_Endosc1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnification endoscopy following instillation of acetic acid in a patient suspected of having short-segment Barrett's esophagus (left panel). The magnified image (right panel) shows a reticular mucosal pattern sugestive of cardiac epithelium (rather than intestinal metaplasia), which was confirmed on pathology.</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 62055 Version 3.0</div></div></div>"},"62059":{"type":"graphic_waveform","displayName":"ECG late evolution of anterior MI","title":"Electrocardiogram (ECG) late in the evolution of an anterior myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) late in the evolution of an anterior myocardial infarction</div><div class=\"cntnt\"><img style=\"width:546px; height:280px;\" src=\"images/CARD/62059_Late_evolution_of_anterior.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Later stage in the evolution of an acute anterior myocardial infarction. There is a QS pattern in leads V1 to V3 and T wave inversion in leads V2 to V4. The ST segment elevations in these leads have almost disappeared.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 62059 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"62060":{"type":"graphic_picture","displayName":"Florid stage of gynecomastia","title":"Florid stage of gynecomastia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Florid stage of gynecomastia</div><div class=\"cntnt\"><img style=\"width:590px; height:390px;\" src=\"images/ENDO/62060_Florid_stage_gynecomastia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology of the florid stage of gynecomastia demonstrating the proliferation of ductal epithelium and periductal stromal cells.</div><div class=\"graphic_reference\">Courtesy of Glenn D Braunstein, MD.</div><div id=\"graphicVersion\">Graphic 62060 Version 2.0</div></div></div>"},"62064":{"type":"graphic_picture","displayName":"Scanning electron micrograph showing dysmorphic red cells","title":"Scanning electron micrograph showing dysmorphic red cells in urine sediment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scanning electron micrograph showing dysmorphic red cells in urine sediment</div><div class=\"cntnt\"><img style=\"width:378px; height:230px;\" src=\"images/NEPH/62064_Dysmorphic_rbc_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scanning microscopy showing dysmorphic red cells in a patient with glomerular bleeding. Acanthocytes can be recognized as ring forms with vesicle-shaped protrusions (arrows).</div><div class=\"graphic_reference\">Courtesy of Hans K&ouml;hler, MD.</div><div id=\"graphicVersion\">Graphic 62064 Version 3.0</div></div></div>"},"62065":{"type":"graphic_diagnosticimage","displayName":"MRI findings Wernicke B","title":"MRI findings Wernicke's encephalopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI findings Wernicke's encephalopathy</div><div class=\"cntnt\"><img style=\"width:385px; height:541px;\" src=\"images/NEURO/62065_MRI_findings_Wernicke_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffusion-weighted imaging (A) and ADC map (B) show restricted diffusion in the thalami, suggestive of cytotoxic edema. Other reports show hyperintensity on diffusion images without restriction seen on ADC maps, more suggestive of vasogenic edema. The underlying pathology and prognostic significance of diffusion findings are unclear. Post-contrast images (C) indicate breakdown of the blood-brain barrier with enhancement of the mammillary bodies. Courtesy Eric D Schwartz, MD.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging;&nbsp;ADC: apparent diffusion coefficient.</div><div id=\"graphicVersion\">Graphic 62065 Version 4.0</div></div></div>"},"62066":{"type":"graphic_table","displayName":"Spinal cord syndromes","title":"Spinal cord syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spinal cord syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Syndrome</td>\n\t\t\t\t\t<td class=\"subtitle1\">Clinical manifestations</td>\n\t\t\t\t\t<td class=\"subtitle1\">Causes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Segmental (transection) syndrome</td>\n\t\t\t\t\t<td>Loss of all sensory modalities, weakness below affected level; bladder dysfunction</td>\n\t\t\t\t\t<td>Trauma, hemorrhage, epidural abscess, transverse myelitis, epidural metastasis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Dorsal cord syndrome</td>\n\t\t\t\t\t<td>Loss of proprioception, vibratory sensation; variable weakness and bladder dysfunction</td>\n\t\t\t\t\t<td>Tabes dorsalis, Friedreich ataxia, subacute combined degeneration, AIDS myelopathy, epidural metastases, cervical spondylotic myelopathy, multiple sclerosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Ventral cord syndrome (anterior spinal artery syndrome)</td>\n\t\t\t\t\t<td>Loss of pain and temperature sensation, weakness, bladder dysfunction</td>\n\t\t\t\t\t<td>Spinal cord infarction, disc herniation, radiation myelopathy, HTLV-1</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Brown Sequard syndrome</td>\n\t\t\t\t\t<td>Ipsilateral weakness and loss of proprioception; contralateral loss of pain and temperature sensation</td>\n\t\t\t\t\t<td>Knife or bullet injury, multiple sclerosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Central cord syndrome</td>\n\t\t\t\t\t<td>Segmental loss of pain and temperature, weakness often greater in the arms than legs</td>\n\t\t\t\t\t<td>Syringomyelia, intramedullary tumor, acute injury in cervical spondylotic myelopathy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Pure motor syndrome</td>\n\t\t\t\t\t<td>Weakness without sensory disturbance</td>\n\t\t\t\t\t<td>Poliomyelitis, amyotrophic lateral sclerosis, HTLV-1, hereditary spastic paraplegia, lathyrism</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Conus medullaris syndrome</td>\n\t\t\t\t\t<td>Bladder and rectal dysfunction, saddle anesthesia</td>\n\t\t\t\t\t<td>Disc herniation, trauma, tumors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cauda equina syndrome</td>\n\t\t\t\t\t<td>Asymmetric multiradicular pain, leg weakness, and sensory loss; bladder dysfunction</td>\n\t\t\t\t\t<td>Disc herniation, arachnoiditis, tumor, lumbar spine stenosis</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62066 Version 1.0</div></div></div>"},"62067":{"type":"graphic_picture","displayName":"Duodenal adenocarcinoma Endosc","title":"Duodenal adenocarcinoma as seen on upper endoscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Duodenal adenocarcinoma as seen on upper endoscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:393px;\" src=\"images/ONC/62067_Duoden_adeno_endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Irregular ulcerated mass in the third portion of the duodenum as seen on upper gastrointestinal endoscopy that was performed for work-up of iron deficiency anemia. Biopsy confirmed a moderately differentiated adenocarcinoma.</div><div class=\"graphic_reference\">Courtesy of Michael J Overman, MD.</div><div id=\"graphicVersion\">Graphic 62067 Version 2.0</div></div></div>"},"62068":{"type":"graphic_figure","displayName":"Repair 4th degree laceration","title":"Layered primary closure of a fourth-degree obstetric laceration","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Layered primary closure of a fourth-degree obstetric laceration</div><div class=\"cntnt\"><img style=\"width:560px; height:367px;\" src=\"images/OBGYN/62068_Repair_4th_degree_laceratio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The anal mucosa is first closed with a running or interrupted layer of a 4-0 delayed absorbable suture. (B) The retracted ends of the internal anal sphincter are reunited with a running layer of a 3-0 delayed absorbable suture. (C) An end-to-end anastomosis of the external anal sphincter (EAS) is accomplished using four or five interrupted 2-0 delayed absorbable sutures placed through the capsule of the EAS. (D) The rectovaginal fascia and puborectalis fibers are approximated with a running 2-0 delayed absorbable suture.</div><div id=\"graphicVersion\">Graphic 62068 Version 1.0</div></div></div>"},"62070":{"type":"graphic_figure","displayName":"Pravastatin improves outcome in hypercholesterolemia","title":"Pravastatin improves outcome in hypercholesterolemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pravastatin improves outcome in hypercholesterolemia</div><div class=\"cntnt\"><img style=\"width:406px; height:264px;\" src=\"images/CARD/62070_Pravastatin_improves_CHD_ri.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Probability (in percent) of a cardiovascular event in patients with a plasma cholesterol concentration between 200 and 300 mg/dL (5.2 to 6.2 mmol/L) and two additional coronary risk factors who were treated with placebo or pravastatin. Pravastatin diminished the incidence of cardiovascular events, a benefit that was demonstrated within six months.</div><div class=\"graphic_reference\">Data from: Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993; 72:1031.</div><div id=\"graphicVersion\">Graphic 62070 Version 2.0</div></div></div>"},"62071":{"type":"graphic_picture","displayName":"Bullous subconjunctival hemorrhage","title":"Bullous subconjunctival hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous subconjunctival hemorrhage</div><div class=\"cntnt\"><img style=\"width:424px; height:271px;\" src=\"images/EM/62071_Bullous_subcon_hemor_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullous, elevated sub-conjunctival hemorrhage is shown in a patient with an underlying scleral laceration. A hyphema is also present in the anterior chamber.</div><div class=\"graphic_reference\">Courtesy of Carolyn Kloek, MD.</div><div id=\"graphicVersion\">Graphic 62071 Version 2.0</div></div></div>"},"62072":{"type":"graphic_diagnosticimage","displayName":"Primary ileal NET somatostatin receptor scintigraphy","title":"Primary ileal neuroendocrine tumor with disseminated liver metastases on somatostatin receptor scintigraphy fused with SPECT/CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary ileal neuroendocrine tumor with disseminated liver metastases on somatostatin receptor scintigraphy fused with SPECT/CT</div><div class=\"cntnt\"><img style=\"width:309px; height:356px;\" src=\"images/ONC/62072_Prim_ileal_tumor_OctreoScan.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SPECT: single photon emission computed tomography; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 62072 Version 5.0</div></div></div>"},"62073":{"type":"graphic_table","displayName":"Differential diagnosis BL","title":"Differential diagnosis of Burkitt lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of Burkitt lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Entity</td>\r\n            <td class=\"subtitle1\">Histology</td>\r\n            <td class=\"subtitle1\">Immunophenotype</td>\r\n            <td class=\"subtitle1\">Genetic features/other</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Burkitt lymphoma</td>\r\n            <td>Monomorphic, medium-sized cells with round nuclei, multiple nucleoli, basophilic cytoplasm, prominent cytoplasmic lipid vacuoles, and a \"starry-sky\" pattern. Ki-67+ fraction approaching 100 percent.</td>\r\n            <td>Express surface IgM and B-cell-associated antigens (CD19, CD20, CD22, CD79a), as well as CD10, HLA-DR, and CD43. They lack CD5, bcl-2, and typically lack CD23.</td>\r\n            <td>Strongly (but not uniformly) associated with a translocation between the long arm of chromosome 8, the site of the c-MYC oncogene (8q24), and one of three locations on Ig genes: t(8;14), t(2;8), or t(8;22). No evidence of t(14;18).</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td>Diffuse large B-cell lymphoma</td>\r\n            <td>Large, transformed B-cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high proliferation (Ki-67+) fraction.</td>\r\n            <td>Generally express pan B-cell antigens (CD19, CD20, CD22, CD79a).</td>\r\n            <td>The majority has genetic abnormalities, but there is no single cytogenetic change that is typical or diagnostic. A subset will have c-MYC rearrangements.</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td>Precursor T-cell lymphoblastic leukemia/lymphoma</td>\r\n            <td>Varied morphology, but may resemble Burkitt lymphoma but have intermediate sized oval or round nuclei, more dispersed chromatin, several distinct nuclei, and more abundant cytoplasm.</td>\r\n            <td>Express TdT and are of T-cell phenotype typically positive for CD7 and either surface or cytoplasmic CD3, and variably express CD2, CD5, CD1a, CD4 and/or CD8.</td>\r\n            <td>No single cytogenetic change is typical or diagnostic.</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td>Precursor B-cell lymphoblastic leukemia/lymphoma</td>\r\n            <td>Varied morphology, but may resemble Burkitt lymphoma but have intermediate sized oval or round nuclei, more dispersed chromatin, several distinct nuclei, and more abundant cytoplasm.</td>\r\n            <td>Lack expression of surface immunoglobulin. Express TdT and variably express the B-cell markers CD19, CD22, CD20, and CD79a, leukocyte common antigen CD45 and common acute lymphoblastic leukemia antigen CD10 (CALLA).</td>\r\n            <td>No single cytogenetic change is typical or diagnostic. May have either or both immunoglobulin heavy chain and T-cell receptor gamma or beta chain gene rearrangements, or may lack rearrangements.</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td>Mantle cell lymphoma, blastoid variant</td>\r\n            <td>Intermediate-sized cells with dispersed chromatin, irregular nuclear contours, and scant cytoplasm with a high mitotic rate.</td>\r\n            <td>Express high levels of surface IgM and IgD and express pan-B cell antigens (CD19, CD20), CD5, and FMC7. Rare cases lack CD5 or express CD23. Nuclear staining for cyclin D1 present in 95 percent of cases.</td>\r\n            <td>Not seen in children. Strongly associated with t(11;14)(q13;q32).</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 62073 Version 1.0</div></div></div>"},"62074":{"type":"graphic_table","displayName":"Syncope causes common","title":"Common causes of syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of syncope</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neurocardiogenic syncope </td> </tr> <tr> <td>Micturition</td> </tr> <tr> <td>Defecation</td> </tr> <tr> <td>Cough mediated</td> </tr> <tr> <td>Deglutition</td> </tr> <tr> <td>Glossopharyngeal nerve</td> </tr> <tr> <td>Situational</td> </tr> <tr> <td class=\"subtitle1_single\">Carotid sinus hypersensitivity </td> </tr> <tr> <td>Head turning</td> </tr> <tr> <td>Circumferential neck compression (neck tie)</td> </tr> <tr> <td>Shaving</td> </tr> <tr> <td class=\"subtitle1_single\">Orthostatic syncope </td> </tr> <tr> <td>Volume loss</td> </tr> <tr> <td>Autonomic dysfunction</td> </tr> <tr> <td>Deconditioning, prolonged bed rest</td> </tr> <tr> <td class=\"subtitle1_single\">Medication related syncope </td> </tr> <tr> <td class=\"sublist1_start\">Vaso active medications </td> </tr> <tr> <td class=\"sublist1\">Alpha and beta blockers, calcium channel blockers, nitrates, antihypertensive medications, diuretics, erectile dysfunction medications </td> </tr> <tr> <td class=\"sublist1_start\">Medications affecting conduction </td> </tr> <tr> <td class=\"sublist1\">Antiarrhythmics, calcium channel and beta blockers, digoxin, </td> </tr> <tr> <td class=\"sublist1_start\">Medications affecting the QT interval </td> </tr> <tr> <td class=\"sublist1\">Antiarrhythmics, antiemetics, antipsychotics/depressants </td> </tr> <tr> <td>Diuretics</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62074 Version 2.0</div></div></div>"},"62075":{"type":"graphic_table","displayName":"Dysfunctional cognitive styles","title":"Dysfunctional cognitive styles","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dysfunctional cognitive styles</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Catastrophization</strong></td> <td>The patient always assumes and expects the worst possible outcome. Imagined negative scenarios are accepted as certain. Any minor problem or setback is interpreted as clear indication that the illness is rapidly progressing and death is imminent, or that no one will care for him/her, even when there is no evidence supporting the belief. For example, if a family member is delayed and does not visit at the usual time, the patient may develop the belief that \"no one cares for me, and I will die in pain and alone\".</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Overgeneralization</strong></td> <td>The patient generalizes beyond the objective facts of a situation and interprets a negative event as a sign that things will just go badly. For example, a patient who experiences adverse effects from a pain medication may over generalize to all pain medication and think \"I cannot tolerate pain medication. This is a sign that my pain cannot be treated. I will not be able to find relief; no medication will work for me; the pain will just get worse\".</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dichotomous thinking</strong></td> <td>This style is commonly described as \"black or white thinking\". The patient tends to polarize on the negative side of the spectrum and feel like a complete failure if the performance is not what was expected.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Filtering</strong></td> <td>The patient emphasizes the negative details of a communication or situation and discounts positive evidence.</td> </tr> <tr> <td><strong>Emotional reasoning</strong></td> <td>The patient cannot differentiate between internal states and outside reality. Every emotional state is interpreted as a fact.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62075 Version 4.0</div></div></div>"},"62076":{"type":"graphic_picture","displayName":"Invasive UC nested variant","title":"Invasive urothelial carcinoma, nested variant","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Invasive urothelial carcinoma, nested variant</div><div class=\"cntnt\"><img style=\"width:518px; height:199px;\" src=\"images/ONC/62076_Invasive_UC_nested_variant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At low power (A, 10x), the nested variant of urothelial carcinoma is characterized by crowded nests with deceptively bland appearance, irregularly invading muscle fibers. At higher power (B, 20x) the cytologic atypia increases, particularly in the deeper portion of the lesion.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 62076 Version 1.0</div></div></div>"},"62078":{"type":"graphic_table","displayName":"Criteria for essential tremor","title":"Criteria for diagnosis of essential tremor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for diagnosis of essential tremor</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Core criteria</td> <td class=\"subtitle1\">Secondary criteria</td> </tr> <tr> <td>Bilateral action tremor of the hands and forearms (but not resting tremor)</td> <td>Long duration (&#62;3 years)</td> </tr> <tr> <td>Absence of other neurologic signs, with the exception of cogwheel phenomenon</td> <td>Positive family history</td> </tr> <tr> <td>May have isolated head tremor with no signs of dystonia</td> <td>Beneficial response to alcohol</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Bain P, Brin M, Deuschl G, et al. Criteria for the diagnosis of essential tremor. Neurology 2000; 54(11 Suppl 4):S7. Copyright Â© 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62078 Version 15.0</div></div></div>"},"62079":{"type":"graphic_table","displayName":"Bronchocentric granulomatosis","title":"Bronchocentric granulomatosis: Causes and associated conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bronchocentric granulomatosis: Causes and associated conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Causes</td> <td class=\"subtitle1\">Associated conditions</td> </tr> <tr> <td>Allergic</td> <td>Allergic bronchopulmonary aspergillosis (ABPA)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Infectious</td> <td>Tuberculosis, atypical mycobacteria</td> </tr> <tr> <td>Fungal: histoplasmosis, blastomycosis, coccidioidomycosis, mucormycosis, aspergillosis (nonallergic)</td> </tr> <tr> <td>Pulmonary echinococcosis</td> </tr> <tr> <td>Influenza A</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Other</td> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td>Bronchogenic carcinoma</td> </tr> <tr> <td>Chronic granulomatous disease</td> </tr> <tr> <td>Other: glomerulonephritis, red cell aplasia, diabetes insipidus, and scleritis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62079 Version 3.0</div></div></div>"},"62080":{"type":"graphic_table","displayName":"Classification PH function","title":"World Health Organization (WHO) functional classification for pulmonary hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) functional classification for pulmonary hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1\">Class</td>\n\t    <td class=\"subtitle1\">WHO functional classification</td>\n\t  </tr>\n\t  <tr>\n\t    <td>I</td>\n\t    <td>Patients with pulmonary hypertension but without resulting limitations of physical activity. Ordinary physical activity does not cause undue fatigue or dyspnea, chest pain, or heart syncope.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>II</td>\n\t    <td>Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in undue fatigue or dyspnea, chest pain, or heart syncope.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>III</td>\n\t    <td>Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes undue fatigue or dyspnea, chest pain, or heart syncope.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>IV</td>\n\t    <td>Patients with pulmonary hypertension resulting in inability to carry on any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by physical activity.</td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Rich, S. Primary pulmonary hypertension: executive summary. Evian, France. World Health Organization, 1998.</div><div id=\"graphicVersion\">Graphic 62080 Version 1.0</div></div></div>"},"62082":{"type":"graphic_diagnosticimage","displayName":"Multimodal MRI and PET periictal imaging","title":"Multimodal MRI and PET periictal imaging in a patient with multifocal seizures","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Multimodal MRI and PET periictal imaging in a patient with multifocal seizures</div><div class=\"cntnt\"><img style=\"width:598px; height:221px;\" src=\"images/NEURO/62082_MRI_PET_acute_sz.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Upper panel) 18FDG-PET images from patient described in Figure 2 obtained on day 25 showing multiple focal areas of hypermetabolism.<br />(Middle panel) FLAIR images obtained on day 28.<br />(Lower panel) Co-registration showing co-localization of areas of hypermetabolism and areas with FLAIR abnormalities. EEG recording (not shown) demonstrated a similar localization of ictal activity involving right frontal pole and left central region.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; PET: positron emission tomography;&nbsp;FDG: fluorodeoxyglucose; FLAIR: fluid-attenuated inversion recovery; EEG: electroencephalogram.</div><div class=\"graphic_reference\">Reproduced with permission from: Cole, AJ. Status epilepticus and periictal imaging. Epilepsia 2004; 45 Suppl 4:72. Copyright &copy;2004 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 62082 Version 4.0</div></div></div>"},"62083":{"type":"graphic_figure","displayName":"Construction RI strains","title":"Construction of a set of RI strains from B6 and DBA progenitors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of a set of RI strains from B6 and DBA progenitors</div><div class=\"cntnt\"><img style=\"width:378px; height:488px;\" src=\"images/ALLRG/62083_Construction_RI_strains.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A single pair of chromosome homologs are followed through the process of RI strain development. Genomic intervals derived from B6 are indicated by shading and intervals derived from DBA are indicated without shading for all genotypes in all generations. The map positions of five fictitious loci, numbered 1-5, are shown in the progenitor generation. In the F2 generation, the genotypes at these five loci are indicated for six different animals with &quot;B&quot; signifying the B6 allele and &quot;D&quot; signifying the DBA allele. The two circled regions represent segments of the genome that are already fixed for one parental type within the two F2 progenitors of particular incipient RI strains. At the F20 generation, four separate animals with the same homozygous genotype are shown for each of the three newly constructed RI strains (fictitiously called BXD-101, BXD-102, and BXD-103).</div><div class=\"graphic_reference\">Reproduced with permission from Professor Lee M. Silver, Princeton University, for use of this illustration, which appeared originally in &quot;Mouse Genetics,&quot; published in hardcopy by Oxford University Press, and online by the Jackson Laboratory (http://www.jax.org).</div><div id=\"graphicVersion\">Graphic 62083 Version 1.0</div></div></div>"},"62084":{"type":"graphic_waveform","displayName":"Lambert Eaton EMG","title":"Lambert Eaton myasthenic syndrome (LEMS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lambert Eaton myasthenic syndrome (LEMS)</div><div class=\"cntnt\"><img style=\"width:376px; height:548px;\" src=\"images/ONC/62084_Lambert_Eaton_EMG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electromyograms showing action potentials from a normal <strong>(N)</strong> patient, a patient with LEMS <strong>(MCa)</strong>, and a patient with myasthenia gravis <strong>(MG)</strong> for comparison.</div><div class=\"graphic_reference\">Reproduced with permission from: Midthun, DE, et al. Clinical presentation of lung cancer. Lung Cancer 1996; :421. Copyright Â© Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 62084 Version 2.0</div></div></div>"},"62085":{"type":"graphic_table","displayName":"Single agent chemo desmoids","title":"Single-agent cytotoxic chemotherapy for desmoid tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Single-agent cytotoxic chemotherapy for desmoid tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Number of patients studied</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Response</td> <td class=\"subtitle1\">Duration of response</td> <td class=\"subtitle1\">Author; year</td> </tr> <tr> <td>Doxorubicin</td> <td>1</td> <td> <p>70 mg/m<sup>2</sup> every three weeks</p> <p>Dose reduced after two cycles to 50 mg/m<sup>2</sup></p> <p>Cumulative dose: 450 mg/m<sup>2</sup></p> </td> <td>PR</td> <td>&#62;4 years after cessation of chemotherapy</td> <td>Seiter K; 1993</td> </tr> <tr class=\"divider_top\"> <td>Doxorubicin</td> <td>6</td> <td>NR</td> <td>3/6 PR</td> <td>NR</td> <td>de Camargo VP; 2010</td> </tr> <tr class=\"divider_top\"> <td>Epirubicin</td> <td>1</td> <td>30 mg/m<sup>2</sup> every three weeks</td> <td>PR</td> <td>&#62;1 year</td> <td>Giaccone G; 1989</td> </tr> <tr class=\"divider_top\"> <td>Pegylated liposomal doxorubicin</td> <td> <p>1 adult</p> <p>3 children</p> </td> <td> <p>20 to 50 mg/m<sup>2</sup></p> <p>Cumulative dose: 160 to 430 mg/m<sup>2</sup></p> </td> <td> <p>3 PR</p> <p>1 SD</p> </td> <td>9-40 months follow-up, no progression seen</td> <td>Wehl G; 2004</td> </tr> <tr class=\"divider_top\"> <td>Pegylated liposomal doxorubicin</td> <td>22</td> <td>NR</td> <td>8 PR</td> <td>NR</td> <td>de Camargo VP; 2010</td> </tr> <tr class=\"divider_top\"> <td>Pegylated liposomal doxorubicin</td> <td>14</td> <td>40 to 50 mg/m<sup>2</sup> every four weeks, up to six cycles</td> <td> <p>4 PR</p> <p><strong>10</strong> SD</p> </td> <td><strong>9 to 45 months</strong></td> <td>Constantinidou A; 2010</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PR: partial response, &#8805;30 percent reduction in maximal dimension; NR: no response; SD: stable disease.</div><div id=\"graphicVersion\">Graphic 62085 Version 11.0</div></div></div>"},"62087":{"type":"graphic_table","displayName":"Dx tests small bowel tumors","title":"Comparison of diagnostic tests used in the evaluation of suspected small bowel tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of diagnostic tests used in the evaluation of suspected small bowel tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnostic test</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td>Plain abdominal film</td> <td>May show obstruction</td> <td>Nonspecific</td> </tr> <tr> <td>Upper gastrointestinal series/small bowel follow through</td> <td>May show mass lesion, mucosal defect, or intussusception</td> <td>No visualization outside lumen; not helpful in staging</td> </tr> <tr> <td>Enteroclysis (CT, MRI, or conventional)</td> <td>More sensitive than conventional small bowel follow through</td> <td>May require a duodenal tube</td> </tr> <tr> <td>CT scan</td> <td>Allows staging; may aid in diagnosis of tumor type</td> <td>Lacks visualization of lumen or mucosal surface</td> </tr> <tr> <td>Upper endoscopy</td> <td>Direct visualization of mucosal surface of duodenum; allows for biopsy; polypectomy possible</td> <td>Invasive; limited to duodenum</td> </tr> <tr> <td>Push enteroscopy</td> <td>Extends visualization into proximal jejunum; allows for biopsy</td> <td>Invasive; does not permit visualization of the entire small bowel</td> </tr> <tr> <td>Double-balloon enteroscopy</td> <td>Allows visualization of entire small bowel with capacity for biopsy and therapeutic intervention</td> <td>Invasive; not widely available; small risk of pancreatitis</td> </tr> <tr> <td>Wireless video capsule endoscopy</td> <td>Noninvasive</td> <td>Does not permit tissue sampling; should not be performed if small bowel obstruction suspected</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62087 Version 3.0</div></div></div>"},"62089":{"type":"graphic_table","displayName":"Risk factors endometrial cancer","title":"Risk factors for endometrial cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for endometrial cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk factor</td> <td class=\"subtitle1\"> <p>Relative risk (RR)</p> (other statistics are noted when used)</td> </tr> <tr> <td>Increasing age</td> <td>1.4% endometrial cancer prevalence in women 50 to 70 years old</td> </tr> <tr> <td>Unopposed estrogen therapy</td> <td>2 to 10</td> </tr> <tr> <td>Tamoxifen therapy</td> <td>2</td> </tr> <tr> <td>Early menarche</td> <td>NA</td> </tr> <tr> <td>Late menopause (after age 55)</td> <td>2</td> </tr> <tr> <td>Nulliparity</td> <td>2</td> </tr> <tr> <td>Polycystic ovary syndrome (chronic anovulation)</td> <td>3</td> </tr> <tr> <td>Obesity</td> <td> <p><span style=\"font-family: Verdana;\"><span style=\"font-size: 13px;\">For type I endometrial cancer: OR 1.5 for overweight (BMI 25.0 to &#60;30 kg/m<sup>2</sup></span><span style=\"font-size: 13px;\">), 2.5 for class 1 obesity (30.0 to &#60;35 kg/m</span><sup><span style=\"font-size: 13px;\">2</span></sup><span style=\"font-size: 13px;\">), 4.5 for class 2 obesity (35.0 to 39.9 kg/m</span><sup><span style=\"font-size: 13px;\">2</span></sup><span style=\"font-size: 13px;\">), and 7.1 for class 3 obesity (&#8805;40.0 kg/m</span><sup><span style=\"font-size: 13px;\">2</span></sup><span style=\"font-size: 13px;\">). </span></span></p> <p><span style=\"font-family: Verdana;\"><span style=\"font-size: 13px;\">For type II: OR 1.2 for overweight (BMI 25.0 to &#60;30 kg/m</span><sup><span style=\"font-size: 13px;\">2</span></sup><span style=\"font-size: 13px;\">), 1.7 for class 1 obesity (30.0 to &#60;35 kg/m</span><sup><span style=\"font-size: 13px;\">2</span></sup><span style=\"font-size: 13px;\">), 2.2 for class 2 obesity (35.0 to 39.9 kg/m</span><sup><span style=\"font-size: 13px;\">2</span></sup><span style=\"font-size: 13px;\">), and 3.1 for class 3 obesity (&#8805;40.0 kg/m</span><sup><span style=\"font-size: 13px;\">2</span></sup><span style=\"font-size: 13px;\">).</span></span></p> </td> </tr> <tr> <td>Diabetes mellitus</td> <td>2</td> </tr> <tr> <td>Estrogen-secreting tumor</td> <td>NA</td> </tr> <tr> <td>Lynch syndrome (hereditary nonpolyposis colorectal cancer)</td> <td>22 to 50% lifetime risk</td> </tr> <tr> <td>Cowden syndrome</td> <td>13 to 19% lifetime risk</td> </tr> <tr> <td>Family history of endometrial, ovarian, breast, or colon cancer</td> <td>NA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index; OR: odds ratio; NA: RR not available.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers. CA Cancer J Clin 2001; 51:38.</LI>&#xD;&#xA;<LI>Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013; 31:2607.</LI></UL></div><div id=\"graphicVersion\">Graphic 62089 Version 13.0</div></div></div>"},"62090":{"type":"graphic_picture","displayName":"Echinocytes","title":"Echinocytes (burr cells)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echinocytes (burr cells)</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/HEME/62090_Echinocytes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear showing numerous echinocytes, also known as burr cells. Echinocytes are often confused with acanthocytes. However, the projections of the red cell membrane in echinocytes are smaller and much more regular in shape and distribution than in acanthocytes. It may be difficult on stained slides to distinguish echinocytes from spur cells.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 62090 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"62091":{"type":"graphic_diagnosticimage","displayName":"Bronchopulm aspergillosis PA","title":"Allergic bronchopulmonary aspergillosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allergic bronchopulmonary aspergillosis</div><div class=\"cntnt\"><img style=\"width:338px; height:345px;\" src=\"images/PULM/62091_Bronchopulm_aspergillosis_P.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows example of bronchial pattern: several dilated bronchi are filled with mucus and form V- shaped and inverted Y- shaped opacities characteristic of mucoid impaction in the right upper lobe and both lower lobes.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 62091 Version 3.0</div></div></div>"},"62092":{"type":"graphic_diagnosticimage","displayName":"Split pleura sign I CT","title":"Split pleura sign in empyema after coronary artery bypass grafting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Split pleura sign in empyema after coronary artery bypass grafting</div><div class=\"cntnt\"><img style=\"width:346px; height:330px;\" src=\"images/PULM/62092_Split_pleura_sign_I_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows a crescentic collection of pleural liquid with enhancing visceral and parietal pleura (\"split pleura\" sign), which is characteristic of an inflammatory process.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 62092 Version 4.0</div></div></div>"},"62093":{"type":"graphic_picture","displayName":"Circinate balanitis","title":"Circinate balanitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circinate balanitis</div><div class=\"cntnt\"><img style=\"width:361px; height:238px;\" src=\"images/RHEUM/62093_Circinate_balanitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circinate balanitis characterized by shallow ulcers on the glans penis and the shaft of the penis (arrows). The lesions are generally asymptomatic.</div><div class=\"graphic_reference\">Courtesy of Professor Victor Newcomer, UCLA.</div><div id=\"graphicVersion\">Graphic 62093 Version 1.0</div></div></div>"},"62094":{"type":"graphic_figure","displayName":"Response to exercise","title":"Normal response to exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal response to exercise</div><div class=\"cntnt\"><img style=\"width:275px; height:418px;\" src=\"images/CARD/62094_Responsetoexercise.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in oxygen uptake (V<SUB>O2</SUB>), carbon dioxide production (V<SUB>CO2</SUB>), and respiratory gas exchange ratio (R) after incremental treadmill exercise in a normal subject. Maximal oxygen uptake (V<SUB>O2</SUB> max) and onset of the anaerobic threshold are identified; the latter occurs as oxygen uptake reaches a plateau. Carbon dioxide is derived from both oxidative metabolism (metabolic CO<SUB>2</SUB>) and, once the anaerobic threshold is reached, from the buffering of lactate by bicarbonate (nonmetabolic CO<SUB>2</SUB>).</div><div class=\"graphic_reference\">Data from Physiologic Principles and Clinical Applications, Weber, Janicki (Eds), 1986, Saunders, Philadelphia, pp. 151-167.</div><div id=\"graphicVersion\">Graphic 62094 Version 2.0</div></div></div>"},"62096":{"type":"graphic_table","displayName":"Cetuximab plus irinotecan for colorectal cancer","title":"Cetuximab plus irinotecan for metastatic, K-ras wild type colorectal cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cetuximab plus irinotecan for metastatic, K-ras wild type colorectal cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cetuximab</td> <td>500 mg/m<sup>2</sup> IV</td> <td>The appropriate dose should be withdrawn from the vials (supplied in a concentration of 2 mg/mL) and aseptically transferred into an empty sterile IV bag without further dilution. The initial dose should be infused over 120 minutes.*<sup>&#182;</sup> If Day 1 is tolerated, subsequent doses may be administered over 60 minutes.</td> <td>Day 1 and 15</td> </tr> <tr class=\"divider_bottom\"> <td>Irinotecan</td> <td>180 mg/m<sup>2&#916;</sup></td> <td>Dilute in 250 mL 5% dextrose in water and administer over 30 minutes, one hour after the end of cetuximab for the first dose, thereafter can be given immediately after cetuximab.</td> <td>Days 1 and 15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE (30 to 90% risk of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedication with diphenhydramine with or without a glucocorticoid at least prior to the first infusion of cetuximab.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia approximately 6%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of irinotecan may be needed for patients with liver impairment or severe renal impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramps and/or diarrhea within 24 hours of treatment, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea. </li> <li>Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Obtain CBC with differential and platelet count prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (including creatinine, magnesium, calcium, and potassium) prior to each treatment. </li> <li>Monitor serum calcium, magnesium, and potassium levels weekly for eight weeks after completion of therapy.<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without antidiarrheal medication. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for skin rash. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelosuppression</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment until absolute neutrophil count is &#62;1500/microL and the platelet count is &#62;100,000/microL. The United States Prescribing Information suggests irinotecan dose reduction for grade 3 or worse hematologic toxicity during a prior cycle.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Withhold treatment until resolution of diarrhea for at least 24 hours off antidiarrheal medications. Reduce irinotecan dose for patients with grade 2 or worse diarrhea during a prior treatment cycle.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dermatologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Severe dermatologic reactions, such as acneiform rash, require delayed administration of cetuximab and/or dose reduction. </li> <li>Refer to UpToDate topic on \"Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"3\"> <ul> <li>If grade 2, hold treatment until less than or equal to grade 1; if grade 3 or 4, hold treatment until less than or equal to grade 2.<sup>[3]</sup> Reduce irinotecan dose for grade 3 or worse other non-hematologic toxicities during a prior treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.<br />* Cetuximab should be administered with an infusion or syringe pump, using a low protein-binding 0.22 micron in line filter. Do not shake or dilute. Flush line with normal saline.<br />Â¶ A slower infusion rate should be considered in areas with a high incidence of infusion reactions (such as the southeast United States). Refer to UpToDate topic on \"Infusion reactions to the therapeutic monoclonal antibodies used in cancer therapy\".<br />Î A lower initial starting dose of irinotecan may be considered for patients with poor performance status, prior pelvic or abdominal radiotherapy, or increased bilirubin levels.<SUP>[3]</SUP> Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Pfeiffer P, et al. Ann Oncol 2008; 19:1141.</LI>&#xD;&#xA;<LI>Cetuximab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 12, 2012).</LI>&#xD;&#xA;<LI>Irinotecan hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 12, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 62096 Version 16.0</div></div></div>"},"62097":{"type":"graphic_figure","displayName":"RR of HF amlo vs chlor ALLHAT","title":"Heart failure with amlodipine versus chlorthalidone in ALLHAT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heart failure with amlodipine versus chlorthalidone in ALLHAT</div><div class=\"cntnt\"><img style=\"width:395px; height:333px;\" src=\"images/NEPH/62097_RR_of_HF_amlo_vs_chlor_ALLH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased relative risk of heart failure with amlodipine. Graph, with natural logarithmic scale, showing the relative risk of heart failure in all studied patients (total) and prespecified subgroups given either amlodipine or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, amlodipine increased the risk of heart failure in total and in all specific subgroups.</div><div class=\"graphic_reference\">Data from the ALLHAT investigators, JAMA 2002; 288:2981.</div><div id=\"graphicVersion\">Graphic 62097 Version 1.0</div></div></div>"},"62099":{"type":"graphic_diagnosticimage","displayName":"TB pleural effusion x-ray","title":"Culture-positive tuberculous pleural effusion in a nine-year-old patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Culture-positive tuberculous pleural effusion in a nine-year-old patient</div><div class=\"cntnt\"><img style=\"width:325px; height:396px;\" src=\"images/ID/62099_TB_pleural_effusion_x-ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a culture-positive tuberculous pleural effusion in a nine-year-old girl. The source case was a school janitor. The child complained only of a mild cough and was discovered through a contact investigation of the school case.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Starke, MD.</div><div id=\"graphicVersion\">Graphic 62099 Version 4.0</div></div></div>"},"62100":{"type":"graphic_picture","displayName":"Warthin Starry staining","title":"Warthin-Starry staining in Bartonella infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Warthin-Starry staining in Bartonella infection</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/ID/62100_Warthin_Starry_staining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The small black clusters represent Bartonella organisms that have taken up the Warthin-Starry stain (red arrows). The larger black staining material represents cell nuclei (blue arrows).</div><div class=\"graphic_reference\">Courtesy of David H Spach, MD.</div><div id=\"graphicVersion\">Graphic 62100 Version 2.0</div></div></div>"},"62103":{"type":"graphic_picture","displayName":"Intravascular lymphoma","title":"Intravascular lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intravascular lymphoma</div><div class=\"cntnt\"><img style=\"width:336px; height:287px;\" src=\"images/HEME/62103_Intravascular_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The blood vessel shown in the center of this section is lined with lymphoma cells (arrows), with red blood cells in the lumen. This tumor can potentially be mistaken for a vascular (endothelial) neoplasm.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 62103 Version 1.0</div></div></div>"},"62104":{"type":"graphic_diagnosticimage","displayName":"Dilated sleeve gastrectomy","title":"Dilated sleeve gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Dilated sleeve gastrectomy</div><div class=\"cntnt\"><img style=\"width:451px; height:449px;\" src=\"images/SURG/62104_Dilated_sleeve_gastrectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow shows hiatal hernia and a dilated sleeve gastrectomy.</div><div id=\"graphicVersion\">Graphic 62104 Version 4.0</div></div></div>"},"62105":{"type":"graphic_picture","displayName":"New lentigo maligna melanoma","title":"Lentigo maligna melanoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lentigo maligna melanoma</div><div class=\"cntnt\"><img style=\"width:504px; height:423px;\" src=\"images/PC/62105_Lentigo_maligna_melanoma_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lentigo maligna melanoma usually arises in areas of sun-damaged skin, particularly on the head and neck. It begins as a freckle-like, tan-brown macule and gradually enlarges and develops darker or lighter asymmetric foci and raised areas, which signify dermal invasion.</div><div class=\"graphic_reference\">Photo courtesy of Susan Swetter, MD.</div><div id=\"graphicVersion\">Graphic 62105 Version 1.0</div></div></div>"},"62106":{"type":"graphic_picture","displayName":"Central line SC infra anat","title":"External landmarks for the infraclavicular approach to the subclavian vein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External landmarks for the infraclavicular approach to the subclavian vein</div><div class=\"cntnt\"><img style=\"width:435px; height:576px;\" src=\"images/EM/62106_Central_line_SC_infra_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 62106 Version 7.0</div></div></div>"},"62108":{"type":"graphic_figure","displayName":"Ablation sites for AVNRT","title":"Radiofrequency ablation sites in Koch's triangle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiofrequency ablation sites in Koch's triangle</div><div class=\"cntnt\"><img style=\"width:446px; height:282px;\" src=\"images/CARD/62108_Ablation_sites_for_AVNRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of Koch's triangle which is bounded by the tricuspid ring and the tendon of Todoro. Koch's triangle can be divided into thirds: the anterior contains the compact AV node; the posterior contains the coronary sinus; and the middle or mid-septal third is between the anterior and posterior portions. The anterior third is associated with fast pathways, and the middle and posterior thirds with slow pathways. The anterior and posterior approaches to ablate the fast and slow pathways, respectively, are indicated by the position of the catheters (shown in green).</div><div id=\"graphicVersion\">Graphic 62108 Version 1.0</div></div></div>"},"62109":{"type":"graphic_figure","displayName":"DLBCL pathogenesis II","title":"Overview of common mechanisms for the pathogenesis of diffuse large B cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Overview of common mechanisms for the pathogenesis of diffuse large B cell lymphoma</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/HEME/62109_DLBCL_pathogenesis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The molecular pathogenesis of diffuse large B cell lymphoma (DLBCL) is a complex, multistep process leading to the replication of a malignant clone of germinal or post-germinal B cell origin. While some steps in this pathway have been elucidated, many remain unknown. The majority of DLBCL tumors demonstrate translocations or mutations that result in the increased expression of the B cell lymphoma 6 (BCL-6) gene. Overexpression of BCL-6 leads to downregulation of target genes, including the p53 tumor suppressor gene, which prevents the cells from undergoing apoptosis in response to DNA damage. Up to 20 percent of DLBCL demonstrate mutations or deletions of the p53 tumor suppressor gene. In addition, p53 transcription is at least partially controlled by the BCL-6 gene. Downregulation of p53 expression or expression of mutant p53 products results in a loss of the normal growth-limiting activities of this gene.</div><div id=\"graphicVersion\">Graphic 62109 Version 2.0</div></div></div>"},"62112":{"type":"graphic_diagnosticimage","displayName":"Sonographic characteristics of parathyroid adenomas","title":"Sonographic characteristics of parathyroid adenomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sonographic characteristics of parathyroid adenomas</div><div class=\"cntnt\"><img style=\"width:348px; height:575px;\" src=\"images/SURG/62112_US_views_parathyr_adeno_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound views of parathyroid adenomas.<br />(A) Sagittal image of the upper pole of the right lobe of the thyroid gland, demonstrating a hypoechoic parathyroid adenoma posterior to the thyroid parenchyma.<br />(B) Sagittal image of the lower pole of the lower pole of the left lobe of the thyroid gland with an adjacent hypoechoic parathyroid adenoma measuring 9 mm in greatest dimension.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland, MW, Maier, RV. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62112 Version 5.0</div></div></div>"},"62113":{"type":"graphic_figure","displayName":"Redistribution of thallium","title":"Redistribution of thallium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Redistribution of thallium</div><div class=\"cntnt\"><img style=\"width:385px; height:249px;\" src=\"images/CARD/62113_Redistributionofthallium.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Myocardial thallium-201 activity in normal and ischemic dog myocardium. Serial determination of myocardial thallium-201 activity (expressed as percent of initial normal activity) in 27 dogs is measured after 20 minutes of coronary artery occlusion and before reflow. Near equalization of thallium-201 activity in normal and previously ischemic myocardial regions appears by four hours after reperfusion.</div><div class=\"graphic_reference\">Redrawn with permission from Beller GA, Watson DD, Ackell P, et al. Time course of thallium-201 redistribution after transient myocardial ischemia. Circulation 1980; 61:791. Copyright 1980 American Heart Association.</div><div id=\"graphicVersion\">Graphic 62113 Version 2.0</div></div></div>"},"62115":{"type":"graphic_table","displayName":"Irinotecan plus cisplatin for advanced gastric cancer","title":"Chemotherapy regimens for advanced esophagogastric cancer: Irinotecan plus cisplatin<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapy regimens for advanced esophagogastric cancer: Irinotecan plus cisplatin<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 42 days (6 weeks).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cisplatin</td> <td>30 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline and administer over 30 minutes. Do not administer with aluminum needles or intravenous sets.</td> <td>Days 1, 8, 15, and 22</td> </tr> <tr class=\"divider_bottom\"> <td>Irinotecan</td> <td>65 mg/m<sup>2</sup> IV*</td> <td>Dilute in 500 mL 5% dextrose in water and administer over 30 minutes immediately following cisplatin.</td> <td>Days 1, 8, 15, and 22</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard prophylactic premedication regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Routine primary prophylaxis with G-CSF is not indicated (incidence of febrile neutropenia was 7% in one study<sup>[1]</sup>). However in another study, 6 of 35 patients (17%) required hospitalization for toxicity, most commonly for neutropenic fever.<sup>[3]</sup> The decision to use G-CSF should be individualized, depending on other risk factors for prolonged neutropenia. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. The original clinical trials required a baseline serum creatinine &#8804;1.5 mg/dL.<sup>[1,3]</sup> A lower starting dose of irinotecan may be needed for patients with hepatic or severe renal impairment.<sup>[4]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramping and/or diarrhea within 24 hours of receiving irinotecan, give atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea. </li> <li>Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (creatinine and electrolytes) and liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>On each day of treatment, the white blood cell count should be &#8805;3000 cells/microL with absolute neutrophil count &#8805;1000 cells/microL and platelets &#8805;100,000/microL.<sup>[3]</sup> Treatment delays up to one week are permitted without dose reduction. Decrease irinotecan dose by 10 mg/m<sup>2</sup> for hematologic toxicity resulting in treatment delay of more than two weeks, febrile neutropenia, or bleeding complications from thrombocytopenia. If hematologic toxicity causes delay of day 22 therapy, shorten treatment course to three weeks (eliminate day 22) with a two week rest period in between cycles.<sup>[3]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Mucositis or diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment for one week if grade &#62;2 diarrhea or mucositis on the day of treatment and further delayed if toxic effects do not diminish to grade &#8804;1.<sup>[1,3]</sup> Reduce subsequent irinotecan doses by 10 mg/m<sup>2</sup> for grade 3 or 4 diarrhea or mucositis. </li> <li>Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Renal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, the cisplatin dose was reduced to 15 mg/m<sup>2</sup> if serum creatinine increased to &#62;1.7 mg/dL but remained &#60;2.0 mg/dL.<sup>[3]</sup> The United States Prescribing Information for cisplatin recommends that subsequent doses of cisplatin be withheld until the serum creatinine is &#60;1.5 mg/dL and/or blood urea nitrogen is &#60;25 mg/dL.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony-stimulating factor; CBC: complete blood count.<br />* A lower initial starting dose of irinotecan may be considered for patients with poor performance status, prior pelvic or abdominal radiotherapy, or increased bilirubin levels.<SUP>[4]</SUP> Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome), and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Ajani JA, et al. Cancer 2002; 94:641.</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI>&#xD;&#xA;<LI>Ilson DH, et al. J Clin Oncol 1999; 17:3270.</LI>&#xD;&#xA;<LI>Irinotecan hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 62115 Version 17.0</div></div></div>"},"62116":{"type":"graphic_table","displayName":"Syndromes fetal macrosomia","title":"Genetic syndromes frequently associated with macrosomia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic syndromes frequently associated with macrosomia</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Syndrome</td>\r\n                    <td class=\"subtitle1\">Main characteristics</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Beckwith-Wiedemann</td>\r\n                    <td>Macroglossia, omphalocele, macrosomia, ear creases</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Marshall-Smith</td>\r\n                    <td>Accelerated growth and maturation, shallow orbits, broad middle phalanges</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Simpson-Golabi-Behmel</td>\r\n                    <td>Macrocephaly, coarse face, ocular hypertelorism, broad flat nose, macrostomia, macroglossia, nail hypoplasia, skeletal abnormalities</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sotos (cerebral gigantism)</td>\r\n                    <td>Large size, large hands and feet, poor coordination</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Berardinelli lipodystrophy</td>\r\n                    <td>Lipoatrophy, phallic hypertrophy, hepatomegaly, hyperlipemia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Weaver</td>\r\n                    <td>Macrosomia, accelerated skeletal maturation, camptodactyly, unusual facies</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Data from: Jones KL. Smith's Recognizable Patterns of Human Malformation. WB Saunders, Philadelphia 2006.</div><div id=\"graphicVersion\">Graphic 62116 Version 3.0</div></div></div>"},"62117":{"type":"graphic_picture","displayName":"Uncomplicated crown fracture","title":"Uncomplicated crown fracture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Uncomplicated crown fracture</div><div class=\"cntnt\"><img style=\"width:504px; height:330px;\" src=\"images/PEDS/62117_Uncomplicated_crown_fractur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has fractures of the maxillary central incisors; only the enamel and dentin are involved.</div><div class=\"graphic_reference\">Reproduced with permission from: McTigue, DJ. Managing traumatic injuries in the young permanent dentition. In: Pediatric Dentistry: Infancy through adolescence, 4th ed, WB Saunders, Philadelphia 2005. Copyright &#169; 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 62117 Version 2.0</div></div></div>"},"62119":{"type":"graphic_picture","displayName":"Telangiectasia of the lower extremity","title":"Telangiectasia (spider veins) of the lower extremity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Telangiectasia (spider veins) of the lower extremity</div><div class=\"cntnt\"><img style=\"width:216px; height:274px;\" src=\"images/PC/62119_Spider_veins_ankle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Telangiectasias are dilated intradermal venules less than one millimeter in diameter. Synonyms include: spider veins, hypen webs and thread veins.</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 62119 Version 2.0</div></div></div>"},"62120":{"type":"graphic_figure","displayName":"Fulguration of vasal ends during vasectomy illustration","title":"Fulguration of vasal ends during vasectomy illustration","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Fulguration of vasal ends during vasectomy illustration</div><div class=\"cntnt\"><img style=\"width:475px; height:460px;\" src=\"images/PC/62120_Vasal_disruption_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vas is divided and a segment removed. A handheld cautery can be used to fulgarate the lumen of each vasal end.</div><div id=\"graphicVersion\">Graphic 62120 Version 4.0</div></div></div>"},"62123":{"type":"graphic_table","displayName":"SEER pan ca survival","title":"SEER pancreatic cancer median survival in months","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">SEER pancreatic cancer median survival in months</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n <tr>\n    <td class=\"subtitle1\">Carcinoma grade</td>\n    <td class=\"subtitle1\">Percent</td>\n    <td class=\"subtitle1\">Median survival in months</td>\n  </tr>\n  <tr>\n    <td>1</td>\n    <td>16</td>\n    <td>5.7</td>\n  </tr>\n  <tr>\n    <td>2</td>\n    <td>35</td>\n    <td>4.4</td>\n  </tr>\n  <tr>\n    <td>3</td>\n    <td>42.5</td>\n    <td>2.8</td>\n  </tr>\n  <tr>\n    <td>4</td>\n    <td>6.6</td>\n    <td>2.2</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">SEER: Survival, epidemiology and end results database.</div><div class=\"graphic_reference\">Data from: Longnecker, DS, Karagas, MR, Tosteson, TD, Mott, LA. Racial differences in pancreatic cancer: comparison of survival and histologic types of pancreatic carcinoma in Asians, Blacks and Whites in the United States. Pancreas 2000; 21:338.</div><div id=\"graphicVersion\">Graphic 62123 Version 1.0</div></div></div>"},"62126":{"type":"graphic_figure","displayName":"HIE pathophysiology","title":"Pathophysiology of  hypoxic-ischemic encephalopathy","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of  hypoxic-ischemic encephalopathy</div><div class=\"cntnt\"><img style=\"width:600px; height:402px;\" src=\"images/PEDS/62126_HIE_pathophysiology.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The downward pointing blue line represents the cascade of events that occurs with oxidative stress, and the downward pointing black line depicts events associated with energy failure.</div><div class=\"graphic_reference\">Sidhartha Tan, MD.</div><div id=\"graphicVersion\">Graphic 62126 Version 2.0</div></div></div>"},"62128":{"type":"graphic_table","displayName":"Abnormalities cirrhotic ascites","title":"Circulatory, vascular, functional, and biochemical abnormalities in patients with cirrhosis and ascites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Circulatory, vascular, functional, and biochemical abnormalities in patients with cirrhosis and ascites</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\t<tr>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Circulatory</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\t\n\t\t\t\t\t\t<td>Reduced systemic vascular resistance</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Reduced arterial pressure</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Increased heart rate</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Increased cardiac index</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Increased plasma volume</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Reduced renal blood flow</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Increased portal blood flow</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t\t</table>\n\t\t</td>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Vascular</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Splanchnic vasodilation</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Renal artery vasoconstriction</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Pulmonary vasodilation</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t\t</table>\n\t\t</td>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Functional</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Activation of systemic vasodilator factors</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Activation of systemic vasoconstrictor factors</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Activation of renal vasodilator factors</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Reduced glomerular filtration rate</td>\n\t\t\t\t</tr>\n\t\t\t</tbody>\n\t\t</table>\n\t</td>\n\t<td class=\"container\">\n\t\t<table cellspacing=\"0\">\n\t\t\t<tbody>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Biochemical</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\t\n\t\t\t\t\t<td>Sodium retention</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\t\n\t\t\t\t\t<td>Water retention</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\t\n\t\t\t\t\t<td>Increased systemic nitric oxide</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\t\n\t\t\t\t\t<td>Increased systemic prostaglandins</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\t\n\t\t\t\t\t<td>Increased renal nitric oxide and prostaglandins</td>\n\t\t\t\t</tr>\n\t\t\t</tbody>\n\t\t</table>\n\t</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62128 Version 1.0</div></div></div>"},"62129":{"type":"graphic_table","displayName":"Lifestyle modifications in managing hypertension","title":"Lifestyle modifications in the management of hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lifestyle modifications in the management of hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Modification </td> <td class=\"subtitle1\">Recommendation </td> <td class=\"subtitle1\">Approximate systolic BP reduction, range* </td> </tr> <tr> <td>Weight reduction</td> <td>Maintain normal body weight (BMI, 18.5 to 24.9 kg/m<sup>2</sup>)</td> <td>5 to 20 mmHg per 10 kg weight loss</td> </tr> <tr> <td>Adopt DASH eating plan</td> <td>Consume a diet rich in fruits, vegetables, and low-fat dairy products with a reduced content of saturated and total fat</td> <td>8 to 14 mmHg</td> </tr> <tr> <td>Dietary sodium reduction</td> <td>Reduce dietary sodium intake to no more than 100 mEq/day (2.4 g sodium or 6 g sodium chloride)</td> <td>2 to 8 mmHg</td> </tr> <tr> <td>Physical activity</td> <td>Engage in regular aerobic physical activity such as brisk walking (at least 30 minutes per day, most days of the week)</td> <td>4 to 9 mmHg</td> </tr> <tr> <td>Moderation of alcohol consumption</td> <td>Limit consumption to no more than&nbsp;two drinks per day in most men and no more than&nbsp;one drink per day in women and lighter-weight persons</td> <td>2 to 4 mmHg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For overall cardiovascular risk reduction, stop smoking. The effects of implementing these modifications are dose- and time-dependent and could be higher for some individuals; they are not all additive.</div><div class=\"graphic_footnotes\">BP: blood pressure; BMI: body mass index; DASH: Dietary Approaches to Stop Hypertension.</div><div class=\"graphic_reference\">Reproduced from: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Available at http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf.</div><div id=\"graphicVersion\">Graphic 62129 Version 6.0</div></div></div>"},"62130":{"type":"graphic_figure","displayName":"Vaccine schedule based on medical conditions","title":"Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications - United States, 2018","html":"<div class=\"graphic\"><div style=\"width: 1068px\" class=\"figure\"><div class=\"ttl\">Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications - United States, 2018</div><div class=\"cntnt\"><img style=\"width:1048px; height:658px;\" src=\"images/ID/62130_Vaxschedmedcond2018.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* <STRONG>Influenza vaccines</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer one dose of age-appropriate inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV) annually.</LI>&#xD;&#xA;<LI>NOTE: Live attenuated influenza vaccine (LAIV) is not recommended for the 2017 to 2018 influenza season. A list of currently available influenza vaccines is available at <A href=\"https://www.cdc.gov/flu/protect/vaccine/vaccines.htm\" target=_blank>www.cdc.gov/flu/protect/vaccine/vaccines.htm</A>.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer age-appropriate IIV or RIV to: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Pregnant women.</LI>&#xD;&#xA;<LI>Adults with hives-only egg allergy.</LI>&#xD;&#xA;<LI>Adults with egg allergy other than hives (eg, angioedema or respiratory distress): Administer IIV or RIV in a medical setting under supervision of a healthcare provider who can recognize and manage severe allergic conditions.</LI></UL></LI></UL></LI></UL>Â¶ <STRONG>Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/tdap-td.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/tdap-td.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to adults who previously did not receive a dose of Tdap as an adult or child (routinely recommended at age 11 to 12 years) one dose of Tdap, followed by a dose of Td booster every 10 years.</LI>&#xD;&#xA;<LI>Information on the use of Tdap or Td as tetanus prophylaxis in wound management is available at <A href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5517a1.htm\" target=_blank>www.cdc.gov/mmwr/preview/mmwrhtml/rr5517a1.htm</A>.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Pregnant women: Administer one dose of Tdap during each pregnancy, preferably in the early part of gestational weeks 27 to 36.</LI></UL></LI></UL>Î <STRONG>Measles, mumps, and rubella (MMR) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer one dose of MMR vaccine to adults with no evidence of immunity to measles, mumps, or rubella.</LI>&#xD;&#xA;<LI>Evidence of immunity is: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Born before 1957 (except for healthcare personnel, refer below).</LI>&#xD;&#xA;<LI>Documentation of receipt of MMR.</LI>&#xD;&#xA;<LI>Laboratory evidence of immunity or disease.</LI></UL></LI>&#xD;&#xA;<LI>Documentation of a healthcare provider-diagnosed disease without laboratory confirmation is not considered evidence of immunity.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Pregnant women and nonpregnant women of childbearing age with no evidence of immunity to rubella: Administer one dose of MMR (if pregnant, administer MMR after pregnancy and before discharge from healthcare facility).</LI>&#xD;&#xA;<LI>HIV infection and CD4 cell count â¥200 cells/mcL for at least six months and no evidence of immunity to measles, mumps, or rubella: Administer two doses of MMR at least 28 days apart.</LI>&#xD;&#xA;<LI>Students in postsecondary educational institutions, international travelers, and household contacts of immunocompromised persons: Administer two doses of MMR at least 28 days apart (or one dose of MMR if previously administered one dose of MMR).</LI>&#xD;&#xA;<LI>Healthcare personnel born in 1957 or later with no evidence of immunity: Administer two doses of MMR at least 28 days apart for measles or mumps, or one dose of MMR for rubella (if born before 1957, consider MMR vaccination).</LI>&#xD;&#xA;<LI>Adults who previously received â¤2 doses of mumps-containing vaccine and are identified by public health authority to be at increased risk for mumps in an outbreak: Administer one dose of MMR.</LI>&#xD;&#xA;<LI>MMR is contraindicated for pregnant women and adults with severe immunodeficiency.</LI></UL></LI></UL><FONT class=lozenge>â</FONT> <STRONG>Varicella (VAR) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to adults without evidence of immunity to varicella two doses of VAR vaccine four to eight weeks apart if previously received no VAR-containing vaccine (if previously received one dose of VAR-containing vaccine, administer one dose of VAR vaccine at least four weeks after the first dose).</LI>&#xD;&#xA;<LI>Evidence of immunity to varicella is: &#xD;&#xA;<UL>&#xD;&#xA;<LI>United States-born before 1980 (except for pregnant women and healthcare personnel, refer below).</LI>&#xD;&#xA;<LI>Documentation of receipt of two doses of VAR vaccine or VAR-containing vaccine at least four weeks apart.</LI>&#xD;&#xA;<LI>Diagnosis or verification of history of varicella or herpes zoster by a healthcare provider.</LI>&#xD;&#xA;<LI>Laboratory evidence of immunity or disease.</LI></UL></LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer two doses of VAR vaccine four to eight weeks apart if previously received no VAR-containing vaccine (if previously received one dose of VAR-containing vaccine, administer one dose of VAR vaccine at least four weeks after the first dose) to: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Pregnant women without evidence of immunity: Administer the first of the two doses or the second dose after pregnancy and before discharge from healthcare facility.</LI>&#xD;&#xA;<LI>Healthcare personnel without evidence of immunity.</LI></UL></LI>&#xD;&#xA;<LI>Adults with HIV infection and CD4 cell count â¥200 cells/mcL: May administer, based on individual clinical decision, two doses of VAR vaccine three months apart.</LI>&#xD;&#xA;<LI>VAR vaccine is contraindicated for pregnant women and adults with severe immunodeficiency.</LI></UL></LI></UL>Â§ <STRONG>Zoster vaccines</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer two doses of recombinant zoster vaccine (RZV) two to six months apart to adults aged 50 years or older regardless of past episode of herpes zoster or receipt of zoster vaccine, live (ZVL).</LI>&#xD;&#xA;<LI>Administer two doses of RZV two to six months apart to adults who previously received ZVL at least two months after ZVL.</LI>&#xD;&#xA;<LI>For adults aged 60 years or older, administer either RZV or ZVL (RZV is preferred).</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>ZVL is contraindicated for pregnant women and adults with severe immunodeficiency.</LI></UL></LI></UL>Â¥ <STRONG>Human papillomavirus (HPV) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer HPV vaccine to females through age 26 years and males through age 21 years (males aged 22 through 26 years may be vaccinated based on individual clinical decision).</LI>&#xD;&#xA;<LI>The number of doses of HPV vaccine to be administered depends on age at initial HPV vaccination: &#xD;&#xA;<UL>&#xD;&#xA;<LI>No previous dose of HPV vaccine: Administer three-dose series at 0, 1 to 2, and 6 months (minimum intervals: 4 weeks between doses 1 and 2, 12 weeks between doses 2 and 3, and 5 months between doses 1 and 3; repeat doses if given too soon).</LI>&#xD;&#xA;<LI>Aged 9 to 14 years at HPV vaccine series initiation and received one dose or two doses less than five months apart: Administer one dose.</LI>&#xD;&#xA;<LI>Aged 9 to 14 years at HPV vaccine series initiation and received two doses at least five months apart: No additional dose is needed.</LI></UL></LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Adults with immunocompromising conditions (including HIV infection) through age 26 years: Administer three-dose series at zero, one to two, and six months.</LI>&#xD;&#xA;<LI>Adult females and males through age 26 years with immunocompromising conditions (described below), including those with HIV infection, should receive a three-dose series of HPV vaccine at zero, one to two, and six months.</LI>&#xD;&#xA;<LI>Men who have sex with men [MSM] through age 26 years: Administer two- or three-dose series depending on age at initial vaccination (refer above); if no history of HPV vaccine, administer three-dose series at zero, one to two, and six months.</LI>&#xD;&#xA;<LI>Pregnant women through age 26 years: HPV vaccination is not recommended during pregnancy, but there is no evidence that the vaccine is harmful and no intervention needed for women who inadvertently receive HPV vaccine while pregnant; delay remaining doses until after pregnancy; pregnancy testing is not needed before vaccination.</LI></UL></LI></UL>â¡ <STRONG>Pneumococcal vaccines</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to immunocompetent adults aged 65 years or older one dose of 13-valent pneumococcal conjugate vaccine (PCV13), if not previously administered, followed by one dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) at least one year after PCV13; if PPSV23 was previously administered but not PCV13, administer PCV13 at least one year after PPSV23.</LI>&#xD;&#xA;<LI>When both PCV13 and PPSV23 are indicated, administer PCV13 first (PCV13 and PPSV23 should not be administered during the same visit); additional information on vaccine timing is available at <A href=\"https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf\" target=_blank>www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf</A>.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to adults aged 19 through 64 years with the following chronic conditions one dose of PPSV23 (at age 65 years or older, administer one dose of PCV13, if not previously received, and another dose of PPSV23 at least one year after PCV13 and at least five years after PPSV23): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Chronic heart disease (excluding hypertension).</LI>&#xD;&#xA;<LI>Chronic lung disease.</LI>&#xD;&#xA;<LI>Chronic liver disease.</LI>&#xD;&#xA;<LI>Alcoholism.</LI>&#xD;&#xA;<LI>Diabetes mellitus.</LI>&#xD;&#xA;<LI>Cigarette smoking.</LI></UL></LI>&#xD;&#xA;<LI>Administer to adults aged 19 years or older with the following indications one dose of PCV13 followed by one dose of PPSV23 at least eight weeks after PCV13, and a second dose of PPSV23 at least five years after the first dose of PPSV23 (if the most recent dose of PPSV23 was administered before age 65 years, at age 65 years or older, administer another dose of PPSV23 at least five years after the last dose of PPSV23): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Immunodeficiency disorders (including B- and T-lymphocyte deficiency, complement deficiencies, and phagocytic disorders).</LI>&#xD;&#xA;<LI>HIV infection.</LI>&#xD;&#xA;<LI>Anatomical or functional asplenia (including sickle cell disease and other hemoglobinopathies).</LI>&#xD;&#xA;<LI>Chronic renal failure and nephrotic syndrome.</LI></UL></LI>&#xD;&#xA;<LI>Administer to adults aged 19 years or older with the following indications one dose of PCV13 followed by one dose of PPSV23 at least eight weeks after PCV13 (if the dose of PPSV23 was administered before age 65 years, at age 65 years or older, administer another dose of PPSV23 at least five years after the last dose of PPSV23): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Cerebrospinal fluid leak.</LI>&#xD;&#xA;<LI>Cochlear implant.</LI></UL></LI></UL></LI></UL>â  <STRONG>Hepatitis A (HepA) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to adults who have a specific risk (refer below), or lack a risk factor but want protection, two-dose series of single antigen HepA vaccine (Havrix at 0 and 6 to 12 months or Vaqta at 0 and 6 to 18 months; minimum interval: 6 months) or a three-dose series of combined hepatitis A and hepatitis B (HepA-HepB) vaccine at 0, 1, and 6 months; minimum intervals: 4 weeks between first and second doses, 5 months between second and third doses.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer HepA vaccine or HepA-HepB vaccine to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Travel to or work in countries with high or intermediate HepA endemicity.</LI>&#xD;&#xA;<LI>MSM.</LI>&#xD;&#xA;<LI>Injection or noninjection drug use.</LI>&#xD;&#xA;<LI>Work with HepA virus in a research laboratory or with nonhuman primates infected with HepA virus.</LI>&#xD;&#xA;<LI>Clotting factor disorders.</LI>&#xD;&#xA;<LI>Chronic liver disease.</LI>&#xD;&#xA;<LI>Close, personal contact with an international adoptee (eg, household or regular babysitting) during the first 60 days after arrival in the United States from a country with high or intermediate endemicity (administer the first dose as soon as the adoption is planned).</LI>&#xD;&#xA;<LI>Healthy adults through age 40 years who have recently been exposed to HepA virus; adults older than age 40 years may receive HepA vaccine or HepA-HepB vaccine if HepA immunoglobulin cannot be obtained.</LI></UL></LI>&#xD;&#xA;<LI>Adults who travel in countries with high or intermediate levels of endemic HepA infection or anticipate close personal contact with an international adoptee (eg, reside in the same household or regularly babysit) from a country with high or intermediate level of endemic HepA infection within the first 60 days of arrival in the United States should receive a HepA series.</LI></UL></LI></UL>** <STRONG>Hepatitis B (HepB) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html</A> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to adults who have a specific risk (refer below), or lack a risk factor but want protection, three-dose series of single antigen HepB vaccine or combined HepA-HepB vaccine at zero, one, and six months (minimum intervals: Four weeks between doses one and two for HepB vaccine and HepA-HepB vaccine; between doses two and three, eight weeks for HepB vaccine and five months for HepA-HepB vaccine).</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer HepB vaccine or HepA-HepB vaccine to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Chronic liver disease (eg, hepatitis C infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal).</LI>&#xD;&#xA;<LI>HIV infection.</LI>&#xD;&#xA;<LI>Percutaneous or mucosal risk of exposure to blood (eg, household contacts of hepatitis B surface antigen [HBsAg]-positive persons; adults younger than age 60 years with diabetes mellitus or aged 60 years or older with diabetes mellitus based on individual clinical decision; adults in predialysis care or receiving hemodialysis or peritoneal dialysis; recent or current injection drug users; healthcare and public safety workers at risk for exposure to blood or blood-contaminated body fluids).</LI>&#xD;&#xA;<LI>Sexual exposure risk (eg, sex partners of HBsAg-positive persons; sexually active persons not in a mutually monogamous relationship; persons seeking evaluation or treatment for a sexually transmitted infection; and MSM).</LI>&#xD;&#xA;<LI>Receive care in settings where a high proportion of adults have risks for HepB infection (eg, facilities providing sexually transmitted disease treatment, drug-abuse treatment and prevention services, hemodialysis and end-stage renal disease programs, institutions for developmentally disabled persons, healthcare settings targeting services to injection drug users or MSM, HIV testing and treatment facilities, and correctional facilities).</LI>&#xD;&#xA;<LI>Travel to countries with high or intermediate HepB endemicity.</LI></UL></LI></UL></LI></UL>Â¶Â¶ <STRONG>Meningococcal vaccines</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html</A> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI><STRONG>Special populations: Serogroups A, C, W, and Y meningococcal vaccine (MenACWY)</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer two doses of MenACWY at least eight weeks apart and revaccinate with one dose of MenACWY every five years, if the risk remains, to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Anatomical or functional asplenia (including sickle cell disease and other hemoglobinopathies).</LI>&#xD;&#xA;<LI>HIV infection.</LI>&#xD;&#xA;<LI>Persistent complement component deficiency.</LI>&#xD;&#xA;<LI>Eculizumab use.</LI></UL></LI>&#xD;&#xA;<LI>Administer one dose of MenACWY and revaccinate with one dose of MenACWY every five years, if the risk remains, to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Travel to or live in countries where meningococcal disease is hyperendemic or epidemic, including countries in the African meningitis belt or during the Hajj.</LI>&#xD;&#xA;<LI>At risk from a meningococcal disease outbreak attributed to serogroup A, C, W, or Y.</LI>&#xD;&#xA;<LI>Microbiologists routinely exposed to <EM>Neisseria meningitidis</EM>.</LI>&#xD;&#xA;<LI>Military recruits.</LI>&#xD;&#xA;<LI>First-year college students who live in residential housing (if they did not receive MenACWY at age 16 years or older).</LI></UL></LI></UL></LI>&#xD;&#xA;<LI><STRONG>General Information: Serogroup B meningococcal vaccine (MenB)</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>May administer, based on individual clinical decision, to young adults and adolescents aged 16 to 23 years (preferred age is 16 to 18 years) who are not at increased risk two-dose series of MenB-4C (Bexsero) at least one month apart or two-dose series of MenB-FHbp (Trumenba) at least six months apart.</LI>&#xD;&#xA;<LI>MenB-4C and MenB-FHbp are not interchangeable.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations: MenB</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer two-dose series of MenB-4C at least one month apart or three-dose series of MenB-FHbp at zero, one to two, and six months to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Anatomical or functional asplenia (including sickle cell disease).</LI>&#xD;&#xA;<LI>Persistent complement component deficiency.</LI>&#xD;&#xA;<LI>Eculizumab use.</LI>&#xD;&#xA;<LI>At risk from a meningococcal disease outbreak attributed to serogroup B.</LI>&#xD;&#xA;<LI>Microbiologists routinely exposed to <EM>Neisseria meningitidis</EM>.</LI></UL></LI></UL></LI></UL>ÎÎ <STRONG><EM>Haemophilus influenzae</EM> type b (Hib) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html</A> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer Hib vaccine to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Anatomical or functional asplenia (including sickle cell disease) or undergoing elective splenectomy: Administer one dose if not previously vaccinated (preferably at least 14 days before elective splenectomy).</LI>&#xD;&#xA;<LI>Hematopoietic stem cell transplant (HSCT): Administer three-dose series with doses 4 weeks apart starting 6 to 12 months after successful transplant regardless of Hib vaccination history.</LI></UL></LI></UL></LI></UL></div><div class=\"graphic_reference\">Reproduced from: Advisory Committee on Immunization Practices (ACIP). Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2018. Available at: <A href=\"http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf\" target=_blank>http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf</A> (Accessed on February 8, 2018).</div><div id=\"graphicVersion\">Graphic 62130 Version 16.0</div></div></div>"},"62132":{"type":"graphic_figure","displayName":"Acute aortic syndromes","title":"Acute aortic syndromes","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Acute aortic syndromes</div><div class=\"cntnt\"><img style=\"width:529px; height:192px;\" src=\"images/CARD/62132_Variations_of_aortic_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Class I â&nbsp;Classic dissection with separation of intima/media and dual lumens; there is a flap between true and false aneurysm and clot in false lumen.<br />Class II â&nbsp;Intramural hematoma with separation of intima/media but no intraluminal tear or flap on imaging.<br />Class III â Limited intimal tear without hematoma and eccentric bulge at tear site (limited dissection).<br />Class IV â Atherosclerotic ulcer penetrating to adventitia with surrounding hematoma that is usually subadventitial.<br />Class V â&nbsp;Iatrogenic or traumatic dissection (eg, due to a cardiac catheterization).</div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>Lahey Clinic, Burlington, MA.</LI>&#xD;&#xA;<LI>Svensson LG, Lalsib JB, Eisenhauer AC, et al. Intimal tear without hematoma: an important variant of aortic dissection that can elude current imaging techniques. Circulation 1999; 99:1331.</LI></OL></div><div id=\"graphicVersion\">Graphic 62132 Version 6.0</div></div></div>"},"62133":{"type":"graphic_waveform","displayName":"EEG lateralized periodic discharges LPDs","title":"Right hemisphere lateralized periodicÂ discharges (LPDs)","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Right hemisphere lateralized periodic&nbsp;discharges (LPDs)</div><div class=\"cntnt\"><img style=\"width:540px; height:354px;\" src=\"images/NEURO/62133_RhemPLEDS.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Chong DJ, Hirsch, LJ. Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol 2005; 22:79. Copyright Â© 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62133 Version 13.0</div></div></div>"},"62134":{"type":"graphic_figure","displayName":"Human TPO sequence","title":"Sequence of human thrombopoietin","html":"<div class=\"graphic\"><div style=\"width: 767px\" class=\"figure\"><div class=\"ttl\">Sequence of human thrombopoietin</div><div class=\"cntnt\"><img style=\"width:747px; height:517px;\" src=\"images/HEME/62134_Human_TPO_sequence.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. T. Kato, Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Takasaki, Gunma, Japan.</div><div id=\"graphicVersion\">Graphic 62134 Version 1.0</div></div></div>"},"62135":{"type":"graphic_diagnosticimage","displayName":"Distal radius central reference point","title":"Distal radius central reference point","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal radius central reference point</div><div class=\"cntnt\"><img style=\"width:428px; height:362px;\" src=\"images/EM/62135_Distal_radius_CRP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The central reference point (CRP) lies midway between the palmar ulnar corner and the dorsal ulnar corner of the distal radius. Use of the CRP provides more accurate measurements of radial inclination, radial height, and ulnar variance.</div><div class=\"graphic_reference\">Courtesy of Erik L Schroeder, MD.</div><div id=\"graphicVersion\">Graphic 62135 Version 3.0</div></div></div>"},"62136":{"type":"graphic_table","displayName":"Pediatric appendicitis score","title":"The Pediatric Appendicitis Score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Pediatric Appendicitis Score</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Item\n   </td>\n   <td  class=\"subtitle1\">\n   Score (point)\n   </td>\n   </tr>\n   <tr>\n   <td>Anorexia</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td>Nausea or vomiting</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td>Migration of pain</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td>Fever &#62;38&#176;C (100.5&#176;F)</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td>Pain with cough, percussion or hopping</td>\n   <td>2</td>\n   </tr>\n   <tr>\n   <td>Right lower quadrant tenderness</td>\n   <td>2</td>\n   </tr>\n   <tr>\n   <td>White blood cell count &#62;10,000 cells/microL</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td>Neutrophils plus band forms &#62;7500 cells/microL</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td><strong>Total</strong></td>\n   <td><strong>10 points</strong></td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">C: Centigrade; F: Fahrenheit.</div><div class=\"graphic_reference\">Data from: Samuel, M. Pediatric appendicitis score. J Pediatr Surg 2002; 37:877.</div><div id=\"graphicVersion\">Graphic 62136 Version 2.0</div></div></div>"},"62139":{"type":"graphic_figure","displayName":"Symptoms of achalasia","title":"Frequency of the symptoms of achalasia","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Frequency of the symptoms of achalasia</div><div class=\"cntnt\"><img style=\"width:544px; height:306px;\" src=\"images/GAST/62139_Symptoms_of_achalasia.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62139 Version 1.0</div></div></div>"},"62141":{"type":"graphic_diagnosticimage","displayName":"Septic knee radiograph","title":"Effusion and bony erosion in septic arthritis of the knee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effusion and bony erosion in septic arthritis of the knee</div><div class=\"cntnt\"><img style=\"width:291px; height:365px;\" src=\"images/RHEUM/62141_Septic_knee_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph of the knee demonstrates an effusion in a patient with septic joint. Swelling is most apparent in the suprapatellar region (arrow). Erosion of the tibial articular surface is also apparent (arrowhead), consistent with infection.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 62141 Version 3.0</div></div></div>"},"62142":{"type":"graphic_figure","displayName":"Primary teeth identification","title":"Conventional identification of the primary teeth (United States)","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Conventional identification of the primary teeth (United States)</div><div class=\"cntnt\"><img style=\"width:505px; height:357px;\" src=\"images/PEDS/62142_Primary-teeth-identification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">By convention in the United States, general dentists identify the 20 primary teeth by the letters A through T, as depicted above. Different identification systems are used in other countries.</div><div class=\"graphic_reference\">Redrawn from: Dentistry 2000 - Human Teeth Numbering Charts. http://www.dentistry2000.com/dentalhealthcare/teeth_numbering.html.</div><div id=\"graphicVersion\">Graphic 62142 Version 3.0</div></div></div>"},"62143":{"type":"graphic_picture","displayName":"Erythrasma fluorescence","title":"Erythrasma under light from a Wood's lamp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythrasma under light from a Wood's lamp</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/62143_Erythrasmafluorescence.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examination with a Wood's lamp reveals coral red fluorescence on the inner thighs of&nbsp;this patient with erythrasma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62143 Version 6.0</div></div></div>"},"62145":{"type":"graphic_picture","displayName":"Dennie-Morgan fold","title":"Dennie-Morgan fold in atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dennie-Morgan fold in atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/DERM/62145_DennieMorganfold.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An extra skin fold is present under the eyes in this patient with facial atopic dermatitis.</div><div class=\"graphic_reference\">Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003.</div><div id=\"graphicVersion\">Graphic 62145 Version 2.0</div></div></div>"},"62146":{"type":"graphic_picture","displayName":"Paraneoplastic pemphigus toxic epidermal necrolysis-like","title":"Paraneoplastic pemphigus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic pemphigus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62146_Paraneopemphiten.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread skin sloughing and erosions in paraneoplastic pemphigus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62146 Version 4.0</div></div></div>"},"62147":{"type":"graphic_figure","displayName":"Types of APBJ","title":"Types of anomalous pancreaticobiliary junction","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Types of anomalous pancreaticobiliary junction</div><div class=\"cntnt\"><img style=\"width:491px; height:340px;\" src=\"images/PEDS/62147_Types_of_APBU.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">B-P: bileopancreatic type; P-B: pancreaticobiliary type.</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 62147 Version 3.0</div></div></div>"},"62148":{"type":"graphic_table","displayName":"Constipation assessment scale","title":"Constipation assessment scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Constipation assessment scale</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_left\" colspan=\"4\" rowspan=\"1\">Directions:</td>\n\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td rowspan=\"1\" colspan=\"4\">Circle the appropriate number to\nindicate whether, during the past three days, you have had NO PROBLEM,\nSOME PROBLEM, or a SEVERE PROBLEM with each of the items listed below.</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">Item</td>\n\n\n      <td class=\"subtitle1\">No problem</td>\n\n\n      <td class=\"subtitle1\">Some problem</td>\n\n\n      <td class=\"subtitle1\">Severe problem</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>1. Abdominal distention or bloating</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>2. Change in amount of gas passed rectally</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>3. Less frequent bowel movements</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>4. Oozing liquid stool</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>5. Rectal fullness or pressure</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>6. Rectal pain with bowel movement</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>7. Small stool size</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>8. Urge but inability to pass stool</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: McMillan, SC, Williams, F. Validity and reliability of the constipation assessment scale. Cancer Nursing 1989; 12:183; and McMillan, SC, Levy, D. Reassessment of the validity and reliability of the CAS (and unpublished study).</div><div id=\"graphicVersion\">Graphic 62148 Version 1.0</div></div></div>"},"62150":{"type":"graphic_diagnosticimage","displayName":"Flock workers lung CT - Mild","title":"Flock worker's lung CT - Mild","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flock worker's lung CT - Mild</div><div class=\"cntnt\"><img style=\"width:317px; height:317px;\" src=\"images/PULM/62150_Flock_workers_lung_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prone CT of the chest reveals mild ground glass opacification (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of David Kern, MD and Robert Crausman, MD.</div><div id=\"graphicVersion\">Graphic 62150 Version 7.0</div></div></div>"},"62151":{"type":"graphic_table","displayName":"Medications and bronchoprovocation testing","title":"Medications that may affect bronchoprovocation challenge test","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications that may affect bronchoprovocation challenge test</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Minimum time to omit medication before challenge tests</td> </tr> <tr> <td class=\"sublist1_start subtitle2_left\" colspan=\"2\"><strong>Inhaled bronchodilators</strong></td> </tr> <tr> <td class=\"indent1\">Albuterol</td> <td>6&nbsp;hours</td> </tr> <tr> <td class=\"indent1\">Metaproterenol</td> <td>6&nbsp;hours</td> </tr> <tr> <td class=\"indent1\">Terbutaline</td> <td>6&nbsp;hours</td> </tr> <tr> <td class=\"indent1\">Ipratropium</td> <td>12&nbsp;hours</td> </tr> <tr> <td class=\"indent1\">Formoterol, salmeterol</td> <td>36&nbsp;hours</td> </tr> <tr> <td class=\"indent1\">Ultra long-acting beta agonists (eg, indacaterol, olodaterol, vilanterol)</td> <td>48 hours</td> </tr> <tr> <td class=\"indent1\">Aclidinium</td> <td>48 hours&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Glycopyrrolate, tiotropium, umeclidinium</td> <td>1 week</td> </tr> <tr> <td class=\"sublist1_start subtitle2_left\" colspan=\"2\">Oral bronchodilators</td> </tr> <tr> <td class=\"indent1\">Liquid theophylline</td> <td>12 hours</td> </tr> <tr> <td class=\"indent1\">Intermediate-acting theophylline</td> <td>24 hours</td> </tr> <tr> <td class=\"indent1\">Long-acting theophylline</td> <td>48 hours</td> </tr> <tr> <td class=\"indent1\">Albuterol tablet</td> <td>12 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Long-acting albuterol tablet</td> <td>24 hours</td> </tr> <tr> <td class=\"subtitle2_left\"><strong>Inhaled glucocorticoid</strong>*</td> <td class=\"divider_bottom\">2-3 weeks</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Oral glucocorticoid*</td> <td>2-3 weeks</td> </tr> <tr> <td class=\"sublist1_start subtitle2_left\" colspan=\"2\">Mast cell stabilizers</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cromolyn sodium<sup>&#182;</sup></td> <td>8 hours</td> </tr> <tr> <td class=\"sublist1_start subtitle2_left\" colspan=\"2\">Antihistamines: generally do not need to discontinue<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist1_start subtitle2_left\" colspan=\"2\">Leukotriene modifiers</td> </tr> <tr> <td class=\"indent1\">Montelukast<sup>&#9674;</sup></td> <td>24 hours</td> </tr> <tr> <td class=\"indent1\">Zafirlukast</td> <td>24 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The authors do not recommend routinely withholding inhaled or oral glucocorticoids, but their anti-inflammatory effect may decrease bronchial responsiveness. A negative test while the patient is using glucocorticoids implies that the patient's current symptoms are not due to asthma.<br />Â¶ Cromolyn has minimal effect on methacholine bronchoprovocation challenge, but should be withheld prior to allergen challenge.<br />Î&nbsp;Antihistamines are discontinued because of their anticholinergic effect.<br />â A single dose of montelukast has minimal effect on methacholine challenge, but a withhold time of 4 to 8 weeks would be needed for full resolution of the anti-inflammatory effects.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>âCoates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J 2017; 49.</LI>&#xD;&#xA;<LI>Cockcroft DW, Davis BE, Roh Y, et al. Effect of ingested H1 antihistamines on methacholine challenge. J Allergy Clin Immunol 2015; 135: 579.</LI></OL></div><div id=\"graphicVersion\">Graphic 62151 Version 7.0</div></div></div>"},"62152":{"type":"graphic_table","displayName":"Drugs and photosensitivity","title":"Some agents that may cause photosensitivity reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some agents that may cause photosensitivity reactions</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Anticancer drugs</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\t\n\t\t\t\t\t\t\t<td>Dacarbazine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Fluorouracil</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Flutamide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Methotrexate</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Vinblastine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Antidepressants</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Amitriptyline</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Amoxapine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Clomipramine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Desipramine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Doxepin</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Imipramine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Maprotiline</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Phenelzine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Protriptyline</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Trazodone</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Trimipramine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Antimicrobials</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Ciprofloxacin</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Clofazimine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Dapsone</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Demeclocycline*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Doxycycline*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Enoxacin</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Flucytosine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Griseofulvin</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Lomefloxacin*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Minocycline</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Nalidixic acid*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Norfloxacin</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Ofloxacin</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Oxytetracycline</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pyrazinamide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Sulfonamides</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Tetracycline</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Trimethopterin</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Antiparasitic drugs</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Chloroquine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Quinine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Antipsychotic drugs</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Chlorpromazine*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Fluphenazine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Haloperidol</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Perphenazine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Prochlorperazine*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Thioridazine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Thiothixene</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Trifluoperazine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Triflupromazine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Diuretics</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Acetazolamide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Amiloride</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Bendroflumethiazide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Benzthiazide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Chlorthiazide*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Furosemide*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Hydrochlorothiazide*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Hydroflumethiazide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Methyclothiazide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Metolazone</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Polythiazide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Trimterene</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Trichlormethiazide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Hypoglycemics</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Acetohexamide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Chlorpropamide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Glipizide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Glyburide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Tolazamide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Tolbutamide*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">NSAIDs</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Difluisal</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Ibuprofen</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Indomethacin</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Ketoprofen</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Nabumetone</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Naproxen</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Phenylbutazone</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Piroxicam*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Sulindac</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Sunscreens</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Aminobenzoic acids*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Avobenzone</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Benzophenonones*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Cinnamates</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Homosalate</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Menthyl anthranilate</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>PABA esters*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Antihistamine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Cyproheptadine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Diphenhydramine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Anthypertensives</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Captopril</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Diltiazem</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Methyldopa</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Minoxidil</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Nifedipine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Others</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Alpazolam</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Amantadine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Amiodarone*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Benzocaine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Benzyl peroxide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Bergamol oil, oils of citron, lavender, lime, sandalwood, cedar*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Carbamazepine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Chlordiazepoxide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Clofibrate</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Desoximetasone</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Disopyramide</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Etretinate</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Fluoroscein</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Gold salts</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Hexachlorophene</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Isotretinoin</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>6-methylcoumRIN*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Musk ambrette*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Oral contraceptives</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Promethazine*</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Quinidine sulfate</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Tretinoin</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Trimeprazine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Reactions which occur more frequently</div><div class=\"graphic_reference\">Adapted from The Medical Letter 1995; 37:35.</div><div id=\"graphicVersion\">Graphic 62152 Version 1.0</div></div></div>"},"62153":{"type":"graphic_table","displayName":"Fetal erythrocyte count by GA","title":"Erythrocyte count, 10<sup>12</sup>/L","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Erythrocyte count, 10<sup>12</sup>/L</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">GA</td>\n<td class=\"subtitle1\">5th percentile</td>\n<td class=\"subtitle1\">Mean</td>\n<td class=\"subtitle1\">95th percentile</td>\n</tr>\n<tr>\n<td>20</td>\n<td>2.26</td>\n<td>2.70</td>\n<td>3.14</td>\n</tr>\n<tr>\n<td>22</td>\n<td>2.41</td>\n<td>2.85</td>\n<td>3.29</td>\n</tr>\n<tr>\n<td>24</td>\n<td>2.56</td>\n<td>3.00</td>\n<td>3.43</td>\n</tr>\n<tr>\n<td>26</td>\n<td>2.71</td>\n<td>3.14</td>\n<td>3.58</td>\n</tr>\n<tr>\n<td>28</td>\n<td>2.85</td>\n<td>3.29</td>\n<td>3.73</td>\n</tr>\n<tr>\n<td>30</td>\n<td>3.00</td>\n<td>3.44</td>\n<td>3.88</td>\n</tr>\n<tr>\n<td>32</td>\n<td>3.15</td>\n<td>3.59</td>\n<td>4.03</td>\n</tr>\n<tr>\n<td>34</td>\n<td>3.30</td>\n<td>3.74</td>\n<td>4.18</td>\n</tr>\n<tr>\n<td>36</td>\n<td>3.44</td>\n<td>3.88</td>\n<td>4.33</td>\n</tr>\n<tr>\n<td>38</td>\n<td>3.59</td>\n<td>4.03</td>\n<td>4.48</td>\n</tr>\n<tr>\n<td>40</td>\n<td>3.74</td>\n<td>4.18</td>\n<td>4.62</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62153 Version 1.0</div></div></div>"},"62155":{"type":"graphic_table","displayName":"TNM panc endo exo CA","title":"TNM staging system for exocrine and endocrine tumors of the pancreas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging system for exocrine and endocrine tumors of the pancreas</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Primary tumor (T)\n   </td>\n   </tr>\n   <tr>\n   <td>TX</td>\n   <td  colspan=\"3\">\n   Primary tumor cannot be assessed\n   </td>\n   </tr>\n   <tr>\n   <td>T0</td>\n   <td  colspan=\"3\">\n   No evidence of primary tumor\n   </td>\n   </tr>\n   <tr>\n   <td>Tis</td>\n   <td  colspan=\"3\">\n   Carcinoma in situ*\n   </td>\n   </tr>\n   <tr>\n   <td>T1</td>\n   <td  colspan=\"3\">\n   Tumor limited to the pancreas, 2 cm or less in greatest dimension\n   </td>\n   </tr>\n   <tr>\n   <td>T2</td>\n   <td  colspan=\"3\">\n   Tumor limited to the pancreas, more than 2 cm in greatest dimension\n   </td>\n   </tr>\n   <tr>\n   <td>T3</td>\n   <td  colspan=\"3\">\n   Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery\n   </td>\n   </tr>\n   <tr>\n   <td>T4</td>\n   <td  colspan=\"3\">\n   Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor)\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Regional lymph nodes (N)\n   </td>\n   </tr>\n   <tr>\n   <td>NX</td>\n   <td  colspan=\"3\">\n   Regional lymph nodes cannot be assessed\n   </td>\n   </tr>\n   <tr>\n   <td>N0</td>\n   <td  colspan=\"3\">\n   No regional lymph node metastasis\n   </td>\n   </tr>\n   <tr>\n   <td>N1</td>\n   <td  colspan=\"3\">\n   Regional lymph node metastasis\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Distant metastasis (M)\n   </td>\n   </tr>\n   <tr>\n   <td>M0</td>\n   <td  colspan=\"3\">\n   No distant metastasis\n   </td>\n   </tr>\n   <tr>\n   <td>M1</td>\n   <td  colspan=\"3\">\n   Distant metastasis\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Anatomic stage/prognostic groups\n   </td>\n   </tr>\n   <tr>\n   <td>Stage 0</td>\n   <td>Tis</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IA</td>\n   <td>T1</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IB</td>\n   <td>T2</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IIA</td>\n   <td>T3</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Stage IIB\n   </td>\n   <td>T1</td>\n   <td>N1</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>T2</td>\n   <td>N1</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>T3</td>\n   <td>N1</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage III</td>\n   <td>T4</td>\n   <td>Any N</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IV</td>\n   <td>Any T</td>\n   <td>Any N</td>\n   <td>M1</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">4/1/2010--These are in the AJCC folder and should be renewed annually for the life of the 7th Edition; this has been paid for 2010 (JD). The total fee of $&amp;quot;160.00&amp;quot;was originally charged to TNM_staging_adrenal_CA TNM_staging_ampullary_CA anal_cancer_TNM_stage anal_cancer_stage_group Anal_outcome_hist_AJCC TNM_stage_append_CA TNM_stage_append_carcinoid Surv_rates_appendix_CA TNM_staging_bone_tumors TNM_stage_breast_cancer Breast_reg_lymph_nodes 2002_TNM_breast_cancer Staging_cervical_cancer TNM_staging_colorec_CA CRC_tumor_regression_grade SEER_surv_adeno_colon SEER_surv_adeno_rectum Reg_nodes_colorec_CA CRC_resection_margin Staging_uterine_carcinoma Staging_uterine_sarcoma TNM_distal_cholangio TNM_staging_esoph_SCC TNM_staging_esoph_EGJ_adenoCA Esoph_CA_site T_stage_esophageal_cancer Staging_fallopian_cancer TNM_staging_gallbladder_CA OS_gallbladder_CA TNM_staging_GIST Dis_prog_gastric_GIST Dis_prog_small_int_GIST Staging_gest_trop_neoplas TNM_stage_hypopharynx TNM_small_bowel_cancer TNM_intrahep_cholangio SEER_surv_intrahep_cholang TNM_staging_RCC TNM_stage_larynx TNM_stage_oral_cavity TNM_staging_HCC 7th_TNM_lung_stage system Lung_CA staging_6th_TNM 7th_TNM_lung_CA_changes TNM_path_staging_mel_conj TNM_clin_staging_mel_conj Melanoma_7thTNM_stage_group Melanoma_7th_TNM_staging TNM_staging_muc_melanoma_HN Muc_melanoma_HN_stage_group Ciliary_choroid_thickness TNM_stage_uveal_melanoma TNM_stage_Merkel_cell_CA TNM_stage_sinonasal_sites TNM_stage_nasopharynx TNM_stage_gastric_carcinoid TNM_gastrointest_carcinoid TNM_amp_sm_bowel_carcinoid TNM_staging_CRC_carcinoid Surv_rates_GI_neuroendo Staging_ovar_prim_perit_ca TNM_panc_endo_exo_CA NCDB_no_surg_surv_panc NCDB_surg_surv_panc Prog_panc_neuroendo_tum TNM_staging_penile_cancer TNM_perihilar_cholangio TNM_stage_oropharynx TNM_stage_mesothelioma TNM_staging_prostate_CA TNM_group_prostate_CA TNM_staging_renal_pelvis TNM_stage_salivary_glands TNM_stage_sarcoma_orbit TNM_staging_soft_tis_sarc 2010_TNM_staging_STS TNM_stage_cutan_SCC 2010_TNM_staging_stomach_CA SEER_survival_gast_CA TMN_staging_testicular_CA Stage_group_testicular_CA TNM_staging_thyroid_cancer Urethral_CA_TNM_women TNM_stage_group_urethra Urethral_CA_TNM_men TNM_staging_bladder_CA Staging_vaginal_cancer Staging_vulvar_cancer</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48366&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>TNM_panc_endo_exo_CA.htm</title></head></div><div class=\"graphic_lgnd\">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_footnotes\">* This includes lesions classified as PanInIII classification.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 62155 Version 11.0</div></div></div>"},"62157":{"type":"graphic_figure","displayName":"Flow function relationship","title":"Flow-function relationship in hibernating and stunned myocardium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow-function relationship in hibernating and stunned myocardium</div><div class=\"cntnt\"><img style=\"width:354px; height:276px;\" src=\"images/CARD/62157_Flow_function_relationship.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The red line demonstrates the relationship between the amount of myocardial blood flow and left ventricular systolic function (flow-function relationship). When myocardium is operating below this line, function is disproportionately depressed relative to flow and when it is above the line, function exceeds blood flow and ischemia is likely to result. Chronically hypoperfused myocardium, resulting from an epicardial stenosis that restricts basal coronary flow, produces hibernation (H). In comparison, stunning (S), resulting from repetitive bouts of ischemia, occurs when the stenosis severely limits flow reserve but not basal coronary flow. Small variations in blood flow may result in a change in myocardial state, between H and S, without any appreciable change in systolic function. Following inotropic stimulation, myocardium operating at both H and S will increase systolic function without a substantial change in blood flow (A and B, respectively). As a result, the two situations cannot be reliably distinguished by stress echocardiography.</div><div class=\"graphic_reference\">Data from: Redwood SR, Ferrari R, Marber MS. Heart 1998; 80:218.</div><div id=\"graphicVersion\">Graphic 62157 Version 3.0</div></div></div>"},"62158":{"type":"graphic_table","displayName":"Congenital anomalies in IDM","title":"Common congenital anomalies in infants of diabetic mothers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common congenital anomalies in infants of diabetic mothers</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">System</td>\n<td class=\"subtitle1\">Manifestations</td>\n</tr>\n<tr>\n<td>Neurologic</td>\n<td>Anencephaly with or without herniation of neural elements, arrhinencephaly, microcephaly, holoprosencephaly, neural tube defects (meningomyelocele and other variants).</td>\n</tr>\n<tr>\n<td>Cardiovascular</td>\n<td>Transposition of the great vessels with or without ventricular septal defect (VSD), VSD, coarctation of the aorta with or without VSD or patent ductus arteriosus, atrial septal defect, single ventricle, hypoplastic left ventricle, pulmonic stenosis, pulmonary valve atresia, double outlet right ventricle truncus arteriosus.</td>\n</tr>\n<tr>\n<td>Gastrointestinal</td>\n<td>Duodenal atresia, imperforate anus, anorectal atresia, small left colon syndrome, situs inversus.</td>\n</tr>\n<tr>\n<td>Genitourinary</td>\n<td>Ureteral duplication, renal agenesis, hydronephrosis.</td>\n</tr>\n<tr>\n<td>Skeletal</td>\n<td>Caudal regression syndrome (sacral agenesis), hemivertebrae.</td>\n</tr>\n<tr>\n<td>Other</td>\n<td>Single umbilical artery.</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Tyrala EE. Obstet Gynecol Clin North Am 1996; 23:221; and Reece EA, Homko CJ. Semin Perinatol 1994; 18:459.</div><div id=\"graphicVersion\">Graphic 62158 Version 2.0</div></div></div>"},"62163":{"type":"graphic_table","displayName":"ORT replacement guide PI","title":"Amount of oral rehydration solution to give child (overÂ four hours) for mild dehydration, based on weight","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Amount of oral rehydration solution to give child (over&nbsp;four hours) for mild dehydration, based on weight</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n \n   <tr>\n  \n   <td  colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">\n  \n   English system\n  \n   </td>\n  \n   <td  rowspan=\"1\" colspan=\"2\" class=\"subtitle1\">\n  \n   Metric system\n  \n   </td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td  class=\"subtitle2\">\n  \n   Weight, lbs\n  \n   </td>\n  \n   <td  class=\"subtitle2\">\n  \n   Volume, ounces\n  \n   </td>\n  \n   <td  class=\"subtitle2\">\n  \n   Weight, kilograms\n  \n   </td>\n  \n   <td  class=\"subtitle2\">\n  \n   Volume, milliliters\n  \n   </td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>10</td>\n  \n   <td>7.5</td>\n  \n   <td>4</td>\n  \n   <td>200</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>15</td>\n  \n   <td>11.5</td>\n  \n   <td>6</td>\n  \n   <td>300</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>20</td>\n  \n   <td>15</td>\n  \n   <td>8</td>\n  \n   <td>400</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>25</td>\n  \n   <td>19</td>\n  \n   <td>10</td>\n  \n   <td>500</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>30</td>\n  \n   <td>22.5</td>\n  \n   <td>12</td>\n  \n   <td>600</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>35</td>\n  \n   <td>26.5</td>\n  \n   <td>14</td>\n  \n   <td>700</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>40</td>\n  \n   <td>30</td>\n  \n   <td>16</td>\n  \n   <td>800</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>&nbsp;</td>\n  \n   <td>&nbsp;</td>\n  \n   <td>18</td>\n  \n   <td>900</td>\n  \n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">12.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=49358&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ORT_replacement_guide_PI.htm</title></head></div><div id=\"graphicVersion\">Graphic 62163 Version 2.0</div></div></div>"},"62164":{"type":"graphic_figure","displayName":"Early events T cell transduction","title":"Early events in T cell receptor signal transduction","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Early events in T cell receptor signal transduction</div><div class=\"cntnt\"><img style=\"width:516px; height:409px;\" src=\"images/ALLRG/62164_Early_events_T_cell_transduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After antigen binds the TCR, Lck is activated and phosphorylates tryosine residues within the ITAMs of the CD3 and zeta chains, allowing ZAP-70 to be recruited to the TCR. Once ZAP-70 binds the phosphorylated ITAMs, it is phosphorylated by Lck, triggering all downstream signaling events required for T cell activation.</div><div class=\"graphic_footnotes\">TCR: T cell receptor; APC: antigen presenting cell; MHC: major histocompatibility complex; ITAMs: immunoreceptor tyrosine-based activation motifs; CD: cluster of differentiation; Lck: lymphocyte cell-specific protein tyrosine kinase; ZAP-70; zeta chain-associated protein kinase 70.</div><div id=\"graphicVersion\">Graphic 62164 Version 4.0</div></div></div>"},"62165":{"type":"graphic_figure","displayName":"Sphincter repair overlap","title":"Anal sphincter repair: Overlap approach","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Anal sphincter repair: Overlap approach</div><div class=\"cntnt\"><img style=\"width:495px; height:473px;\" src=\"images/OBGYN/62165_Sphincter_repair_overlap.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62165 Version 1.0</div></div></div>"},"62167":{"type":"graphic_picture","displayName":"Chronic periodontitis","title":"Localized severe chronic periodontitis","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Localized severe chronic periodontitis</div><div class=\"cntnt\"><img style=\"width:570px; height:432px;\" src=\"images/PC/62167_Chronic_periodontitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">69 year-old Caucasian female with generalized gingival recession and localized areas with deep probing depths and significant alveolar bone loss (ie, maxillary right posterior teeth).</div><div id=\"graphicVersion\">Graphic 62167 Version 1.0</div></div></div>"},"62168":{"type":"graphic_picture","displayName":"Plantar verrucae","title":"Plantar verrucae","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Plantar verrucae</div><div class=\"cntnt\"><img style=\"width:568px; height:331px;\" src=\"images/PC/62168_Plantar_verrucae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note disruption of the skin lines on the left.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 62168 Version 1.0</div></div></div>"},"62170":{"type":"graphic_table","displayName":"Immunosuppressants and skin cancer","title":"Immunosuppressive agents and nonmelanoma skin cancer risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunosuppressive agents and nonmelanoma skin cancer risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug name</td> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Risk of NMSC</td> <td class=\"subtitle1\">Dermatologic side effects</td> </tr> <tr class=\"divider_bottom\"> <td>Systemic glucocorticoids</td> <td>Inhibit antigen presentation, induce lymphocyte toxicity, alter cytokine production</td> <td>+</td> <td>Acne, striae, skin fragility, ecchymosis</td> </tr> <tr class=\"divider_bottom\"> <td>Azathioprine</td> <td>Inhibits purine synthesis</td> <td>++++</td> <td>Hypersensitivity reaction including urticaria, maculopapular and vasculitic eruptions</td> </tr> <tr class=\"divider_bottom\"> <td>Mycophenolate mofetil</td> <td>Inhibits guanine nucleotide synthesis</td> <td>+++</td> <td>Nonspecific rash</td> </tr> <tr class=\"divider_bottom\"> <td>Cyclosporine</td> <td> <p>Calcineurin inhibitor</p> Decreases T cell activation and IL-2 production</td> <td>++++</td> <td>Hirsutism, sebaceous hyperplasia, gingival hyperplasia</td> </tr> <tr class=\"divider_bottom\"> <td>Tacrolimus</td> <td>Calcineurin inhibitor</td> <td>+++</td> <td>Alopecia</td> </tr> <tr class=\"divider_bottom\"> <td>Sirolimus</td> <td> <p>Inhibits mammalian target of rapamycin</p> Abrogates IL-2 signal transduction</td> <td>+<br /> (decreased skin cancer in clinical trials)</td> <td>Impaired wound healing, acne/folliculitis, edema</td> </tr> <tr> <td>Everolimus</td> <td> <p>Inhibits mammalian target of rapamycin</p> Abrogates IL-2 signal transduction</td> <td>+<br /> (similar to sirolimus)</td> <td>Mouth ulcers, stomatitis</td> </tr> <tr> <td>Belatacept<sup>[1]</sup></td> <td>Selective T cell costimulation blockade&nbsp;</td> <td> <p>+++</p> <p>(similar to or slightly less than cyclosporine)<sup>[2]</sup></p> </td> <td> <p>Alopecia, impaired wound healing, edema</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NMSC: nonmelanoma skin cancer; IL: interleukin.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplant. N Engl J Med 2016; 374:333.</li>&#xD;&#xA;    <li>Vincenti F, Blancho G, Durrbach A, el al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21:1587.</li>&#xD;&#xA;</ol>&#xD;&#xA;Original table modified for this publication. From: Rigel DS, Robinson JK, Ross MI, et al (Eds). Cancer of the Skin, 2nd ed, Philadelphia: Elsevier, 2011. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 62170 Version 7.0</div></div></div>"},"62171":{"type":"graphic_picture","displayName":"One hand technique","title":"One-handed chest compressions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">One-handed chest compressions</div><div class=\"cntnt\"><img style=\"width:307px; height:433px;\" src=\"images/EM/62171_One_hand_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For children (from one year until the start of puberty), chest compressions may be performed with the heel of one hand placed over the lower half of the sternum.</div><div id=\"graphicVersion\">Graphic 62171 Version 2.0</div></div></div>"},"62173":{"type":"graphic_picture","displayName":"Campylobacter morphology","title":"Electron micrography of Campylobacter jejuni","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrography of Campylobacter jejuni</div><div class=\"cntnt\"><img style=\"width:368px; height:198px;\" src=\"images/ID/62173_Campylobacter_morphology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shadowed electron micrograph of Campylobacter jejuni showing spiral shape and long unsheathed polar flagella (the black sub- polar spots are artifacts).</div><div class=\"graphic_reference\">Reproduced with permission from Skirrow MB. Postgrad Doctor Middle East 1985; 8:50.</div><div id=\"graphicVersion\">Graphic 62173 Version 2.0</div></div></div>"},"62175":{"type":"graphic_figure","displayName":"Lateral medullary infarct","title":"Medulla oblongata","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Medulla oblongata</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/NEURO/62175_Lateral_medullary_infarct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The usual location of lateral medullary infarcts is hatch-marked in the upper right of the figure. The anatomical structures are labeled on the diagram.</div><div id=\"graphicVersion\">Graphic 62175 Version 1.0</div></div></div>"},"62179":{"type":"graphic_picture","displayName":"Truview detail photo","title":"Truview detail photo","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Truview detail photo</div><div class=\"cntnt\"><img style=\"width:486px; height:533px;\" src=\"images/EM/62179_Truview_detail_photo_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Truview EVO video-laryngoscope in adult, pediatric and infant sizes for indirect laryngoscopy in routine and difficult airways, manufactured by Truphatek International Ltd., Israel. www.truphatek.com.</div><div id=\"graphicVersion\">Graphic 62179 Version 4.0</div></div></div>"},"62180":{"type":"graphic_picture","displayName":"Vespula species","title":"Vespula species","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Vespula species</div><div class=\"cntnt\"><img style=\"width:526px; height:382px;\" src=\"images/ALLRG/62180_Vespula_species.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 62180 Version 1.0</div></div></div>"},"62182":{"type":"graphic_table","displayName":"Coagulant factors and DVT risk","title":"Risks for a first DVT associated with elevated procoagulant factor activity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risks for a first DVT associated with elevated procoagulant factor activity</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Factor and levels</td>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Frequency, percent</td>\n\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Adjusted odds ratio</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">Patients</td>\n\n      <td class=\"subtitle2\">Controls</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>VIII:C &#62;150 percent</td>\n\n      <td>25</td>\n\n      <td>11</td>\n\n      <td>4.8</td>\n\n    </tr>\n\n    <tr>\n\n      <td>XI:A &#62;121 percent</td>\n\n      <td>19</td>\n\n      <td>10</td>\n\n      <td>2.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>IX:A &#62;129 percent</td>\n\n      <td>20</td>\n\n      <td>10</td>\n\n      <td>2.8</td>\n\n    </tr>\n\n    <tr>\n\n      <td>TAFI &#62;122 percent</td>\n\n      <td>14</td>\n\n      <td>9</td>\n\n      <td>1.7</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Interleukin 8 &#62;8.2 pg/mL*</td>\n\n      <td>14</td>\n\n      <td>5</td>\n\n      <td>3.3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>VIII:C &#62;150 percent <strong>and</strong> IX:A &#62;129 percent</td>\n\n      <td>10</td>\n\n      <td>1.5</td>\n\n      <td>8.2</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">Adult subjects only.</div><div class=\"graphic_footnotes\">DVT: Deep vein thrombosis; C: Coagulant activity; A: Antigen concentration; TAFI: Thrombin-activatable fibrinolysis inhibitor.<br> * Inflammatory chemokine; not a coagulation factor.</div><div class=\"graphic_reference\">Data from the Leiden Thrombophilia Study.</div><div id=\"graphicVersion\">Graphic 62182 Version 1.0</div></div></div>"},"62183":{"type":"graphic_picture","displayName":"Postvenectomy cellulitis","title":"Postvenectomy cellulitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postvenectomy cellulitis</div><div class=\"cntnt\"><img style=\"width:289px; height:199px;\" src=\"images/ID/62183_Postvenectomy_cellulitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cellulitis occurring after saphenous venectomy. The inflammation begins along the medial aspect of the mid-tibial region at the saphenous venectomy site.</div><div class=\"graphic_reference\">Courtesy of Larry M Baddour, MD.</div><div id=\"graphicVersion\">Graphic 62183 Version 1.0</div></div></div>"},"62184":{"type":"graphic_table","displayName":"Major causes of sudden death","title":"Major causes of sudden death","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of sudden death</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Ischemic heart disease</td> </tr> <tr> <td>Coronary artery disease with myocardial infarction or angina</td> </tr> <tr> <td>Coronary artery embolism</td> </tr> <tr> <td>Nonatherogenic coronary artery disease (arteritis, dissection, congenital coronary artery anomalies)</td> </tr> <tr> <td>Coronary artery spasm</td> </tr> <tr> <td class=\"subtitle1_single\">Nonischemic heart disease</td> </tr> <tr> <td>Hypertrophic cardiomyopathy</td> </tr> <tr> <td>Dilated cardiomyopathy</td> </tr> <tr> <td>Valvular heart disease</td> </tr> <tr> <td>Congenital heart disease</td> </tr> <tr> <td>Arrhythmogenic right ventricular dysplasia</td> </tr> <tr> <td>Myocarditis</td> </tr> <tr> <td>Acute pericardial tamponade</td> </tr> <tr> <td>Acute myocardial rupture</td> </tr> <tr> <td>Aortic dissection</td> </tr> <tr> <td class=\"subtitle1_single\">No structural heart disease</td> </tr> <tr> <td>Primary electrical disease (idiopathic ventricular fibrillation)</td> </tr> <tr> <td>Brugada syndrome (right bundle branch block and ST segment elevation in leads V1 to V3)</td> </tr> <tr> <td>Long QT syndrome</td> </tr> <tr> <td>Preexcitation syndrome</td> </tr> <tr> <td>Complete heart block</td> </tr> <tr> <td>Familial sudden cardiac death</td> </tr> <tr> <td>Chest wall trauma (commotio cordis)</td> </tr> <tr> <td class=\"subtitle1_single\">Noncardiac disease</td> </tr> <tr> <td>Pulmonary embolism</td> </tr> <tr> <td>Intracranial hemorrhage</td> </tr> <tr> <td>Drowning</td> </tr> <tr> <td>Pickwickian syndrome</td> </tr> <tr> <td>Drug-induced</td> </tr> <tr> <td>Central airway obstruction</td> </tr> <tr> <td>Sudden infant death syndrome</td> </tr> <tr> <td>Sudden unexplained death in epilepsy (SUDEP)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62184 Version 3.0</div></div></div>"},"62188":{"type":"graphic_table","displayName":"Postsecondary transition skills","title":"Skills required for transition to postsecondary educational setting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Skills required for transition to postsecondary educational setting</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>The ability to establish social interaction with peers, neighbors, and other community members</td> </tr> <tr> <td class=\"sublist1_start\">The ability to develop skills and competencies that permit independence</td> </tr> <tr> <td class=\"sublist1\">The ability to advocate for oneself:</td> </tr> <tr> <td class=\"sublist2\">Understand personal learning weaknesses and strengths</td> </tr> <tr> <td class=\"sublist2\">Understand legal rights under Section 504 and the Americans with Disabilities Act</td> </tr> <tr> <td>The ability to participate in community, social, and recreational activities</td> </tr> <tr> <td class=\"sublist1_start\">The ability to demonstrate skills required to be productive members of society</td> </tr> <tr> <td class=\"sublist1\">Independent problem-solving skills</td> </tr> <tr> <td class=\"sublist1\">Independent organization, time-management, and study skills</td> </tr> <tr> <td class=\"sublist1\">Personal recognition of the postsecondary program accommodations and supports necessary for personal success:</td> </tr> <tr> <td class=\"sublist2\">Part-time schedule</td> </tr> <tr> <td class=\"sublist2\">Increased time to complete postsecondary program</td> </tr> <tr> <td class=\"sublist2\">Ability to repeat classes without penalty</td> </tr> <tr> <td class=\"sublist2\">Waiver of foreign language requirements</td> </tr> <tr> <td class=\"sublist2\">Late course withdrawal without penalty</td> </tr> <tr> <td class=\"sublist2\">Priority registration</td> </tr> <tr> <td class=\"sublist2\">Additional time to complete courses</td> </tr> <tr> <td class=\"sublist2\">Course substitution</td> </tr> <tr> <td class=\"sublist2\">Tutoring</td> </tr> <tr> <td class=\"sublist2\">Personal counseling</td> </tr> <tr> <td class=\"sublist1\">Effective use of assistive technology devices:</td> </tr> <tr> <td class=\"sublist2\">Electronic spell checkers</td> </tr> <tr> <td class=\"sublist2\">Word processors</td> </tr> <tr> <td class=\"sublist2\">Personal organizers</td> </tr> <tr> <td class=\"sublist2\">Time-management software</td> </tr> <tr> <td class=\"sublist2\">Calculators</td> </tr> <tr> <td class=\"sublist2\">Speech-control tape recorders</td> </tr> <tr> <td class=\"sublist2\">Listening aids</td> </tr> <tr> <td class=\"sublist2\">Speech-synthesis systems</td> </tr> <tr> <td class=\"sublist2\">Speech-recognition systems</td> </tr> <tr> <td class=\"sublist2\">Data managers</td> </tr> <tr> <td>The ability to recognize personal strengths and self-worth</td> </tr> <tr> <td class=\"sublist1_start\">The ability to evaluate the various educational, work, living, recreational, and social options to achieve personal goals</td> </tr> <tr> <td class=\"sublist1\"><span class=\"indent1\">Recognize</span> personal program support requirements and evaluate postsecondary school programs realistically (comprehensive versus minimal support services)</td> </tr> <tr> <td class=\"sublist1\">Recognize the need for a comprehensive postsecondary LD program with the following characteristics:</td> </tr> <tr> <td class=\"sublist2\">Coordination of program by a specialist in LD and individualization</td> </tr> <tr> <td class=\"sublist3\">Diagnostic testing</td> </tr> <tr> <td class=\"sublist3\">Individualized educational program</td> </tr> <tr> <td class=\"sublist3\">Academic and program advising</td> </tr> <tr> <td class=\"sublist3\">Basic-skills remediation</td> </tr> <tr> <td class=\"sublist3\">Subject-area tutoring</td> </tr> <tr> <td class=\"sublist3\">Specialized courses</td> </tr> <tr> <td class=\"sublist3\">Auxiliary aids and services</td> </tr> <tr> <td class=\"sublist3\">Counseling</td> </tr> <tr> <td class=\"sublist1\">Identify programs with minimal support services at postsecondary level</td> </tr> <tr> <td class=\"sublist2\">Minimal requirements as mandated by Section 504 for all students with disabilities</td> </tr> <tr> <td class=\"sublist3\">Access to taped textbooks, tape recorders</td> </tr> <tr> <td class=\"sublist3\">Assistance arranging testing accommodations, readers, note-takers</td> </tr> <tr> <td class=\"sublist3\">Provisions for arranging course substitutions</td> </tr> <tr> <td class=\"sublist2\">Demonstrate the ability to select activities, options, and services to meet personal needs</td> </tr> <tr> <td class=\"sublist1\">Provide assistance selecting course work at the high school level that will be required for college entrance</td> </tr> <tr> <td class=\"sublist1\">Provide learning-strategy instruction training and study-skill training</td> </tr> <tr> <td class=\"sublist1\">Provide explicit career exploration</td> </tr> <tr> <td class=\"sublist1\">Provide Scholastic Assessment Test (SAT) and ACT assessment preparation</td> </tr> <tr> <td class=\"sublist2\">Assist students to register for the Preliminary Scholastic Assessment Test (PSAT)</td> </tr> <tr> <td class=\"sublist2\">Encourage students to apply to take examinations with accommodations</td> </tr> <tr> <td class=\"sublist3\">Tape-recorded versions</td> </tr> <tr> <td class=\"sublist3\">Large block print on answer sheets</td> </tr> <tr> <td class=\"sublist3\">Extended time</td> </tr> <tr> <td class=\"sublist3\">Use of a private room</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LD: learning disability.</div><div id=\"graphicVersion\">Graphic 62188 Version 4.0</div></div></div>"},"62189":{"type":"graphic_figure","displayName":"Menstrual cycle","title":"Menstrual cycle","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Menstrual cycle</div><div class=\"cntnt\"><img style=\"width:541px; height:726px;\" src=\"images/ENDO/62189_Menstrualcycle.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62189 Version 4.0</div></div></div>"},"62190":{"type":"graphic_figure","displayName":"Sliding versus paraesophageal hiatus hernia","title":"Sliding versus paraesophageal hiatus hernia","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Sliding versus paraesophageal hiatus hernia</div><div class=\"cntnt\"><img style=\"width:523px; height:684px;\" src=\"images/GAST/62190_Hiatus_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distinction between a sliding hiatus hernia (type I) and paraesophageal hernia (type II). With type I hernia, the leading edge is the gastric cardia while with type II it is the gastric fundus. The squamocolumnar junction maintains its native position in the paraesophageal hernia while it is displaced upward with the sliding hernia.</div><div class=\"graphic_footnotes\">SC: squamocolumnar.</div><div class=\"graphic_reference\">Kahrilas PJ, Kim HC, Pandolfino JE. Approaches to the diagnosis and grading of hiatal hernia. Best Pract Res Clin Gastroenterol 2008; 22:601.</div><div id=\"graphicVersion\">Graphic 62190 Version 5.0</div></div></div>"},"62191":{"type":"graphic_table","displayName":"Causes of hemolysis that may be associated with transfusion","title":"Causes of hemolysis that may be present in a patient receiving a transfusion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hemolysis that may be present in a patient receiving a transfusion</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Immune-mediated</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Acute hemolytic transfusion reaction (AHTR) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Delayed hemolytic transfusion reaction (DHTR) </li> </ul> </td> </tr> <tr> <td>Non-immune-mediated</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Thermal injury </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Heat </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Cold </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Osmotic injury </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Mechanical injury </li> </ul> </td> </tr> <tr> <td>Infection</td> </tr> <tr> <td>Congenital hemolytic anemia</td> </tr> <tr> <td>Acquired hemolytic anemia</td> </tr> <tr> <td>Drug-induced hemolytic anemia</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for discussion of hemolytic transfusion reactions. Some of these conditions may occur in a patient receiving a transfusion but are not caused by the transfusion.</div><div id=\"graphicVersion\">Graphic 62191 Version 3.0</div></div></div>"},"62192":{"type":"graphic_picture","displayName":"Pseudomonas corneal ulcer","title":"Pseudomonas corneal ulcer in soft contact lens wearer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudomonas corneal ulcer in soft contact lens wearer</div><div class=\"cntnt\"><img style=\"width:320px; height:236px;\" src=\"images/PC/62192_Pseudomonas_corneal_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With hypopyon (layering of white cells in the anterior chamber).</div><div id=\"graphicVersion\">Graphic 62192 Version 2.0</div></div></div>"},"62194":{"type":"graphic_diagnosticimage","displayName":"Remodeling postsurgery in SSc","title":"Remodeling of metacarpal heads after resection arthroplasty in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Remodeling of metacarpal heads after resection arthroplasty in scleroderma</div><div class=\"cntnt\"><img style=\"width:411px; height:249px;\" src=\"images/RHEUM/62194_Remodeling_postsurgery_in_S.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph showing spontaneous remodeling of metacarpal heads three years after resection arthroplasty and proximal interphalangeal joint fusion. This patient with scleroderma had severe metacarpophalangeal hyperextension deformity.</div><div class=\"graphic_reference\">Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright Â© 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62194 Version 8.0</div></div></div>"},"62195":{"type":"graphic_algorithm","displayName":"Evaluation algorithm for morphea","title":"Algorithm for the evaluation of patients with morphea","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation of patients with morphea</div><div class=\"cntnt\"><img style=\"width:534px; height:524px;\" src=\"images/DERM/62195_Eval_algo_local_sclero_edt.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62195 Version 2.0</div></div></div>"},"62196":{"type":"graphic_diagnosticimage","displayName":"Ascariasis - computed tomography","title":"Ascariasis - computed tomography (CT)","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Ascariasis - computed tomography (CT)</div><div class=\"cntnt\"><img style=\"width:512px; height:392px;\" src=\"images/ID/62196_Ascariais_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnified views of orally contrasted axial CT of the abdomen.<br />(A) Longitudinal views of <EM>Ascaris lumbricoides </EM>within the jejunal lumen. Note the lack of contrast in the gut of the worm.<br />(B) Axial views of ascarids, again without contrast in worm gut.</div><div class=\"graphic_reference\">Reproduced with permission from: Pylant A, Hinshaw JW, Leonard RB, et al. Intestinal Ascariasis: CT findings and diagnosis. South Med J 2006; 99:317. Copyright Â© 2006 Lippincott Williams &amp; Williams.</div><div id=\"graphicVersion\">Graphic 62196 Version 7.0</div></div></div>"},"62199":{"type":"graphic_waveform","displayName":"Basic case 10 with answer","title":"Atrial flutter and incomplete RBBB","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial flutter and incomplete RBBB</div><div class=\"cntnt\"><img style=\"width:450px; height:99px;\" src=\"images/CARD/62199_Basic_case_10_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial flutter with a variable degree of atrioventricular block and incomplete right bundle branch block. The latter is characterized by the rSR' pattern in lead V1 without a prolonged QRS duration.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 62199 Version 2.0</div></div></div>"},"62200":{"type":"graphic_table","displayName":"Oral antimicrobials for pneumococcal pneumonia","title":"Oral antimicrobials for pneumococcal pneumonia in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral antimicrobials for pneumococcal pneumonia in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antimicrobial </td> <td class=\"subtitle1\">Dose </td> <td class=\"subtitle1\">Interval </td> </tr> <tr> <td>Penicillin V</td> <td>500 mg</td> <td>Four times daily</td> </tr> <tr> <td>Amoxicillin-clavulanate XR</td> <td>2 g (extended-release formulation)</td> <td>Twice daily</td> </tr> <tr> <td>Amoxicillin</td> <td>1 g</td> <td>Three times daily</td> </tr> <tr> <td rowspan=\"3\">Clarithromycin </td> <td>250 mg</td> <td>Twice daily</td> </tr> <tr> <td colspan=\"2\"><strong>or</strong> </td> </tr> <tr> <td>1000 mg (two 500 mg extended-release tablets)</td> <td>Once&nbsp;daily</td> </tr> <tr> <td rowspan=\"5\">Azithromycin </td> <td>500 mg on day one</td> <td>250 mg thereafter once daily for&nbsp;four days</td> </tr> <tr> <td colspan=\"2\"><strong>or</strong> </td> </tr> <tr> <td>500 mg</td> <td>Once daily for three days</td> </tr> <tr> <td colspan=\"2\"><strong>or</strong> </td> </tr> <tr> <td>2 g</td> <td>As a single dose microsphere regimen</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These doses are intended for patients with normal renal function. For some of these antibiotics, dosing must be adjusted in patients with impaired renal function.</div><div id=\"graphicVersion\">Graphic 62200 Version 4.0</div></div></div>"},"62204":{"type":"graphic_table","displayName":"Summary of tests for blunt aortic injury","title":"Summary of tests for blunt aortic injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of tests for blunt aortic injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Diagnostic tests for aortic rupture</td> </tr> <tr class=\"divider_bottom\"> <td>Plain radiograph</td> <td> <p>Upright preferable; sensitivity of supine unclear</p> <p>Normal PA radiograph has high negative predictive value; good test for patients with low to moderate suspicion</p> If high clinical suspicion, or abnormal radiograph, further testing required</td> </tr> <tr class=\"divider_bottom\"> <td>Chest CT scan</td> <td> <p><strong>Test of choice</strong></p> <p>Highly sensitive and specific</p> <p>Requires IV contrast</p> <p>Can usually proceed directly to OR with a positive CT</p> Equivocal study necessitates angiography</td> </tr> <tr class=\"divider_bottom\"> <td>Arteriography</td> <td> <p>Highly sensitive and specific</p> <p>Mainly used for equivocal CT scans</p> Rarely adds value in the setting of a diagnostic CT and delays potentially life-saving operative intervention</td> </tr> <tr> <td>Transesphosageal echocardiography</td> <td> <p>Highly accurate</p> <p>Can be performed at bedside, in OR, or in patients who cannot tolerate contrast</p> Limited in proximal ruptures, but overall an excellent test when CT is unavailable or contraindicated</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 62204 Version 4.0</div></div></div>"},"62206":{"type":"graphic_table","displayName":"Treatment of DR","title":"Management options for diabetic retinopathy*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management options for diabetic retinopathy*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Level of DR</td> <td class=\"subtitle1\" colspan=\"3\">Evaluation</td> <td class=\"subtitle1\" colspan=\"3\">Treatment</td> <td class=\"subtitle1\" rowspan=\"2\">Follow-up interval<br /> (months; approx)</td> </tr> <tr> <td class=\"subtitle2\">Fundus photo</td> <td class=\"subtitle2\">OCT exam</td> <td class=\"subtitle2\">Fluorescein angiography</td> <td class=\"subtitle2\">Intravitreal anti-VEGF</td> <td class=\"subtitle2\">Focal photocoagulation</td> <td class=\"subtitle2\">Scatter photocoagulation</td> </tr> <tr> <td>None</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>12</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Mild NPDR</td> </tr> <tr> <td class=\"indent1\">&ndash;ME</td> <td>Occasional</td> <td>Yes</td> <td>Occasional</td> <td>No</td> <td>No</td> <td>No</td> <td>12</td> </tr> <tr> <td class=\"indent1\">+ME</td> <td>Occasional</td> <td>Yes</td> <td>Occasional</td> <td>Yes</td> <td>Yes or no along with anti-VEGF</td> <td>No</td> <td>1 to 3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Moderate NPDR</td> </tr> <tr> <td class=\"indent1\">&ndash;ME</td> <td>Occasional</td> <td>Yes</td> <td>Occasional</td> <td>No</td> <td>No</td> <td>No</td> <td>6 to 12</td> </tr> <tr> <td class=\"indent1\">+ME</td> <td>Occasional</td> <td>Yes</td> <td>Occasional</td> <td>Yes</td> <td>Yes or no along with anti-VEGF</td> <td>No</td> <td>1 to 3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Severe NPDR</td> </tr> <tr> <td class=\"indent1\">&ndash;ME</td> <td>Occasional</td> <td>Yes</td> <td>Occasional</td> <td>No</td> <td>No</td> <td>Consider</td> <td>2 to 3</td> </tr> <tr> <td class=\"indent1\">+ME</td> <td>Occasional</td> <td>Yes</td> <td>Likely</td> <td>Yes</td> <td>Yes or no along with anti-VEGF</td> <td>Consider</td> <td>1 to 3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Very severe NPDR</td> </tr> <tr> <td class=\"indent1\">&ndash;ME</td> <td>Occasional</td> <td>Yes</td> <td>Likely</td> <td>No</td> <td>No</td> <td>Consider</td> <td>2 to 3</td> </tr> <tr> <td class=\"indent1\">+ME</td> <td>Occasional</td> <td>Yes</td> <td>Likely</td> <td>Yes</td> <td>Yes or no along with anti-VEGF</td> <td>Consider</td> <td>1 to 3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Early PDR</td> </tr> <tr> <td class=\"indent1\">&ndash;ME</td> <td>Occasional</td> <td>Yes</td> <td>Likely</td> <td>No</td> <td>No</td> <td>Likely</td> <td>2 to 3</td> </tr> <tr> <td class=\"indent1\">+ME</td> <td>Occasional</td> <td>Yes</td> <td>Likely</td> <td>Yes</td> <td>Yes or no along with anti-VEGF</td> <td>Likely</td> <td>1 to 3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">High risk PDR</td> </tr> <tr> <td class=\"indent1\">&ndash;ME</td> <td>Occasional</td> <td>Yes</td> <td>Likely</td> <td>No</td> <td>No</td> <td>Yes</td> <td>2 to 3</td> </tr> <tr> <td class=\"indent1\">+ME</td> <td>Occasional</td> <td>Yes</td> <td>Likely</td> <td>Yes</td> <td>Yes or no along with anti-VEGF</td> <td>Yes</td> <td>1 to 3</td> </tr> <tr> <td><strong>Severe PDR</strong></td> <td colspan=\"3\">Photos/OCT/fluorescein angiogram/ultrasound as indicated</td> <td colspan=\"3\">Panretinal photocoagulation, focal laser, vitrectomy with endolaser, and anti-VEGF as indicated</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DR: diabetic retinopathy; OCT: optical coherence tomography; VEGF: vascular endothelial growth factor; NPDR: nonproliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy; âME: macular edema absent; +ME: macular edema present.<br />* Precise management guidelines have not yet been established at the time of this writing. This table summarizes current recommendations of Donald J D'Amico, MD and Szilard Kiss, MD and includes modifications from earlier recommendations from: Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136:122.</div><div id=\"graphicVersion\">Graphic 62206 Version 5.0</div></div></div>"},"62207":{"type":"graphic_diagnosticimage","displayName":"PTC Klatskin tumor","title":"Percutaneous transhepatic cholangiography in a patient with a Klatskin tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Percutaneous transhepatic cholangiography in a patient with a Klatskin tumor</div><div class=\"cntnt\"><img style=\"width:333px; height:432px;\" src=\"images/GAST/62207_PTC_Klatskin_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following insertion of a percutaneous needle into the biliary system (black arrow), contrast has been injected and shows dilated intrahepatic bile ducts. No contrast passes into the extrahepatic bile ducts due to a Klatskin tumor at the confluence of the left and right hepatic ducts. A stent has been inserted (white arrow) in an attempt to alleviate the obstruction.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 62207 Version 3.0</div></div></div>"},"62209":{"type":"graphic_picture","displayName":"Reactive lymphocytosis","title":"Reactive lymphocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reactive lymphocytosis</div><div class=\"cntnt\"><img style=\"width:360px; height:241px;\" src=\"images/HEME/62209_Reactive_lymphocytosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood smear showing lymphocytosis of normal-appearing lymphocytes, as seen in pertussis and infectious lymphocytosis.</div><div class=\"graphic_reference\">Courtesy of Robert Baehner, MD.</div><div id=\"graphicVersion\">Graphic 62209 Version 2.0</div></div></div>"},"62211":{"type":"graphic_table","displayName":"Adjuv Rx colon CA INT0089","title":"Results from United States Intergroup Adjuvant Trial 0089","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results from United States Intergroup Adjuvant Trial 0089</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Regimen</td>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">DFS,\npercent</td>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">OS,\npercent</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">5 year</td>\n\n      <td class=\"subtitle2\">10 year</td>\n\n      <td class=\"subtitle2\">5 year</td>\n\n      <td class=\"subtitle2\">10 year</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5-FU/levamisole</td>\n\n      <td>55</td>\n\n      <td>45</td>\n\n      <td>64</td>\n\n      <td>50</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5-FU/high-dose leucovorin</td>\n\n      <td>58</td>\n\n      <td>47</td>\n\n      <td>66</td>\n\n      <td>52</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5-FU/low-dose leucovorin</td>\n\n      <td>60</td>\n\n      <td>49</td>\n\n      <td>66</td>\n\n      <td>52</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5-FU/leucovorin/levamisole</td>\n\n      <td>49</td>\n\n      <td>68</td>\n\n      <td>54</td>\n\n      <td>59</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">DFS: disease-free survival; OS: overall survival; 5-FU: 5-fluorouracil.</div><div class=\"graphic_reference\">Data from Haller D, et al. J Clin Oncol 2005; 23:8671.</div><div id=\"graphicVersion\">Graphic 62211 Version 2.0</div></div></div>"},"62212":{"type":"graphic_algorithm","displayName":"Eisenmenger high HCT management","title":"Management of erythrocytosis in Eisenmenger syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of erythrocytosis in Eisenmenger syndrome</div><div class=\"cntnt\"><img style=\"width:446px; height:354px;\" src=\"images/CARD/62212_Eisenmengerhighhctmanage.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">GI: gastrointestinal. </div><div class=\"graphic_footnotes\">* Volume depletion from pure water loss must be associated with hypernatremia.</div><div class=\"graphic_reference\">Redrawn from Vongpatanasin, W, Brickner, E, Hillis, LD, et al, Ann Intern Med 1998; 128:749.</div><div id=\"graphicVersion\">Graphic 62212 Version 3.0</div></div></div>"},"62213":{"type":"graphic_picture","displayName":"How to stop a nosebleed PI","title":"How to stop a nosebleed","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">How to stop a nosebleed</div><div class=\"cntnt\"><img style=\"width:715px; height:641px;\" src=\"images/PI/62213_Pnch_alae_stp_nsbld_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To stop a nosebleed, sit or stand while bending forward a little at the waist. Then pinch the soft area towards the bottom of your nose, below the bone. Squeeze both sides of your nose shut for at least 15 minutes. (In children, squeeze for only 5 minutes.) Do not check to see if the bleeding has stopped until your time is up.</div><div id=\"graphicVersion\">Graphic 62213 Version 5.0</div></div></div>"},"62214":{"type":"graphic_table","displayName":"Causes of hemoptysis in children","title":"Conditions associated with hemoptysis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with hemoptysis in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"sublist2_start\">Bacterial</td> </tr> <tr> <td class=\"sublist2\">Tuberculosis</td> </tr> <tr> <td class=\"sublist2\">Lung abscess</td> </tr> <tr> <td class=\"sublist2_start\">Fungal</td> </tr> <tr> <td class=\"sublist2\">Histoplasmosis</td> </tr> <tr> <td class=\"sublist2\">Coccidioidomycosis</td> </tr> <tr> <td class=\"sublist2\">Invasive pulmonary aspergillosis</td> </tr> <tr> <td class=\"sublist2\">Aspergilloma</td> </tr> <tr> <td class=\"sublist2\">Stachybotrys atra</td> </tr> <tr> <td class=\"sublist2_start\">Viral</td> </tr> <tr> <td class=\"sublist2\">Tracheobronchitis (multiple viruses)</td> </tr> <tr> <td class=\"sublist2\">HIV</td> </tr> <tr> <td class=\"sublist2\">Influenza (especially H1N1)</td> </tr> <tr> <td class=\"subtitle1_single\">Vasculitis and associated syndromes</td> </tr> <tr> <td class=\"sublist2_start\">Immune complex mediated</td> </tr> <tr> <td class=\"sublist2\">Henoch-Sch&#246;nlein purpura</td> </tr> <tr> <td class=\"sublist2_start\">Pauci-immune vasculitis</td> </tr> <tr> <td class=\"sublist2\">Granulomatosis with polyangiitis (formerly Wegener's)</td> </tr> <tr> <td class=\"sublist2\">Microscopic polyangiitis</td> </tr> <tr> <td class=\"sublist2\">Polyarteritis nodosa</td> </tr> <tr> <td class=\"sublist2_start\">Other immune mediated diseases</td> </tr> <tr> <td class=\"sublist2\">Idiopathic pulmonary hemosiderosis</td> </tr> <tr> <td class=\"sublist2\">Goodpasture's syndrome</td> </tr> <tr> <td class=\"sublist2\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"sublist2\">Beh&#231;et syndrome</td> </tr> <tr> <td class=\"sublist2\">Heiner's syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital heart disease and cardiac-related conditions</td> </tr> <tr> <td class=\"indent1\">Tetralogy of Fallot</td> </tr> <tr> <td class=\"indent1\">Absence of pulmonary artery or veins</td> </tr> <tr> <td class=\"indent1\">Pulmonary hypertension from Eisenmenger syndrome</td> </tr> <tr> <td class=\"indent1\">Heart failure with pulmonary edema</td> </tr> <tr> <td class=\"indent1\">Post Fontan procedure</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital lung malformations</td> </tr> <tr> <td class=\"indent1\">Bronchopulmonary sequestration</td> </tr> <tr> <td class=\"indent1\">Bronchogenic cyst</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary vascular disorders</td> </tr> <tr> <td class=\"indent1\">Pulmonary embolism</td> </tr> <tr> <td class=\"indent1\">Arteriovenous malformation</td> </tr> <tr> <td class=\"indent1\">Pulmonary artery aneurism</td> </tr> <tr> <td class=\"indent1\">Bronchial artery aneurism</td> </tr> <tr> <td class=\"indent1\">Portal vein obstruction</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Pulmonary masses</td> </tr> <tr> <td class=\"sublist2_start\">Tracheobronchial tumors</td> </tr> <tr> <td class=\"sublist2\">Adenoma</td> </tr> <tr> <td class=\"sublist2\">Papillomatosis</td> </tr> <tr> <td class=\"sublist2\">Carcinoid tumor</td> </tr> <tr> <td class=\"sublist2\">Mucoepidermoid carcinoma</td> </tr> <tr> <td class=\"sublist2_start\">Malignancy</td> </tr> <tr> <td class=\"sublist2\">Metastatic</td> </tr> <tr> <td class=\"sublist2\">Primary pulmonary tumor</td> </tr> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr> <td class=\"indent1\">Pulmonary contusion</td> </tr> <tr> <td class=\"indent1\">Airway laceration</td> </tr> <tr> <td class=\"indent1\">Suctioning with mucosal injury</td> </tr> <tr> <td class=\"sublist2_start\">Iatrogenic</td> </tr> <tr> <td class=\"sublist2\">Pulmonary artery catheterization</td> </tr> <tr> <td class=\"sublist2\">Transbronchial biopsy</td> </tr> <tr> <td class=\"sublist2\">Tracheostomy</td> </tr> <tr> <td class=\"subtitle1_single\">Idiopathic</td> </tr> <tr> <td class=\"indent1\">Idiopathic hemoptysis</td> </tr> <tr> <td class=\"indent1\">Idiopathic pulmonary hemorrhage of infancy</td> </tr> <tr> <td class=\"subtitle1_single\">Coagulopathy and thrombosis</td> </tr> <tr> <td class=\"indent1\">Von Willebrand disease</td> </tr> <tr> <td class=\"indent1\">Anticoagulant therapy</td> </tr> <tr> <td class=\"indent1\">Thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Thrombosis with pulmonary embolus</td> </tr> <tr> <td class=\"subtitle1_single\">Bronchiectasis</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Primary ciliary dyskinesia</td> </tr> <tr> <td class=\"indent1\">Immunodeficiency</td> </tr> <tr> <td class=\"indent1\">Idiopathic</td> </tr> <tr> <td class=\"indent1\">Retained foreign body</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic inhalation</td> </tr> <tr> <td class=\"indent1\">Nitrogen dioxide (eg, in ice arena)</td> </tr> <tr> <td class=\"indent1\">Pesticides</td> </tr> <tr> <td class=\"indent1\">Crack cocaine</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Bone marrow transplant</td> </tr> <tr> <td class=\"indent1\">Pulmonary veno-occlusive disease</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> </tr> <tr> <td class=\"indent1\">Connective tissue disorders (Ehlers Danlos syndrome and Loeys Dietz syndrome)</td> </tr> <tr> <td class=\"indent1\">Plasma cell granuloma</td> </tr> <tr> <td class=\"indent1\">Catamenial hemoptysis (females)</td> </tr> <tr> <td class=\"indent1\">Factitious (M&#252;nchausen syndrome and M&#252;nchausen syndrome by proxy)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Godfrey S. Pulmonary hemorrhage/hemoptysis in children. Pediatr Pulmonol 2004; 37:476.</li>&#xD;&#xA;    <li>Vece TJ, de Guzman MM, Langston C, Fan LL. Diffuse alveolar hemorrhage in children. In: Kendig and Chernick's disorders of the respiratory tract in children, 8th ed, Wilmott RW, Boat TF, Bush A, et al. (Eds), Elsevier, Philadelphia 2012. p.848.</li>&#xD;&#xA;    <li>Tom LW, Weisman RA, Handler SD. Hemoptysis in children. Ann Otol Rhinol Laryngol 1980; 89:419.</li>&#xD;&#xA;    <li>Coss-Bu JA, Sachdeva RC, Bricker JT, et al. Hemoptysis: a 10-year retrospective study. Pediatrics 1997; 100:E7.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 62214 Version 11.0</div></div></div>"},"62216":{"type":"graphic_diagnosticimage","displayName":"Ultrathin pancreatoscope ERCP","title":"Pancreatoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatoscopy</div><div class=\"cntnt\"><img style=\"width:360px; height:249px;\" src=\"images/GAST/62216_Ultrathin_pancreatoscope_ER.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiologic view of an ultrathin pancreatoscope in the pancreatic duct.</div><div class=\"graphic_reference\">Courtesy of Jurgen F Riemann, MD, PhD.</div><div id=\"graphicVersion\">Graphic 62216 Version 2.0</div></div></div>"},"62217":{"type":"graphic_figure","displayName":"HLAB5701 carriage frequency","title":"HLAB5701 carriage frequency","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">HLAB5701 carriage frequency</div><div class=\"cntnt\"><img style=\"width:582px; height:354px;\" src=\"images/ID/62217_HLAB5701_carriage_frequency.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.<br><strong>* Thailand B*57 carriage:</strong><br>&#160;- Urban Bangkok 3.6 percent<br>&#160;- Thai Dai Lue (N.E. Thai) &#8764;11 percent<br>&#160;- Southern Thai Muslim 3 percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther 2003; 8:36. Copyright &#169; 2003 Mediscript Limited.</div><div id=\"graphicVersion\">Graphic 62217 Version 1.0</div></div></div>"},"62218":{"type":"graphic_picture","displayName":"Tuberculoma of the eye","title":"Tuberculoma of the eye","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculoma of the eye</div><div class=\"cntnt\"><img style=\"width:271px; height:289px;\" src=\"images/ID/62218_Tuberculoma_of_the_eye.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Raised yellowish choriodal lesion with surrounding serous elevation of the neurosensory retina, intraretinal exudation, and macular star. Retinal vessels are seen over the lesion and appear normal.</div><div class=\"graphic_reference\">Reproduced with permission from: Cangemi FE, Friedman R, Josephberg R. Opthalmology 1980; 87:252.</div><div id=\"graphicVersion\">Graphic 62218 Version 2.0</div></div></div>"},"62221":{"type":"graphic_figure","displayName":"Basic effects of electrosurgery","title":"Basic effects of electrosurgery","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Basic effects of electrosurgery</div><div class=\"cntnt\"><img style=\"width:542px; height:328px;\" src=\"images/OBGYN/62221_Electrosurgical_effects.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Desiccation:</strong> Direct contact of the instrument and the tissue causes dehydration and protein denaturation. Continued application of heat with no or minimal tissue penetration results in superficial carbonization (char).<br> <strong>Vaporization:</strong> No direct contact, electrode is held at the tissue surface; the high heat generated by the current vaporizes tissue. Since the cells &quot;explode,&quot; no char is produced.<br> <strong>Fulguration:</strong> No direct contact, electrode is held a bit further away than in vaporization; electrical current (sparks) arcs between the electrode tip and the nearby tissue, which causes it to char.</div><div id=\"graphicVersion\">Graphic 62221 Version 4.0</div></div></div>"},"62223":{"type":"graphic_picture","displayName":"Alkali injury esophagus endoscopy","title":"Alkali injury to the esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alkali injury to the esophagus</div><div class=\"cntnt\"><img style=\"width:320px; height:318px;\" src=\"images/GAST/62223_Alkali_injury_esophagus_End.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of caustic esophageal injury 24 hours after intentional ingestion of battery fluid (alkali) A: Proximal esophagus with superficial ulcers, bleeding and exudates (grade 2A) B: Distal esophagus with circumeferential ulcers and exudates (grade 2B) C: Gastric antrum with extensive necrosis and ulceration (grade 3B) D: Duodenum with mucosal edema and hyperemia (grade 1).</div><div class=\"graphic_reference\">Courtesy of George Triadafilopoulos, MD.</div><div id=\"graphicVersion\">Graphic 62223 Version 2.0</div></div></div>"},"62224":{"type":"graphic_figure","displayName":"Mag colon AP image","title":"Magnetic endoscope imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic endoscope imaging</div><div class=\"cntnt\"><img style=\"width:396px; height:257px;\" src=\"images/GAST/62224_Mag_colon_AP_image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) AP image of endoscope inserted to the distal transverse colon; note the 3-D illusion created by the grey-scale shading and the (electronically placed) rib margin (light and dark blue markers) and anal site (green marker) markers. (B) Lateral view of the same image; the purple sphere is the hand marker showing the site of assistant hand-pressure on the sigmoid colon loop.</div><div class=\"graphic_reference\">Courtesy of Christopher B Williams BM, FRCP, FRCS.</div><div id=\"graphicVersion\">Graphic 62224 Version 1.0</div></div></div>"},"62226":{"type":"graphic_figure","displayName":"Form for documentation POP-Q","title":"Form for clinical documentation of pelvic organ prolapse quantitative","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Form for clinical documentation of pelvic organ prolapse quantitative</div><div class=\"cntnt\"><img style=\"width:496px; height:600px;\" src=\"images/OBGYN/62226_Form_for_documentation_POP-.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62226 Version 1.0</div></div></div>"},"62227":{"type":"graphic_figure","displayName":"The Philadelphia chromosome","title":"The Philadelphia chromosome in chronic myeloid leukemia","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">The Philadelphia chromosome in chronic myeloid leukemia</div><div class=\"cntnt\"><img style=\"width:490px; height:238px;\" src=\"images/HEME/62227_Genesis_Philadelphia_chromo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">G-band ideograms (left) and partial karyotype (right) of the CML-associated chromosome translocation t(9;22)(q34;q11.2). Breakpoints are indicated with arrows on the normal chromosome homologs. Translocated segments are framed on the der(9) and Ph ideograms. The translocation results in a slightly longer chromosome 9 [der(9)] and a shorter chromosome 22 [der(22)], which is termed the Philadelphia (Ph) chromosome.</div><div class=\"graphic_reference\">Courtesy of Athena Cherry, PhD.</div><div id=\"graphicVersion\">Graphic 62227 Version 2.0</div></div></div>"},"62229":{"type":"graphic_figure","displayName":"CRP, cholesterol, and future CV event risk in women","title":"C-reactive protein predicts cardiovascular events in healthy postmenopausal women","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">C-reactive protein predicts cardiovascular events in healthy postmenopausal women</div><div class=\"cntnt\"><img style=\"width:385px; height:341px;\" src=\"images/CARD/62229_Role_CRP_cholesterol_women.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 28,263 postmenopausal women enrolled in the Women's Health study, C-reactive protein (CRP) was a significant predictor of cardiovascular events; the relative risk of events for women in the highest as compared with the lowest quartile for this marker was 4.4. Prediction models that incorporated CRP in addition to lipids were significantly better at predicting risk than models based on lipid levels alone (p&lt;0.001).</div><div class=\"graphic_reference\">Data from: Ridker PM, Hennekens CH, Buring JE, Rifai N. N Engl J Med 2000; 342:836.</div><div id=\"graphicVersion\">Graphic 62229 Version 4.0</div></div></div>"},"62230":{"type":"graphic_figure","displayName":"Female pelvic muscles","title":"Female pelvic muscles at the level of the pelvic floor","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Female pelvic muscles at the level of the pelvic floor</div><div class=\"cntnt\"><img style=\"width:515px; height:385px;\" src=\"images/SURG/62230_Female-pelvic-muscles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the muscles of the floor of the female pelvis. Note the close proximity of the rectum to the vagina, the anococcygeal ligament that holds the rectum to the sacrum, and the pubococcygeus muscles.</div><div id=\"graphicVersion\">Graphic 62230 Version 2.0</div></div></div>"},"62231":{"type":"graphic_picture","displayName":"Necrotizing fasciitis","title":"Necrotizing fasciitis","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Necrotizing fasciitis</div><div class=\"cntnt\"><img style=\"width:505px; height:655px;\" src=\"images/SURG/62231_Necrotizing_fasciitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotizing fasciitis is a rapidly progressing, life-threatening soft tissue infection. Surgical treatment consists of wide debridement of skin, subcutaneous tissue, fascia, and any necrotic muscle.<br />(A) Necrotizing fasciitis in an immune-compromised elderly patient. Note that the proximal extent of the erythema has been marked with an indelible marker.<br />(B) Necrotizing fasciitis of the upper extremity. Left: Preoperative appearance. Center: Intraoperative appearance. Arrow shows the bubbly purulent material. Right: Result after multiple debridements. </div><div id=\"graphicVersion\">Graphic 62231 Version 3.0</div></div></div>"},"62232":{"type":"graphic_table","displayName":"Antigenic alterations in epidermolysis bullosa skin","title":"Antigenic alterations in epidermolysis bullosa skin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antigenic alterations in epidermolysis bullosa skin</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antigen</td> <td class=\"subtitle1\">Abnormal staining</td> <td class=\"subtitle1\">Usual pattern of staining</td> </tr> <tr class=\"divider_bottom\"> <td>Keratin 14</td> <td>EBS-AR</td> <td>Absent or markedly reduced</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Laminin-332 (laminin-5)</td> <td>JEB-generalized severe</td> <td>Absent or markedly reduced</td> </tr> <tr class=\"divider_bottom\"> <td>JEB-generalized intermediate*</td> <td>Reduced</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Type XVII collagen</td> <td>JEB-generalized intermediate<sup>&#182;</sup></td> <td>Absent</td> </tr> <tr class=\"divider_bottom\"> <td>JEB-localized</td> <td>Reduced</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Type VII collagen</td> <td>RDEB, severe generalized</td> <td>Absent or markedly reduced</td> </tr> <tr> <td>RDEB, generalized intermediate</td> <td>Reduced</td> </tr> <tr> <td>RDEB, inversa</td> <td>Variable</td> </tr> <tr class=\"divider_bottom\"> <td>DEB-BDN (only during period of active blistering)</td> <td>Granular staining within basal and suprabasal keratinocytes; absent or markedly reduced staining along DEJ</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Plectin</td> <td>EBS-MD</td> <td>Absent or reduced</td> </tr> <tr> <td>EBS-PA</td> <td>Absent or reduced</td> </tr> <tr class=\"divider_bottom\"> <td>EBS-Ogna</td> <td>Reduced</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Alpha-6 beta-4 integrin</td> <td>JEB-PA</td> <td>Absent or reduced</td> </tr> <tr> <td>EBS-PA</td> <td>Absent or reduced</td> </tr> <tr class=\"divider_bottom\"> <td>JEB-localized<sup>&#916;</sup></td> <td>Reduced</td> </tr> <tr> <td>Kindlin-1</td> <td>Kindler syndrome</td> <td>Absent, reduced, or normal<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EBS: epidermolysis bullosa simplex; AR: autosomal recessive;&nbsp;JEB: junctional epidermolysis bullosa; RDEB: recessive dystrophic epidermolysis bullosa; DEB: dystrophic epidermolysis bullosa; BDN: bullous dermolysis of the newborn; DEJ: dermoepidermal junction; MD: muscular dystrophy; PA: pyloric atresia.<br />* In the majority of JEB-generalized intermediate patients.<br />Â¶ In a minority of patients with generalized JEB-generalized intermediate (previously referred to as generalized atrophic benign epidermolysis bullosa); these patients lack concurrent abnormal staining by antibodies to laminin-332.<br />Î Reported in one patient.<br /><FONT class=lozenge>â</FONT> Loss-of-function mutations in both KIND1 alleles may be associated with normal immunostaining.</div><div class=\"graphic_reference\">Terminology has been updated to reflect current classification of EB. Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol 2014; 70:1103. <br />Original figure modified for this publication. Fine JD, Eady RAJ, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 62232 Version 3.0</div></div></div>"},"62233":{"type":"graphic_picture","displayName":"Cricothyrotomy equipment","title":"Cricothyrotomy equipment","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Cricothyrotomy equipment</div><div class=\"cntnt\"><img style=\"width:565px; height:516px;\" src=\"images/EM/62233_Cricequipment.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Custalow, CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright Â©2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 62233 Version 4.0</div></div></div>"},"62234":{"type":"graphic_picture","displayName":"Infected eczema ear","title":"Staphylococcus aureus infection in atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Staphylococcus aureus infection in atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/PC/62234_Infected_eczema_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Honey-colored crusts are seen on the postauricular skin of this patient with infected atopic dermatitis.</div><div class=\"graphic_reference\">Courtesy of Joseph Morelli, MD.</div><div id=\"graphicVersion\">Graphic 62234 Version 2.0</div></div></div>"},"62236":{"type":"graphic_table","displayName":"Exposures associated with ILD I","title":"Occupational and environmental exposures associated with interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Occupational and environmental exposures associated with interstitial lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Inhaled\norganic dusts</td>\n\n    </tr>\n\n    <tr>\n\n      <td>(hypersensitivity pneumonitis)\n(Partial list)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"1\">Thermophilic fungi (ie,\nMacropolyspora faeni, Thermactinomyces vulgaris, T. sacchari)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Farmer's lung&nbsp;&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Grain handler's lung</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Humidifier or air conditioner\nlung</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Bacteria (ie, Bacillus subtilis, B. cereus)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Humidifier lung</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">True fungi (ie, Aspergillus,\nCryptostroma corticale, Aureobasidium pullulans, Penicillium species)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Animal proteins (eg, bird fancier's disease)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Inhaled agents other\nthan inorganic or organic dusts</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Chemical sources</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Synthetic - fiber lung (Orlon,\npolyesters, nylon, acrylic)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Bakelite worker's lung</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Vinyl chloride, polyvinyl\nchloride powder</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Gases</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Oxygen</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Oxides of nitrogen </td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Sulfur dioxide</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Chlorine gas</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Methyl isocyanate</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Fumes</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\" colspan=\"1\">Oxides of\nzinc, copper, manganese, cadmium, iron, magnesium, nickel, brass,\nselenium, tin, and antimony</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Diphenylmethane diisocyanate</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Trimellitic anhydride toxicity</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Vapors</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hydrocarbons</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Thermosetting resins (rubber\ntire workers)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Toluene diisocyanate (TDI -\nasthmatic reactions prominent)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Mercury</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Aerosols</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Oils</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Fats</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Pyrethrum (a natural insecticide)</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Crystal, RG. Interstitial lung disease. In: Wyngaarden, JB, Smith, LH, Jr, Bennett, JC, (Eds), Cecil Textbook of Medicine, 19th ed, WB Saunders Co, Philadelphia, 1992.</div><div id=\"graphicVersion\">Graphic 62236 Version 1.0</div></div></div>"},"62237":{"type":"graphic_table","displayName":"Polysomnographic values","title":"Polysomnographic values in healthy children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Polysomnographic values in healthy children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"17%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mean &#177; SD</td> <td class=\"subtitle1\">Range</td> <td class=\"subtitle1\">Recommended normal values</td> <td class=\"subtitle1\">Children classified as abnormal <br /> n (percent)</td> </tr> <tr> <td><strong>Apnea index (n/h)</strong></td> <td class=\"centered\">0.1 &#177; 0.5</td> <td class=\"centered\">0 to 3.1</td> <td class=\"centered\">&#8804; 1<sup>&#182;</sup></td> <td class=\"centered\">1 (2)</td> </tr> <tr> <td><strong>Maximum PETCO2 (mmHg)</strong></td> <td class=\"centered\">46 &#177; 4</td> <td class=\"centered\">38 to 53</td> <td class=\"centered\">&#8804; 53<sup>&#182;</sup></td> <td class=\"centered\">0 (0)</td> </tr> <tr> <td><strong>Minimum PETCO2 (mmHg)</strong></td> <td class=\"centered\">38 &#177; 3</td> <td class=\"centered\">28 to 44</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> </tr> <tr> <td><strong>Change in PETCO2 (mmHg)</strong></td> <td class=\"centered\">7 &#177; 3</td> <td class=\"centered\">2 to 11</td> <td class=\"centered\">&#8804; 13</td> <td class=\"centered\">0</td> </tr> <tr> <td><strong>Duration of hypoventilation (percent TST)</strong></td> <td class=\"centered\">6.9 &#177; 19.1</td> <td class=\"centered\">0 to 90.5</td> <td class=\"centered\">&#8804; 60<sup>&#916;</sup></td> <td class=\"centered\">3 (6)</td> </tr> <tr> <td><strong>Maximum SaO2 (percent)</strong></td> <td class=\"centered\">100 &#177; 1</td> <td class=\"centered\">98 to 100</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> </tr> <tr> <td><strong>Minimum SaO2 (percent)</strong></td> <td class=\"centered\">96 &#177; 2</td> <td class=\"centered\">89 to 98</td> <td class=\"centered\">&#8805; 92<sup>&#916;</sup></td> <td class=\"centered\">2 (4) </td> </tr> <tr> <td><strong>Desaturation &#62;4 percent/h TST (n)</strong></td> <td class=\"centered\">0.3 &#177; 0.7</td> <td class=\"centered\">0 to 4.4</td> <td class=\"centered\">&#8804; 1.4<sup>&#916;</sup></td> <td class=\"centered\">1 (2)</td> </tr> <tr> <td><strong>Change in SaO2 (percent)</strong></td> <td class=\"centered\">4 &#177; 2</td> <td class=\"centered\">0 to 11</td> <td class=\"centered\">&#8804; 8<sup>&#182;</sup></td> <td class=\"centered\">2 (4)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Apnea index: number of obstructive apneas of any length per hour of sleep; TST: total sleeping time.<br />* The number of children classified as abnormal represents the number of children who would be judged to have an abnormality based on the recommended values. Apnea index is defined as the number N of obstructive apneas of any length per hour of sleep. <br />Â¶ Recommended normal values based on mean Â± 2 SD when parameters follow a normal distribution.<br />Î For data that are not normally distributed, the recommended normal values are based on inclusion of 97 percent of subjects tested for one-tailed distribution.</div><div class=\"graphic_reference\">Reproduced with permission from: Marcus EL, Omlin K, Basinski D, et al. Normal polysomnographic values for children and adolescents. Am Rev Respir Dis 1992; 146:1236.</div><div id=\"graphicVersion\">Graphic 62237 Version 3.0</div></div></div>"},"62238":{"type":"graphic_table","displayName":"Cytokine sources in scleroderma","title":"Potential sources for cytokines implicated in scleroderma pathogenesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential sources for cytokines implicated in scleroderma pathogenesis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Cell type</td>\n<td class=\"subtitle1\">Major cytokine products</td>\n</tr>\n<tr>\n<td class=\"subtitle2_left\" colspan=\"2\">Endothelial cells</td>\n\n</tr>\n<tr>\n<td class=\"indent1\">Activated or damaged</td>\n<td>IL-1, IL-6, IL-8, IGF-1, PDGF, TGF-beta, ET-1</td>\n</tr>\n<tr>\n<td class=\"subtitle2_left\" colspan=\"2\">Immune or inflammatory cells</td>\n\n</tr>\n<tr>\n<td class=\"indent1\">Monocyte/macrophage</td>\n<td>IL-1, TNF</td>\n</tr>\n<tr>\n<td class=\"indent1\">Lymphocytes</td>\n<td>IL-2, -4, -6, -8</td>\n</tr>\n<tr>\n<td class=\"indent1\">Mast cells, neutrophils, eosinophils</td>\n<td>bFGF, proteases</td>\n</tr>\n<tr>\n<td class=\"subtitle2_left\" colspan=\"2\">Fibroblasts</td>\n\n</tr>\n<tr>\n<td class=\"indent1\">Scleroderma fibroblasts</td>\n<td>TNF, IL-1, IL-6, TGF-beta, IGF-1, DGF</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62238 Version 1.0</div></div></div>"},"62239":{"type":"graphic_figure","displayName":"Genetic pleiotropy","title":"Genetic pleiotropy","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Genetic pleiotropy</div><div class=\"cntnt\"><img style=\"width:537px; height:346px;\" src=\"images/PC/62239_Genetic-pleiotropy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In Mendelian randomization, the effect of the genetic variant on the outcome (association 3) is assumed to act solely via the &quot;intermediate factor&quot; (association 1). Any alternate pathway due to pleiotropy (denoted here by the dotted line) threatens this core assumption of the Mendelian randomization design.</div><div id=\"graphicVersion\">Graphic 62239 Version 2.0</div></div></div>"},"62240":{"type":"graphic_table","displayName":"Changes in last hours of life","title":"Checklist for discussions with family about the last hours of life","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Checklist for discussions with family about the last hours of life</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Progressive unresponsiveness</td>\n</tr>\n<tr>\n<td>Purposeless movements, facial expressions</td>\n</tr>\n<tr>\n<td>Noisy breathing</td>\n</tr>\n<tr>\n<td>Unlikely periods of awareness just before death</td>\n</tr>\n<tr>\n<td>Possible acute events and action plan</td>\n</tr>\n<tr>\n<td>Any other questions the family may have</td>\n</tr>\n<tr>\n<td>Ask about previous deaths in the family (where, when, how)</td>\n</tr>\n<tr>\n<td>Phone number (24 hours) for help</td>\n</tr>\n<tr>\n<td>What to do after death</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62240 Version 1.0</div></div></div>"},"62244":{"type":"graphic_table","displayName":"Low-fat low-sugar menus","title":"Low-fat, low-sugar eating guidelines sample menus*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Low-fat, low-sugar eating guidelines sample menus*</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Breakfast</td></tr>\n\t\t\t\t\t\t<tr><td>2 slices whole-grain bread or frozen waffles</td></tr>\n\t\t\t\t\t\t<tr><td>2 teaspoons almond butter</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup skim milk or yogurt</td></tr>\n\t\t\t\t\t\t<tr><td>1 small banana</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Lunch</td></tr>\n\t\t\t\t\t\t<tr><td>Turkey sandwich (2 ounces turkey breast on a whole- grain bread or roll)</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup green grapes</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup baby carrots, jicama and bell pepper strips</td></tr>\n\t\t\t\t\t\t<tr><td>2 tablespoons fat-free ranch dressing</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup skim milk or fat-free, reduced-calorie yogurt</td></tr>\n\t\t\t\t\t\t<tr><td>Bottled water or diet soda</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Dinner</td></tr>\n\t\t\t\t\t\t<tr><td>3-4 ounces grilled salmon</td></tr>\n\t\t\t\t\t\t<tr><td>2/3 cup steamed/boiled brown rice</td></tr>\n\t\t\t\t\t\t<tr><td>2 cups mixed salad greens</td></tr>\n\t\t\t\t\t\t<tr><td>1 tablespoon balsamic vinegar with 2 teaspoons olive oil</td></tr>\n\t\t\t\t\t\t<tr><td>1/2 cup steamed green beans</td></tr>\n\t\t\t\t\t\t<tr><td>Water with lemon</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Snack</td></tr>\n\t\t\t\t\t\t<tr><td>Fruit smoothie</td></tr>\n\t\t\t\t\t\t<tr><td> (1 cup skim milk, 1 cup frozen fruit such as peaches or mixed berries)</td></tr>\n\t\t\t\t\t\t<tr><td>3 cups low-fat popcorn</td></tr>\n\t\t\t\t\t\t<tr><td>1 ounce peanuts</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Breakfast</td></tr>\n\t\t\t\t\t\t<tr><td>Breakfast taco (small whole-wheat flour tortilla, 1/2 cup egg substitute, 1 ounce reduced-fat cheese, 2 tablespoons salsa)</td></tr>\n\t\t\t\t\t\t<tr><td>1 small orange</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Lunch</td></tr>\n\t\t\t\t\t\t<tr><td>2 ounces water-packed tuna mixed with 1 tablespoon light mayonnaise, chopped celery</td></tr>\n\t\t\t\t\t\t<tr><td>10 whole grain crackers</td></tr>\n\t\t\t\t\t\t<tr><td>1 small apple</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup skim milk or fat-free,</td></tr>\n\t\t\t\t\t\t<tr><td>reduced-calorie yogurt</td></tr>\n\t\t\t\t\t\t<tr><td>Water or diet soda</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Dinner</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup vegetable soup (carrots, celery, onions, tomato)</td></tr>\n\t\t\t\t\t\t<tr><td>2-3 ounces grilled chicken breast (skinless)</td></tr>\n\t\t\t\t\t\t<tr><td>1/2 cup black beans</td></tr>\n\t\t\t\t\t\t<tr><td>1/2 cup steamed/boiled brown rice</td></tr>\n\t\t\t\t\t\t<tr><td>2 corn tortillas</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup lettuce and tomato salad with 1/8 avocado slice</td></tr>\n\t\t\t\t\t\t<tr><td>Water or unsweetened iced tea</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Snack</td></tr>\n\t\t\t\t\t\t<tr><td>1/2 mango</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup fat-free, reduced-calorie yogurt with 1 ounce almond slivers</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Breakfast</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup old-fashioned oatmeal</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup skim milk</td></tr>\n\t\t\t\t\t\t<tr><td>1 small pear</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Lunch</td></tr>\n\t\t\t\t\t\t<tr><td>Peanut butter sandwich on whole wheat bread</td></tr>\n\t\t\t\t\t\t<tr><td>Apple</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup carrot and celery sticks</td></tr>\n\t\t\t\t\t\t<tr><td>2 tablespoons light ranch dressing</td></tr>\n\t\t\t\t\t\t<tr><td>1 cup skim milk or fat-free, reduced-calorie yogurt</td></tr>\n\t\t\t\t\t\t<tr><td>Water or diet soda</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Dinner</td></tr>\n\t\t\t\t\t\t<tr><td>3-4 ounces baked barbeque chicken breast (skinless)</td></tr>\n\t\t\t\t\t\t<tr><td>1/2 cup mashed sweet potato</td></tr>\n\t\t\t\t\t\t<tr><td>1/2 cup steamed cabbage</td></tr>\n\t\t\t\t\t\t<tr><td>1/2 cup steamed turnip greens</td></tr>\n\t\t\t\t\t\t<tr><td>1 small whole grain roll with 1 tablespoon light margarine</td></tr>\n\t\t\t\t\t\t<tr><td>Water or unsweetened iced tea</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Snack</td></tr>\n\t\t\t\t\t\t<tr><td>6 cups low-fat popcorn</td></tr>\n\t\t\t\t\t\t<tr><td>Diet soda or sugar-free Kool-Aid</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* All meals are prepared without added fat.</div><div class=\"graphic_reference\">Courtesy of Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 62244 Version 1.0</div></div></div>"},"62245":{"type":"graphic_picture","displayName":"TM change not cholesteatoma","title":"Abnormalities of the tympanic membrane that are not cholesteatoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abnormalities of the tympanic membrane that are not cholesteatoma</div><div class=\"cntnt\"><img style=\"width:360px; height:363px;\" src=\"images/ALLRG/62245_TMchangenotcholesteatoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White abnormalities of the tympanic membrane that are not cholesteatoma. There is a shallow retraction of the pars flaccida (asterisk).</div><div class=\"graphic_footnotes\">T: tympanosclerosis; B: bone (promontory below, stapes head above); F: foreign body (a white tympanostomy tube).</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 120, Pages 603-8, Copyright Â© 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 62245 Version 13.0</div></div></div>"},"62246":{"type":"graphic_table","displayName":"Risk factors for SSI","title":"Patient and operation characteristics that may influence the risk of surgical site infection development","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient and operation characteristics that may influence the risk of surgical site infection development</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patient</td> </tr> <tr> <td>Age</td> </tr> <tr> <td>Nutritional status</td> </tr> <tr> <td>Diabetes</td> </tr> <tr> <td>Smoking</td> </tr> <tr> <td>Obesity</td> </tr> <tr> <td>Coexistent infections at a remote body site</td> </tr> <tr> <td>Colonization with microorganisms</td> </tr> <tr> <td>Altered immune response</td> </tr> <tr> <td>Length of preoperative stay</td> </tr> <tr> <td class=\"subtitle1_single\">Operation</td> </tr> <tr> <td>Duration of surgical scrub</td> </tr> <tr> <td>Skin antisepsis</td> </tr> <tr> <td>Preoperative shaving</td> </tr> <tr> <td>Preoperative skin prep</td> </tr> <tr> <td>Duration of operation</td> </tr> <tr> <td>Antimicrobial prophylaxis</td> </tr> <tr> <td>Operating room ventilation</td> </tr> <tr> <td>Inadequate sterilization of instruments</td> </tr> <tr> <td>Foreign material in the surgical site</td> </tr> <tr> <td>Surgical drains</td> </tr> <tr> <td class=\"sublist1_start\">Surgical technique</td> </tr> <tr> <td class=\"sublist1\">- Poor hemostasis</td> </tr> <tr> <td class=\"sublist1\">- Failure to obliterate dead space</td> </tr> <tr> <td class=\"sublist1\">- Tissue trauma</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br> <ol> <li>SHEA, APIC, CDC, SIS. Consensus paper on the surveillance of surgical wound infections. Infect Control Hosp Epidemiol 1992; 13:599. </li> <li>Cruse PJ. Surgical wound infection. In: Infectious Diseases, Wonsiewicz MJ (Ed), WB Saunders Co, Philadelphia 1992. p.758. </li> </ol></div><div id=\"graphicVersion\">Graphic 62246 Version 3.0</div></div></div>"},"62247":{"type":"graphic_movie","displayName":"Left ventricular aneurysm four chamber echocardiogram 1","title":"Left ventricular aneurysm","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular aneurysm</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/62247_4chlvaneconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:274px; height:446px;\" src=\"images/CARD/62247_4chlvane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram shows a large left ventricular apical aneurysm resulting from an anterior wall myocardial infarction. Also noted is a thinned interventricular septum and anterior left ventricular wall.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 62247 Version 2.0</div></div></div>"},"62252":{"type":"graphic_picture","displayName":"Taenia proglottids","title":"<em>Taenia</em> proglottids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Taenia</em> proglottids</div><div class=\"cntnt\"><img style=\"width:438px; height:585px;\" src=\"images/ID/62252_Taenia_proglottids.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Mature proglottids of <EM>T. saginata</EM>. Injection of India ink into the genital pore in figure B helps with the visualization of the primary lateral uterine branches. Note the number of branches (&gt;12).<br />(C) Cross-section of a proglottid of <EM>Taenia</EM> spp, stained with hematoxylin and eosin (H&amp;E). Note the thick outer tegument and the loose parenchyma filling the body. Calcareous corpuscles (red arrows), characteristic of the cestodes, can be seen in the parenchyma. Eggs (blue arrows) can also be seen.<br />(D) Higher magnification of figure C showing a close-up of the eggs. Note the characteristic striations, typical for the taeniids. Not visible in these images are the hooks commonly seen in cestode eggs. Hooks do not stain with H&amp;E but are refractile and visible with fine focusing of the microscope.<br />(E) Close-up of a cross-section of a <EM>Taenia</EM> spp proglottid stained with H&amp;E, showing numerous calcareous corpuscles (yellow arrows).<br />(F) Close-up of a cross-section of a <EM>Taenia</EM> spp proglottid stained with H&amp;E, showing numerous calcareous corpuscles.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention.&nbsp;DPDx: Taeniasis. Available at: <A href=\"http://www.cdc.gov/dpdx/taeniasis/index.html\">http://www.cdc.gov/dpdx/taeniasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 62252 Version 7.0</div></div></div>"},"62253":{"type":"graphic_picture","displayName":"Penile lentigines pigmented macules of the penis","title":"Penile lentigines (pigmented macules) of the penis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penile lentigines (pigmented macules) of the penis</div><div class=\"cntnt\"><img style=\"width:336px; height:492px;\" src=\"images/ONC/62253_Pigmented_macules_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Hendriks YM, Verhallen JT, van der Smagt JJ, et al. BannayanâRileyâRuvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation-positive cases. Familial Cancer 2003; 2:79, with kind permission from Springer Science + Business Media B.V. Copyright Â© 2003.</div><div id=\"graphicVersion\">Graphic 62253 Version 4.0</div></div></div>"},"62254":{"type":"graphic_picture","displayName":"Leiomyosarcoma gross appearance","title":"Leiomyosarcoma: Gross appearance compared with leiomyoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leiomyosarcoma: Gross appearance compared with leiomyoma</div><div class=\"cntnt\"><img style=\"width:450px; height:337px;\" src=\"images/OBGYN/62254_Leiomyosarcoma_gross_appear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leiomyoma and leiomyosarcoma. The small nodule on the left is well circumscribed, with the bulging, white, firm, and whorled cut surface, typical of leiomyoma. The large, soft, hemorrhagic, and fleshy mass represents a leiomyosarcoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Berek JS, Hacker NF. Practical Gynecologic Oncology, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright Â© 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62254 Version 2.0</div></div></div>"},"62255":{"type":"graphic_figure","displayName":"Anatomic boundaries of axillary lymph node dissection","title":"Anatomic boundaries of axillary lymph node dissection","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Anatomic boundaries of axillary lymph node dissection</div><div class=\"cntnt\"><img style=\"width:507px; height:468px;\" src=\"images/SURG/62255_Anatboundaxillymphnode.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anatomic boundaries of axillary lymph node dissection, as seen in a transverse section through the midportion of the axilla, showing the pectoralis major and minor anteriorly, the serratus medially, and the latissimus and subscapularis posteriorly.</div><div class=\"graphic_reference\">Reproduced with permission from: Cody H. Axillary dissection. In: Diseases of the breast, Harris, Lippman, Morrow, Osborne (Eds.), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62255 Version 10.0</div></div></div>"},"62256":{"type":"graphic_diagnosticimage","displayName":"MRI of Thornwaldt cyst","title":"Magnetic resonance imaging of Thornwaldt cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of Thornwaldt cyst</div><div class=\"cntnt\"><img style=\"width:396px; height:313px;\" src=\"images/ALLRG/62256_MRI_Thornwaldt_cyst.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62256 Version 3.0</div></div></div>"},"62258":{"type":"graphic_picture","displayName":"Disseminated superficial actinic porokeratosis close view","title":"Disseminated superficial actinic porokeratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Disseminated superficial actinic porokeratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62258_Dis_actin_porokeratosis_cv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, well-defined macules with a peripheral rim of scale are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62258 Version 3.0</div></div></div>"},"62259":{"type":"graphic_diagnosticimage","displayName":"Idiopathic chondrolysis of the hip","title":"Plain radiographs: Idiopathic chondrolysis of the hip","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Plain radiographs: Idiopathic chondrolysis of the hip</div><div class=\"cntnt\"><img style=\"width:583px; height:241px;\" src=\"images/PEDS/62259_Idiopathic_chondrolysis_hip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hallmark of idiopathic chondrolysis of the hip is narrowing of the hip joint space without frank osteophyte formation in conjunction with periarticular osteopenia in a young female. The plain radiographs A and B above depict bilateral idiopathic chondrolysis of the hip. Note the concentric and uniform narrowing of the joint space bilaterally. Also observe the bilateral protrusio acetabuli (arrows) and periarticular osteopenia. Both of these hips were active on nuclear bone scan.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62259 Version 2.0</div></div></div>"},"62260":{"type":"graphic_table","displayName":"Muscle fiber characteristics","title":"Muscle fiber characteristics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscle fiber characteristics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type&nbsp;</td> <td class=\"subtitle1\">Color</td> <td class=\"subtitle1\">Contraction</td> <td class=\"subtitle1\">Metabolism</td> <td class=\"subtitle1\">Myoglobin content</td> </tr> <tr> <td>I</td> <td>Red</td> <td>Slow twitch</td> <td>Oxidative</td> <td>High</td> </tr> <tr> <td>IIA</td> <td>Red</td> <td>Fast twitch</td> <td>Fast oxidative</td> <td>High</td> </tr> <tr> <td>IIX</td> <td>White</td> <td>Fast twitch</td> <td>Anaerobic glycolysis</td> <td>Low</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Wasserman K, Hansen JE, Sue DY, et al. Physiology of exercise. In: Principles of exercise testing and interpretation: Including pathophysiology and clinical applications, 5th ed, Lippincott Williams &amp; Wilkins, 2011. Copyright Â© 2011 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62260 Version 4.0</div></div></div>"},"62261":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM CT I","title":"Arteriovenous malformation in right lower lobe in patient who developed a stroke","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation in right lower lobe in patient who developed a stroke</div><div class=\"cntnt\"><img style=\"width:360px; height:295px;\" src=\"images/PULM/62261_Pulm_AVM_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan confirms a tangle of vessels in right lower lobe and draining vein coursing towards left atrium.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 62261 Version 3.0</div></div></div>"},"62262":{"type":"graphic_figure","displayName":"Transverse relaxation in MRI","title":"Transverse relaxation in MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse relaxation in MRI</div><div class=\"cntnt\"><img style=\"width:338px; height:204px;\" src=\"images/PULM/62262_Transverse_relaxation_in_MR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Evolution of transverse magnetization following a 90&#176; radiofrequency excitation. There is maximal alignment of magnetization vectors at time t=0 immediately after excitation. Vectors have lost phase coherence at time t=T<sub>2</sub>. At time t&gt;&gt;T<sub>2</sub>, the magnetization vectors are randomly distributed and no macroscopic signal can be measured.</div><div id=\"graphicVersion\">Graphic 62262 Version 1.0</div></div></div>"},"62263":{"type":"graphic_figure","displayName":"Finger arthrocentesis","title":"Metacarpophalangeal and finger interphalangeal arthrocenteses","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Metacarpophalangeal and finger interphalangeal arthrocenteses</div><div class=\"cntnt\"><img style=\"width:483px; height:280px;\" src=\"images/RHEUM/62263_Finger_arthrocentesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the digit straight or slightly flexed, a small and short needle is inserted on either side just under the extensor tendon mechanism. It is not necessary for the needle to be interposed between the articular surfaces.</div><div class=\"graphic_reference\">Reproduced from Owen, DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley, WN, Harris, ED Jr, Ruddy, S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.</div><div id=\"graphicVersion\">Graphic 62263 Version 1.0</div></div></div>"},"62264":{"type":"graphic_diagnosticimage","displayName":"Takayasu arteritis aneurysm 1","title":"Fusiform aneurysm and wall thickening in a patient with Takayasu arteritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fusiform aneurysm and wall thickening in a patient with Takayasu arteritis</div><div class=\"cntnt\"><img style=\"width:367px; height:277px;\" src=\"images/RHEUM/62264_Takayasu_arteritis_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enlargement of the descending thoracic aorta and thickening of the vessel wall (arrows) is apparent in this contrast-enhanced CT scan. These findings suggest an active inflammatory process.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Sueyoshi E, Sakamoto I, Hayashi K. Aortic aneurysms in patients with Takayasu's arteritis: CT evaluation. Am J Roentgenology 2000; 175:1727. Copyright Â© 2000 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 62264 Version 6.0</div></div></div>"},"62265":{"type":"graphic_table","displayName":"Drugs causing SCLE","title":"Drugs implicated in the development of subacute cutaneous lupus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs implicated in the development of subacute cutaneous lupus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>ACE inhibitors (captopril, cilazapril)</td> </tr> <tr> <td>Antiarrhythmics (procainamide)</td> </tr> <tr> <td>Anticonvulsants (phenytoin, lamotrigine)</td> </tr> <tr> <td>Antifungals (griseofulvin, terbinafine)</td> </tr> <tr> <td>Antihistamines (cinnarizine/thiethylperazine)</td> </tr> <tr> <td>Antineoplastics (docetaxel, paclitaxel, anastrozole, gemcitabine, doxorubicin, tamoxifen, leuprorelin)</td> </tr> <tr> <td>Beta blockers (acebutolol, oxprenolol)</td> </tr> <tr> <td>Calcium channel blockers (diltiazem, nifedipine, nitrendipine, verapamil)</td> </tr> <tr> <td>Diuretics (hydrochlorothiazide, spironolactone)</td> </tr> <tr> <td>Immune modulators (leflunomide, interferon-alpha, interferon-beta)</td> </tr> <tr> <td>Lipid-lowering agents (pravastatin, simvastatin)</td> </tr> <tr> <td>NSAIDs (naproxen, piroxicam)</td> </tr> <tr> <td>Proton pump inhibitors&nbsp;(omeprazole, lansoprazole, pantoprazole)</td> </tr> <tr> <td>Sulfonylureas (glyburide)</td> </tr> <tr> <td>TNF-alpha inhibitors (etanercept, infliximab, adalimumab, golimumab)</td> </tr> <tr> <td>Others (D-penicillamine, bupropion, ticlopidine, ranitidine)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; NSAIDs: nonsteroidal anti-inflammatory drugs; TNF: tumor necrosis factor.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009; 301:65. </LI>&#xD;&#xA;<LI>Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res 2009; 301:99. </LI>&#xD;&#xA;<LI>Sheth N, Greenblatt D, Patel S, Acland K. Adalimumab-induced cutaneous lupus. Clin Exp Dermatol 2007; 32:593. </LI>&#xD;&#xA;<LI>Adachi A, Horikawa T. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol 2007; 34:473. </LI>&#xD;&#xA;<LI>Trancart M, Cavailhes A, Balme B, Skowron F. Anastrozole-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2008; 158:628. </LI>&#xD;&#xA;<LI>Wiechert A, Tuting T, Bieber T, et al. Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma. Br J Dermatol 2008; 159:231.</LI>&#xD;&#xA;<LI>Funke AA, Kulp-Shorten CL, Callen JP. Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Arch Dermatol 2010; 146:1113.</LI>&#xD;&#xA;<LI>Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol 2013; 149:1071.</LI>&#xD;&#xA;<LI>GrÃ¶nhagen CM, Fored CM, Linder M, et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol 2012; 167:296.</LI></OL></div><div id=\"graphicVersion\">Graphic 62265 Version 7.0</div></div></div>"},"62266":{"type":"graphic_table","displayName":"Diet stages RYGBP","title":"Sample diet recommendations after Roux-en-Y gastric bypass and gastric sleeve procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample diet recommendations after Roux-en-Y gastric bypass and gastric sleeve procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"32.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diet stage*</td> <td class=\"subtitle1\">Begin</td> <td class=\"subtitle1\">Fluids/food</td> <td class=\"subtitle1\">Guidelines</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stage 1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td>Postoperative days 1 and 2</td> <td> <p><strong>Clear liquids:</strong></p> <p>Non-carbonated; no calories</p> No sugar; no caffeine</td> <td>Patients undergo a Gastrografin swallow test to rule out a leak on postoperative day 1 after Roux-en-Y gastric bypass. Sips of clear liquids may be started after the test.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stage 2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td>Postoperative day 3 (discharge diet)</td> <td> <p><strong>Clear liquids:</strong></p> <p>Variety of no-sugar liquids or artificially sweetened liquids.</p> <p>Encourage patients to have salty fluids at home.</p> <p>Solid liquids: Sugar-free ice pops.</p> <p><strong>Plus full liquids:</strong></p> Less than 25 grams sugar per serving; protein-rich liquids (limit 25 to 30 grams protein per serving of added powders).</td> <td>Patients should consume a minimum of 48 to 64 ounces of total fluids per day, 24 to 32 ounces or more ounces of clear liquids, plus 24 to 32 ounces of any combination of full liquids (meal replacement liquids): <ul class=\"decimal_heading\"> <li>1% or skim milk, plain or mixed with: <ul> <li>Whey or soy protein powder (limit 30 g protein per serving). </li> <li>Whey isolates if lactose intolerant. </li> <li>Lactaid milk or soy milk mix with soy protein powder. </li> <li>Light yogurt, no fruit chunks; less than 20 grams of sugar per 8 ounces. </li> <li>Plain yogurt; Greek yogurt. </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stage 3</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Postoperative days 10 to 14*</td> <td> <p>Increase clear liquids (total liquids 60 plus ounces per day) and replace full liquids with soft, moist, diced, ground, or pureed protein sources as tolerated.</p> <strong>Soft solid foods</strong> including eggs; ground meats; poultry; soft, moist fish; added gravy; bouillon; light mayonnaise to moisten; cooked beans; hearty bean soups; cottage cheese; low-fat cheese; yogurt. </td> <td> <p>Protein food choices are encouraged for 3 to 6 small meals per day; patients may only be able to tolerate a couple of tablespoons of food at each meal/snack. Protein should be moist and ground, pureed, or diced.</p> <p>Encourage patients not to drink with meals and to wait &sim;30 minutes <strong>after</strong> each meal before resuming fluids.</p> May continue to replace one meal or snack with a nutritional shake. </td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Patients continue to advance diet as tolerated; emphasis on slow, mindful eating; planning 5 to 6 small meals/snacks and adequate hydration</td> <td>Advance diet (amount and texture) as tolerated; patients should be incorporating well-cooked, soft vegetables and soft and/or peeled fruit. Include salads as tolerated.</td> <td>Adequate hydration is essential and a priority for all patients during the rapid weight loss phase.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>&nbsp;</p> </td> <td> <p>Stage 3 lasts for months; every patient is different, and all patients should be encouraged to advance diet (texture and portions) at their own pace</p> Frequent nutrition follow-up during this phase is imperative </td> <td>Continue to consume protein with some fruit or vegetable at each meal; some people tolerate salads one month postoperatively.</td> <td><strong>AVOID</strong> rice, bread, and pasta until patient is comfortably consuming 60 grams protein per day and 3 to 5 servings of fruits/vegetables per day. Since grains are a rapid source of energy, they are not \"essential\" during the rapid weight loss phase, as caloric needs are met through utilizing body fat stores. The diet should provide all \"essential\" nutrients through food choices and supplementation. May switch to pill form of supplement.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stage 4</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Stage 4 is a \"maintenance\" diet, reached when patients' weights are stable</td> <td> <p>Healthy solid food diet, as hunger increases and more food is tolerated.</p> Vitamin and mineral supplement daily.<sup>&#182;</sup> </td> <td>Healthy, balanced diet consisting of adequate protein, fruits, vegetables, and whole grains. Calorie needs are determined based on height, weight, and age of the patient.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* There is no standardization of diet stages; there is a wide variety of diet protocols varying from how long patients stay on each stage to what types of fluids/foods are recommended. Dietary advancement is based on nutritional needs and increasing tolerance for dietary texture, meaning that soft foods should be introduced successfully before any hard solids are allowed.<br />Â¶ Nutritional labs should be drawn at 2, 6, and 12 months and yearly indefinitely; bone density test at baseline and every 2 years.</div><div class=\"graphic_reference\">Table provided with permission: Sue Cummings, MS, RD, LDN; MGH Weight Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 62266 Version 4.0</div></div></div>"},"62268":{"type":"graphic_picture","displayName":"Sensation anterolateral thigh","title":"Sensation over the anterolateral thigh","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sensation over the anterolateral thigh</div><div class=\"cntnt\"><img style=\"width:346px; height:284px;\" src=\"images/EM/62268_Sensation_anterolateral_thi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sensory testing is performed in patients with suspected lateral femoral cutaneous nerve entrapment (meralgia paresthetica) to assess the anterolateral thigh. The skin is tested for light touch, pinprick, and deep pain sensation. Loss of sensation (hypesthesia) or a feeling of heightened sensation (dysesthesia) is characteristic of meralgia paresthetica.</div><div class=\"graphic_reference\">Courtesy of Bruce C Andrson, MD.</div><div id=\"graphicVersion\">Graphic 62268 Version 4.0</div></div></div>"},"62269":{"type":"graphic_diagnosticimage","displayName":"Alveolar proteinosis chest xray","title":"Pulmonary alveolar proteinosis chest radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary alveolar proteinosis chest radiograph</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/PULM/62269_Alveolar_proteinosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows large perihilar and lower lobe opacities with normal cardiac silhouette.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 62269 Version 4.0</div></div></div>"},"62270":{"type":"graphic_diagnosticimage","displayName":"Congenital emphysema left","title":"Newborn with congenital lobar emphysema, left upper lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Newborn with congenital lobar emphysema, left upper lobe</div><div class=\"cntnt\"><img style=\"width:360px; height:297px;\" src=\"images/PULM/62270_Congenital_emphysema_left.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph reveals marked hyperexpansion of left upper lobe with cardiomediastinal shift to the right.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 62270 Version 2.0</div></div></div>"},"62271":{"type":"graphic_picture","displayName":"Hamartoma with cartilage","title":"Pulmonary hamartoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary hamartoma</div><div class=\"cntnt\"><img style=\"width:404px; height:263px;\" src=\"images/PULM/62271_Hamartoma_with_cartilage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows a predominance of cartilagenous tissue. The cleft-like space on the left of the image is lined with cuboidal respiratory epithelium.</div><div class=\"graphic_reference\">From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 62271 Version 1.0</div></div></div>"},"62273":{"type":"graphic_picture","displayName":"Dacryocystocele","title":"Dacryocystocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dacryocystocele</div><div class=\"cntnt\"><img style=\"width:360px; height:193px;\" src=\"images/PEDS/62273_Dacryocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the bluish swelling of the skin overlying the lacrimal sac and the upward displacement of the medial canthal tendon.</div><div class=\"graphic_reference\">Adapted with permission from: Paysse EA, Coats DK, and Cassidy M. Refinements Volume III/Number 2. San Francisco: American Academy of Opthalmology, 1999.</div><div id=\"graphicVersion\">Graphic 62273 Version 4.0</div></div></div>"},"62274":{"type":"graphic_picture","displayName":"Glaucoma Haab striae","title":"Break in the basement (Descemet) membrane (Haab striae) secondary to corneal enlargement in congenital glaucoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Break in the basement (Descemet) membrane (Haab striae) secondary to corneal enlargement in congenital glaucoma</div><div class=\"cntnt\"><img style=\"width:396px; height:272px;\" src=\"images/PEDS/62274_Glaucoma_Haabs_striae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a transverse break in Descemet membrane crossing the pupil. Note both edges of the break forming the appearance of railroad tracks.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright Â© 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62274 Version 2.0</div></div></div>"},"62275":{"type":"graphic_diagnosticimage","displayName":"Multiple NB metastases","title":"Multiple neuroblastoma metastases","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Multiple neuroblastoma metastases</div><div class=\"cntnt\"><img style=\"width:504px; height:515px;\" src=\"images/PEDS/62275_Multiple_NB_metastases.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MIBG scan of a newly diagnosed patient with multiple metastases. Arrows specifically demonstrate cranial and leg bone metastases as well as the primary adrenal tumor.</div><div class=\"graphic_footnotes\">MIBG: Metaiodobenzylguanidine.</div><div class=\"graphic_reference\">Courtesy of Heidi V Russell, MD, Jason M Shohet, MD, and Jed G Nuchtern, MD.</div><div id=\"graphicVersion\">Graphic 62275 Version 3.0</div></div></div>"},"62277":{"type":"graphic_table","displayName":"Vision screen infants children","title":"Assessment of the visual system in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of the visual system in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Important aspects of history</td> <td class=\"subtitle1\">Examination</td> <td class=\"subtitle1\">Ophthalmology referral indications</td> </tr> <tr class=\"divider_bottom\"> <td>Newborn to 6 months</td> <td> <p>Birth weight &#60;1500 grams or gestational age &#60;30 weeks</p> Family history of: <ul> <li>Congenital cataracts </li> <li>Retinoblastoma </li> <li>Metabolic or genetic disease </li> </ul> </td> <td>Vision assessment (fixate and follow response) <p>External eye examination (lids, orbit, conjunctiva, cornea, iris)</p> <p>Pupillary response</p> Simultaneous red reflex</td> <td> <ul> <li>Positive history </li> <li>Abnormal examination (eg, abnormal red reflex, pupillary asymmetry of &#8805;1 mm, unilateral ptosis, unable to fix and follow by age 3 months) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>6 to 12 months</td> <td> <p>Neurologic abnormality</p> <p>Systemic disease associated with eye abnormalities</p> <p>Does the infant recognize faces and objects?</p> <p>Does the infant fix and follow?</p> Do the parents notice: <ul> <li>Eye deviation? </li> <li>Tearing? </li> </ul> </td> <td> <p>Vision assessment (fixate and follow response)</p> <p>External eye examination (lids, orbit, conjunctiva, cornea, iris)</p> <p>Ocular motility</p> <p>Pupillary response</p> Simultaneous red reflex</td> <td> <ul> <li>Positive history </li> <li>Abnormal examination (eg, abnormal red reflex, pupillary asymmetry of &#8805;1 mm, unilateral ptosis, unable to fix and follow) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>1&nbsp;to 3 years</td> <td> <p>Neurologic abnormality</p> <p>Systemic disease associated with eye abnormalities</p> <p>Does the&nbsp;child recognize faces and objects?</p> <p>Does the&nbsp;child fix and follow?</p> Do the parents notice: <ul> <li>Eye deviation? </li> <li>Tearing? </li> </ul> </td> <td> <p>Age-appropriate visual assessment:</p> <ul> <li>Infants and young toddlers: Fixate and follow response </li> <li>Cooperative older toddlers: Monocular visual acuity with HOTV* or LEA<sup>&#182;</sup> optotypes </li> </ul> <p>Instrument-based vision screening (eg, photoscreening, autorefraction) if available</p> <p>External eye examination (lids, orbit, conjunctiva, cornea, iris)</p> <p>Ocular motility</p> <p>Pupillary response</p> <p>Simultaneous red reflex</p> <p>Ophthalmoscopy if possible</p> </td> <td> <ul> <li>Positive history&nbsp; </li> <li>Abnormal examination (eg, abnormal red reflex, pupillary asymmetry of &#8805;1 mm, unilateral ptosis) </li> <li>Eye preference or unable to fix and follow </li> <li>Ocular alignment abnormalities </li> <li>Visual acuity worse than 20/50 in one or both eyes </li> <li>Visual acuity difference of two or more lines between eyes </li> <li>Failed instrument-based screening as indicated by the device </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>4&nbsp;to 5 years</td> <td> <p>Neurologic abnormality</p> <p>Systematic disease associated with eye abnormalities</p> <p>Does the child recognize faces and objects?</p> Do the parents notice: <ul> <li>Abnormal head posturing? </li> <li>Squinting or blepharospasm? </li> <li>Eye deviation? </li> <li>Tearing? </li> </ul> </td> <td> <p>External eye examination (lids, orbit, conjunctiva, cornea, iris)</p> <p>Ocular motility</p> <p>Pupillary response</p> <p>Simultaneous red reflex</p> <p>Corneal light reflex</p> <p>Ocular alignment (cover-uncover test)</p> Monocular visual acuity<sup>&#916;&#9674;</sup>: <ul> <li>Snellen letters or numbers </li> <li>Surrounded HOTV* or LEA<sup>&#182;</sup><span style=\"font-size: 13px;\"> optotypes</span>&nbsp; </li> </ul> <p>Instrument-based vision screening (eg, photoscreening, autorefraction) if available</p> Ophthalmoscopy if possible</td> <td> <ul> <li>Positive history&nbsp; </li> <li>Abnormal examination (eg, abnormal red reflex, pupillary asymmetry of &#8805;1 mm, unilateral ptosis) </li> <li>Eye preference </li> <li>Ocular alignment abnormalities </li> <li>Visual acuity worse than 20/40 for children 48 through 59 months or worse than 20/30 for children &#8805;60 months in one or both eyes </li> <li>Visual acuity difference&nbsp;of two or more&nbsp;lines between eyes </li> <li>Failed instrument-based screening as indicated by the device </li> </ul> </td> </tr> <tr> <td>&#62;6 years</td> <td> <p>Neurologic abnormality</p> <p>Systematic disease associated with eye abnormalities</p> <p>Does the child recognize faces and objects?</p> Do the parents notice: <ul> <li>Abnormal head posturing? </li> <li>Squinting or blepharospasm? </li> <li>Eye deviation? </li> <li>Tearing? </li> </ul> </td> <td> <p>External eye examination (lids, orbit, conjunctiva, cornea, iris)</p> <p>Ocular motility</p> <p>Pupillary response</p> <p>Simultaneous red reflex</p> <p>Monocular visual acuity<sup>&#9674;</sup>: </p> <ul> <li>Sloan or Snellen letters or numbers </li> <li>Surrounded HOTV* </li> <li>LEA symbols<sup><span style=\"font-size: 13px;\">&#182;</span></sup> </li> </ul> <p>Ophthalmoscopy if possible</p> </td> <td> <ul> <li>Positive history&nbsp; </li> <li>Abnormal examination (eg, abnormal red reflex, pupillary asymmetry of &#8805;1 mm, unilateral ptosis) </li> <li>Eye preference </li> <li>Ocular alignment abnormalities </li> <li>Visual acuity worse than 20/30 in one or both eyes </li> <li>Visual acuity difference of two or more&nbsp;lines between eyes </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*&nbsp;HOTV is an optotype vision chart using only the letters H, O, T, and V. \"Surrounded\" HOTV refers to the use of crowding bars around the letters.&nbsp;Crowding bars&nbsp;improve detection of amblyopia and should be used when single optotypes rather than a row of figures are presented.<br />Â¶&nbsp;LEA is an optotype vision chart using four simple shapes (an apple, a pentagon, a square, and a circle).<br />Î&nbsp;Testing distance of 10 feet is recommended; testing with line of figures rather than single figures is preferred.<br />â&nbsp;Instrument-based vision screening (eg, photoscreening, autorefraction) is suggested if visual acuity testing cannot be performed with age-appropriate optotypes.</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>COMMITTEE ON PRACTICE AND AMBULATORY MEDICINE, SECTION ON OPHTHALMOLOGY, AMERICAN ASSOCIATION OF CERTIFIED ORTHOPTISTS, et al. Visual System Assessment in Infants, Children, and Young Adults by Pediatricians. Pediatrics 2015.</LI>&#xD;&#xA;<LI>Donahue SP, Baker CN, Committee on Practice and Ambulatory Medicine, et al. Procedures for the Evaluation of the Visual System by Pediatricians. Pediatrics 2015.</LI>&#xD;&#xA;<LI>Essman SW, Essman TF. Screening for pediatric eye disease. Am Fam Phys 1992; 46:1243.</LI></OL></div><div id=\"graphicVersion\">Graphic 62277 Version 11.0</div></div></div>"},"62279":{"type":"graphic_table","displayName":"Hematologic causes of fetal hydrops","title":"Causes of severe fetal anemia potentially leading to hydrops fetalis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of severe fetal anemia potentially leading to hydrops fetalis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Alpha-thalassemia</td> </tr> <tr> <td>Fetomaternal hemorrhage</td> </tr> <tr> <td>In utero fetal hemorrhage</td> </tr> <tr> <td>Pure red cell aplasia</td> </tr> <tr> <td>Pyruvate kinase deficiency</td> </tr> <tr> <td>Glucose phosphate isomerase deficiency</td> </tr> <tr> <td>Glucose-6-phosphate dehydrogenase deficiency</td> </tr> <tr> <td>Spectrin protein abnormality or deficiency</td> </tr> <tr> <td>Transient myeloproliferative disorder</td> </tr> <tr> <td>Leukemoid reaction in response to congenital infection</td> </tr> <tr> <td>Congenital leukemia</td> </tr> <tr> <td>Kasabach-Merritt syndrome (microangiopathic hemolytic anemia, DIC)</td> </tr> <tr> <td>Blackfan Diamond anemia</td> </tr> <tr> <td>Infections, such as cytomegalovirus, toxoplasmosis, syphilis, parvovirus</td> </tr> <tr> <td>Lysosomal storage diseases</td> </tr> <tr> <td>Fanconi anemia</td> </tr> <tr> <td>Aneuploidy</td> </tr> <tr> <td>Twin-twin transfusion syndrome, twin anemia-polycythemia sequence</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Immune mediated fetal anemia is related to alloimmunization to red blood cell antigens, Rhesus or non-Rhesus.</div><div class=\"graphic_footnotes\">DIC: disseminated intravascular coagulation.</div><div class=\"graphic_reference\">Modified from: Arcasoy M, Gallagher P. Hematologic Disorders and Nonimmune Hydrops Fetalis. Semin Perinatol 1995; 19:502.</div><div id=\"graphicVersion\">Graphic 62279 Version 5.0</div></div></div>"},"62281":{"type":"graphic_diagnosticimage","displayName":"CT panc adenocarcinoma","title":"Typical appearance of pancreatic adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical appearance of pancreatic adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:332px; height:563px;\" src=\"images/ONC/62281_CT_panc_adenocarcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multidetector enhanced CT of two different patients, in which ill-defined hypodense, solid tumors are present in the head and uncinate process of the pancreas (arrows). Typically, normal pancreatic tissue enhances to a greater extent than do pancreatic adenocarcinomas.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Rocio Perez-Johnston.</div><div id=\"graphicVersion\">Graphic 62281 Version 3.0</div></div></div>"},"62285":{"type":"graphic_picture","displayName":"Electron micro kid LPG","title":"Electron microscopic findings in lipoprotein glomerulopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron microscopic findings in lipoprotein glomerulopathy</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/NEPH/62285_Electron_micro_kid_LPG.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">A fingerprint-like substance with fine granules is occupied in the lumen of glomerular capillary.</div><div class=\"graphic_reference\">Courtesy of Shizue Mochizuki.</div><div id=\"graphicVersion\">Graphic 62285 Version 2.0</div></div></div>"},"62286":{"type":"graphic_figure","displayName":"Pregnancy rates with ART at maternal age 40 and older","title":"Percentages of ART cycles using fresh nondonor eggs or embryos that resulted in pregnancies, live births, and singleton live births among women aged 40 or older,* 2006","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Percentages of ART cycles using fresh nondonor eggs or embryos that resulted in pregnancies, live births, and singleton live births among women aged 40 or older,* 2006</div><div class=\"cntnt\"><img style=\"width:541px; height:441px;\" src=\"images/OBGYN/62286_PregratesARTage40ando.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Success rates decline with each year of age and are particularly low for women 40 or older. The above figure shows the percentages of pregnancies, live births, and singleton live births in 2006 for women 40 or older who used fresh nondonor eggs or embryos. The average chance for pregnancy was 23 percent for women age 40; the percentage of ART cycles resulting in live births for this age was about 15 percent, and the percentage of ART cycles resulting in singleton live births was about 12 percent. All percentages dropped steadily with each 1-year increase in age. For women older than 44, the percentages of live births and singleton live births were both a little more than 1 percent. Women 40 or older generally have much higher success rates using donor eggs.</div><div class=\"graphic_footnotes\">* For consistency, all percentages are based on cycles started.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2006 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2008.</div><div id=\"graphicVersion\">Graphic 62286 Version 2.0</div></div></div>"},"62287":{"type":"graphic_table","displayName":"Plat combinations NSCLC","title":"Platinum-based combination regimens for advanced NSCLC","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Platinum-based combination regimens for advanced NSCLC</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Dose and schedule</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td rowspan=\"2\">Carboplatin/Paclitaxel</td> <td> <p>Paclitaxel 225 mg/m<sup>2</sup> over 3 hours</p> Carboplatin AUC 6 mg/mL/min</td> <td>Every 3 weeks</td> <td>J Clin Oncol 2005; 23:190.</td> </tr> <tr> <td> <p>Paclitaxel 100 mg/m<sup>2</sup></p> Carboplatin AUC 2 mg/mL/min</td> <td>Weekly</td> <td>Clin Lung Cancer 2006; 7:338.</td> </tr> <tr> <td>Carboplatin/Docetaxel</td> <td> <p>Carboplatin AUC 6 mg/mL/min</p> Docetaxel 75 mg/m<sup>2</sup></td> <td>Every 3 weeks</td> <td>J Clin Oncol 2003; 21:3016.</td> </tr> <tr> <td>Carboplatin/Gemcitabine</td> <td> <p>Carboplatin AUC 5 mg/mL/min</p> Gemcitabine 1200 mg/m<sup>2</sup> days 1, 8</td> <td>Every 3 weeks</td> <td>Lung Cancer 2003; 41:321.</td> </tr> <tr> <td>Carboplatin/Paclitaxel/Bevacizumab</td> <td> <p>Carboplatin AUC 6 mg/mL/min day 1</p> <p>Paclitaxel 200 mg/m<sup>2</sup> day 1</p> Bevacizumab 15 mg/kg day 1</td> <td>Every 3 weeks*</td> <td>N Engl J Med 2006; 355:2542.</td> </tr> <tr> <td>Carboplatin/Pemetrexed</td> <td> <p>Carboplatin AUC 5 mg/mL/min day 1</p> Pemetrexed 500 mg/m<sup>2</sup> day 1</td> <td>Every 3 weeks</td> <td>J Clin Oncol 2007; 25:388s.</td> </tr> <tr class=\"divider_bottom\"> <td>Carboplatin/Vinorelbine</td> <td> <p>Carboplatin AUC 4 day 1</p> Vinorelbine 25 mg/m<sup>2</sup> day 1, 8</td> <td>Every 3 weeks</td> <td>Br J Cancer 2007; 97:283.</td> </tr> <tr> <td>Cisplatin/Etoposide</td> <td> <p>Cisplatin 100 mg/m<sup>2</sup></p> Etoposide 100 mg/m<sup>2</sup> days 1, 2, 3</td> <td>Every 3 weeks</td> <td>Ann Oncol 1997; 8:525.</td> </tr> <tr> <td>Cisplatin/Vinorelbine</td> <td> <p>Cisplatin 100 mg/m<sup>2</sup> day 1</p> Vinorelbine 25 mg/m<sup>2</sup> days 1, 8, 15, 22</td> <td>Every 4 weeks</td> <td>J Clin Oncol 1998; 16:2459.</td> </tr> <tr> <td>Cisplatin/Paclitaxel</td> <td> <p>Cisplatin 75 mg/m<sup>2</sup></p> Paclitaxel 135 mg/m<sup>2</sup></td> <td>Every 3 weeks</td> <td>J Clin Oncol 2000; 18:623.</td> </tr> <tr> <td>Cisplatin/Docetaxel</td> <td> <p>Cisplatin 75 mg/m<sup>2</sup></p> Docetaxel 75 mg/m<sup>2</sup></td> <td>Every 3 weeks</td> <td>J Clin Oncol 2003; 21:3016.</td> </tr> <tr> <td>Cisplatin/Gemcitabine</td> <td> <p>Cisplatin 100 mg/m<sup>2</sup> day 1</p> Gemcitabine 1000 mg/m<sup>2</sup> days 1, 8, 15</td> <td>Every 4 weeks</td> <td>J Clin Oncol 2000; 18:122.</td> </tr> <tr> <td>Cisplatin/Pemetrexed</td> <td> <p>Cisplatin 75 mg/m<sup>2</sup> day 1</p> Pemetrexed 500 mg/m<sup>2</sup> day 1</td> <td>Every 3 weeks</td> <td>Scagliotti G. J Clin Oncol 2008.</td> </tr> <tr> <td>Cisplatin/Irinotecan</td> <td> <p>Cisplatin 80 mg/m<sup>2</sup> day 1</p> Irinotecan 60 mg/m<sup>2</sup> days 1, 8, 15</td> <td>Every 4 weeks</td> <td>Proc Am Soc Clin Oncol 2004; 22:618s.</td> </tr> <tr> <td>Cisplatin/Gemcitabine/Necitumumab</td> <td> <p>Necitumumab 800 mg days 1 and 8</p> <p>Gemcitabine 1250 mg/m<sup>2</sup> days 1 and 8</p> Cisplatin 75 mg/m<sup>2</sup> day 1</td> <td>Every 3 weeks</td> <td>Lancet Oncol 2015; 16:763.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These are representative doses and schedules, which have varied in different trials.</div><div class=\"graphic_footnotes\">AUC: area under the concentration x time curve; NSCLC: non-small cell lung cancer.<br />* Bevacizumab continued every 3 weeks after completion of six cycles.</div><div id=\"graphicVersion\">Graphic 62287 Version 3.0</div></div></div>"},"62288":{"type":"graphic_figure","displayName":"Pertussis epidemiology US","title":"Pertussis cases in the United States","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pertussis cases in the United States</div><div class=\"cntnt\"><img style=\"width:403px; height:709px;\" src=\"images/PEDS/62288_PertussisepidemiologyUS.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. Pertussis. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book, 12<SUP>th</SUP> ed, Atkinson W, Wolfe S, Hamborsky J (Eds), Public Health Foundation, Washington DC 2011. Available at: <A href=\"http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf\" target=_blank>www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf</A> (Accessed on September 12, 2012).</div><div id=\"graphicVersion\">Graphic 62288 Version 5.0</div></div></div>"},"62289":{"type":"graphic_picture","displayName":"Great toe digital block I","title":"Great toe digital block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Great toe digital block</div><div class=\"cntnt\"><img style=\"width:369px; height:277px;\" src=\"images/EM/62289_Digital_block_great_toe_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform a three-sided toe block or four-sided ring block, insert the needle just distal to the MTP (metatarsal/phalangeal) joint at the lateral edge of the toe. Slowly advance the needle straight from the dorsal to the plantar surface, injecting as the needle is advanced. This picture shows the position of the needle just after it has been inserted.</div><div class=\"graphic_reference\">Courtesy of Robert Baldor, MD.</div><div id=\"graphicVersion\">Graphic 62289 Version 3.0</div></div></div>"},"62296":{"type":"graphic_diagnosticimage","displayName":"Grade V traumatic laceration of the spleen","title":"Grade V traumatic laceration of the spleen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grade V traumatic laceration of the spleen</div><div class=\"cntnt\"><img style=\"width:388px; height:339px;\" src=\"images/EM/62296_Grade_V_trauma_laceration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The spleen is fragmented into five discreet pieces on this image.</div><div class=\"graphic_reference\">Courtesy of David Wesson, MD.</div><div id=\"graphicVersion\">Graphic 62296 Version 3.0</div></div></div>"},"62298":{"type":"graphic_picture","displayName":"Chronic bullous disease of childhood","title":"Linear IgA bullous dermatosis of childhood","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear IgA bullous dermatosis of childhood</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62298_Chronic_bull_disease_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tense bullae, crusts, and healing erosions are present. Note the annular configuration of several lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62298 Version 3.0</div></div></div>"},"62299":{"type":"graphic_diagnosticimage","displayName":"Anterior column and hemitransverse acetabular fracture","title":"Anterior column and hemitransverse acetabular fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior column and hemitransverse acetabular fracture</div><div class=\"cntnt\"><img style=\"width:444px; height:516px;\" src=\"images/EM/62299_Acetabularfxantcolhemi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The anteroposterior pelvis radiograph demonstrates medial subluxation of the femoral head with segmental displacement of the iliopectineal line. Ilioischial line displacement is present and, unlike the anterior wall fracture, the relationship of the ischium to the ilioischial line is preserved.<br> (B) The obturator oblique radiograph appears similar to that seen in the isolated anterior wall fracture but the fracture is seen to be multifragmentary with impaction.<br> (C) The iliac oblique view shows disruption of the posterior border of the innominate and displacement through the greater sciatic notch.</div><div class=\"graphic_reference\">Reproduced with permission from: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62299 Version 15.0</div></div></div>"},"62300":{"type":"graphic_picture","displayName":"Refractile cell wall in yeast","title":"<EM>Blastomyces dermatitidis</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Blastomyces dermatitidis</EM></div><div class=\"cntnt\"><img style=\"width:373px; height:252px;\" src=\"images/ID/62300_Refractile_cell_wall_in_yea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The yeast phase of <EM>Blastomyces dermatitidis</EM> has a thick refractile cell wall (arrows).</div><div class=\"graphic_reference\">Courtesy of Stanley W Chapman, MD.</div><div id=\"graphicVersion\">Graphic 62300 Version 3.0</div></div></div>"},"62301":{"type":"graphic_table","displayName":"Extraction ratios HP and HD","title":"Extraction ratios for some drugs and chemicals with hemodialysis, charcoal hemoperfusion and resin hemoperfusion*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Extraction ratios for some drugs and chemicals with hemodialysis, charcoal hemoperfusion and resin hemoperfusion*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Cuprophane hemodialysis</td> <td class=\"subtitle1\">Coated OR uncoated charcoal hemoperfusion</td> <td class=\"subtitle1\">XAD-2 or XAD-4 resin hemoperfusion</td> </tr> <tr> <td><strong>Acetylsalicyclic acid</strong></td> <td>0.5</td> <td>0.5</td> <td>-</td> </tr> <tr> <td><strong>Digoxin</strong></td> <td>0.2</td> <td>0.3 to 0.6</td> <td>0.4</td> </tr> <tr> <td><strong>Glutethimide</strong></td> <td>0.16</td> <td>0.65</td> <td>0.8</td> </tr> <tr> <td><strong>Paraquat</strong></td> <td>0.5</td> <td>0.6</td> <td>0.9<sup>&#182;</sup></td> </tr> <tr> <td><strong>Phenobarbital<sup>&#916;</sup></strong></td> <td>0.27</td> <td>0.5</td> <td>0.85</td> </tr> <tr> <td><strong>Theophylline</strong></td> <td>0.5</td> <td>0.7</td> <td>0.75</td> </tr> <tr> <td><strong>Tricyclic antidepressants<sup>&#9674;</sup></strong></td> <td>0.35</td> <td>0.35</td> <td>0.8</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Calculated for blood flow rate of 200 mL/min.<br />Â¶ Specially prepared ion-exchange resin.<br />Î 0.36 to 0.47 with high-flux membranes.<br /><FONT class=lozenge>â</FONT> Large volume of distribution mitigates against removal of appreciable quantities of drug.</div><div id=\"graphicVersion\">Graphic 62301 Version 4.0</div></div></div>"},"62303":{"type":"graphic_diagnosticimage","displayName":"Placentomegaly and ascites","title":"Longitudinal view of fetus with ascites and enlarged placenta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal view of fetus with ascites and enlarged placenta</div><div class=\"cntnt\"><img style=\"width:396px; height:278px;\" src=\"images/OBGYN/62303_Placentomegaly_and_ascites.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Svena Julien, MD and Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 62303 Version 3.0</div></div></div>"},"62304":{"type":"graphic_table","displayName":"Physiologic Rx Malnutrition C","title":"Physiologic basis for treatment of severe malnutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic basis for treatment of severe malnutrition</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Affected organ or system</td>\n\n      <td class=\"subtitle1\">Effects </td>\n\n      <td class=\"subtitle1\">Treatment</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cellular function</td>\n\n      <td>Sodium pump activity is reduced and cell membranes are more\npermeable than normal, which leads to an increase in intracellular\nsodium and a decrease in intracellular potassium and magnesium<br />Protein synthesis is reduced</td>\n\n      <td>Give large doses of potassium and magnesium to all children<br />Restrict sodium intake</td>\n\n    </tr>\n\n    \n\n\n    <tr>\n\n      <td>Skin, muscles and glands</td>\n\n      <td colspan=\"1\" rowspan=\"1\">The skin and subcutaneous fat are atrophied, which leads to loose folds of skin<br />Many signs of dehydration are unreliable; eyes may be sunken because of loss of subcutaneous fat in the orbit<br />Many glands, including the sweat, tear and salivary glands,\nare atrophied; the child has dryness of the mouth and eyes and sweat\nproduction is reduced<br />Respiratory muscles are easily fatigued; the child is lacking in energy</td>\n\n      <td>Rehydrate the child with ReSoMal or F-75 diet</td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &#169; 1999 World Health Organization.</div><div id=\"graphicVersion\">Graphic 62304 Version 1.0</div></div></div>"},"62306":{"type":"graphic_diagnosticimage","displayName":"Inspiratory Arteriogram Celiac Artery Compression Syndrome","title":"Inspiratory Arteriogram Celiac Artery Compression Syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inspiratory Arteriogram Celiac Artery Compression Syndrome</div><div class=\"cntnt\"><img style=\"width:287px; height:360px;\" src=\"images/GAST/62306_Celiac_artery_inspiration_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral arteriogram with widely patent origins of the celiac artery (most superior vessel) and SMA (inferior vessel). This image was taken upon end-inspiration in a patient suspected of having celiac axis syndrome.</div><div class=\"graphic_reference\">Courtesy of Sherry Scovell, MD.</div><div id=\"graphicVersion\">Graphic 62306 Version 3.0</div></div></div>"},"62307":{"type":"graphic_table","displayName":"Drugs causing constipation","title":"Drugs associated with constipation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs associated with constipation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Analgesics</td> </tr> <tr> <td class=\"subtitle1_single\">Anticholinergics</td> </tr> <tr> <td>Antihistamines</td> </tr> <tr> <td>Antispasmodics</td> </tr> <tr> <td>Antidepressants</td> </tr> <tr> <td>Antipsychotics</td> </tr> <tr> <td class=\"subtitle1_single\">Cation-containing agents</td> </tr> <tr> <td>Iron supplements</td> </tr> <tr> <td>Aluminum (antacids, sucralfate)</td> </tr> <tr> <td>Barium</td> </tr> <tr> <td class=\"subtitle1_single\">Neurally active agents</td> </tr> <tr> <td>Opiates</td> </tr> <tr> <td>Antihypertensives</td> </tr> <tr> <td>Ganglionic blockers</td> </tr> <tr> <td>Vinca alkaloids</td> </tr> <tr> <td>Calcium channel blockers</td> </tr> <tr> <td>5HT3 antagonists</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62307 Version 2.0</div></div></div>"},"62309":{"type":"graphic_diagnosticimage","displayName":"Ultrasound showing stones","title":"Transabdominal ultrasound showing common bile duct stones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transabdominal ultrasound showing common bile duct stones</div><div class=\"cntnt\"><img style=\"width:400px; height:330px;\" src=\"images/GAST/62309_Ultrasound_showing_stone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transverse ultrasound in the region of the porta hepatis shows multiple shadowing stones (arrows) within a dilated distal common bile duct.</div><div class=\"graphic_reference\">Courtesy of ML Freeman, MD.</div><div id=\"graphicVersion\">Graphic 62309 Version 5.0</div></div></div>"},"62310":{"type":"graphic_diagnosticimage","displayName":"Airway stenosis tomogram","title":"Airway stenosis tomogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Airway stenosis tomogram</div><div class=\"cntnt\"><img style=\"width:316px; height:210px;\" src=\"images/PULM/62310_Airway_stenosis_tomogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two tomographic images demonstrate focal tracheal stenosis (red arrows).</div><div id=\"graphicVersion\">Graphic 62310 Version 2.0</div></div></div>"},"62311":{"type":"graphic_picture","displayName":"Irritant asthma Late","title":"Irritant-induced asthma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Irritant-induced asthma</div><div class=\"cntnt\"><img style=\"width:370px; height:242px;\" src=\"images/PULM/62311_Irritant_asthma_Late.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchial biopsy taken two years after an acute accidental inhalation of chlorine showing severe desquamation of epithelial cells. Smooth muscle cells are surrounded by reticulocollagenic fibrous tissue seen in the center part of the figure. Weigert-Masson trichrome stain.</div><div class=\"graphic_reference\">Courtesy of Lemiere, C, Malo, JL, Boulet, M.</div><div id=\"graphicVersion\">Graphic 62311 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/54820_Normal_lung_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 54820 Version 1.0</div></div></div>"},"62312":{"type":"graphic_figure","displayName":"Insertion of the intubating LMA","title":"Insertion of the intubating laryngeal mask airway","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Insertion of the intubating laryngeal mask airway</div><div class=\"cntnt\"><img style=\"width:517px; height:744px;\" src=\"images/EM/62312_Insertion_intubating_LMA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A-C) Insertion of the LMA Fastrach. Note that only a short segment of the tubular portion of the device extends beyond the lips. This metal tube accepts a bag-mask device fitting to enable bag-mask ventilation.<br> (D) Lift the handle of the LMA Fastrach as the endotracheal tube is about to pass into the larynx to improve the success rate of intubation. This is called the Vergese maneuver after Dr. Archie Brain's associate Dr. Chandy Vergese.<br> (E) Use of the stabilizer rod to ensure the endotracheal tube is not inadvertently dragged out of the trachea as the LMA Fastrach is removed.<br> (F) The stabilizer rod is removed from the LMA Fastrach to permit the pilot balloon of the endotracheal tube (ETT) to go through the LMA Fastrach and prevent it from being avulsed from the ETT.<br> (G) The pilot balloon of the endotracheal tube emerges from the end of the LMA Fastrach intact.</div><div class=\"graphic_reference\">Reproduced with permission from: Brown CA, Carleton SC, Reardon RF. Supplemental Oxygen. In: Manual of Emergency Airway Management, 4th ed, Walls RM, Murphy MF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62312 Version 7.0</div></div></div>"},"62313":{"type":"graphic_diagnosticimage","displayName":"Mycoplasma pneumonia lung imaging A","title":"<em>Mycoplasma</em> pneumonia","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\"><em>Mycoplasma</em> pneumonia</div><div class=\"cntnt\"><img style=\"width:584px; height:466px;\" src=\"images/ID/62313_MycoplasmapneulungimgA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph (A) shows a bilateral reticulonodular pattern. High-resolution computed tomography (CT) image at the level of the main bronchi (B) demonstrates bilateral ground-glass opacities and centrilobular nodules (arrows). High-resolution CT scan at the level of the basal segmental bronchi (C) shows centrilobular nodules (straight arrows), branching opacities (tree-in-bud pattern; curved arrow), ground-glass opacities, small foci of consolidation, and mild thickening of the interlobular septa (arrowheads). The patient was a 20-year-old man with <EM>Mycoplasma pneumoniae </EM>pneumonia.</div><div class=\"graphic_reference\">Reproduced with permission from: Viruses, Mycoplasma, and Chlamydia. In: Imaging of Pulmonary Infections, MÃ¼ller NL, Franquet T, Lee KS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62313 Version 12.0</div></div></div>"},"62314":{"type":"graphic_picture","displayName":"Sweet syndrome bulla","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62314_Sweet_syndrome_bulla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesiculation is present in this inflammatory plaque of Sweet syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62314 Version 2.0</div></div></div>"},"62315":{"type":"graphic_diagnosticimage","displayName":"Adrenocortical carcinoma","title":"Adrenocortical carcinoma","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Adrenocortical carcinoma</div><div class=\"cntnt\"><img style=\"width:456px; height:159px;\" src=\"images/ENDO/62315_Adrenal_carcinoma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance images of a functioning adrenocortical carcinoma. Left: T1-weighted scan showing large left adrenal mass with low signal intensity similar to that of liver tissue. Right: T2-weighted scan showing enhanced signal intensity of the same mass.</div><div class=\"graphic_reference\">Courtesy of George P Chrousos, MD.</div><div id=\"graphicVersion\">Graphic 62315 Version 3.0</div></div></div>"},"62317":{"type":"graphic_figure","displayName":"Prognosis of HIV according to CD4 cell count and HIV viral load","title":"Prognosis according to CD4 cell count and viral load in the eras before and after the availability of potent antiretroviral therapy","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Prognosis according to CD4 cell count and viral load in the eras before and after the availability of potent antiretroviral therapy</div><div class=\"cntnt\"><img style=\"width:599px; height:533px;\" src=\"images/ID/62317_PrognosisofHIVinHAARTe.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HAART: highly active antiretroviral therapy.</div><div class=\"graphic_reference\">Reproduced with permission from: Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119. Copyright &copy; 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 62317 Version 5.0</div></div></div>"},"62320":{"type":"graphic_diagnosticimage","displayName":"Apical 2 chamber long axis LA volume by planimetry","title":"Planimetry of the left atrium for volume calculation from the apical 2 chamber (long axis) view","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Planimetry of the left atrium for volume calculation from the apical 2 chamber (long axis) view</div><div class=\"cntnt\"><img style=\"width:474px; height:233px;\" src=\"images/CARD/62320_LAvolume2chamberplanime.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A is a schematic of the structures imaged from the apical two-chamber view and panel B is the actual echocardiogram. The apical two-chamber view at end-systole is used for a computer-generated planimetric tracing from which both single and biplane atrial volumes can be obtained (panel C). A biplane volume estimation, combining the two- and four-chamber planimetric information, is preferred.</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium; mv: mitral valve; pv: pulmonic valve; R: right; L: left; A: apex; B: base.</div><div id=\"graphicVersion\">Graphic 62320 Version 7.0</div></div></div>"},"62321":{"type":"graphic_picture","displayName":"Drug-induced exfoliation","title":"Drug-induced exfoliation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Drug-induced exfoliation</div><div class=\"cntnt\"><img style=\"width:504px; height:237px;\" src=\"images/PC/62321_Drug_induced_exfoliation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Vaibhav Parekh, MD, MBA. Copyright Â© Vaibhav Parekh, MD, MBA.</div><div id=\"graphicVersion\">Graphic 62321 Version 3.0</div></div></div>"},"62322":{"type":"graphic_diagnosticimage","displayName":"ERCP in chronic pancreatitis","title":"ERCP in chronic pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ERCP in chronic pancreatitis</div><div class=\"cntnt\"><img style=\"width:360px; height:248px;\" src=\"images/GAST/62322_Chronic_pancr_ERCP_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe pancreatic duct changes with dilation of the main pancreatic duct and of the primary and secondary branches.</div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography.</div><div class=\"graphic_reference\">Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK, 1997. Copyright Â© 1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 62322 Version 6.0</div></div></div>"},"62324":{"type":"graphic_diagnosticimage","displayName":"Type I biliary cyst","title":"Type I biliary cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Type I biliary cyst</div><div class=\"cntnt\"><img style=\"width:247px; height:415px;\" src=\"images/GAST/62324_Type_I_biliary_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image obtained after endoscopic retrograde cholangiopancreatography (ERCP) showing a type I biliary cyst associated with an abnormal pancreaticobiliary junction.</div><div class=\"graphic_reference\">Courtesy of Dr. Morton Burrell.</div><div id=\"graphicVersion\">Graphic 62324 Version 4.0</div></div></div>"},"62325":{"type":"graphic_figure","displayName":"ACE inhibitor advanced HF","title":"ACE inhibitor improves survival in advanced HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ACE inhibitor improves survival in advanced HF</div><div class=\"cntnt\"><img style=\"width:438px; height:242px;\" src=\"images/CARD/62325_ACE_inhibitor_advanced_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Decreased mortality in patients with advanced NYHA class III or IV heart failure after treatment with enalapril compared to placebo (p = 0.003).</div><div class=\"graphic_reference\">Data from: The CONSENSUS Trial Study Group, N Engl J Med 1987; 316:1429.</div><div id=\"graphicVersion\">Graphic 62325 Version 1.0</div></div></div>"},"62326":{"type":"graphic_table","displayName":"Focal transient neurologic symptoms","title":"Focal or nonfocal symptoms of transient neurologic attacks","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Focal or nonfocal symptoms of transient neurologic attacks</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Focal symptoms</td> <td class=\"subtitle1\">Nonfocal symptoms</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Common disorders</td> </tr> <tr> <td class=\"indent1\">Seizure</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> </tr> <tr> <td class=\"indent1\">Transient ischemic attack</td> <td class=\"centered\">++++</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Migraine aura</td> <td class=\"centered\">++++</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Syncope</td> <td class=\"centered\">0</td> <td class=\"centered\">++++</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Less common disorders</td> </tr> <tr> <td class=\"indent1\">Vestibulopathy</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> </tr> <tr> <td class=\"indent1\">Metabolic</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> </tr> <tr> <td class=\"indent1\">\"Tumor attacks\"</td> <td class=\"centered\">+++</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> <td class=\"centered\">++++</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Psychiatric</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> </tr> <tr> <td class=\"indent1\">Nerve and nerve root</td> <td class=\"centered\">++++</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Transient global amnesia</td> <td class=\"centered\">++++</td> <td class=\"centered\">0</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62326 Version 5.0</div></div></div>"},"62332":{"type":"graphic_picture","displayName":"Botfly larva","title":"<em>Dermatobia hominis</em> larva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Dermatobia hominis</em> larva</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/ID/62332_Botfly_larva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An extracted <EM>Dermatobia hominis </EM>larva.</div><div class=\"graphic_reference\">Courtesy of Peter Lio, MD.</div><div id=\"graphicVersion\">Graphic 62332 Version 3.0</div></div></div>"},"62333":{"type":"graphic_picture","displayName":"Pseudallescheria boydii microscopy","title":"<EM>Pseudallescheria boydii</EM> microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Pseudallescheria boydii</EM> microscopy</div><div class=\"cntnt\"><img style=\"width:396px; height:309px;\" src=\"images/ID/62333_P_boydii_microscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic appearance of cleistothecia, the spherical sexual structures&nbsp;that characterize <EM>P. boydii</EM>.</div><div class=\"graphic_reference\">Courtesy of Barbara D. Alexander, MD, MHS and Sylvia F. Costa, MD.</div><div id=\"graphicVersion\">Graphic 62333 Version 4.0</div></div></div>"},"62336":{"type":"graphic_waveform","displayName":"ECG junctional premature beat","title":"Electrocardiogram (ECG) strips showing junctional premature beats","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) strips showing junctional premature beats</div><div class=\"cntnt\"><img style=\"width:360px; height:547px;\" src=\"images/CARD/62336_Junctional_premature_beat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three simultaneous electrocardiographic surface leads V1, II, and V5 show a junctional premature beat (asterisk). In panel A, there is a sinus P wave seen in lead II just prior to the junctional premature beat, which alters its initial deflection (arrow). The junctional premature beat has a QRS morphology that is identical to that of the sinus beat. In panel B, a sinus P wave is seen immediately after the junctional premature beat in lead II (arrow). The junctional premature beat has a QRS morphology which is slightly different from the sinus QRS complex.</div><div id=\"graphicVersion\">Graphic 62336 Version 3.0</div></div></div>"},"62340":{"type":"graphic_picture","displayName":"Severe acute rejection","title":"ITx severe acute rejection (low power view)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ITx severe acute rejection (low power view)</div><div class=\"cntnt\"><img style=\"width:432px; height:279px;\" src=\"images/GAST/62340_Severe_acute_rejection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of surface epithelium with denudation of the mucosa layer.</div><div class=\"graphic_reference\">Courtesy of Farrukh Khan, MD.</div><div id=\"graphicVersion\">Graphic 62340 Version 1.0</div></div></div>"},"62342":{"type":"graphic_table","displayName":"Features of mono by age","title":"Clinical features of infectious mononeucleosis in younger and older age groups","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of infectious mononeucleosis in younger and older age groups</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">&nbsp;</td>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Patients,\npercent</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">&#8804;35 years</td>\n\n      <td class=\"subtitle2\">&#8805;40\nyears</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lymphadenopathy</td>\n\n      <td>94</td>\n\n      <td>47</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pharyngitis</td>\n\n      <td>84</td>\n\n      <td>43</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fever</td>\n\n      <td>75</td>\n\n      <td>95</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Splenomegaly</td>\n\n      <td>52</td>\n\n      <td>33</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hepatomegaly</td>\n\n      <td>12</td>\n\n      <td>42</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rash</td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Jaundice</td>\n\n      <td>9</td>\n\n      <td>27</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data in patients &#8804;35 years from Schooley, RT. In: Mandell, GL, Bennett, JE, Dolin, R (eds), Mandell, Douglas and Bennett's Principles and Practice of Infectious Disease, 4th ed, Churchill Livingstone, Inc, New York 1995, p.1364. Data in patients &#8805;40 years from Axelrod, P, Finestone, AJ. Am Fam Physician 1990; 42:1599.</div><div id=\"graphicVersion\">Graphic 62342 Version 1.0</div></div></div>"},"62343":{"type":"graphic_table","displayName":"Driving restrictions after an event","title":"Driving restrictions after a medical event","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Driving restrictions after a medical event</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Medical condition</td> <td class=\"subtitle1\">Wait time (months)</td> </tr> <tr> <td>Control of angina</td> <td>1</td> </tr> <tr> <td>Myocardial infarction/coronary artery bypass graft</td> <td>1</td> </tr> <tr> <td>Arrhythmia with syncope</td> <td>3</td> </tr> <tr> <td>Transient ischemic attack, single</td> <td>1</td> </tr> <tr> <td>Transient ischemic attack, recurrent</td> <td>3</td> </tr> <tr> <td>Hypoglycemia</td> <td>3</td> </tr> <tr> <td>Seizures</td> <td>6 to 12 months*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Laws vary from state to state.</div><div class=\"graphic_reference\">Adapted from Retchin, S, in Yoshikawa, Cobbs, Brummel-Smith, Practical Ambulatory Geriatrics, St. Louis, Mosby 1998, p 109.</div><div id=\"graphicVersion\">Graphic 62343 Version 2.0</div></div></div>"},"62344":{"type":"graphic_figure","displayName":"Adherence to asthma meds","title":"Compliance with medication regimens in asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Compliance with medication regimens in asthma</div><div class=\"cntnt\"><img style=\"width:340px; height:266px;\" src=\"images/PULM/62344_Adherence_to_asthma_meds.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adherence to inhaled glucocorticoids, slow-release theophylline, and cromolyn among 14 adolescents in an HMO. Adherence was determined by dividing the amount of medication used (based on refill rates obtained from pharmacy reimbursement-claims data) by the expected amount (based on the prescribed doses recorded in the patients' charts). Adherence with the inhaled-drug regimens was particularly low among adolescents.</div><div class=\"graphic_footnotes\">HMO: health maintenance organization.</div><div class=\"graphic_reference\">Data from: Kelloway JS, Wyatt RA, Adlis SA. Arch Intern Med 1994; 154:1349.</div><div id=\"graphicVersion\">Graphic 62344 Version 2.0</div></div></div>"},"62345":{"type":"graphic_picture","displayName":"Bedbug bites in a group","title":"Bedbug bites - \"Breakfast, lunch, and dinner\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bedbug bites - &quot;Breakfast, lunch, and dinner&quot;</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/62345_Bedbug_bites_in_a_group.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rows of hemorrhagic macules and papules on this patient with bedbug bites. The phrase \"breakfast, lunch, and dinner\" has been used to describe this distribution.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62345 Version 6.0</div></div></div>"},"62346":{"type":"graphic_figure","displayName":"Visual analog scale","title":"Visual analog scale","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Visual analog scale</div><div class=\"cntnt\"><img style=\"width:592px; height:482px;\" src=\"images/PC/62346_VAS_final_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Visual Analog Scale (VAS) (10 cm line).<br />Score = 0&nbsp;to 100 mm: measuring in millimeters from the left hand end of the line to the point that the patient marks.</div><div id=\"graphicVersion\">Graphic 62346 Version 4.0</div></div></div>"},"62347":{"type":"graphic_table","displayName":"Clin manif hypocalcemia","title":"Clinical manifestations of hypocalcemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of hypocalcemia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Acute\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Neuromuscular irritability (Tetany)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Paresthesias (peri-oral, extremities)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Muscle twitching\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Carpopedal spasm\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Trousseau's sign\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Chvostek's sign\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Seizures\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Laryngospasm\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Bronchospasm\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Cardiac\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Prolonged QT interval\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Hypotension\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Heart failure\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Arrhythmia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Papilledema</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Chronic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ectopic calcification (basal ganglia)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Extrapyramidal signs</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Parkinsonism</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Dementia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Subcapsular cataracts</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Abnormal dentition</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Dry skin</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 62347 Version 1.0</div></div></div>"},"62349":{"type":"graphic_picture","displayName":"AVM posttreatment angiography","title":"Arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:331px; height:327px;\" src=\"images/NEURO/62349_AVM_posttreatment_angiograp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiogram obtained after the AVM seen in prior radiograph was treated.</div><div class=\"graphic_reference\">Courtesy of Guy Rordorf, MD.</div><div id=\"graphicVersion\">Graphic 62349 Version 1.0</div></div></div>"},"62352":{"type":"graphic_diagnosticimage","displayName":"Parasternal long axis echo aortic valve vegetations","title":"Parasternal long axis echocardiogram showing aortic valve vegetations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal long axis echocardiogram showing aortic valve vegetations</div><div class=\"cntnt\"><img style=\"width:372px; height:277px;\" src=\"images/CARD/62352_Long_axis_AV_endocarditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal long axis view shows a bulky vegetation (veg) arising from the aortic (Ao) valve; the vegetation is large enough to prolapse into the left ventricular (LV) outflow tract. There is also a left atrial (LA) vegetation (arrows). Both the Ao and LA masses were shown to be bacterial vegetations.</div><div class=\"graphic_footnotes\">RVOT: right ventricular outflow tract; MV: mitral valve.</div><div id=\"graphicVersion\">Graphic 62352 Version 5.0</div></div></div>"},"62353":{"type":"graphic_figure","displayName":"Age-related LV remodeling in HCM","title":"Left ventricular remodeling in hypertrophic cardiomyopathy (HCM)Â as an age-related phenomenon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular remodeling in hypertrophic cardiomyopathy (HCM)&nbsp;as an age-related phenomenon</div><div class=\"cntnt\"><img style=\"width:403px; height:196px;\" src=\"images/CARD/62353_LVremodelingHCM.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LVH: left ventricular hypertrophy.</div><div class=\"graphic_reference\">Reprinted from Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 1998; 81(11):1339-44. Copyright 1998, with permission from Excerpta Medica, Inc.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 62353 Version 4.0</div></div></div>"},"62354":{"type":"graphic_picture","displayName":"Granuloma annulare foot","title":"Granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granuloma annulare</div><div class=\"cntnt\"><img style=\"width:350px; height:398px;\" src=\"images/DERM/62354_Granuloma_annulare_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This child with granuloma annulare has a nonscaly, erythematous, annular plaque.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62354 Version 2.0</div></div></div>"},"62355":{"type":"graphic_figure","displayName":"CGM output","title":"Accuracy of CGM: Correlation of CGM and simultaneous hemocue","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Accuracy of CGM: Correlation of CGM and simultaneous hemocue</div><div class=\"cntnt\"><img style=\"width:527px; height:404px;\" src=\"images/ENDO/62355_CGMSoutput.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results of&nbsp;CGM compared with intermittent values checked with a laboratory-quality assay.</div><div class=\"graphic_footnotes\">CGM: continuous glucose monitoring.</div><div class=\"graphic_reference\">Courtesy of David Nathan, MD.</div><div id=\"graphicVersion\">Graphic 62355 Version 3.0</div></div></div>"},"62358":{"type":"graphic_table","displayName":"Causes of weight loss in older adults","title":"Causes of weight loss in older adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of weight loss in older adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>M</strong>edications (eg, digoxin, theophylline, SSRIs, antibiotics)</td> </tr> <tr> <td><strong>E</strong>motional (eg, depression, anxiety)</td> </tr> <tr> <td><strong>A</strong>lcoholism,&nbsp;older adult&nbsp;abuse</td> </tr> <tr> <td><strong>L</strong>ate-life paranoia or bereavement</td> </tr> <tr> <td><strong>S</strong>wallowing problems</td> </tr> <tr> <td class=\"sublist_other\">&nbsp; </td> </tr> <tr> <td><strong>O</strong>ral factors (tooth loss, xerostomia)</td> </tr> <tr> <td><strong>N</strong>osocomial infections (eg, tuberculosis, pneumonia)</td> </tr> <tr> <td class=\"sublist_other\">&nbsp; </td> </tr> <tr> <td><strong>W</strong>andering and other dementia-related factors</td> </tr> <tr> <td><strong>H</strong>yperthyroidism, hypercalcemia, hypoadrenalism</td> </tr> <tr> <td><strong>E</strong>nteral problems (eg, esophageal stricture, gluten enteropathy)</td> </tr> <tr> <td><strong>E</strong>ating problems</td> </tr> <tr> <td><strong>L</strong>ow salt, low cholesterol, and other therapeutic diets</td> </tr> <tr> <td><strong>S</strong>ocial isolation, stones (chronic cholecystitis)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SSRIs: selective serotonin reuptake inhibitors.</div><div class=\"graphic_reference\">Reproduced with permission from: Morley JE. Anorexia of aging: physiologic and pathologic. Am J Clin Nutr 1997; 66:760. Copyright &#169;1997 American Society for Nutrition.</div><div id=\"graphicVersion\">Graphic 62358 Version 3.0</div></div></div>"},"62359":{"type":"graphic_picture","displayName":"HP infiltrate Light","title":"Hypersensitivity pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypersensitivity pneumonitis</div><div class=\"cntnt\"><img style=\"width:288px; height:193px;\" src=\"images/PULM/62359_HP_infiltrate_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph shows an intense interstitial lymphoplasmacytic infiltrate in a peribronchiolar pattern. Small accumulations of epithelioid histiocytes may be present.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 62359 Version 1.0</div></div></div>"},"62360":{"type":"graphic_figure","displayName":"Margin of pulmonary nodules","title":"Margin of pulmonary nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Margin of pulmonary nodules</div><div class=\"cntnt\"><img style=\"width:367px; height:359px;\" src=\"images/PULM/62360_Margin_of_pulmonary_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of different patterns of the margin of pulmonary nodules. In clockwise orientation from top left: smooth, scalloped, corona radiata, and spiculated.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 62360 Version 1.0</div></div></div>"},"62362":{"type":"graphic_figure","displayName":"Anatomy of the right popliteal fossa","title":"Anatomy of the right popliteal fossa","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Anatomy of the right popliteal fossa</div><div class=\"cntnt\"><img style=\"width:523px; height:648px;\" src=\"images/SURG/62362_Pop_fossa.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">m: muscle; n: nerve; v: vein; a: artery.</div><div id=\"graphicVersion\">Graphic 62362 Version 3.0</div></div></div>"},"62363":{"type":"graphic_picture","displayName":"Ulcerative sarcoidosis","title":"Ulcerative sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulcerative sarcoidosis</div><div class=\"cntnt\"><img style=\"width:272px; height:360px;\" src=\"images/DERM/62363_Ulcerative_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcerative sarcoidosis. Atrophic, hyperpigmented plaques are present; the inferior lesion is ulcerated. These ulcerations are often misdiagnosed as venous ulcers.</div><div id=\"graphicVersion\">Graphic 62363 Version 1.0</div></div></div>"},"62366":{"type":"graphic_picture","displayName":"Normal placenta","title":"Normal placenta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal placenta</div><div class=\"cntnt\"><img style=\"width:432px; height:282px;\" src=\"images/OBGYN/62366_Normal_placenta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Placenta, umbilical cord, and some of the membranes.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 62366 Version 3.0</div></div></div>"},"62367":{"type":"graphic_picture","displayName":"Multifoc atroph gastritis","title":"Multifocal atrophic gastritis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Multifocal atrophic gastritis</div><div class=\"cntnt\"><img style=\"width:468px; height:504px;\" src=\"images/ONC/62367_Multifoc_atroph_gastritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Focal loss of glands, partially replaced by fibrosis. Mononuclear leukocytes infiltrate the stroma.</div><div id=\"graphicVersion\">Graphic 62367 Version 1.0</div></div></div>"},"62368":{"type":"graphic_table","displayName":"Left vs right ventricular MI","title":"Differences between left and right ventricular myocardial infarction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differences between left and right ventricular myocardial infarction</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Left ventricular MI</td>\n\n      <td class=\"subtitle1\">Right ventricular MI</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"4\" class=\"subtitle2_left\">Clinical features</td>\n\n      <td>Pulmonary congestion</td>\n\n      <td>Clear lung fields</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Third and fourth heart sounds</td>\n\n      <td>Right-sided third heart sound</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>New mitral regurgitation</td>\n\n      <td>New tricuspid regurgitation</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>&nbsp;</td>\n\n      <td>Hypotension with distended neck veins</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\" class=\"subtitle2_left\">Electrocardiogram</td>\n\n      <td>ST elevation in standard leads</td>\n\n      <td>ST elevation in V4R</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>&nbsp;</td>\n\n      <td>Commonly associated with inferior MI</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>&nbsp;</td>\n\n      <td>Frequent atrioventricular block</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle2_left\">Hemodynamic findings</td>\n\n      <td>Increased pulmonary capillary wedge pressure (PCWP)</td>\n\n      <td>Right atrial pressure (RAP) &#8805;10 mmHg</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>&nbsp;</td>\n\n      <td>RAP:PCWP &#8805;0.8</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"4\" class=\"subtitle2_left\">Specific management</td>\n\n      <td>Fluid restriction</td>\n\n      <td>Fluid resuscitation</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Preload and afterload reduction</td>\n\n      <td>Avoid preload reduction</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Reperfusion therapy</td>\n\n      <td>Reperfusion therapy</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Inotropic agents, if necessary</td>\n\n      <td>Inotropic agents, if necessary</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62368 Version 1.0</div></div></div>"},"62370":{"type":"graphic_picture","displayName":"Erythema multiforme acral","title":"Erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/62370_Erythema_multiforme_acral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple acrally distributed target lesions and mucosal erosions are present in this patient with erythema multiforme majus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62370 Version 5.0</div></div></div>"},"62371":{"type":"graphic_figure","displayName":"BP norm birth to 1yr boys","title":"Age-specific percentiles of BP measurements in boys - birth to 12 months of age; Korotkoff phase IV (K4) used for diastolic BP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Age-specific percentiles of BP measurements in boys - birth to 12 months of age; Korotkoff phase IV (K4) used for diastolic BP</div><div class=\"cntnt\"><img style=\"width:450px; height:606px;\" src=\"images/EM/62371_BPnormbirthto1yrboys.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 79, Pages 1-25, Copyright Â© 1987 by the AAP.</div><div id=\"graphicVersion\">Graphic 62371 Version 12.0</div></div></div>"},"62372":{"type":"graphic_table","displayName":"Causes of delayed puberty","title":"Causes of delayed puberty","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of delayed puberty</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary hypogonadism - High FSH and LH</td> </tr> <tr> <td class=\"subtitle2_single\">Congenital</td> </tr> <tr> <td class=\"indent1\">Chromosomal abnormalities (Turner syndrome - 45,XO; Klinefelter syndrome - 47,XXY)</td> </tr> <tr> <td class=\"indent1\">Anorchia (vanishing testis)</td> </tr> <tr> <td class=\"subtitle2_single\">Acquired</td> </tr> <tr> <td class=\"indent1\">Autoimmune or postinfectious</td> </tr> <tr> <td class=\"indent1\">Following trauma or surgery</td> </tr> <tr> <td class=\"indent1\">Chemotherapy, radiation therapy</td> </tr> <tr> <td class=\"subtitle1_single\">Secondary hypogonadism - Low to normal FSH and LH</td> </tr> <tr> <td class=\"subtitle2_single\">Acquired</td> </tr> <tr> <td class=\"sublist2_start\">Tumors</td> </tr> <tr> <td class=\"sublist2\">Benign tumors and cysts</td> </tr> <tr> <td class=\"sublist2\">Craniopharyngiomas</td> </tr> <tr> <td class=\"sublist2\">Germinomas, meningiomas, gliomas, astrocytomas</td> </tr> <tr> <td class=\"sublist2_start\">\"Functional\" gonadotropin deficiency</td> </tr> <tr> <td class=\"sublist2\">Constitutional delay of puberty</td> </tr> <tr> <td class=\"sublist2\">Chronic systemic disease</td> </tr> <tr> <td class=\"sublist2\">Acute illness</td> </tr> <tr> <td class=\"sublist2\">Malnutrition</td> </tr> <tr> <td class=\"sublist2\">Hypothyroidism, hyperprolactinemia, diabetes mellitus, Cushing's disease</td> </tr> <tr> <td class=\"sublist2\">Anorexia nervosa, bulimia</td> </tr> <tr> <td class=\"sublist2_start\">Infiltrative diseases</td> </tr> <tr> <td class=\"sublist2\">Hemochromatosis</td> </tr> <tr> <td class=\"sublist2\">Granulomatous diseases</td> </tr> <tr> <td class=\"sublist2\">Histiocytosis</td> </tr> <tr> <td class=\"indent1\">Head trauma</td> </tr> <tr> <td class=\"indent1\">Pituitary apoplexy</td> </tr> <tr> <td class=\"indent1\">Drugs - Marijuana</td> </tr> <tr> <td class=\"subtitle2_single\">Congenital</td> </tr> <tr> <td class=\"sublist2_start\">Isolated GnRH deficiency</td> </tr> <tr> <td class=\"sublist2\">Without anosmia</td> </tr> <tr> <td class=\"sublist2\">Kallmann syndrome</td> </tr> <tr> <td class=\"sublist2\">Associated with adrenal hypoplasia congenita</td> </tr> <tr> <td class=\"sublist2_start\">GnRH deficiency associated with mental retardation/obesity</td> </tr> <tr> <td class=\"sublist2\">Laurence-Moon-Biedl syndrome</td> </tr> <tr> <td class=\"sublist2\">Prader-Willi syndrome</td> </tr> <tr> <td class=\"indent1\">Idiopathic forms of multiple anterior pituitary hormone deficiencies</td> </tr> <tr> <td class=\"indent1\">Congenital malformations often associated with craniofacial anomalies</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FSH: follicle stimulating hormone; LH: luteinizing hormone; GnRH: gonadotropin-releasing hormone.</div><div id=\"graphicVersion\">Graphic 62372 Version 6.0</div></div></div>"},"62373":{"type":"graphic_diagnosticimage","displayName":"Anomalous left circumflex","title":"Anomalous left coronary artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anomalous left coronary artery</div><div class=\"cntnt\"><img style=\"width:299px; height:357px;\" src=\"images/CARD/62373_Anomalous_left_circumflex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Selective coronary angiography of the left main coronary artery in the right anterior oblique (RAO, panel A) and left anterior oblique (LAO, panel B) views demonstrates a normal left anterior descending artery (LAD); however, the left circumflex artery (LCX) is absent. Angiography of the pulmonary artery in the RAO and LAO views (panels C and D) shows that the LCX arises from the junction of the junction of the main pulmonary artery and right pulmonary artery (RPA). This patient also had previous mitral valve replacement with a Bjork-Shiley valve (arrow).</div><div id=\"graphicVersion\">Graphic 62373 Version 2.0</div></div></div>"},"62374":{"type":"graphic_diagnosticimage","displayName":"Idiopathic hemosiderosis PA","title":"Idiopathic pulmonary hemosiderosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic pulmonary hemosiderosis</div><div class=\"cntnt\"><img style=\"width:293px; height:450px;\" src=\"images/PULM/62374_Idiopathic_hemosiderosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Film A shows the posteroanterior radiograph of a 32 year old woman with hemoptysis due to her first attack of idiopathic pulmonary hemosiderosis. There is diffuse, ground-glass opacification in both lungs. Film B taken one month later shows complete regression of the opacities following treatment with prednisolone.</div><div class=\"graphic_reference\">Courtesy of Nils Milman, MD.</div><div id=\"graphicVersion\">Graphic 62374 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"62376":{"type":"graphic_table","displayName":"Treatment of auto PEEP","title":"Treatment of auto-PEEP","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of auto-PEEP</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Changes in ventilator setting</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Increase expiratory duration</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Decrease respiratory rate</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Decrease tidal volume</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Reduction in the ventilatory demand</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Decrease carbohydrate intake</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Reduce dead space</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Reduce anxiety, pain, fever, shivering</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Reduction of total flow resistance</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use of large bore endotracheal tubes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Frequent suctioning</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bronchodilators</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Application of external PEEP nearly up to the level of initial PEEPi</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62376 Version 1.0</div></div></div>"},"62377":{"type":"graphic_table","displayName":"Weaning clinical criteria","title":"Clinical criteria used to determine readiness for trials of spontaneous breathing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical criteria used to determine readiness for trials of spontaneous breathing</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Required criteria\n   </td>\n   </tr>\n   <tr>\n   <td>1. The cause of the respiratory failure has improved</td>\n   </tr>\n   <tr>\n   <td>2. PaO<sub>2</sub>/FiO<sub>2</sub>&#8805;150* or SpO<sub>2</sub>&#8805;90 percent on FiO<sub>2</sub>&#8804;40 percent and positive end-expiratory pressure (PEEP) &#8804;5 cmH<sub>2</sub>O</td>\n   </tr>\n   <tr>\n   <td>3. pH &#62;7.25</td>\n   </tr>\n   <tr>\n   <td>4. Hemodynamic stability (no or low dose vasopressor medications)</td>\n   </tr>\n   <tr>\n   <td>5. Able to initiate an inspiratory effort</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Additional criteria (optional criteria)\n   </td>\n   </tr>\n   <tr>\n   <td>1. Hemoglobin &#8805;8 to 10 mg/dL</td>\n   </tr>\n   <tr>\n   <td>2. Core temperature &#8804;38 to 38.5 degrees Centigrade</td>\n   </tr>\n   <tr>\n   <td>3. Mental status awake and alert or easily arousable</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">* A threshold of PaO<sub>2</sub>/FiO<sub>2</sub>&#8805;120 can be used for patients with chronic hypoxemia. Some patients require higher levels of PEEP to avoid atelectasis during mechanical ventilation.</div><div class=\"graphic_reference\">Adapted from: MacIntyre, NR, Cook, DJ, Ely, EW, Jr., et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians, the American Association for Respiratory Care, and the American College of Critical Care Medicine. Chest 2001; 120:375S.</div><div id=\"graphicVersion\">Graphic 62377 Version 1.0</div></div></div>"},"62380":{"type":"graphic_picture","displayName":"Focal GN light","title":"Light micrograph showing mesangial proliferative glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing mesangial proliferative glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/62380_Focal_GN_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a mesangial glomerulonephritis showing segmental areas of increased mesangial matrix and cellularity (arrows). This finding alone can be seen in many diseases, including IgA nephropathy and lupus nephritis.</div><div class=\"graphic_footnotes\">IgA: immunoglobulin A.</div><div class=\"graphic_reference\">Courtesy of Helmut G&nbsp;Rennke, MD.</div><div id=\"graphicVersion\">Graphic 62380 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"62381":{"type":"graphic_table","displayName":"ABCD2 score","title":"ABCD<sup>2</sup> score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ABCD<sup>2</sup> score</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"2\">The ABCD<sup>2</sup> score can be used to estimate the risk of ischemic stroke in the first two days after TIA. The score is tallied as follows:</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Age:</td> </tr> <tr> <td class=\"indent1\">&#8805;60 years</td> <td>1 point</td> </tr> <tr> <td class=\"indent1\">&#60;60 years</td> <td>0 points</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Blood pressure elevation when first assessed after TIA:</td> </tr> <tr> <td class=\"indent1\">Systolic &#8805;140 mmHg <strong>or</strong> diastolic &#8805;90 mmHg</td> <td>1 point</td> </tr> <tr> <td class=\"indent1\">Systolic &#60;140 mmHg <strong>and</strong> diastolic &#60;90 mmHg</td> <td>0 points</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Clinical features:</td> </tr> <tr> <td class=\"indent1\">Unilateral weakness</td> <td>2 points</td> </tr> <tr> <td class=\"indent1\">Isolated speech disturbance</td> <td>1 point</td> </tr> <tr> <td class=\"indent1\">Other</td> <td>0 points</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Duration of TIA symptoms:</td> </tr> <tr> <td class=\"indent1\">&#8805;60 minutes</td> <td>2 points</td> </tr> <tr> <td class=\"indent1\">10 to 59 minutes</td> <td>1 point</td> </tr> <tr> <td class=\"indent1\">&#60;10 minutes</td> <td>0 points</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Diabetes:</td> </tr> <tr> <td class=\"indent1\">Present</td> <td>1 point</td> </tr> <tr> <td class=\"indent1\">Absent</td> <td>0 points</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007; 369:283.</div><div id=\"graphicVersion\">Graphic 62381 Version 3.0</div></div></div>"},"62382":{"type":"graphic_table","displayName":"Poser criteria for MS","title":"Poser diagnostic criteria for multiple sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Poser diagnostic criteria for multiple sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinically definite multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">1. Two attacks plus two separate clinical lesions*</td> </tr> <tr> <td class=\"indent2\">or</td> </tr> <tr> <td class=\"indent1\">2. Two attacks plus one clinical lesion plus another separate paraclinical lesion<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory supported definite multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">1. Two attacks plus one clinical lesion plus CSF, OCB, or IgG</td> </tr> <tr> <td class=\"indent2\">or</td> </tr> <tr> <td class=\"indent1\">2. Two attacks plus one paraclinical lesion plus CSF, OCB, or IgG</td> </tr> <tr> <td class=\"indent2\">or</td> </tr> <tr> <td class=\"indent1\">3. One attack plus two separate clinical lesions plus CSF, OCB, or IgG</td> </tr> <tr> <td class=\"indent2\">or</td> </tr> <tr> <td class=\"indent1\">4. One attack plus one clinical lesion plus one paraclinical lesion plus CSF, OCB, or IgG</td> </tr> <tr> <td class=\"subtitle1_single\">Clinically probably multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">1. Two attacks plus one clinical lesion</td> </tr> <tr> <td class=\"indent2\">or</td> </tr> <tr> <td class=\"indent1\">2. One attack plus two separate clinical lesions</td> </tr> <tr> <td class=\"indent2\">or</td> </tr> <tr> <td class=\"indent1\">3. One attack plus one clinical lesion plus one paraclinical lesion</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory supported probable multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">1. Two attacks plus CSF, OCB, or IgG</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; OCB: oligoclonal banding; IgG: Immunoglobulin G.<br />* Clinical lesion: lesion detected on history and physical examination.<br />Â¶ Paraclinical lesion: lesion detected by evoked response testing, MRI, or urodynamic studies.</div><div class=\"graphic_reference\">Modified from: Poser CM, Paty DW, Scheinberg L, et al, Ann Neurol 1983; 13:227.</div><div id=\"graphicVersion\">Graphic 62382 Version 4.0</div></div></div>"},"62386":{"type":"graphic_diagnosticimage","displayName":"Bipartite medial (tibial) sesamoid","title":"Bipartite medial (tibial) sesamoid","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Bipartite medial (tibial) sesamoid</div><div class=\"cntnt\"><img style=\"width:494px; height:396px;\" src=\"images/SM/62386_Bipartite_medial_sesamoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the rounded corners and smooth contours of each of the two pieces of this sesamoid, best seen in panel A (white arrow).</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 62386 Version 4.0</div></div></div>"},"62387":{"type":"graphic_picture","displayName":"Traumatic hemotympanum","title":"Hemotympanum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemotympanum</div><div class=\"cntnt\"><img style=\"width:360px; height:348px;\" src=\"images/EM/62387_Traumatic_hemotympanum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the very dark fluid filling the middle ear space behind the tympanic membrane.</div><div class=\"graphic_reference\">Courtesy of Adele Karen Evans, MD, FAAP and Steven D Handler MD, MBE.</div><div id=\"graphicVersion\">Graphic 62387 Version 1.0</div></div></div>"},"62388":{"type":"graphic_figure","displayName":"Calcium versus estrogen on bone","title":"Methods to slow bone loss in postmenopausal women","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Methods to slow bone loss in postmenopausal women</div><div class=\"cntnt\"><img style=\"width:472px; height:249px;\" src=\"images/ENDO/62388_Calcium_versus_estrogen_on.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effects of three interventions on distal forearm bone density in postmenopausal women with low baseline forearm bone density. Bone loss was significantly slowed or prevented with either exercise plus estrogen or exercise plus calcium supplementation. The former regimen was both more effective and associated with a higher incidence of side effects, such as breast tenderness and vaginal bleeding.</div><div class=\"graphic_reference\">Data from: Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy.&nbsp;N Engl J Med 1991; 325:1189.</div><div id=\"graphicVersion\">Graphic 62388 Version 2.0</div></div></div>"},"62390":{"type":"graphic_table","displayName":"Increased osmolal and O2 gaps","title":"Increased osmolal and oxygen saturation gaps","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Increased osmolal and oxygen saturation gaps</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Increased osmolal gap (normal 5 &#177; 7 [SD] m0sm/L)</td> </tr> <tr> <td>Acetone</td> </tr> <tr> <td>Ethanol</td> </tr> <tr> <td>Ethylene glycol</td> </tr> <tr> <td>Glycerol</td> </tr> <tr> <td>Hypermagnesemia (&#62;9.5 mEq/L)</td> </tr> <tr> <td>Isopropyl alcohol</td> </tr> <tr> <td>Mannitol</td> </tr> <tr> <td>Methanol</td> </tr> <tr> <td>Propylene glycol</td> </tr> <tr> <td>Benzyl alcohol</td> </tr> <tr> <td>Sorbitol</td> </tr> <tr> <td>Ethyl ethers</td> </tr> <tr> <td>Glycol ethers</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Increased oxygen saturation gap (&#62;5 percent difference)</td> </tr> <tr> <td>Carbon monoxide</td> </tr> <tr> <td>Cyanide</td> </tr> <tr> <td>Sulfhemoglobinemia</td> </tr> <tr> <td>Hydrogen sulfide</td> </tr> <tr> <td>Methemoglobin</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62390 Version 3.0</div></div></div>"},"62393":{"type":"graphic_diagnosticimage","displayName":"Tracheoplast tracheomalacia","title":"Tracheoplasty for tracheomalacia","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Tracheoplasty for tracheomalacia</div><div class=\"cntnt\"><img style=\"width:516px; height:222px;\" src=\"images/PULM/62393_Tracheoplast_tracheomalacia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT images of a patient with tracheomalacia. A) Before surgery; B) After surgical tracheoplasty. Postoperatively, the trachea has a normal shape and size.</div><div id=\"graphicVersion\">Graphic 62393 Version 2.0</div></div></div>"},"62394":{"type":"graphic_table","displayName":"LR after neoadj tx and BCT","title":"Locoregional recurrence rate for breast-conserving surgery after NACT","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Locoregional recurrence rate for breast-conserving surgery after NACT</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">LRR (percent)</td> <td class=\"subtitle1\">Median follow-up (mo)</td> <td class=\"subtitle1\">Year of publication</td> </tr> <tr> <td>Asoglu, et al<sup>[1]</sup></td> <td>28</td> <td>14</td> <td>60</td> <td>2005</td> </tr> <tr> <td>Chen, et al<sup>[2]</sup></td> <td>340</td> <td>5</td> <td>60</td> <td>2004</td> </tr> <tr> <td>Clark, et al<sup>[3]</sup></td> <td>34</td> <td>6.6</td> <td>30</td> <td>1998</td> </tr> <tr> <td>Hunt, et al<sup>[4]</sup></td> <td>93</td> <td>9.7</td> <td>55</td> <td>1998</td> </tr> <tr> <td>Mauriac, et al<sup>[5]</sup></td> <td>272</td> <td>22.5</td> <td>124</td> <td>1999</td> </tr> <tr> <td>McIntoch, et al<sup>[6]</sup></td> <td>173<sup>*</sup></td> <td>2</td> <td>62</td> <td>2003</td> </tr> <tr> <td>NSABP B18<sup>[7]</sup></td> <td>1531</td> <td>10.7</td> <td>114</td> <td>2001</td> </tr> <tr> <td>Shen, et al<sup>[8]</sup></td> <td>33</td> <td>6</td> <td>60</td> <td>2004</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BCS: breast-conserving surgery; LRR: locoregional recurrence rate; NSABP: National Surgical Adjuvant Breast and Bowel Project.<br />* Data available for 166.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Asoglu, O, Muslumanoglu, M, Igci, A, et al. Breast conserving surgery after primary chemotherapy in locally advanced breast cancer. Acta Chir Belg 2005; 105:62.</li>&#xD;&#xA;    <li>Chen, AM, Meric-Bernstam, F, Hunt, KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 2004; 22:2303.</li>&#xD;&#xA;    <li>Clark, J, Rosenman, J, Cance, W, et al. Extending the indications for breast-conserving treatment to patients with locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1998; 42:345.</li>&#xD;&#xA;    <li>Hunt, KK, Singletary, SE, Smith, TL. Conservation surgery and radiation: the M.D. Anderson experience. In: The Breast, 2nd ed, Bland, KI, Copeland, EM III (Eds), Saunders, Philadelphia 1998. p.1179.</li>&#xD;&#xA;    <li>Mauriac, L, MacGrogan, G, Avril, A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999; 10:47.</li>&#xD;&#xA;    <li>McIntosh, SA, Ogston, KN, Payne, S, et al. Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg 2003; 185:525.</li>&#xD;&#xA;    <li>Wolmark, N, Wang, J, Mamounas, E, et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30:96.</li>&#xD;&#xA;    <li>Shen, J, Valero, V, Buchholz, TA, et al. Effective local control and longterm survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 2004; 11:854.</li>&#xD;&#xA;</ol>&#xD;&#xA;Data from: Alm El-Din, M, Taghian, A. Breast conserving therapy for patients with locally advanced breast cancer. Semin Radiat Oncol 2009; 19:229.</div><div id=\"graphicVersion\">Graphic 62394 Version 2.0</div></div></div>"},"62395":{"type":"graphic_picture","displayName":"Scabies burrow 3","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/62395_Scabies_burrow_3_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and multiple small burrows with overlying scale are present in the interdigital space in this patient with acquired immunodeficiency syndrome (AIDS).</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62395 Version 7.0</div></div></div>"},"62397":{"type":"graphic_table","displayName":"Anatomic physiologic classification of myoclonus","title":"Anatomic and physiologic classification of common types of myoclonus*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anatomic and physiologic classification of common types of myoclonus*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cortical</td> </tr> <tr> <td class=\"indent1\">Asterixis (some cases)</td> </tr> <tr> <td class=\"indent1\">Epilepsia partialis continua</td> </tr> <tr> <td class=\"indent1\">Cortical reflex myoclonus</td> </tr> <tr> <td class=\"indent1\">Cortical myoclonus without exaggerated reflex features</td> </tr> <tr> <td class=\"indent1\">Certain drug-induced and toxic-metabolic etiologies of myoclonus</td> </tr> <tr> <td class=\"sublist2_start\">Neurodegenerative disease with cortical involvement:</td> </tr> <tr> <td class=\"sublist2\">- Alzheimer disease</td> </tr> <tr> <td class=\"sublist2\">- Corticobasal degeneration</td> </tr> <tr> <td class=\"sublist2\">- Creutzfeldt-Jakob disease</td> </tr> <tr> <td class=\"sublist2\">- Huntington disease</td> </tr> <tr> <td class=\"sublist2\">- Parkinson disease and other Lewy body disorders</td> </tr> <tr> <td class=\"indent1\">Posthypoxic action myoclonus (Lance-Adams myoclonus)</td> </tr> <tr> <td class=\"indent1\">Progressive myoclonic ataxias</td> </tr> <tr> <td class=\"indent1\">Progressive myoclonic epilepsies</td> </tr> <tr> <td class=\"subtitle1_single\">Cortical-subcortical</td> </tr> <tr> <td class=\"indent1\">Absence seizures</td> </tr> <tr> <td class=\"indent1\">Primary generalized epileptic myoclonus</td> </tr> <tr> <td class=\"indent1\">Primary generalized myoclonic seizures</td> </tr> <tr> <td class=\"subtitle1_single\">Subcortical-nonsegmental</td> </tr> <tr> <td class=\"indent1\">Essential myoclonus (hereditary)</td> </tr> <tr> <td class=\"indent1\">Hyperekplexia</td> </tr> <tr> <td class=\"indent1\">Opsoclonus-myoclonus syndrome</td> </tr> <tr> <td class=\"indent1\">Propriospinal myoclonus</td> </tr> <tr> <td class=\"indent1\">Reticular reflex myoclonus</td> </tr> <tr> <td class=\"subtitle1_single\">Segmental</td> </tr> <tr> <td class=\"indent1\">Palatal myoclonus</td> </tr> <tr> <td class=\"indent1\">Segmental spinal myoclonus</td> </tr> <tr> <td class=\"subtitle1_single\">Peripheral</td> </tr> <tr> <td class=\"indent1\">Hemifacial spasm</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* More than one mechanism may be operative in an individual patient or disease.</div><div class=\"graphic_reference\">Modified from: Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol 2004; 3:598.</div><div id=\"graphicVersion\">Graphic 62397 Version 6.0</div></div></div>"},"62398":{"type":"graphic_table","displayName":"Cortical dysgenesis","title":"Malformations of cortical development","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Malformations of cortical development</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Malformations due to abnormal neuronal and glial proliferation or apoptosis</td> </tr> <tr> <td class=\"indent1\">Decreased proliferation/increased apoptosis: microcephalies</td> </tr> <tr> <td class=\"indent1\">Increased proliferation/decreased apoptosis: megalencepalies</td> </tr> <tr> <td class=\"indent1\">Abnormal proliferation (abnormal cell types):</td> </tr> <tr> <td class=\"indent2\">- Non-neoplastic (tuberous sclerosis, cortical dysplasia with balloon cells, hemimegalencepalie)</td> </tr> <tr> <td class=\"indent2\">- Neoplastic (association with disordered cortex): DNET, ganglioglioma, gangliocytoma</td> </tr> <tr> <td class=\"subtitle2_left\">Malformations due to abnormal neuronal migration</td> </tr> <tr> <td class=\"indent1\">Lissencephaly/subcortical band heterotopia spectrum</td> </tr> <tr> <td class=\"indent1\">Cobblestone complex</td> </tr> <tr> <td class=\"indent1\">Heterotopia (subependymal, subcortical, marginal glioneuronal)</td> </tr> <tr> <td class=\"subtitle2_left\">Malformations due to abnormal cortical organisation</td> </tr> <tr> <td class=\"indent1\">Polymicrogyria and schizencepahly</td> </tr> <tr> <td class=\"indent1\">Cortical dysplasia without balloon cells</td> </tr> <tr> <td class=\"indent1\">Microdysgenesis</td> </tr> <tr> <td class=\"subtitle2_left\">Malformations of cortical development, not otherwise classified</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DNET: dysembryoplastic neuroepithelioma.</div><div class=\"graphic_reference\">Modified from: Barkovich AJ, Kuzniecky RI, Jackson GD, et al. Classification system for malformations of cortical development. Neurology 2001; 57:2168.</div><div id=\"graphicVersion\">Graphic 62398 Version 3.0</div></div></div>"},"62402":{"type":"graphic_table","displayName":"Topical corticosteroids","title":"Comparison of representative topical corticosteroid preparations (classified according to the US system)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of representative topical corticosteroid preparations (classified according to the US system)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Potency group*</td> <td class=\"subtitle1\">Corticosteroid</td> <td class=\"subtitle1\">Vehicle type/form</td> <td class=\"subtitle1\">Trade names<br /> (United States)</td> <td class=\"subtitle1\">Available strength(s), percent<br /> (except as noted)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"19\"><strong>Super-high potency<br /> (group 1)</strong></td> <td rowspan=\"3\">Betamethasone dipropionate, augmented</td> <td>Ointment, optimized</td> <td>Diprolene</td> <td>0.05</td> </tr> <tr> <td>Lotion</td> <td>Diprolene</td> <td>0.05</td> </tr> <tr> <td>Gel</td> <td>Diprolene</td> <td>0.05</td> </tr> <tr> <td rowspan=\"10\">Clobetasol propionate</td> <td>Ointment</td> <td>Temovate</td> <td>0.05</td> </tr> <tr> <td>Cream</td> <td>Temovate</td> <td>0.05</td> </tr> <tr> <td>Cream, emollient base</td> <td>Temovate E</td> <td>0.05</td> </tr> <tr> <td>Gel</td> <td>Temovate</td> <td>0.05</td> </tr> <tr> <td>Lotion</td> <td>Clobex</td> <td>0.05</td> </tr> <tr> <td>Foam aerosol</td> <td>Olux-E</td> <td>0.05</td> </tr> <tr> <td>Foam aerosol (scalp)</td> <td>Olux</td> <td>0.05</td> </tr> <tr> <td>Shampoo</td> <td>Clobex</td> <td>0.05</td> </tr> <tr> <td>Solution (scalp)</td> <td>Temovate, Cormax</td> <td>0.05</td> </tr> <tr> <td>Spray aerosol</td> <td>Clobex</td> <td>0.05</td> </tr> <tr> <td>Diflucortolone valerate (not available in United States)</td> <td>Ointment, oily cream</td> <td>Nerisone Forte (United Kingdom, others)</td> <td>0.3</td> </tr> <tr> <td>Fluocinonide</td> <td>Cream</td> <td>Vanos</td> <td>0.1</td> </tr> <tr> <td>Flurandrenolide</td> <td>Tape (roll)</td> <td>Cordran</td> <td>4 mcg/cm<sup>2</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Halobetasol propionate</td> <td>Ointment</td> <td>Ultravate</td> <td>0.05</td> </tr> <tr> <td>Cream</td> <td>Ultravate</td> <td>0.05</td> </tr> <tr class=\"divider_bottom\"> <td>Lotion</td> <td>Ultravate</td> <td>0.05</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"15\"><strong>High potency<br /> (group 2)</strong></td> <td>Amcinonide</td> <td>Ointment</td> <td>Cyclocort<sup>&#182;</sup>, Amcort<sup>&#182;</sup></td> <td>0.1</td> </tr> <tr> <td rowspan=\"2\">Betamethasone dipropionate</td> <td>Ointment</td> <td>Diprosone</td> <td>0.05</td> </tr> <tr> <td>Cream, augmented formulation (AF)</td> <td>Diprolene AF</td> <td>0.05</td> </tr> <tr> <td>Clobetasol propionate</td> <td>Cream</td> <td>Impoyz</td> <td>0.025</td> </tr> <tr> <td rowspan=\"3\">Desoximetasone</td> <td>Ointment</td> <td>Topicort</td> <td>0.25</td> </tr> <tr> <td>Cream</td> <td>Topicort</td> <td>0.25</td> </tr> <tr> <td>Gel</td> <td>Topicort</td> <td>0.05</td> </tr> <tr> <td rowspan=\"2\">Diflorasone diacetate</td> <td>Ointment</td> <td>ApexiCon<sup>&#182;</sup>, Florone<sup>&#182;</sup></td> <td>0.05</td> </tr> <tr> <td>Cream, emollient</td> <td>ApexiCon E</td> <td>0.05</td> </tr> <tr> <td rowspan=\"4\">Fluocinonide</td> <td>Ointment</td> <td>Lidex<sup>&#182;</sup></td> <td>0.05</td> </tr> <tr> <td>Gel</td> <td>Lidex<sup>&#182;</sup></td> <td>0.05</td> </tr> <tr> <td>Cream anhydrous</td> <td>Lidex<sup>&#182;</sup></td> <td>0.05</td> </tr> <tr> <td>Solution</td> <td>Lidex<sup>&#182;</sup></td> <td>0.05</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Halcinonide</td> <td>Ointment</td> <td>Halog</td> <td>0.1</td> </tr> <tr class=\"divider_bottom\"> <td>Cream</td> <td>Halog</td> <td>0.1</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"13\"><strong>High potency<br /> (group 3)</strong></td> <td rowspan=\"2\">Amcinonide</td> <td>Cream</td> <td>Cyclocort<sup>&#182;</sup>, Amcort<sup>&#182;</sup></td> <td>0.1</td> </tr> <tr> <td>Lotion</td> <td>Amcort<sup>&#182;</sup></td> <td>0.1</td> </tr> <tr> <td>Betamethasone dipropionate</td> <td>Cream, hydrophilic emollient</td> <td>Diprosone</td> <td>0.05</td> </tr> <tr> <td rowspan=\"2\">Betamethasone valerate</td> <td>Ointment</td> <td>Valisone<sup>&#182;</sup></td> <td>0.1</td> </tr> <tr> <td>Foam</td> <td>Luxiq</td> <td>0.12</td> </tr> <tr> <td>Desoximetasone</td> <td>Cream</td> <td>Topicort LP</td> <td>0.05</td> </tr> <tr> <td>Diflorasone diacetate</td> <td>Cream</td> <td>Florone<sup>&#182;</sup></td> <td>0.05</td> </tr> <tr> <td>Diflucortolone valerate (not available in United States)</td> <td>Cream, oily cream, ointment</td> <td>Nerisone (Canada, United Kingdom, others)</td> <td>0.1</td> </tr> <tr> <td>Fluocinonide</td> <td>Cream aqueous emollient</td> <td>Lidex-E<sup>&#182;</sup></td> <td>0.05</td> </tr> <tr> <td>Fluticasone propionate</td> <td>Ointment</td> <td>Cutivate</td> <td>0.005</td> </tr> <tr> <td>Mometasone furoate</td> <td>Ointment</td> <td>Elocon</td> <td>0.1</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Triamcinolone acetonide</td> <td>Ointment</td> <td>Kenalog<sup>&#182;</sup></td> <td>0.5</td> </tr> <tr class=\"divider_bottom\"> <td>Cream</td> <td>Triderm, Aristocort HP<sup>&#182;</sup></td> <td>0.5</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"11\"><strong>Medium potency<br /> (group 4)</strong></td> <td>Betamethasone dipropionate</td> <td>Spray</td> <td>Sernivo</td> <td>0.05</td> </tr> <tr> <td>Clocortolone pivalate</td> <td>Cream</td> <td>Cloderm</td> <td>0.1</td> </tr> <tr> <td>Fluocinolone acetonide</td> <td>Ointment</td> <td>Synalar<sup>&#182;</sup></td> <td>0.025</td> </tr> <tr> <td>Flurandrenolide</td> <td>Ointment</td> <td>Cordran</td> <td>0.05</td> </tr> <tr> <td>Hydrocortisone valerate</td> <td>Ointment</td> <td>Westcort</td> <td>0.2</td> </tr> <tr> <td rowspan=\"3\">Mometasone furoate</td> <td>Cream</td> <td>Elocon</td> <td>0.1</td> </tr> <tr> <td>Lotion</td> <td>Elocon</td> <td>0.1</td> </tr> <tr> <td>Solution</td> <td>Elocon<sup>&#182;</sup></td> <td>0.1</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Triamcinolone acetonide</td> <td>Cream</td> <td>Kenalog<sup>&#182;</sup></td> <td>0.1</td> </tr> <tr> <td>Ointment</td> <td>Kenalog<sup>&#182;</sup></td> <td>0.1</td> </tr> <tr class=\"divider_bottom\"> <td>Aerosol spray</td> <td>Kenalog</td> <td>0.2 mg per 2 second spray</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"20\"><strong>Lower-mid potency<br /> (group 5)</strong></td> <td>Betamethasone dipropionate</td> <td>Lotion</td> <td>Diprosone</td> <td>0.05</td> </tr> <tr> <td>Betamethasone valerate</td> <td>Cream</td> <td>Beta-Val, Valisone<sup>&#182;</sup></td> <td>0.1</td> </tr> <tr> <td rowspan=\"2\">Desonide</td> <td>Ointment</td> <td>DesOwen, Tridesilon<sup>&#182;</sup></td> <td>0.05</td> </tr> <tr> <td>Gel</td> <td>Desonate</td> <td>0.05</td> </tr> <tr> <td>Fluocinolone acetonide</td> <td>Cream</td> <td>Synalar<sup>&#182;</sup></td> <td>0.025</td> </tr> <tr> <td rowspan=\"2\">Flurandrenolide</td> <td>Cream</td> <td>Cordran</td> <td>0.05</td> </tr> <tr> <td>Lotion</td> <td>Cordran</td> <td>0.05</td> </tr> <tr> <td rowspan=\"2\">Fluticasone propionate</td> <td>Cream</td> <td>Cutivate</td> <td>0.05</td> </tr> <tr> <td>Lotion</td> <td>Cutivate</td> <td>0.05</td> </tr> <tr> <td rowspan=\"5\">Hydrocortisone butyrate</td> <td>Ointment</td> <td>Locoid</td> <td>0.1</td> </tr> <tr> <td>Cream</td> <td>Locoid, Locoid Lipocream</td> <td>0.1</td> </tr> <tr> <td>Lotion, spray</td> <td>Cortizone 10 maximum</td> <td>0.1</td> </tr> <tr> <td>Lotion</td> <td>Locoid</td> <td>0.1</td> </tr> <tr> <td>Solution</td> <td>Locoid</td> <td>0.1</td> </tr> <tr> <td>Hydrocortisone probutate</td> <td>Cream</td> <td>Pandel</td> <td>0.1</td> </tr> <tr> <td>Hydrocortisone valerate</td> <td>Cream</td> <td>Westcort<sup>&#182;</sup></td> <td>0.2</td> </tr> <tr> <td rowspan=\"2\">Prednicarbate</td> <td>Cream, emollient</td> <td>Dermatop</td> <td>0.1</td> </tr> <tr> <td>Ointment</td> <td>Dermatop</td> <td>0.1</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Triamcinolone acetonide</td> <td>Lotion</td> <td>Kenalog<sup>&#182;</sup></td> <td>0.1</td> </tr> <tr class=\"divider_bottom\"> <td>Ointment</td> <td>Kenalog<sup>&#182;</sup></td> <td>0.025</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"13\"><strong>Low potency<br /> (group 6)</strong></td> <td rowspan=\"2\">Alclometasone dipropionate</td> <td>Ointment</td> <td>Aclovate</td> <td>0.05</td> </tr> <tr> <td>Cream</td> <td>Aclovate</td> <td>0.05</td> </tr> <tr> <td>Betamethasone valerate</td> <td>Lotion</td> <td>Beta-Val, Valisone<sup>&#182;</sup></td> <td>0.1</td> </tr> <tr> <td rowspan=\"3\">Desonide</td> <td>Cream</td> <td>DesOwen, Tridesilon<sup>&#182;</sup></td> <td>0.05</td> </tr> <tr> <td>Lotion</td> <td>DesOwen, LoKara</td> <td>0.05</td> </tr> <tr> <td>Foam</td> <td>Verdeso</td> <td>0.05</td> </tr> <tr> <td rowspan=\"5\">Fluocinolone acetonide</td> <td>Cream</td> <td>Synalar<sup>&#182;</sup></td> <td>0.01</td> </tr> <tr> <td>Solution</td> <td>Synalar<sup>&#182;</sup></td> <td>0.01</td> </tr> <tr> <td>Shampoo</td> <td>Capex</td> <td>0.01</td> </tr> <tr> <td>Oil (scalp)<sup>&#916;</sup></td> <td>Derma-Smoothe/FS Scalp</td> <td>0.01</td> </tr> <tr> <td>Oil (body)<sup>&#916;</sup></td> <td>Derma-Smoothe/FS Body</td> <td>0.01</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Triamcinolone acetonide</td> <td>Cream</td> <td>Kenalog<sup>&#182;</sup>, Aristocort<sup>&#182;</sup></td> <td>0.025</td> </tr> <tr class=\"divider_bottom\"> <td>Lotion</td> <td>Kenalog<sup>&#182;</sup></td> <td>0.025</td> </tr> <tr> <td rowspan=\"15\"><strong>Least potent<br /> (group 7)</strong></td> <td rowspan=\"4\">Hydrocortisone (base, &#8805;2%)</td> <td>Ointment</td> <td>Hytone</td> <td>2.5</td> </tr> <tr> <td>Cream</td> <td>Hytone, Nutracort<sup>&#182;</sup></td> <td>2.5</td> </tr> <tr> <td>Lotion</td> <td>Hytone, Ala Scalp, Scalacort</td> <td>2.5 or 2</td> </tr> <tr> <td>Solution</td> <td>Texacort</td> <td>2.5</td> </tr> <tr> <td rowspan=\"7\">Hydrocortisone (base, &#60;2%)</td> <td>Ointment</td> <td>Cortaid, Hytone, Nutracort</td> <td>1</td> </tr> <tr> <td>Cream</td> <td>Cortaid, Hytone, Synacort</td> <td>1</td> </tr> <tr> <td>Lotion</td> <td>Aquanil HC, Sarnol-HC, Cortizone 10</td> <td>1</td> </tr> <tr> <td>Spray</td> <td>Cortaid</td> <td>1</td> </tr> <tr> <td>Solution</td> <td>Cortaid, Noble, Scalp relief</td> <td>1</td> </tr> <tr> <td>Ointment</td> <td>Cortaid</td> <td>0.5</td> </tr> <tr> <td>Cream</td> <td>Cortaid</td> <td>0.5</td> </tr> <tr> <td rowspan=\"4\">Hydrocortisone acetate with pramoxine 1% combination</td> <td>Ointment</td> <td>Pramosone</td> <td>1 or 2.5</td> </tr> <tr> <td>Cream</td> <td>Pramosone, Analpram-HC</td> <td>1 or 2.5</td> </tr> <tr> <td>Lotion</td> <td>Pramosone, Analpram-HC</td> <td>1 or 2.5</td> </tr> <tr> <td>Aerosol foam</td> <td>Epifoam</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">US: United States.<br />* Listed by potency according to the US classification system: group 1 is the most potent, group 7 is the least potent. Other countries use a different classification system with only four or five groups.<br />&para; Inactive United States trade name for specific product; brand may be available outside United States.<br />&Delta; 48% refined peanut oil.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lexicomp Online. Copyright Â© 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI>&#xD;&#xA;<LI>Tadicherla S, Ross K, Shenefelt D. Topical corticosteroids in dermatology. Journal of Drugs in Dermatology 2009; 12:1093.</LI>&#xD;&#xA;<LI>U.S. Food &amp; Drug Administration Approved Drug Products with Therapeutic Equivalence (Orange Book). Available at: <A href=\"https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm\" target=_blank>https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm</A> (Accessed on June 18, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 62402 Version 45.0</div></div></div>"},"62403":{"type":"graphic_table","displayName":"Signs of antipsychotic medication overdose","title":"Atypical antipsychotic overdose: Signs and symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Atypical antipsychotic overdose: Signs and symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Alpha-1:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Dizziness, orthostatic hypotension, reflex tachycardia, miosis, nasal congestion</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Histamine-1:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>CNS depression, appetite stimulation, hypotension</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Muscarinic-1:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\">Central</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Agitation, hallucinations, memory dysfunction</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\">Peripheral</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"sublist1\">Dry skin and mucous membranes, hypertension, constipation, mydriasis, blurry vision, tachycardia, urinary retention</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62403 Version 2.0</div></div></div>"},"62404":{"type":"graphic_figure","displayName":"Simple and complex dorsal metacarpophalangeal thumb dislocations","title":"Simple versus complex dorsal metacarpophalangeal dislocations of the thumb","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Simple versus complex dorsal metacarpophalangeal dislocations of the thumb</div><div class=\"cntnt\"><img style=\"width:324px; height:441px;\" src=\"images/EM/62404_Thumbdislocationfig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simple and complex dorsal dislocations of the thumb MCP joint. Simple dislocations (A) are in extension and reducible. Complex dislocations (B) are in bayonet apposition and are irreducible because of the interposed volar plate.</div><div class=\"graphic_reference\">Reproduced with permission from: Kozin SH, Waters PM. Fractures and dislocations of the hand and carpus in children. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62404 Version 11.0</div></div></div>"},"62406":{"type":"graphic_picture","displayName":"Malignant mesothelioma Surgical","title":"Malignant mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant mesothelioma</div><div class=\"cntnt\"><img style=\"width:229px; height:322px;\" src=\"images/PULM/62406_Malignant_mesothelioma_Surg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse section of an extrapleural pneumonectomy surgical specimen with the entire right lung, parietal and visceral pleurae, portions of pericardium and the majority of the right hemidiaphragm. Note the thick rind of tumor along the pleural surface encasing the lung, interlobar fissures, and invading the diaphragm.</div><div id=\"graphicVersion\">Graphic 62406 Version 2.0</div></div></div>"},"62407":{"type":"graphic_diagnosticimage","displayName":"Subpleural cavitating lesion","title":"Small subpleural cavitating lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small subpleural cavitating lesion</div><div class=\"cntnt\"><img style=\"width:366px; height:278px;\" src=\"images/PULM/62407_Subpleural_cavitating_lesio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small peripheral cavitating lesion in a subpleural location, detected only with high resolution CT scan.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 62407 Version 3.0</div></div></div>"},"62408":{"type":"graphic_picture","displayName":"TPO Gross","title":"Tracheopathia osteochondroplastic","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheopathia osteochondroplastic</div><div class=\"cntnt\"><img style=\"width:251px; height:426px;\" src=\"images/PULM/62408_TPO_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathologic specimen with characteristic lateral tracheal wall thickening.</div><div class=\"graphic_reference\">Courtesy of Luis LG Fajardo, MD.</div><div id=\"graphicVersion\">Graphic 62408 Version 1.0</div></div></div>"},"62410":{"type":"graphic_picture","displayName":"Vitreous reaction in toxo","title":"Vitreous reaction in toxoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vitreous reaction in toxoplasmosis</div><div class=\"cntnt\"><img style=\"width:340px; height:259px;\" src=\"images/RHEUM/62410_Vitreous_reaction_in_toxo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Funduscopic photograph from a patient with toxoplasmosis reveals a severe vitreous reaction.</div><div class=\"graphic_reference\">Courtesy of Michael Tolentino, MD.</div><div id=\"graphicVersion\">Graphic 62410 Version 1.0</div></div></div>"},"62411":{"type":"graphic_picture","displayName":"Inverse psoriasis gluteal 2","title":"Inverse psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inverse psoriasis</div><div class=\"cntnt\"><img style=\"width:306px; height:432px;\" src=\"images/DERM/62411_Inverse_psoriasis_gluteal_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous plaque is present on the intergluteal skin.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62411 Version 2.0</div></div></div>"},"62412":{"type":"graphic_picture","displayName":"Chronic paracocci","title":"Clinical aspects of chronic paracoccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinical aspects of chronic paracoccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:382px; height:272px;\" src=\"images/ID/62412_Chronic_paracocci.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical findings associated with chronic paracoccidioidomycosis. (A) Cutaneous lesions of the face resulting from hematologic dissemination. The lesions are papular and ulcerating. (B) Perioral and chin lesions. (C) Cervical and submandibular lymphadenopathy with fistulization. (D) Verrucous lesion with irregular borders in the perianal region.</div><div class=\"graphic_reference\">Reproduced with permission from: Shikanai-Yasuda MA, Queiroz Telles Filho F, Mendes RP, et al. Consenso em paracoccidioidomicose [Guidelines in paracoccidioidomycosis]. Revista da Sociedade Brasileira de Medicina Tropical 2006; 39:297-310. Copyright Â©2006 Sociedade Brasileira de Medicina Tropical.</div><div id=\"graphicVersion\">Graphic 62412 Version 3.0</div></div></div>"},"62413":{"type":"graphic_algorithm","displayName":"Management of peritoneal catheter ESIs in absence of peritonitis","title":"Management of peritoneal catheter exit-site infections that occur in the absence of peritonitis in adults*","html":"<div class=\"graphic\"><div style=\"width: 1198px\" class=\"figure\"><div class=\"ttl\">Management of peritoneal catheter exit-site infections that occur in the absence of peritonitis in adults*</div><div class=\"cntnt\"><img style=\"width:1178px; height:807px;\" src=\"images/NEPH/62413_MngperitonealcthtrESIs.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* This algorithm does not address fungal infections. Fungal infections are a rare cause of exit-site infections and warrant removal of the catheter. However, it is important to confirm that cultured fungus is not a contaminant by repeating the culture and demonstrating the absence of other organisms.<br />&para; We diagnose exit-site infection if there is purulent discharge from the exit-site with or without erythema or if there is severe acute erythema without purulent discharge, which develops in the absence of acute trauma to the catheter.<br />&Delta; If the patient has a history of infection or colonization with methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), we empirically treat gram-positive infections with oral cephalexin or oral ciprofloxacin for broad-spectrum coverage plus intraperitoneal vancomycin. Vancomycin should not be used for empiric therapy in the absence of history of MRSA, since there is a high incidence of vancomycin-resistant organisms.<br /><span class=\"lozenge\">&loz;</span> If the patient has a history of infection or colonization with <em>Pseudomonas</em>, some clinicians treat gram-negative organisms or an indeterminate Gram stain with an intraperitoneal aminoglycoside, such as amikacin, in addition to other antibiotics (ie, oral ciprofloxacin or intraperitoneal ceftazidime, for gram-negative organisms, or oral ciprofloxacin and an oral penicillinase-resistant penicillin or oral first-generation cephalosporin for an indeterminate Gram stain).<br />&sect; Refer to UpToDate topic on peritoneal catheter exit-site and tunnel infections in peritoneal dialysis for discussion of treatment of resistant infection.</div><div class=\"graphic_reference\">Adapted from: Keane WF, Bailie GR, Boeschoten E, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 2000; 20:396.</div><div id=\"graphicVersion\">Graphic 62413 Version 7.0</div></div></div>"},"62415":{"type":"graphic_table","displayName":"Solute reabsorption by kidney","title":"Solute reabsorption by the kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Solute reabsorption by the kidney</div><div class=\"cntnt\"><img style=\"width:377px; height:164px;\" src=\"images/NEPH/62415_Solute_reabsorption_by_kidn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Summary of the net daily reabsorptive work performed by the kidney. These values are for a normal adult man on a typical Western diet. The glomerular filtration rate and therefore the filtered load of solutes and water is approximately 25 percent lower in women.</div><div id=\"graphicVersion\">Graphic 62415 Version 3.0</div></div></div>"},"62416":{"type":"graphic_table","displayName":"Initial coma eval and Rx childr","title":"Emergent evaluation and management of stupor and coma in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Emergent evaluation and management of stupor and coma in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Evaluation</td> </tr> <tr> <td class=\"indent1\">Vital signs and general and trauma examination</td> </tr> <tr> <td class=\"indent1\">Neurologic examination and GCS</td> </tr> <tr> <td class=\"indent1\"> <p>Fingerstick blood glucose</p> <p>Blood gas (arterial or venous)</p> <p>Screening laboratories (CBC, glucose, electrolytes, BUN, creatinine, blood and urine&nbsp;cultures, LFTs, urinalysis, urine drug screen)</p> </td> </tr> <tr> <td class=\"indent1\">Head CT scan: do urgently if focal neurologic signs, papilledema, or fever;&nbsp;consider rapid MRI instead if available</td> </tr> <tr> <td class=\"indent1\">Lumbar puncture: do urgently after CT scan if fever, elevated WBC, meningismus; otherwise do according to level of suspicion for diagnosis or if cause remains obscure</td> </tr> <tr> <td class=\"indent1\">Other laboratory tests: for metabolic conditions*, coagulation tests, carboxyhemoglobin, specific drug concentrations; do according to level of suspicion for diagnosis or if cause remains obscure</td> </tr> <tr> <td class=\"indent1\">EEG: for possible nonconvulsive seizure, or if diagnosis remains obscure</td> </tr> <tr> <td class=\"indent1\">Brain MRI with DWI, if cause remains obscure</td> </tr> <tr> <td class=\"subtitle1_single\">Management</td> </tr> <tr> <td class=\"subtitle2_single\">ABCs:</td> </tr> <tr> <td class=\"indent1\">Intubate if GCS &#8804;8 or respiratory failure</td> </tr> <tr> <td class=\"indent1\">Stabilize cervical spine</td> </tr> <tr> <td class=\"indent1\">Supplement O<sub>2</sub></td> </tr> <tr> <td class=\"indent1\">IV access</td> </tr> <tr> <td class=\"indent1\">Blood pressure support as needed</td> </tr> <tr> <td class=\"subtitle2_single\">Treat hypoglycemia identified on fingerstick. Dextrose 0.25 g/kg (2.5 mL/kg of 10% dextrose solution) after blood glucose drawn, before results back; do NOT delay pending results.</td> </tr> <tr> <td class=\"subtitle2_single\">Treat definite seizures. Initial treatment with lorazepam (0.1 mg/kg, maximum single dose&nbsp;4 mg). If seizures continue treat as for status epilepticus.</td> </tr> <tr> <td class=\"subtitle2_single\">Empiric treatments:</td> </tr> <tr> <td class=\"sublist2_start\">For suspected infection:</td> </tr> <tr> <td class=\"sublist2\">Ceftriaxone 100 mg/kg (maximum single dose 2 grams) and vancomycin (age-specific dose)</td> </tr> <tr> <td class=\"sublist2\">Acyclovir (age-specific dose)</td> </tr> <tr> <td class=\"sublist2_start\">For suspected ingestion:</td> </tr> <tr> <td class=\"sublist2\">Naloxone 0.1 mg/kg IV in patients up to 20 kg or &#8804;5 years; maximum 2 mg IV (use if opioid toxidrome: miosis, respiratory depression, hypotonia)</td> </tr> <tr> <td class=\"sublist2_start\">For suspected increased ICP:</td> </tr> <tr> <td class=\"sublist2\"> <p>Mannitol 0.5 to 1 g/kg IV; or</p> <p>Hypertonic saline 3% 5 mL/kg<em></em></p> <em>Also, elevate head and keep midline</em></td> </tr> <tr> <td class=\"sublist2_start\">For suspected nonconvulsive status epilepticus:</td> </tr> <tr> <td class=\"sublist2\">Lorazepam (0.1 mg/kg, maximum single dose&nbsp;4 mg). If suspicion of seizures continues, treat as for status epilepticus.</td> </tr> <tr> <td class=\"sublist2\">Fosphenytoin (10 to 20 PE equivalents/kg). If suspicion of seizures continues, treat as for status epilepticus.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GCS: Glasgow coma scale; CBC: complete blood count; BUN: blood urea nitrogen; LFT: liver function tests; CT: computed tomography; MRI: magnetic resonance imaging; WBC: white blood cells; EEG: electroencephalography; MRI: magnetic resonance imaging; DWI: diffusion weighted imaging; IV: intravenously;&nbsp;ICP: intracranial pressure; PE: phenytoin equivalents.<br />*&nbsp;Please refer to UpToDate topics on stupor and coma in children and toxic metabolic encephalopathy in children.</div><div id=\"graphicVersion\">Graphic 62416 Version 4.0</div></div></div>"},"62418":{"type":"graphic_picture","displayName":"Intraductal carcinoma of the prostate","title":"Intraductal carcinoma of the prostate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraductal carcinoma of the prostate</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ONC/62418_Intraduct_carcin_prostate.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62418 Version 1.0</div></div></div>"},"62419":{"type":"graphic_picture","displayName":"Jessner lymphocytic infiltration of the skin on face","title":"Jessner's lymphocytic infiltration of the skin","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Jessner's lymphocytic infiltration of the skin</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62419_Jessner_lymphocytic_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous, round plaque is present on the lateral forehead.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62419 Version 3.0</div></div></div>"},"62421":{"type":"graphic_picture","displayName":"Bleeding sessile polyp APC","title":"Argon plasma coagulation for postpolypectomy bleeding in the colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Argon plasma coagulation for postpolypectomy bleeding in the colon</div><div class=\"cntnt\"><img style=\"width:317px; height:327px;\" src=\"images/GAST/62421_Bleeding_sessile_polyp_APC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sessile polyp at hepatic flexture; (B) Immediate bleeding following polypectomy; (C + D) Bleeding controlled with the argon plasma coagulator.</div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 62421 Version 3.0</div></div></div>"},"62422":{"type":"graphic_picture","displayName":"Pseudomembranous colitis Gross","title":"Pseudomembranous colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudomembranous colitis</div><div class=\"cntnt\"><img style=\"width:398px; height:247px;\" src=\"images/GAST/62422_Pseudomembranous_colitis_Gr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross appearance of the colon from a patient with pseudomembranous colitis. The pseudomembranes are yellow or off-white raised plaques 0.2 to 2.0 cm in diameter, which are scattered over fairly normal-appearing intervening mucosa.</div><div class=\"graphic_reference\">Courtesy of J Thomas LaMont, MD.</div><div id=\"graphicVersion\">Graphic 62422 Version 1.0</div></div></div>"},"62423":{"type":"graphic_picture","displayName":"Mycosis fungoides tumor leg","title":"Mycosis fungoides - tumor stage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides - tumor stage</div><div class=\"cntnt\"><img style=\"width:419px; height:498px;\" src=\"images/HEME/62423_Mycosis_fungoides_tumor_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tumor nodules are present in this patient with tumor stage mycosis fungoides.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62423 Version 4.0</div></div></div>"},"62424":{"type":"graphic_diagnosticimage","displayName":"CPAM newborn chest x-ray","title":"Chest radiograph of a type 2 congenital pulmonary airway malformation (CPAM)*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a type 2 congenital pulmonary airway malformation (CPAM)*</div><div class=\"cntnt\"><img style=\"width:414px; height:351px;\" src=\"images/PEDS/62424_CCAM_newborn_chest_x-ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a newborn with a type 2 congenital pulmonary airway malformation (CPAM) in the right upper lobe. Large cysts are present inferiorly, and smaller more homogeneous cysts are present superiorly.</div><div class=\"graphic_footnotes\">* CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).</div><div class=\"graphic_reference\">Courtesy of Christopher M Oermann, MD.</div><div id=\"graphicVersion\">Graphic 62424 Version 4.0</div></div></div>"},"62426":{"type":"graphic_picture","displayName":"Hypermature cataract","title":"Hypermature cataract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypermature cataract</div><div class=\"cntnt\"><img style=\"width:289px; height:183px;\" src=\"images/PC/62426_Hypermature_cataract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dilated penlight photo of a hypermature cataract reveals a brown nucleus (arrow) sinking in an opaque, white, liquified cortex. There is no view of the posterior pole.</div><div class=\"graphic_reference\">Courtesy of Deborah S Jacobs, MD.</div><div id=\"graphicVersion\">Graphic 62426 Version 1.0</div></div></div>"},"62427":{"type":"graphic_picture","displayName":"Asperg tracheobronchitis","title":"Acute <em>Aspergillus</em> tracheobronchitis in a lung transplant recipient at the anastomotic site showing pseudomembrane formation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute <em>Aspergillus</em> tracheobronchitis in a lung transplant recipient at the anastomotic site showing pseudomembrane formation</div><div class=\"cntnt\"><img style=\"width:288px; height:292px;\" src=\"images/ID/62427_Asperg_tracheobronchitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14:211. Copyright Â© 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62427 Version 10.0</div></div></div>"},"62431":{"type":"graphic_figure","displayName":"Atrial tachycardia foci","title":"A schematic representation of the anatomic distribution of focal atrial tachycardias","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">A schematic representation of the anatomic distribution of focal atrial tachycardias</div><div class=\"cntnt\"><img style=\"width:510px; height:422px;\" src=\"images/CARD/62431_Atrial_tachycardia_foci.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The atrioventricular valvular annuli have been removed.</div><div class=\"graphic_footnotes\">%: percent; CS: coronary sinus; CT: crista terminalis; LA: left atrium; LAA: left atrial appendage; MA: mitral annulus; PV: pulmonary vein; RA: right atrium; RAA: right atrial appendage; TA: tricuspid annulus.</div><div class=\"graphic_reference\">Reproduced with permission from: Kistler, PM, Roberts-Thomson, KC, Haqqani, HM, et al. P-wave morphology in focal atrial tachycardia: development of an algorithm to predict the anatomic site of origin. J Am Coll Cardiol 2006; 48:1010. Copyright &#169;2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 62431 Version 1.0</div></div></div>"},"62435":{"type":"graphic_picture","displayName":"Corneal perferation in steroid-treated HSV keratitis","title":"Corneal perforation in steroid-treated herpes simplex (HSV) stromal keratitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corneal perforation in steroid-treated herpes simplex (HSV) stromal keratitis</div><div class=\"cntnt\"><img style=\"width:396px; height:266px;\" src=\"images/PC/62435_Corneal_perf_steroid_treat.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62435 Version 2.0</div></div></div>"},"62438":{"type":"graphic_picture","displayName":"Tinea capitis KOH","title":"Tinea capitis: Potassium hydroxide (KOH) preparation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea capitis: Potassium hydroxide (KOH) preparation</div><div class=\"cntnt\"><img style=\"width:414px; height:245px;\" src=\"images/PC/62438_Tinea_capitis_KOH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">KOH preparations of hairs from tinea capitis lesions. Left: Ectothrix infection (<EM>Microsporum canis</EM>). The hair shaft is encased in myriad small spores. Right: Endothrix infection (<EM>Trichophyton tonsurans</EM>). The hair matrix is packed with spores.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 62438 Version 3.0</div></div></div>"},"62441":{"type":"graphic_table","displayName":"Growth hormone insensitivity syndromes","title":"Clinical and biochemical features of growth hormone insensitivity syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and biochemical features of growth hormone insensitivity syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Growth hormone</td> <td class=\"subtitle1\">GHBP</td> <td class=\"subtitle1\">IGF-I</td> <td class=\"subtitle1\">IGFBP-3</td> <td class=\"subtitle1\">ALS</td> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">MIM</td> </tr> <tr> <td>Growth hormone receptor mutations (classic Laron syndrome)</td> <td>Postnatal growth failure, infantile facies, abnormal body composition. Mediterranean or Middle Eastern ancestry is common.*</td> <td>N or &#8593;</td> <td> <p>&#8595; (if mutation affects extracellular domain of the GH receptor)</p> <p>Otherwise N or &#8593;</p> </td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8595;</td> <td>rIGF-I</td> <td>262500</td> </tr> <tr> <td>Abnormal growth hormone receptor signal transduction (STAT5b mutation)</td> <td>Postnatal growth failure, immune dysregulation</td> <td>N or &#8593;</td> <td>N</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8595;</td> <td>rIGF-I</td> <td>245590</td> </tr> <tr> <td>IGF-I gene mutation (partial loss of function)</td> <td>Marked prenatal growth failure; postnatal growth failure, neurocognitive defects, sensorineural hearing loss</td> <td>N or &#8593;</td> <td>N</td> <td>&#8595;</td> <td>&#8593;</td> <td>N</td> <td>rIGF-I</td> <td>608747</td> </tr> <tr> <td>Defective stabilization of circulating IGF-I (acid-labile subunit deficiency)</td> <td>Mild postnatal growth failure, usually delayed puberty</td> <td>N or &#8593;</td> <td>N</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8595;&#8595;</td> <td>? rIGF-I</td> <td>601489</td> </tr> <tr> <td>IGF-I receptor mutation (partial loss of function or tissue-specific defect)</td> <td>Pre- and postnatal growth failure, delayed bone maturation, variable phenotype</td> <td>N or &#8593;</td> <td>N</td> <td>&#8593;&#8593;</td> <td>N or &#8593;</td> <td>N</td> <td>?</td> <td>270450</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GHBP: growth hormone binding protein; IGF-I: insulin-like growth factor I; IGFBP-3: insulin-like growth factor binding protein 3; ALS: acid-labile subunit; MIM: Mendelian Inheritance in Man database (National Institutes of Health); N: normal levels; rIGF-I: recombinant insulin-like growth factor I (mecasermin); STAT5b: signal transducer and activator of transcription 5B.</div><div class=\"graphic_reference\">*&nbsp;This includes a&nbsp;population with Laron syndrome in Ecuador,&nbsp;with Mediterranean (Spanish) ancestry.</div><div id=\"graphicVersion\">Graphic 62441 Version 8.0</div></div></div>"},"62442":{"type":"graphic_picture","displayName":"Nevus patchy reticular","title":"Dermoscopic image of a nevus with a patchy reticular pattern","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nevus with a patchy reticular pattern</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62442_Nevus_patchy_reticular.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 62442 Version 3.0</div></div></div>"},"62443":{"type":"graphic_figure","displayName":"Skull PI","title":"Skull bones","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Skull bones</div><div class=\"cntnt\"><img style=\"width:482px; height:556px;\" src=\"images/PI/62443_Skull-PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62443 Version 1.0</div></div></div>"},"62448":{"type":"graphic_picture","displayName":"Micrograph neurofibroma","title":"Micrograph neurofibroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micrograph neurofibroma</div><div class=\"cntnt\"><img style=\"width:278px; height:418px;\" src=\"images/NEURO/62448_Micrographneurofibroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low-power (H&amp;E, x100) and (B) High-power (H&amp;E, x600) micrographs illustrate a neurofibroma of the C1 nerve root. The tumor is moderately cellular, and the tumor cells are spindle shaped. The tumor is rich in collagen (B, arrow). Axons course through the middle of neurofibromas; a Bielschowsky or neurofilament stain is required to see them.</div><div class=\"graphic_reference\">Courtesy of John E Donahue, MD.</div><div id=\"graphicVersion\">Graphic 62448 Version 4.0</div></div></div>"},"62449":{"type":"graphic_diagnosticimage","displayName":"Omphalocele 3D ultrasound","title":"Omphalocele 3D ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Omphalocele 3D ultrasound</div><div class=\"cntnt\"><img style=\"width:360px; height:286px;\" src=\"images/OBGYN/62449_Omphalocele_3D_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a 3-dimensional ultrasound examination of a fetus with an omphalocele at 15 weeks gestation. The omphalocele sac is seen anterior to the fetal body. Note the smoothness of the outer contour of the sac.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 62449 Version 2.0</div></div></div>"},"62450":{"type":"graphic_waveform","displayName":"ECG AF via Mahaim fiber pathway","title":"12-lead electrocardiogram (ECG) showing preexcited atrial fibrillationÂ (AF) due to Mahaim fibers","html":"<div class=\"graphic normal\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing preexcited atrial fibrillation&nbsp;(AF) due to Mahaim fibers</div><div class=\"cntnt\"><img style=\"width:541px; height:305px;\" src=\"images/CARD/62450_AF_via_Mahaim_pathway.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transmission of atrial impulses to the ventricle is via an atriofascicular (Mahaim) fiber, resulting in a ventricular rate that averages 350 beats/min. The QRS complexes are wide or aberrant and have a left bundle branch block morphology and a left axis deviation, suggesting an insertion at the right ventricular apex.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 62450 Version 4.0</div></div><div style=\"width: 466px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:466px; height:324px;\" src=\"images/CARD/58149_Sinusrhythm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal sinus rhythm at a rate of 71 beats/minute, a P wave axis of 45Â°, and a PR interval of 0.15 seconds.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 58149 Version 4.0</div></div></div>"},"62452":{"type":"graphic_picture","displayName":"En coup de sabre - alopecia","title":"En coup de sabre with secondary alopecia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">En coup de sabre with secondary alopecia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/62452_En_coup_de_sabre_alopecia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A shiny, linear, hypopigmented and hyperpigmented sclerotic plaque is present on the forehead and scalp in this patient with en coup de sabre. Note the presence of secondary alopecia.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62452 Version 4.0</div></div></div>"},"62453":{"type":"graphic_diagnosticimage","displayName":"Cystic pancreatic neuroendocrine tumor","title":"Axial image of a contrast enhanced CT of the abdomen demonstrating a cystic pancreatic neuroendocrine tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axial image of a contrast enhanced CT of the abdomen demonstrating a cystic pancreatic neuroendocrine tumor</div><div class=\"cntnt\"><img style=\"width:386px; height:326px;\" src=\"images/ONC/62453_Cystic_pancreatic_tumor.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62453 Version 2.0</div></div></div>"},"62454":{"type":"graphic_figure","displayName":"Accessory AV pathways III","title":"Conduction through an accessory pathway with AV nodal delay","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Conduction through an accessory pathway with AV nodal delay</div><div class=\"cntnt\"><img style=\"width:427px; height:293px;\" src=\"images/CARD/62454_AccessoryAVpathIIIedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compared&nbsp;with conduction through an AP with normal AV node conduction, delayed conduction through the AV node allows more of the ventricular myocardium to be activated by preexcitation (shown in blue). The inset on the right shows the ECG timing of these events. The atrial to His interval is increased due to the AV nodal delay (RA to H); His activation is so delayed that it follows activation caused by the AP (V<SUB>P</SUB>). The PR interval is short due to the preexcitation, the delta wave (arrow) is more pronounced due to the greater and unopposed early forces (blue), and the QRS duration is prolonged due to the later than normal ventricular activation caused by the AV nodal delay (yellow).</div><div id=\"graphicVersion\">Graphic 62454 Version 5.0</div></div></div>"},"62455":{"type":"graphic_picture","displayName":"Resection sessile polyp Endosc","title":"Resection of a large sessile colonic polyp","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Resection of a large sessile colonic polyp</div><div class=\"cntnt\"><img style=\"width:472px; height:213px;\" src=\"images/GAST/62455_Resection_sessile_polyp_End.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sessile polyp in the sigmoid colon measuring approximately 4 cm; (B/C) A monofilament stiff snare is applied tangentially to ensnare a flat portion of the lesion. For complete resection, it is advisable to begin working from a lateral margin of the polyp; (D/E) In repeated maneuvers the polyp is resected in a piecemeal technique. (F) A retrieval net is used to collect the resected pieces; (G/H) The net can be opened and closed repeatedly without losing the previously collected pieces; (I) Resection site after complete mucosectomy; (J) Clean scar at follow-up three months later.</div><div class=\"graphic_reference\">Courtesy of Uwe Seitz, MD, Sabine Bohnacker, MD, and Nib Soehendra, MD.</div><div id=\"graphicVersion\">Graphic 62455 Version 2.0</div></div></div>"},"62456":{"type":"graphic_picture","displayName":"Unified uterine cavity","title":"Septum resected and uterine cavity now unified","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Septum resected and uterine cavity now unified</div><div class=\"cntnt\"><img style=\"width:504px; height:417px;\" src=\"images/OBGYN/62456_Unifieduterinecavity.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62456 Version 12.0</div></div></div>"},"62457":{"type":"graphic_diagnosticimage","displayName":"Severe fetal hydronephrosis","title":"Severe bilateral fetal hydronephrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe bilateral fetal hydronephrosis</div><div class=\"cntnt\"><img style=\"width:348px; height:335px;\" src=\"images/OBGYN/62457_Severe_fetal_hydronephrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial view of the fetal abdomen demonstrating spine and two kidneys with hydronephrosis in a second trimester fetus.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 62457 Version 2.0</div></div></div>"},"62458":{"type":"graphic_table","displayName":"Neoadj chemo hepatic mets CRC","title":"Results of neoadjuvant (downstaging) chemotherapy for initially unresectable colorectal cancer liver metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of neoadjuvant (downstaging) chemotherapy for initially unresectable colorectal cancer liver metastases</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Author, year</td>\r\n            <td class=\"subtitle1\" rowspan=\"2\">N</td>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Chemotherapy regimen</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">Conversion rate</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">Complete resection rate</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">n</td>\r\n            <td class=\"subtitle2\">Percent</td>\r\n            <td class=\"subtitle2\">n</td>\r\n            <td class=\"subtitle2\">Percent</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Wein A, 2001</td>\r\n            <td class=\"centered\">53</td>\r\n            <td>Infusional FU/LV</td>\r\n            <td class=\"centered\">9</td>\r\n            <td class=\"centered\">17</td>\r\n            <td class=\"centered\">6</td>\r\n            <td class=\"centered\">11</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Adam R, 2004</td>\r\n            <td class=\"centered\">1104</td>\r\n            <td>FU/LV &#177; oxaliplatin (70 percent), irinotecan, or both</td>\r\n            <td class=\"centered\">138</td>\r\n            <td class=\"centered\">12.5</td>\r\n            <td class=\"centered\">128</td>\r\n            <td class=\"centered\">11.6</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"3\">Delaunoit T, 2005</td>\r\n            <td class=\"centered\" rowspan=\"3\">795</td>\r\n            <td>Irinotecan/FU/LV</td>\r\n            <td class=\"centered\">NR</td>\r\n            <td class=\"centered\">NR</td>\r\n            <td class=\"centered\">24</td>\r\n            <td class=\"centered\">3.3*</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Oxaliplatin/FU/LV</td>\r\n            <td class=\"centered\">NR</td>\r\n            <td class=\"centered\">NR</td>\r\n            <td class=\"centered\">24</td>\r\n            <td class=\"centered\">3.3*</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Irinotecan/oxaliplatin</td>\r\n            <td class=\"centered\">NR</td>\r\n            <td class=\"centered\">NR</td>\r\n            <td class=\"centered\">24</td>\r\n            <td class=\"centered\">3.3*</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Alberts S, 2005</td>\r\n            <td class=\"centered\">42</td>\r\n            <td>Oxaliplatin/FU/LV</td>\r\n            <td class=\"centered\">17</td>\r\n            <td class=\"centered\">40</td>\r\n            <td class=\"centered\">14</td>\r\n            <td class=\"centered\">33</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\">Falcone A, 2007</td>\r\n            <td class=\"centered\">122</td>\r\n            <td>Irinotecan/FU/LV</td>\r\n            <td class=\"centered\">15</td>\r\n            <td class=\"centered\">12</td>\r\n            <td class=\"centered\">15</td>\r\n            <td class=\"centered\">12</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">122</td>\r\n            <td>Oxaliplatin/irinotecan + FU/LV</td>\r\n            <td class=\"centered\">44</td>\r\n            <td class=\"centered\">36</td>\r\n            <td class=\"centered\">44</td>\r\n            <td class=\"centered\">36</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Barone C, 2007</td>\r\n            <td class=\"centered\">40</td>\r\n            <td>Irinotecan/FU/LV</td>\r\n            <td class=\"centered\">13</td>\r\n            <td class=\"centered\">33</td>\r\n            <td class=\"centered\">13</td>\r\n            <td class=\"centered\">33</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Ychou M, 2007</td>\r\n            <td class=\"centered\">34</td>\r\n            <td>Oxaliplatin/irinotecan + FU/LV</td>\r\n            <td class=\"centered\">28</td>\r\n            <td class=\"centered\">82</td>\r\n            <td class=\"centered\">9</td>\r\n            <td class=\"centered\">27</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Masi G, 2009</td>\r\n            <td class=\"centered\">196</td>\r\n            <td>Oxaliplatin/irinotecan + FU/LV</td>\r\n            <td class=\"centered\">47</td>\r\n            <td class=\"centered\">24</td>\r\n            <td class=\"centered\">37</td>\r\n            <td class=\"centered\">19</td>\r\n        </tr>\r\n    </tbody>\r\n</table>\r\n<!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=47202&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_lgnd\">Conversion rate: number of patients with initially unresectable hepatic metastases who underwent hepatic resection after downstaging chemotherapy; Complete resection rate: number of patients who underwent complete (R0) potentially curative resection after downstaging chemotherapy.<BR>FU: fluorouracil; LV: leucovorin</div><div class=\"graphic_footnotes\">* 22 of 25 resectable patients had received an oxaliplatin-containing regimen.</div><div id=\"graphicVersion\">Graphic 62458 Version 4.0</div></div></div>"},"62459":{"type":"graphic_figure","displayName":"Ibutilide sotalol duration AF","title":"Reversion of AF with antiarrhythmic drugs is related to arrhythmia duration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reversion of AF with antiarrhythmic drugs is related to arrhythmia duration</div><div class=\"cntnt\"><img style=\"width:379px; height:235px;\" src=\"images/CARD/62459_Ibutilidesotalolduration.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study comparing two doses of intravenous ibutilide with intravenous sotalol for acute reversion of atrial fibrillation, the rate of successful reversion was inversely related to the duration of the arrhythmia prior to therapy.</div><div class=\"graphic_reference\">Data from: Vos MA, Golitsyn SR, Stangl K, et al for the Ibutilide/Sotalol Comparator Study Group, Heart 1998; 79:568.</div><div id=\"graphicVersion\">Graphic 62459 Version 2.0</div></div></div>"},"62460":{"type":"graphic_figure","displayName":"Rx precocious puberty","title":"Treatment of children with precocious puberty","html":"<div class=\"graphic\"><div style=\"width: 639px\" class=\"figure\"><div class=\"ttl\">Treatment of children with precocious puberty</div><div class=\"cntnt\"><img style=\"width:619px; height:462px;\" src=\"images/PEDS/62460_Rxprecociouspuberty.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic depiction of the pathways leading to precious puberty and the mechanisms of action for several drugs used for treatment. Central precocious puberty is also known as gonadotropin-dependent precocious puberty. For peripheral precocity (also known as gonadotropin-independent precocious puberty), the pathway for boys is shown on the left, and girls on the right.</div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone; GnRHa: gonadotropin-releasing hormone analogue (eg, leuprolide, histrelin); LH: luteinizing hormone; FSH: follicle-stimulating hormone; AR: androgen receptor; ER: estrogen receptor.<br />* Preliminary data have been reported; treatment is still experimental.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Reiter EO, Mauras N, McCormick K, et al. Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). J Pediatr Endocrinol Metab 2010; 23:999.</LI>&#xD;&#xA;<LI>Lenz AM, Shulman D, Eugster EA, et al. Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. Pediatrics 2012; 126:e728.</LI>&#xD;&#xA;<LI>Leschek EW, Jones J, Barnes KM, et al. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999; 84:175.</LI>&#xD;&#xA;<LI>Leschek EW, Flor AC, Bryant JC, et al. Effect of antiandrogen, aromatase inhibitor, and gonadotropin-releasing hormone analog on adult height in familial male precocious puberty. J Pediatr 2017; 190:229.</LI>&#xD;&#xA;<LI>Feuillan PP, Jones J, Cutler GB, et al. Letrozole treatment of precocious puberty in girls with the McCune Albright syndrome: A pilot study. J Clin Endocrinol Metab 2007; 92:2100.</LI>&#xD;&#xA;<LI>Feuillan PP, Jones J, Cutler GB Jr. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993; 77:647.</LI>&#xD;&#xA;<LI>Eugster EA, Rubin SD, Reiter EO, et al. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003; 143:60.</LI>&#xD;&#xA;<LI>Sims EK, Garnett S, Guzman F, et al. Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome. Int J Pediatr Endocrinol 2012; 2012:26.</LI></OL>Fuqua JS. Treatment and outcomes of precocious puberty: An update. J Clin Endocrinol Metab 2013; 98:2198.</div><div id=\"graphicVersion\">Graphic 62460 Version 7.0</div></div></div>"},"62461":{"type":"graphic_table","displayName":"Hazards in hobbies","title":"Examples of hazards in hobbies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of hazards in hobbies</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Activity</td>\n\n      <td class=\"subtitle1\">Potential hazard</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left_left\">Painting</td>\n\n      <td>Toxic pigments (eg, arsenic (emerald green), cadmium, chromium, lead, mercury), acrylic emulsions, solvents</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">Ceramics</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Raw materials</td>\n\n      <td class=\"sublist_other\">Colors and glazes containing barium carbonate, lead, chromium, uranium, cadmium, manganese</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist1\">Firing</td>\n\n      <td class=\"sublist_other\">Vapors of fluoride, chlorine, sulfur dioxide</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Gas-fired kilns</td>\n\n      <td class=\"sublist_other\">Carbon monoxide</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">Sculpture and casting</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Grinding silica-containing stone</td>\n\n      <td class=\"sublist_other\">Silica (silicon dioxide)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Serpentine rock with asbestos</td>\n\n      <td class=\"sublist_other\">Asbestos</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Woodworking</td>\n\n      <td class=\"sublist_other\">Wood dust</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Metal casting</td>\n\n      <td class=\"sublist_other\">Metal fume, sand (silica) from molding, binders of phenol formaldehyde or urea formaldehyde</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left_left\">Welding</td>\n\n      <td>Metal\nfume, ultraviolet light exposure, welding (metal-containing) fumes,\ncarbon dioxide, carbon monoxide, nitrogen dioxide, ozone, or phosgene\n(if solvents nearby)</td>\n\n    </tr>\n\n\n\n\n    <tr>\n\n      <td class=\"subtitle2_left_left\">Plastics</td>\n\n      <td>Monomers\nreleased during heating (polyvinyl chloride), methyl methacrylate,\nacrylic glues, polyurethanes (toluene 2,4-diisocyanate), polystyrene\n(methylchloride release), fiberglass, polyester or epoxy resins</td>\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n      <td class=\"subtitle2_left_left\">Woodstripping</td>\n\n      <td>Solvents, especially methylene chloride</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">Photography</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Developer</td>\n\n      <td class=\"sublist_other\">Hydroquinone, metal</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Stop bath</td>\n\n      <td class=\"sublist_other\">Weak acetic acid</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Stop hardener</td>\n\n      <td class=\"sublist_other\">Potassium chrome alum (chromium)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Fixer</td>\n\n      <td class=\"sublist_other\">Sodium sulfite, acetic acid-sulfur dioxide</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hardeners and stabilizers</td>\n\n      <td class=\"sublist_other\">Formaldehyde</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Goldman RH, Peters JM. JAMA 1981; 246:2831.</div><div id=\"graphicVersion\">Graphic 62461 Version 2.0</div></div></div>"},"62462":{"type":"graphic_figure","displayName":"The Calgary Depression Scale","title":"The Calgary Depression Scale","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">The Calgary Depression Scale</div><div class=\"cntnt\"><img style=\"width:605px; height:788px;\" src=\"images/PSYCH/62462_Calgary_scale_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Donald Addington, MD. For more information please visit <a href=\"http://www.ucalgary.ca/cdss\">http://www.ucalgary.ca/cdss</a>. Copyright &#169; 2010 Dr. Donald Addington and Dr. Jean Addington. All rights reserved.</div><div id=\"graphicVersion\">Graphic 62462 Version 3.0</div></div></div>"},"62465":{"type":"graphic_figure","displayName":"Distal HCO3 secretion","title":"Bicarbonate-secreting type B intercalated cells","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Bicarbonate-secreting type B intercalated cells</div><div class=\"cntnt\"><img style=\"width:467px; height:360px;\" src=\"images/NEPH/62465_DistalHCO3secretion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transport mechanisms involved in the secretion of bicarbonate (HCO<SUB>3</SUB><SUP innerHtml>â</SUP>) into the tubular lumen in the type B intercalated cells. These cells are located in the distal convoluted tubules and the connecting tubule. Water within the cell dissociates into hydrogen (H<SUP innerHtml>+</SUP>) and hydroxide (OH<SUP innerHtml>â</SUP>) ions. The former are secreted into the peritubular capillary by H-ATPase pumps in the basolateral membrane. The OH<SUP>â</SUP> ions combine with carbon dioxide (CO<SUB>2</SUB>)&nbsp;to form HCO<SUB>3</SUB><SUP>â</SUP> in a reaction catalyzed by carbonic anhydrase (CA). HCO<SUB>3</SUB><SUP>â</SUP> is then secreted into the tubular lumen via chloride (Cl)-HCO<SUB>3</SUB> exchangers in the luminal membrane. This exchanger is a unique protein called pendrin. The favorable inward concentration gradient for Cl<SUP innerHtml>â</SUP> (lumen concentration greater than that in the cell) provides the energy for HCO<SUB>3</SUB><SUP>â</SUP> secretion.</div><div id=\"graphicVersion\">Graphic 62465 Version 7.0</div></div></div>"},"62466":{"type":"graphic_picture","displayName":"Ragged red fibers","title":"Ragged red fibers","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Ragged red fibers</div><div class=\"cntnt\"><img style=\"width:540px; height:372px;\" src=\"images/NEURO/62466_Ragged_red_fibers_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skeletal muscle biopsy from another patient shows ragged red muscle fibers admixed with a population of relatively normal muscle fibers (Gomori trichrome stain). The ragged red fibers represent abnormal accumulations of mitochondria beneath the plasma membrane and between the myofibrils.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright Â© 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62466 Version 7.0</div></div></div>"},"62467":{"type":"graphic_diagnosticimage","displayName":"U-S cervix in PTL","title":"Endovaginal ultrasound image of the cervix in a woman with preterm labor","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Endovaginal ultrasound image of the cervix in a woman with preterm labor</div><div class=\"cntnt\"><img style=\"width:468px; height:308px;\" src=\"images/OBGYN/62467_U-S_cervix_in_PTL.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jay D Iams, MD.</div><div id=\"graphicVersion\">Graphic 62467 Version 2.0</div></div></div>"},"62468":{"type":"graphic_picture","displayName":"Consequences of treatment delay for breast abscess","title":"Consequences of treatment delay for breast abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Consequences of treatment delay for breast abscess</div><div class=\"cntnt\"><img style=\"width:363px; height:504px;\" src=\"images/PC/62468_Treatment_delay.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast abscess where there was a delay (A) at diagnosis and (B) poor cosmetic outcome due to delay in treatment.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 62468 Version 3.0</div></div></div>"},"62471":{"type":"graphic_picture","displayName":"Eruptive xanthoma","title":"Eruptive xanthoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eruptive xanthoma</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/62471_Eruptive_xanthoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 37-year-old woman underwent in vitro fertilization and was treated with 800 mg of progesterone each day for&nbsp;seven days. She developed cholestasis, jaundice, and small pruritic papules on elbows, hands, and knees. She had a family history of diabetes but was free of disease. Blood tests were characteristic of type IV hyperlipoproteinemia with hypertriglyceridemia, hypercholesterolemia, decreased LDLs, decreased HDLs, and elevated liver enzymes.</div><div class=\"graphic_reference\">Copyright Â© Ana Maria Sortino-Rachou, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 62471 Version 6.0</div></div></div>"},"62473":{"type":"graphic_figure","displayName":"Efficacy octreotide acromegaly","title":"Effect of octreotide on serum IGF-1","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Effect of octreotide on serum IGF-1</div><div class=\"cntnt\"><img style=\"width:506px; height:528px;\" src=\"images/ENDO/62473_Efficacyoctreotideacromeg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this study of previously untreated acromegalic patients, 18 with macroadenomas and 6 with microadenomas, short-acting octreotide was administered for 24 weeks and then long-acting octreotide to 15 of the patients for another 24 weeks. Open circles represent the pre-treatment IGF-1 concentration, bull's eye marks the values at 24 weeks, and the closed circles the values at 48 weeks. N indicates normal age-related IGF-1 concentration at latest assessment.</div><div class=\"graphic_footnotes\">IGF-1: insulin-like growth factor-1.</div><div class=\"graphic_reference\">Data from: Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002; 87:4554.</div><div id=\"graphicVersion\">Graphic 62473 Version 2.0</div></div></div>"},"62474":{"type":"graphic_figure","displayName":"ER Barretts","title":"Schematic drawing showing the consecutive steps of the endoscopic resection-cap procedure of a focal lesion in a Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic drawing showing the consecutive steps of the endoscopic resection-cap procedure of a focal lesion in a Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:447px; height:441px;\" src=\"images/GAST/62474_EMR_Barretts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A and B) A transparent cap is attached to the distal tip of the endoscope and the target lesion is lifted by injection of a fluid, usually diluted epinephrine (1:100.000), into the submucosal layer, using a standard sclerotherapy needle.<BR>(C and D) After removal of the needle, a crescent shaped snare is positioned into a distal ridge within the cap. The lesion is sucked into the cap thus creating a pseudo-polyp that is immediately captured by forcefully closing the pre-positioned EMR-snare.<BR>(E) The lesion is removed using electrocoagulation.</div><div class=\"graphic_footnotes\">EMR: endoscopic mucosal resection.</div><div class=\"graphic_reference\">Reproduced with permission from: www.Barrett.nl. Copyright &copy; Amsterdam Esophageal Research Foundation.</div><div id=\"graphicVersion\">Graphic 62474 Version 4.0</div></div></div>"},"62477":{"type":"graphic_picture","displayName":"Penicillium marneffei in an AIDS patient","title":"Penicillium marneffei in an AIDS patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penicillium marneffei in an AIDS patient</div><div class=\"cntnt\"><img style=\"width:312px; height:432px;\" src=\"images/ID/62477_Penicillium_marneffei_HIV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous lesions resulted from the dissemination of the fungus from the lungs. The patient's underlying disease is AIDS.</div><div class=\"graphic_reference\">Courtesy of www.doctorfungus.org. Copyright &#169; 2006.</div><div id=\"graphicVersion\">Graphic 62477 Version 2.0</div></div></div>"},"62480":{"type":"graphic_picture","displayName":"Erythema migrans bulls eye","title":"Classic \"bull's eye\" erythema migrans lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic &quot;bull's eye&quot; erythema migrans lesion</div><div class=\"cntnt\"><img style=\"width:396px; height:298px;\" src=\"images/PEDS/62480_Erythema_migrans_bulls_eye.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Eugene D Shapiro, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 62480 Version 1.0</div></div></div>"},"62481":{"type":"graphic_table","displayName":"Patient instructions regarding fever and infections","title":"Patient instructions regarding fever and infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient instructions regarding fever and infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Selective IgM deficiency - What you should know about infections</td> </tr> <tr> <td>Name:</td> </tr> <tr> <td>Date:</td> </tr> <tr> <td> <p>Health care provider's name and contact information:</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\">What is it?</td> </tr> <tr> <td class=\"indent1\">Selective IgM deficiency is a condition of the immune system in which a person has very low levels of a protein called antibody M in the blood. In people with this condition, the levels of other antibodies are normal.</td> </tr> <tr> <td class=\"subtitle2_left\">What problems can occur in people with selective IgM deficiency?</td> </tr> <tr> <td class=\"indent1\"> <p>Some people with selective IgM deficiency are completely well and have no problems.</p> <p>Others get severe infections or repeated infections with viruses and bacteria. Such infections most commonly involve the lungs, sinuses, ears, skin, or blood stream (called sepsis).</p> </td> </tr> <tr> <td class=\"subtitle2_left\">What should I do if I get sick?</td> </tr> <tr> <td class=\"indent1\"> <p>You should contact a health care provider if you have a fever (a temperature higher than 100.5&#176;F or 38&#176;C) or an infection that seems to be anything worse than a normal cold.</p> <p>You should tell the provider that you have selective IgM deficiency and that you have been told to be seen when you get sick.</p> <p>Blood stream infections can begin as a fever that does not seem to be related to a cold or an infection in a specific part of the body. If you develop an unexplained fever like this, see a health care provider right away. Your blood may need to be tested for infection.</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgM: immunoglobulin M.</div><div id=\"graphicVersion\">Graphic 62481 Version 4.0</div></div></div>"},"62483":{"type":"graphic_table","displayName":"Features CVS children","title":"Clinical/epidemiological features of cyclic vomiting syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical/epidemiological features of cyclic vomiting syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Feature</td>\r\n                    <td class=\"subtitle1\">Characterization</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Female:male ratio</td>\r\n                    <td>55:45</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Age of onset</td>\r\n                    <td>5.3 years</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Morbidity</td>\r\n                    <td>20 days of missed school per year, 50 percent of patients require intravenous hydration</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\" colspan=\"2\">Symptoms:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Vomiting</td>\r\n                    <td class=\"sublist_other\">6 times/hr at peak, with bile (76 percent) and blood (32 percent)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Autonomic</td>\r\n                    <td class=\"sublist_other\">Lethargy (91 percent), pallor (87 percent), fever (29 percent), salivation (13 percent)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Gastrointestinal</td>\r\n                    <td class=\"sublist_other\">Abdominal pain (80 percent), retching (78 percent), anorexia (74 percent), nausea (72 percent), diarrhea (36 percent)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Neurologic</td>\r\n                    <td class=\"sublist_other\">Headache (40 percent), photophobia (32 percent), phonophobia (28 percent), vertigo (22 percent)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Temporal pattern</td>\r\n                    <td>24 to 48 hours duration; 47 percent of patients have episodes at regular intervals, usually two to four weeks; episodes occur at night or early morning in 34 to 60 percent of patients; 98 percent of patients show a stereotypical pattern</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Precipitating events</td>\r\n                    <td>Infection (41 percent), psychological stress (34 percent), dietary (26 percent), menstrual (13 percent), some trigger identified in 68 percent of patients</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Natural history</td>\r\n                    <td>3.4 year duration; 28 percent of patients progress to migraine headaches; predicted 75 percent progress to migraines by age 18 years</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Family history of migraine</td>\r\n                    <td>Present in 82 percent of patients</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Adapted from: Li BU, Balint JP. Cyclic vomiting syndrome: Evolution in understanding of a brain-gut disorder. Adv Pediatr 2000; 47:117 and Li BU. Cyclic vomiting: New understanding of an old disorder. Contemp Pediatr 1996; 17:48.</div><div id=\"graphicVersion\">Graphic 62483 Version 3.0</div></div></div>"},"62485":{"type":"graphic_figure","displayName":"T shaped uterus 3","title":"Diethylstilbestrol (DES)-related anomalies: T-shaped uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diethylstilbestrol (DES)-related anomalies: T-shaped uterus</div><div class=\"cntnt\"><img style=\"width:352px; height:202px;\" src=\"images/OBGYN/62485_VariationofTshapeduteru.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62485 Version 12.0</div></div></div>"},"62487":{"type":"graphic_table","displayName":"Cardioactive herbal ingredients","title":"Cardioactive herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardioactive herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Drug</td>\n\n      <td class=\"subtitle1\">Effect</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Broom</td>\n\n      <td>Alkaloid constituents; cardiac depressant activity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Calamus</td>\n\n      <td>Antiarrhythmic activity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cereus</td>\n\n      <td>Tyramine; cardiotonic amine</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cola</td>\n\n      <td>Caffeine</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Coltsfoot</td>\n\n      <td>Cardiac calcium channel blocking activity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Devil's claw</td>\n\n      <td>Activity in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fenugreek</td>\n\n      <td>Activity in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Figwort</td>\n\n      <td>Cardioactive glycoside constituents; activity in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fumitory</td>\n\n      <td>Alkaloid constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ginger</td>\n\n      <td>Activity in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ginseng, panax</td>\n\n      <td>Activity in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Golden seal alkaloid</td>\n\n      <td>Berberine; cardioactive</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Hawthorn</td>\n\n      <td>Tyramine; cardiotonic amine; activity in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Horehound, white</td>\n\n      <td>Activity in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lime flower</td>\n\n      <td>Activity reputed with excessive ingestion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mat&#233;</td>\n\n      <td>Caffeine</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mistletoe</td>\n\n      <td>Viscotoxin; negative inotropic effect</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Motherwort</td>\n\n      <td>Cardiac glycoside constituents; activity in vitro</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Parsley</td>\n\n      <td>Apiole poisoning, high doses</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pleurisy root</td>\n\n      <td>Cardenolides, active in vitro and in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Prickly ash, nothern</td>\n\n      <td>Interaction with Na-K-ATPase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Prickly ash, southern</td>\n\n      <td>Interaction with Na-K-ATPase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Quassia</td>\n\n      <td>Activity in vitro</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Shepherd's purse</td>\n\n      <td>Activity in vitro</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Squill</td>\n\n      <td>Cardiac glycoside constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wild carrot</td>\n\n      <td>Depressant activity in vivo</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals. The Pharmaceutical Press 1996, p. 277.</div><div id=\"graphicVersion\">Graphic 62487 Version 2.0</div></div></div>"},"62488":{"type":"graphic_table","displayName":"Side effects antidepressants","title":"Side effects of antidepressant medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Side effects of antidepressant medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Anticholinergic</td> <td class=\"subtitle1\">Drowsiness</td> <td class=\"subtitle1\">Insomnia/agitation</td> <td class=\"subtitle1\">Orthostatic hypotension</td> <td class=\"subtitle1\">QTc prolongation*</td> <td class=\"subtitle1\">Gastrointestinal toxicity</td> <td class=\"subtitle1\">Weight gain</td> <td class=\"subtitle1\">Sexual dysfunction</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Selective serotonin reuptake inhibitors (SSRIs)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Citalopram</td> <td>0</td> <td>0</td> <td>1+</td> <td>1+</td> <td>1+<sup>&#916;</sup></td> <td>1+ (all SSRIs: see<sup>&#182;</sup>)</td> <td>1+</td> <td>3+</td> </tr> <tr> <td class=\"indent1\">Escitalopram</td> <td>0</td> <td>0</td> <td>1+</td> <td>1+</td> <td>1+</td> <td>1+</td> <td>1+</td> <td>3+</td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> <td>0</td> <td>0</td> <td>2+</td> <td>1+</td> <td>1+</td> <td>1+</td> <td>1+</td> <td>3+</td> </tr> <tr> <td class=\"indent1\">Fluvoxamine</td> <td>0</td> <td>1+</td> <td>1+</td> <td>1+</td> <td>0 to 1+</td> <td>1+</td> <td>1+</td> <td>3+</td> </tr> <tr> <td class=\"indent1\">Paroxetine</td> <td>1+</td> <td>1+</td> <td>1+</td> <td>2+</td> <td>0 to 1+</td> <td>1+</td> <td>2+</td> <td>4+</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sertraline</td> <td>0</td> <td>0</td> <td>2+</td> <td>1+</td> <td>0 to 1+</td> <td>2+<sup>&#9674;</sup></td> <td>1+</td> <td>3+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Atypical agents</td> </tr> <tr> <td class=\"indent1\">Agomelatine<sup>&#167;</sup> (not available in United States)</td> <td>0</td> <td>1+</td> <td>1+</td> <td>0</td> <td>0</td> <td>1+</td> <td>0</td> <td>0 to 1+</td> </tr> <tr> <td class=\"indent1\">Bupropion</td> <td>0</td> <td>0</td> <td> <p>2+ (immediate release)</p> 1+ (sustained release)</td> <td>0</td> <td>1+</td> <td>1+</td> <td>0</td> <td>0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mirtazapine</td> <td>1+</td> <td>4+</td> <td>0</td> <td>0</td> <td>1+</td> <td>0</td> <td>4+</td> <td>1+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Serotonin-norepinephrine reuptake inhibitors (SNRIs)<sup>&#182;,&#9674;&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Desvenlafaxine<sup>&#165;</sup></td> <td>0</td> <td>0</td> <td>1+</td> <td>0</td> <td>0</td> <td> <p>2+</p> </td> <td>unknown</td> <td>1+</td> </tr> <tr> <td class=\"indent1\">Duloxetine</td> <td>0</td> <td>0</td> <td>1+</td> <td>0</td> <td>0</td> <td>2+<sup>&#182;</sup></td> <td>0-1+</td> <td>1+</td> </tr> <tr> <td class=\"indent1\">Levomilnacipran<sup>&#165;</sup></td> <td>0<sup>&#135;</sup></td> <td>0</td> <td>0-1+</td> <td>0-1+</td> <td>0</td> <td>2+<sup>&#182;</sup></td> <td>0</td> <td>1+</td> </tr> <tr> <td class=\"indent1\">Milnacipran<sup>&#165;</sup></td> <td>0</td> <td>1+</td> <td>0</td> <td>0</td> <td>0</td> <td>2+<sup>&#182;</sup></td> <td>0</td> <td>1+</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Venlafaxine<sup>&#165;</sup></td> <td>0</td> <td>1+</td> <td>1+</td> <td>0</td> <td>1+</td> <td> <p>2+ </p> </td> <td>0-1+</td> <td>3+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Serotonin modulators</td> </tr> <tr> <td class=\"indent1\">Nefazodone<sup>&#182;&#182;</sup></td> <td>1+</td> <td>2+</td> <td>0</td> <td>1+</td> <td>0</td> <td>2+</td> <td>0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Trazodone</td> <td>0</td> <td>4+</td> <td>0</td> <td> <p>1+ (hypnotic dose)</p> 3+ (antidepressant dose)</td> <td> <p>1+ (hypnotic dose)</p> 2+ (antidepressant dose)</td> <td> <p>1+ (hypnotic dose)</p> 3+ (antidepressant dose)</td> <td> <p>0 (hypnotic dose)</p> 1+ (antidepressant dose)</td> <td>1+<sup>&#134;</sup></td> </tr> <tr> <td class=\"indent1\">Vilazodone</td> <td>0</td> <td>0</td> <td>2+</td> <td>0</td> <td>0</td> <td>4+**</td> <td>0</td> <td>2+</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vortioxetine</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>3+</td> <td>0</td> <td>1+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Tricyclic and tetracyclic antidepressants (TCAs)<sup>&#916;&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Amitriptyline</td> <td>4+</td> <td>4+</td> <td>0</td> <td>3+</td> <td>3+</td> <td>1+ (all TCAs see<sup>&#916;&#916;</sup>)</td> <td>4+</td> <td>3 to 4+</td> </tr> <tr> <td class=\"indent1\">Amoxapine</td> <td>2+</td> <td>2+</td> <td>2+</td> <td>2+</td> <td>2+</td> <td>0</td> <td>2+</td> <td>ND</td> </tr> <tr> <td class=\"indent1\">Clomipramine</td> <td>4+</td> <td>4+</td> <td>1+</td> <td>2+</td> <td>2+</td> <td>1+</td> <td>4+</td> <td>4+</td> </tr> <tr> <td class=\"indent1\">Desipramine</td> <td>1+</td> <td>2+</td> <td>1+</td> <td>2+</td> <td>3+</td> <td>0</td> <td>1+</td> <td>ND</td> </tr> <tr> <td class=\"indent1\">Doxepin</td> <td>3+</td> <td>3+</td> <td>0</td> <td>2+</td> <td>3+</td> <td>0</td> <td>4+</td> <td>3+</td> </tr> <tr> <td class=\"indent1\">Imipramine</td> <td>3+</td> <td>3+</td> <td>1+</td> <td>4+</td> <td>3+</td> <td>1+</td> <td>4+</td> <td>3+</td> </tr> <tr> <td class=\"indent1\">Maprotiline</td> <td>2+</td> <td>3+</td> <td>0</td> <td>2+</td> <td>3+</td> <td>0</td> <td>2+</td> <td>ND</td> </tr> <tr> <td class=\"indent1\">Nortriptyline</td> <td>2+</td> <td>2+</td> <td>0</td> <td>1+</td> <td>3+</td> <td>0</td> <td>1+</td> <td>ND</td> </tr> <tr> <td class=\"indent1\">Protriptyline</td> <td>2+</td> <td>1+</td> <td>1+</td> <td>2+</td> <td>3+</td> <td>1+</td> <td>1+</td> <td>3 to 4+</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trimipramine</td> <td>4+</td> <td>4+</td> <td>1+</td> <td>3+</td> <td>1+</td> <td>0</td> <td>4+</td> <td>ND</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Monoamine oxidase inhibitors</td> </tr> <tr> <td class=\"indent1\">Isocarboxazid</td> <td>1+</td> <td>1+</td> <td>2+</td> <td>2+</td> <td>0</td> <td>1+</td> <td>1+</td> <td>4+</td> </tr> <tr> <td class=\"indent1\">Phenelzine</td> <td>1+</td> <td>2+</td> <td>1+</td> <td>3+</td> <td>0</td> <td>1+</td> <td>2+</td> <td>4+</td> </tr> <tr> <td class=\"indent1\">Selegiline</td> <td>1+</td> <td>0</td> <td>1+</td> <td>1+</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Tranylcypromine</td> <td>1+</td> <td>1+</td> <td>2+</td> <td>2+</td> <td>0</td> <td>1+</td> <td>1+</td> <td>4+</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Scale: 0 = none; 1+ = slight; 2+ = low; 3+ = moderate; 4+ = high; ND = inadequate data.</div><div class=\"graphic_footnotes\">* Risk of QTc prolongation or torsades de pointes is also elevated with advanced age, female sex, heart disease, congenital long QT syndrome, hypokalemia or hypomagnesemia, elevated serum drug concentrations (eg, drug overdose, interacting drugs, organ failure) and combination of drugs with QTc prolonging effects. Refer to topic on acquired long QT syndrome.<br />Â¶ All SSRIs and SNRIs are associated with transient nausea and gastrointestinal discomfort upon initiation or dose increase.<br />Î Based upon reports of dose related QTc prolongation and arrhythmia, the maximum recommended dose of citalopram is 20 mg for patients at increased risk of elevated citalopram serum concentrations.<br /><FONT class=lozenge>â</FONT> Sertraline is associated with higher rates of diarrhea.<br />Â§ Agomelatine may be hepatotoxic and is contraindicated with any degree of liver impairment. Transaminase monitoring is required.<br />Â¥ May cause persistent dose-related increases in blood pressure (primarily diastolic) and heart rate. Monitor blood pressure regularly.<br />â¡ Levomilnacipran has dose dependent effects on urinary hesitancy.<br />â  Trazodone is associated rarely with priapism, which is considered a medical emergency. Refer to UpToDate topic on Serotonin modulators.<br />** Vilazodone is associated with higher rates of nausea, vomiting, and diarrhea.<br />Â¶Â¶ Caution: can cause liver failure. Not available in Europe, Canada, and several other countries.<br />ÎÎ Gastrointestinal forms of anticholinergic side effects include: dry mouth, constipation, epigastric distress, decreased esophagogastric tone. Refer to \"Anticholinergic\" data for frequency rankings.<br />ââ None of the SNRIs have anticholinergic activity. However,&nbsp;SNRIs can produce anticholinergic-like effects (which appear to be mediated by noradrenergic effects on the autonomic nervous system) such as dry mouth and constipation,&nbsp;and should be used with caution in narrow angle glaucoma.&nbsp;In addition, levomilnacipran is associated with urinary hesitancy.&nbsp;</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Nelson JC. Tricyclic and tetracyclic drugs. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed, Schatzberg AF, Nemeroff CB (Ed), American Psychiatric Publishing, Washington, DC 2009. p.263.</LI>&#xD;&#xA;<LI>Wenzel-Seifert K, Wittmann M, Haen E: QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int 2011; 108:687.</LI>&#xD;&#xA;<LI>Reichenpfader U, Gartlehner G, Morgan LC, et al.&nbsp;Sexual dysfunction associated with second generation antidepressants in patients with major depressive disorder: Results from a systematic review with network meta-analysis. Drug Saf&nbsp;2014; 37:19.</LI>&#xD;&#xA;<LI>Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf 2011; 34:709.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright Â© 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI>&#xD;&#xA;<LI>Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016; 30:242.</LI></OL></div><div id=\"graphicVersion\">Graphic 62488 Version 17.0</div></div></div>"},"62490":{"type":"graphic_diagnosticimage","displayName":"3D ultrasound of displaced IUD","title":"Three-dimensional ultrasound of displaced IUD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three-dimensional ultrasound of displaced IUD</div><div class=\"cntnt\"><img style=\"width:413px; height:444px;\" src=\"images/OBGYN/62490_US_displaced_IUD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional (3D) reconstructed ultrasound images can be helpful in assessing intrauterine contraceptive device (IUD) position. This 3D image shows the shaft of the IUD in the expected location. The right cross bar is slightly low, deviated downward.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 62490 Version 2.0</div></div></div>"},"62491":{"type":"graphic_picture","displayName":"Cellulitis of the forearm","title":"Cellulitis of the forearm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cellulitis of the forearm</div><div class=\"cntnt\"><img style=\"width:360px; height:540px;\" src=\"images/SURG/62491_Cellulitis_hand_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cellulitis is characterized by a warm, tender area of erythema that is well demarcated and progresses over time. The skin surrounding the area of erythema may be edematous. The photograph shows forearm cellulitis that developed following repair of lacerations.</div><div id=\"graphicVersion\">Graphic 62491 Version 3.0</div></div></div>"},"62492":{"type":"graphic_table","displayName":"B19 associated conditions","title":"Conditions associated with parvovirus B19 infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with parvovirus B19 infection</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td>Acute heart failure</td> </tr> <tr> <td>Myocarditis</td> </tr> <tr> <td>Pericardial effusions</td> </tr> <tr> <td>Pericarditis</td> </tr> <tr> <td>Generalized edema&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Cutaneous</td> </tr> <tr> <td><strong><em>Gianotti-Crosti syndrome (papular acrodermatitis of childhood and papulovesicular acrolated syndrome)</em></strong></td> </tr> <tr> <td><strong><em>Papular-purpuric gloves and socks syndrome</em></strong></td> </tr> <tr> <td><strong><em>Vascular purpura</em></strong></td> </tr> <tr> <td>Acute renal failure</td> </tr> <tr> <td>Erythema nodosum</td> </tr> <tr> <td>Erythema multiforme</td> </tr> <tr> <td>Livedo reticularis</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic</td> </tr> <tr> <td><strong><em>Hemophagocytic syndrome</em></strong></td> </tr> <tr> <td>Aplastic anemia (not transient)</td> </tr> <tr> <td>Autoimmune hemolytic anemia</td> </tr> <tr> <td>Chronic neutropenia</td> </tr> <tr> <td>Thrombocytopenia purpura</td> </tr> <tr> <td>Transient erythroblastopenia of childhood</td> </tr> <tr> <td>Juvenile idiopathic arthritis</td> </tr> <tr> <td class=\"subtitle1_single\">Hepatobiliary</td> </tr> <tr> <td>Elevated liver enzymes</td> </tr> <tr> <td>Acute liver failure</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td><strong><em>Brachial plexus abnormalities</em></strong></td> </tr> <tr> <td>Sensorineural abnormalities</td> </tr> <tr> <td>Meningitis/encephalopathy</td> </tr> <tr> <td>Seizures</td> </tr> <tr> <td class=\"subtitle1_single\">Ocular</td> </tr> <tr> <td>Conjunctivitis</td> </tr> <tr> <td>Ophthalmoplegia</td> </tr> <tr> <td class=\"subtitle1_single\">Renal</td> </tr> <tr> <td>Acute renal failure</td> </tr> <tr> <td>Nephrotic syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Respiratory</td> </tr> <tr> <td>Acute chest syndrome in sickle cell disease</td> </tr> <tr> <td>Pleural effusions</td> </tr> <tr> <td>Pneumonia</td> </tr> <tr> <td class=\"subtitle1_single\">Rheumatic</td> </tr> <tr> <td>Autoimmunity and immune mediated inflammation</td> </tr> <tr> <td>Juvenile idiopathic arthritis</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Vasculitis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Those for which B19 is more likely to have a causal link appear in bold.</div><div class=\"graphic_reference\">Adapted from: Torok TJ. Unusual clinical manifestations reported in patients with parvovirus B19 infection. In: Monographys in Virology: Human Parvovirus B19, Anderson LJ, Young NS (Eds), Karger 1997; p.61.</div><div id=\"graphicVersion\">Graphic 62492 Version 5.0</div></div></div>"},"62493":{"type":"graphic_figure","displayName":"Prostate cancer by race","title":"Prostate cancer is more common in black men","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Prostate cancer is more common in black men</div><div class=\"cntnt\"><img style=\"width:458px; height:364px;\" src=\"images/ONC/62493_Prostate_cancer_by_race.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age-adjusted incidence rates for prostate cancer by race from 1973 to 1994 in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) data base. Screening in the 1980s led to a progressive risk in the incidence of disease, with the rate being higher in blacks. The removal of these incident cases led to a decline in new cases of prostate cancer after 1992.</div><div class=\"graphic_reference\">Data from Farkas A, Schneider D, Perrotti M, et al. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening.&nbsp;Urology 1998; 52:444.</div><div id=\"graphicVersion\">Graphic 62493 Version 2.0</div></div></div>"},"62494":{"type":"graphic_table","displayName":"Exercise ECG in aortic stenosis","title":"Criteria for a positive exercise test in asymptomatic patients with aortic stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for a positive exercise test in asymptomatic patients with aortic stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Development of dyspnea, angina, or presyncope or syncope, which should lead to stopping of the test</td>\n</tr>\n\n<tr>\n<td>A rise in systolic pressure during exercise of less than 20 mmHg; the test is stopped if the systolic pressure falls more than 10 mmHg with exercise</td>\n</tr>\n\n<tr>\n<td>Inability to reach 80 percent of the predicted normal level of exercise tolerance</td>\n</tr>\n<tr>\n<td>More than 2 mm horizontal or downsloping ST segment depression compared to baseline that cannot be attributed to other causes; the test is stopped if there is more than 5 mm ST segment depression</td>\n</tr>\n\n<tr>\n<td>The development of complex ventricular arrhythmias, such as ventricular tachycardia or more than four ventricular premature beats in succession, which should lead to stopping of the test</td>\n</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from Otto CM, Burwash IG, Legget ME, et al. Circulation 1997; 95:2262; and from Iung B, Gohlke-Barwolf C, Tornos P, et al. Eur Heart J 2002; 23:1253.</div><div id=\"graphicVersion\">Graphic 62494 Version 2.0</div></div></div>"},"62495":{"type":"graphic_diagnosticimage","displayName":"Cobb angle measurement","title":"Cobb angle measurement","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cobb angle measurement</div><div class=\"cntnt\"><img style=\"width:576px; height:422px;\" src=\"images/PEDS/62495_Cobb_angle_measurement.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Cobb angle (arrow in radiograph) is formed by the intersection of a line parallel to the superior end plate of the most cephalad vertebra in a particular curve, with the line parallel to the inferior end plate of the most caudad vertebra of the curve. The intersection of these lines may occur outside the border of the actual film. Therefore, by convention, perpendiculars to the parallels are drawn, and the angle between their intersection is measured. The Cobb angle in the above radiograph is 63&deg;. The most cephalad vertebra is the vertebra that has the greatest tilt from horizontal of its superior end plate (solid line). The most caudal vertebra is the vertebra that has the greatest tilt from horizontal of its inferior end plate (dotted line). Drawing lines along several vertebrae near each end of a curve (dashed lines) is helpful in determining that with the greatest tilt.</div><div class=\"graphic_reference\">Radiograph courtesy of Susan A Scherl, MD.</div><div id=\"graphicVersion\">Graphic 62495 Version 10.0</div></div></div>"},"62496":{"type":"graphic_diagnosticimage","displayName":"PUV VUR","title":"Voiding cystourethrogram of patient with posterior urethral valves","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Voiding cystourethrogram of patient with posterior urethral valves</div><div class=\"cntnt\"><img style=\"width:288px; height:401px;\" src=\"images/PEDS/62496_PUV_VUR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows outline dilated urethra. Arrowheads outline dilated ureter with associated vesicoureteral reflux.</div><div class=\"graphic_reference\">Courtesy of Nicholas Holmes, MD.</div><div id=\"graphicVersion\">Graphic 62496 Version 4.0</div></div></div>"},"62498":{"type":"graphic_picture","displayName":"Stone fragmentation in vitro","title":"A cholesterol gallstone before and after in-vitro laser lithotripsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A cholesterol gallstone before and after in-vitro laser lithotripsy</div><div class=\"cntnt\"><img style=\"width:266px; height:384px;\" src=\"images/GAST/62498_Stone_fragmentation_in_vitr.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lingenfelser TH, Dette S, Scheurlen M, Grund KE. Lithotripsy with the Flashlamp Exited Dye Laser: In vitro effects on gallstones. Lasermedizin 1992; 8:4. Copyright Â© 1992 Urban &amp;Fischer.</div><div id=\"graphicVersion\">Graphic 62498 Version 3.0</div></div></div>"},"62499":{"type":"graphic_table","displayName":"Antigen expression in AML","title":"Antigen expression in acute myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antigen expression in acute myeloid leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antigen</td> <td class=\"subtitle1\">Expressed at diagnosis (percent)</td> <td class=\"subtitle1\">Expressed at relapse (percent)</td> </tr> <tr> <td>CD2</td> <td class=\"centered\">11</td> <td class=\"centered\">22</td> </tr> <tr> <td>CD3</td> <td class=\"centered\">2 </td> <td class=\"centered\">0</td> </tr> <tr> <td><strong>CD4dim</strong></td> <td class=\"centered\">72</td> <td class=\"centered\">78</td> </tr> <tr> <td>CD7</td> <td class=\"centered\">22</td> <td class=\"centered\">30</td> </tr> <tr> <td>CD8</td> <td class=\"centered\">1</td> <td class=\"centered\">5</td> </tr> <tr> <td>CD11b</td> <td class=\"centered\">41</td> <td class=\"centered\">37</td> </tr> <tr> <td><strong>CD13</strong></td> <td class=\"centered\">98</td> <td class=\"centered\">97</td> </tr> <tr> <td>CD14</td> <td class=\"centered\">12</td> <td class=\"centered\">8</td> </tr> <tr> <td><strong>CD15</strong></td> <td class=\"centered\">82</td> <td class=\"centered\">78</td> </tr> <tr> <td>CD16</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td>CD19</td> <td class=\"centered\">5</td> <td class=\"centered\">8</td> </tr> <tr> <td><strong>CD32</strong></td> <td class=\"centered\">76</td> <td class=\"centered\">74</td> </tr> <tr> <td><strong>CD33</strong></td> <td class=\"centered\">75</td> <td class=\"centered\">78</td> </tr> <tr> <td><strong>CD34</strong></td> <td class=\"centered\">64</td> <td class=\"centered\">74</td> </tr> <tr> <td><strong>CD38</strong></td> <td class=\"centered\">96</td> <td class=\"centered\">94</td> </tr> <tr> <td>CD56</td> <td class=\"centered\">17</td> <td class=\"centered\">21</td> </tr> <tr> <td>CD64</td> <td class=\"centered\">50</td> <td class=\"centered\">45</td> </tr> <tr> <td><strong>HLADr</strong></td> <td class=\"centered\">76</td> <td class=\"centered\">74</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table indicates the frequencies of antigen expression at diagnosis and at relapse in 153 adult patients with de novo acute myeloid leukemia enrolled in CALGB 8361. Testing was performed by multiparameter flow cytometry in a single reference laboratory. Those antigens present in the majority of the cases are shown in bold type.</div><div class=\"graphic_reference\">Adapted from: Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001; 97:3574.</div><div id=\"graphicVersion\">Graphic 62499 Version 3.0</div></div></div>"},"62500":{"type":"graphic_diagnosticimage","displayName":"Immunoglobin pattern MM","title":"Immunoglobulins in multiple myeloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunoglobulins in multiple myeloma</div><div class=\"cntnt\"><img style=\"width:428px; height:269px;\" src=\"images/HEME/62500_Immuno_pattern_myeloma_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The electrophoretic pattern of serum proteins in a normal subject is shown in panel A. The area containing proteins of &quot;gamma&quot; mobility is shown in the blue boxed area. This area contains most of the immunoglobulins. For the patient with multiple myeloma (panel B), there is a monoclonal immunoglobulin band in the gamma mobility region (asterisk), but little or no protein staining in the rest of the gamma mobility region, suggesting the presence of reduced amounts of normal polyclonal immunoglobulins.</div><div class=\"graphic_reference\">Reproduced with permission from: Kyle RA, Rajkumar SV. Plasma cell disorders. In: Cecil textbook of medicine, 22nd ed, Goldman L, Ausiello DA (Eds), WB Saunders, Philadelphia 2004. p.1184. Copyright Â© 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 62500 Version 4.0</div></div></div>"},"62501":{"type":"graphic_diagnosticimage","displayName":"TB chest radiograph 2","title":"Chest radiographs of different presentations of tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Chest radiographs of different presentations of tuberculosis</div><div class=\"cntnt\"><img style=\"width:550px; height:424px;\" src=\"images/ID/62501_TB_chest_radiograph_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Primary tuberculosis in a child (note the right-sided hilar adenopathy, right-sided lower lobe infiltrates, and volume loss).<br> (B) Lower lung field tuberculosis infiltration and cavity with air-fluid level in lingula.<br> (C) Reactivated tuberculosis, far-advanced disease with bronchogenic spread.<br> (D) Miliary tuberculosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Gorbach SL, Bartlett JG, et al. Infectious Diseases. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62501 Version 3.0</div></div></div>"},"62502":{"type":"graphic_table","displayName":"ECF for advanced esophagogastric cancer","title":"Epirubicin, cisplatin, and fluorouracil (ECF) for advanced esophagogastric cancer<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epirubicin, cisplatin, and fluorouracil (ECF) for advanced esophagogastric cancer<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Epirubicin</td> <td>50 mg/m<sup>2</sup> IV</td> <td>Administer into a free flowing IV solution with normal saline (NS),* generally over 3 to 20 minutes.</td> <td>Day 1</td> </tr> <tr> <td>Cisplatin</td> <td>60 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL NS and administer over two hours. Do not administer with aluminum needles or intravenous sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil (FU)</td> <td>200 mg/m<sup>2</sup> per day IV</td> <td>Infuse through a central line as a continuous infusion via a portable infusion device.</td> <td>Daily for up to six months</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Give IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Epirubicin plus cisplatin: HIGH; daily low-dose continuous infusion. </li> <li>FU: LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There are no recommended premedications to prevent infusion reactions with the ECF regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Epirubicin is a vesicant; cisplatin is an irritant but can cause significant tissue damage. Avoid extravasation of either agent. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors is not warranted (incidence of grade 3 or 4 febrile neutropenia was 9% in one trial;<sup>[3]</sup> in a second trial, 14% developed either febrile neutropenia or infection<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. In the original ECF protocol, cisplatin was not given to patients with a GFR &#60;40 mL/min, full-dose cisplatin was administered to patients with a GFR &#8805;60 mL/min, and if the GFR was between 40 and 60 mL/min, the dose of cisplatin (in mg) equaled the GFR value in mL/min.<sup>[2]</sup> Lower starting doses of epirubicin may be needed in patients with preexisting renal or hepatic impairment.<sup>[4]</sup> Lower starting doses of FU may be needed with severe liver impairment.<sup>[5]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Epirubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline LVEF prior to initiating therapy. Epirubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines. In the original protocol, patients were excluded from receiving epirubicin if their baseline LVEF was less than 50%.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count on day 1 prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel including creatinine and liver function tests once per cycle on day 1 prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor cumulative epirubicin dose. Reassess LVEF periodically during ECF therapy as clinically indicated. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold epirubicin until the platelets are &#8805;100,000/microL and the absolute neutrophil count is &#8805;1500 cells/microL.<sup>[4]</sup> In the original ECF protocol, cisplatin and epirubicin doses were delayed by one week or until myelosuppression was resolved if the platelet count was &#60;100,000/microL or the total WBC was &#60;2000 cells/microL on day 1.<sup>[2]</sup> The dose of epirubicin was reduced by 25% for a second episode of treatment delay due to myelosuppression or for febrile neutropenia. There were no dose reductions for infusional FU based on blood counts, but the United States Prescribing Information recommends treatment discontinuation for neutropenia (WBC &#60;3500 cells/microL or rapidly declining) or platelet count &#60;100,000/microL.<sup>[5]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL.<sup>[6]</sup> In the original trial of ECF, full dose cisplatin was given each cycle if the estimated GFR was &#62;60 mL/min, and the drug was held if the estimated GFR was &#60;40 mL/min.<sup>[2]</sup> For an estimated GFR of 40 to 60 mL/min, the dose of cisplatin (in mg) was equivalent to the estimated GFR (in mL/min).<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Mucositis or diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, a treatment break from FU was recommended for grade 2 or worse diarrhea. Treatment was withheld until symptoms resolved, then restarted at 150 mg/m<sup>2</sup> per day for grade 2 toxicity, and at 100 mg/m<sup>2</sup> per day for grade 3 or 4 toxicity.<sup>[2]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea and mucositis after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. If neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Palmar-plantar erythrodysesthesias</strong></td> <td colspan=\"3\"> <ul> <li>In the original trial, FU was withheld for one week for any grade of palmar-plantar erythrodysesthesia and then restarted at a dose of 150 mg/m<sup>2</sup> per day.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold epirubicin until all non-hematologic toxicity resolved to &#8804;grade 1.<sup>[4]</sup> Reduce epirubicin dose by 25% for any grade 3/4 non-hematologic toxicity in previous cycles. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intraveneous; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; CBC: complete blood count; WBC: white blood cell count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Webb A, et al. J Clin Oncol 1997; 15:261.</LI>&#xD;&#xA;<LI>Findlay M, et al. Ann Oncol 1994; 5:609.</LI>&#xD;&#xA;<LI>Cunningham D, et al. N Engl J Med 2008; 358:36.</LI>&#xD;&#xA;<LI>Epirubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 62502 Version 24.0</div></div></div>"},"62503":{"type":"graphic_picture","displayName":"Botulinum toxin injection sites for perioral rhytides","title":"Example of botulinum toxin injection sites for perioral rhytides","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Example of botulinum toxin injection sites for perioral rhytides</div><div class=\"cntnt\"><img style=\"width:502px; height:288px;\" src=\"images/DERM/62503_Inject_sites_peri_rhyt_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62503 Version 3.0</div></div></div>"},"62505":{"type":"graphic_picture","displayName":"Epidermolysis bullosa acquisita","title":"Epidermolysis bullosa acquisita","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa acquisita</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/62505_Epidermolysisbullosaacquisita.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tense bullae, erosions, and crusts on skin of a&nbsp;patient with epidermolysis bullosa acquisita.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62505 Version 5.0</div></div></div>"},"62506":{"type":"graphic_figure","displayName":"Spore surfaces","title":"Spore surfaces","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Spore surfaces</div><div class=\"cntnt\"><img style=\"width:519px; height:355px;\" src=\"images/ALLRG/62506_Spore_surfaces.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from Burge HA, Burge W, Muilenberg ML, et al. Airborne pollen and fungus spore identification: Hands On Workshop, Postgraduate Course, University of Michigan Medical School, Ann Arbor, MI, May 1990.</div><div id=\"graphicVersion\">Graphic 62506 Version 2.0</div></div></div>"},"62508":{"type":"graphic_figure","displayName":"Aminoglycoside nomogram","title":"Extended-interval dosing nomogram for gentamicin and tobramycin*","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Extended-interval dosing nomogram for gentamicin and tobramycin*</div><div class=\"cntnt\"><img style=\"width:470px; height:308px;\" src=\"images/ID/62508_Aminoglycoside_nomogram.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The serum gentamicin or tobramycin concentration should be obtained&nbsp;6 hours (or up to 14 hours) after the initial dose of 7 mg/kg and plotted on the above nomogram. The interval for drug administration of subsequent doses of 7 mg/kg is then determined based on the interval specified on the graph.</div><div class=\"graphic_footnotes\">* Application of the nomogram for amikacin requires the measured concentration be divided by two. The new value should be plotted on the nomogram in order to obtain the appropriate dosing interval.</div><div class=\"graphic_reference\">Reproduced with permission from: Nicolau D, Quintiliani R, Nightingale CH. Once-daily aminoglycosides. Conn Med 1992; 56:561. Copyright &copy; 1992 Connecticut State Medical Society.</div><div id=\"graphicVersion\">Graphic 62508 Version 7.0</div></div></div>"},"62509":{"type":"graphic_table","displayName":"Less common causes of FUO","title":"Less common diagnoses of fever of unknown origin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Less common diagnoses of fever of unknown origin</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"indent1\"><strong>Abscesses (especially intra-abdominal)</strong></td> </tr> <tr> <td class=\"indent1\">African tick bite fever*</td> </tr> <tr> <td class=\"indent1\">Amebic liver abscess*</td> </tr> <tr> <td class=\"indent1\">Anaplasmosis/ehrichiosis*</td> </tr> <tr> <td class=\"indent1\">Babesiosis*</td> </tr> <tr> <td class=\"indent1\">Brucellosis*</td> </tr> <tr> <td class=\"indent1\">Castleman's disease</td> </tr> <tr> <td class=\"indent1\">Chikungunya*</td> </tr> <tr> <td class=\"indent1\">Chronic active hepatitis</td> </tr> <tr> <td class=\"indent1\">Culture-negative endocarditis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Dental abscesses</td> </tr> <tr> <td class=\"indent1\">Dengue*</td> </tr> <tr> <td class=\"indent1\">Diskitis</td> </tr> <tr> <td class=\"indent1\">Epididymitis</td> </tr> <tr> <td class=\"indent1\">Fascioloiasis*</td> </tr> <tr> <td class=\"indent1\">Filariasis*</td> </tr> <tr> <td class=\"indent1\">Gonococcal arthritis</td> </tr> <tr> <td class=\"indent1\">Herpes simplex encephalitis</td> </tr> <tr> <td class=\"indent1\">Infectious mononeucleosis</td> </tr> <tr> <td class=\"indent1\">Kala azar (visceral leishmaniasis)*</td> </tr> <tr> <td class=\"indent1\">Kikuchi's disease</td> </tr> <tr> <td class=\"indent1\">Lassa fever*</td> </tr> <tr> <td class=\"indent1\">Leptospirosis*</td> </tr> <tr> <td class=\"indent1\">Lyme disease*</td> </tr> <tr> <td class=\"indent1\"><strong>Osteomyelitis</strong></td> </tr> <tr> <td class=\"indent1\">Prostatitis</td> </tr> <tr> <td class=\"indent1\">Pyelonephritis</td> </tr> <tr> <td class=\"indent1\">Pyometria</td> </tr> <tr> <td class=\"indent1\">Q fever*</td> </tr> <tr> <td class=\"indent1\">Relapsing fever (<em>Borrelia recurrentis</em>)*</td> </tr> <tr> <td class=\"indent1\">Rheumatic fever</td> </tr> <tr> <td class=\"indent1\">Sinusitis</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis</td> </tr> <tr> <td class=\"indent1\">Typhoid fever*</td> </tr> <tr> <td class=\"indent1\"><strong>Tuberculosis</strong></td> </tr> <tr> <td class=\"indent1\">Whipple's disease</td> </tr> <tr> <td class=\"indent1\">Zika virus*</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Malignancies</td> </tr> <tr> <td class=\"indent1\">Aleukemic leukemia</td> </tr> <tr> <td class=\"indent1\">Atrial myxoma</td> </tr> <tr> <td class=\"indent1\">Colon cancer</td> </tr> <tr> <td class=\"indent1\"><strong>Hepatocellular carcinoma </strong>or other tumors metastatic to the liver</td> </tr> <tr> <td class=\"indent1\">Kaposi's sarcoma</td> </tr> <tr> <td class=\"indent1\"><strong>Leukemia</strong></td> </tr> <tr> <td class=\"indent1\">Lung cancer</td> </tr> <tr> <td class=\"indent1\"><strong>Lymphoma, especially non-Hodgkin's</strong></td> </tr> <tr> <td class=\"indent1\">Multiple myeloma</td> </tr> <tr> <td class=\"indent1\">Myelodysplastic syndromes</td> </tr> <tr> <td class=\"indent1\"><strong>Renal cell carcinoma</strong></td> </tr> <tr> <td class=\"indent1\">Sarcoma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Systemic inflammatory diseases</td> </tr> <tr> <td class=\"indent1\">Allergic granulomatous angiitis</td> </tr> <tr> <td class=\"indent1\">Antiphospholipid syndrome</td> </tr> <tr> <td class=\"indent1\">Beh&#231;et's disease</td> </tr> <tr> <td class=\"indent1\">Cryoglobulinemia</td> </tr> <tr> <td class=\"indent1\"><strong>Giant cell arteritis</strong></td> </tr> <tr> <td class=\"indent1\">Granulomatosis with polyangiitis (formerly Wegener's disease)</td> </tr> <tr> <td class=\"indent1\">Granulomatous hepatitis</td> </tr> <tr> <td class=\"indent1\">Hypersensitivity vasculitis</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">Panaortitis</td> </tr> <tr> <td class=\"indent1\"><strong>Polyarteritis nodosa</strong></td> </tr> <tr> <td class=\"indent1\">Reactive arthritis (formerly Reiter's syndrome)</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Still's disease</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosis</td> </tr> <tr> <td class=\"indent1\">Takayasu's arteritis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Disorders of temperature regulation (neurologic and dermatologic)</td> </tr> <tr> <td class=\"indent1\">Drug fever<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Environmental (metal and polymer fume fevers)</td> </tr> <tr> <td class=\"indent1\">Factitious fever</td> </tr> <tr> <td class=\"indent1\">Familial Mediterranean fever</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">Neuroleptic malignant syndrome</td> </tr> <tr> <td class=\"indent1\">Periodic fever</td> </tr> <tr> <td class=\"indent1\">Pulmonary emboli</td> </tr> <tr> <td class=\"indent1\">Retroperitoneal hematomas</td> </tr> <tr> <td class=\"indent1\">Chronic fatigue syndrome (systemic exertion intolerance disease)</td> </tr> <tr> <td class=\"indent1\">Thyroiditis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">More common causes are in <STRONG>bold type</STRONG>.</div><div class=\"graphic_footnotes\">* Travel and environmental exposure histories are especially relevant. <br />Â¶ Causes include <EM>Actinobacillus</EM> spp, <EM>Bartonella</EM> spp, <EM>Brucella</EM> spp, <EM>Cardiobacterium</EM> spp, <EM>Chlamydia</EM> spp, <EM>Coxiella burnetii</EM>, <EM>Eikenella </EM>spp, <EM>Haemophilus </EM>spp, <EM>Histoplasma capsulatum</EM>, <EM>Kingella </EM>spp, <EM>Legionella </EM>spp, <EM>Mycoplasma </EM>spp, <EM>Tropheryma whipplei</EM>, and marantic endocarditis.<br />Î Antimicrobials (especially sulfonamides and penicillins), antiepileptic, antithyroid, and nonsteroidal anti-inflammatory drugs.</div><div id=\"graphicVersion\">Graphic 62509 Version 5.0</div></div></div>"},"62511":{"type":"graphic_table","displayName":"Differential diagnosis of pediatric limp etiology by gait","title":"Causes of limp by gait abnormality in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of limp by gait abnormality in children</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td   class=\"subtitle1\">\r\n  \r\n   Type of limp\r\n  \r\n   </td>\r\n  \r\n   <td   class=\"subtitle1\">\r\n  \r\n   Characteristics\r\n  \r\n   </td>\r\n  \r\n   <td   class=\"subtitle1\">\r\n  \r\n   Etiology\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Antalgic gait</td>\r\n  \r\n   <td>Most common; short stance phase caused by pain in the weight-bearing extremity</td>\r\n  \r\n   <td>Fracture (including toddler or Salter I fracture), soft tissue injury, transient synovitis, osteomyelitis, septic arthritis, foreign body in forefoot, osteochondritis dissecans, tumor</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Trendelenberg gait</td>\r\n  \r\n   <td>Downward pelvic tilt during the swing phase caused by weakness or spasm in the contralateral gluteus medius muscle</td>\r\n  \r\n   <td>Legg-Calv&#233;-Perthes, slipped capital femoral epiphysis, developmental dysplasia of the hip</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Steppage gait</td>\r\n  \r\n   <td>Seen with a foot drop; presents with exaggerated hip and knee flexion during the swing phase to clear the dropped foot from the floor</td>\r\n  \r\n   <td>Neurologic diseases which cause loss of dorsiflexion of the ankle</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Toe-walking gait</td>\r\n  \r\n   <td>Child walks on his/her toes caused by heel pain or by increased flexor muscle tone in the lower leg</td>\r\n  \r\n   <td>Mild cerebral palsy, Sever disease, heel foreign body, idiopathic, toddler calcaneal fx</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Vaulting gait</td>\r\n  \r\n   <td>The knee is hyperextended and locked at the end of the stance phase of the gait and the child vaults over the extremity</td>\r\n  \r\n   <td>Limb length discrepancy or abnormal knee mobility</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Stooping gait</td>\r\n  \r\n   <td>Patient shuffles with hip flexed due to irritation of the psoas muscle by intraabdominal inflammation.</td>\r\n  \r\n   <td>Appendicitis, pelvic inflammatory disease, psoas muscle abscess</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_lgnd\">See Figure 1 for detailed description of the gait cycle.</div><div id=\"graphicVersion\">Graphic 62511 Version 2.0</div></div></div>"},"62512":{"type":"graphic_table","displayName":"Encephalitis infxs causes in children","title":"Possible infectious etiologies of encephalitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible infectious etiologies of encephalitis in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Viruses</td> </tr> <tr> <td><strong>Enteroviruses</strong> (echovirus, parechovirus, coxsackievirus A and B, poliovirus, and the numbered enteroviruses)</td> </tr> <tr> <td><strong><span class=\"red\">Herpes simplex type 1</span></strong></td> </tr> <tr> <td><strong><span class=\"red\">Herpes simplex type 2</span></strong></td> </tr> <tr> <td><strong>Parechoviruses</strong></td> </tr> <tr> <td><span class=\"red\"><strong>Varicella zoster virus</strong></span></td> </tr> <tr> <td><strong>Epstein-Barr virus</strong></td> </tr> <tr> <td><strong><span class=\"red\">Cytomegalovirus</span></strong></td> </tr> <tr> <td><strong><span class=\"red\">Human herpesvirus 6</span></strong></td> </tr> <tr> <td><span class=\"red\">Human immunodeficiency virus</span></td> </tr> <tr> <td><strong>Arboviruses</strong> (LaCrosse virus, West Nile virus, <span class=\"red\">St. Louis encephalitis virus</span>, Eastern and Western equine encephalitis virus, Japanese encephalitis virus)</td> </tr> <tr> <td>Rabies virus</td> </tr> <tr> <td><strong>Influenza virus</strong></td> </tr> <tr> <td><span class=\"red\">Measles virus</span></td> </tr> <tr> <td>Mumps virus</td> </tr> <tr> <td>Rubella virus</td> </tr> <tr> <td>Murray Valley encephalitis virus</td> </tr> <tr> <td><span class=\"red\">Nipah virus</span></td> </tr> <tr> <td>Hendra virus</td> </tr> <tr> <td>Tick-borne encephalitis virus</td> </tr> <tr> <td>Powassan virus</td> </tr> <tr> <td>Herpes B virus</td> </tr> <tr> <td>Hepatitis E virus</td> </tr> <tr> <td>Creutzfeldt-Jakob disease</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Bacteria</td> </tr> <tr> <td><span class=\"red\"><em><strong>Mycoplasma pneumoniae</strong></em></span></td> </tr> <tr> <td><span class=\"red\"><em>Listeria monocytogenes</em></span></td> </tr> <tr> <td><span class=\"red\"><em>Mycobacterium tuberculosis</em></span></td> </tr> <tr> <td><span class=\"red\"><em>Treponema pallidum</em></span></td> </tr> <tr> <td><span class=\"red\"><em>Bartonella henselae</em> (cat scratch disease)</span></td> </tr> <tr> <td><span class=\"red\"><em>Bartonella quintana</em> (\"trench fever\")</span></td> </tr> <tr> <td><span class=\"red\"><em>Borrelia burgdorferi</em> (Lyme disease)</span></td> </tr> <tr> <td><span class=\"red\"><em>Coxiella burnetii</em> (Q fever)</span></td> </tr> <tr> <td><span class=\"red\"><em>Rickettsia rickettsii</em> (Rocky Mountain spotted fever)</span></td> </tr> <tr> <td><span class=\"red\"><em>Ehrlichia chaffeensis</em> (human monocytotrophic ehrlichiosis)</span></td> </tr> <tr> <td><span class=\"red\"><em>Anaplasma phagocytophilum</em> (human granulocytotrophic ehrlichiosis)</span></td> </tr> <tr> <td><em><span style=\"color: #ff0000;\">Tropheryma whipplei</span></em></td> </tr> <tr> <td class=\"subtitle1_single\">Fungi</td> </tr> <tr> <td><span class=\"red\"><em>Cryptococcus neoformans</em></span></td> </tr> <tr> <td><span class=\"red\"><em>Coccidioides species</em></span></td> </tr> <tr> <td><span class=\"red\"><em>Histoplasma capsulatum</em></span></td> </tr> <tr> <td class=\"subtitle1_single\">Parasites</td> </tr> <tr> <td><span class=\"red\"><em>Toxoplasma gondii</em></span></td> </tr> <tr> <td><span class=\"red\"><em>Plasmodium falciparum</em></span></td> </tr> <tr> <td><span class=\"red\"><em>Naegleria fowleri</em></span></td> </tr> <tr> <td><span class=\"red\"><em>Acanthamoeba spp</em></span></td> </tr> <tr> <td><span class=\"red\"><em>Balamuthia mandrillaris</em></span></td> </tr> <tr> <td><span class=\"red\"><em>Taenia solium</em> (cysticercosis)</span></td> </tr> <tr> <td><span class=\"red\"><em>Baylisascaris procyonis</em></span></td> </tr> <tr> <td><span class=\"red\"><em>Gnathostoma spinigerum</em></span></td> </tr> <tr> <td><em><span style=\"color: #ff0000;\">Trypanosoma brucei gambiense</span></em></td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Pathogens depicted in <span style=\"color:#ff0000\">red</span> may require specific antimicrobial therapy. Pathogens depicted in <strong>bold</strong> text are the most commonly isolated.</div><div class=\"graphic_reference\">Courtesy of Hordur Hardarson, MD.</div><div id=\"graphicVersion\">Graphic 62512 Version 9.0</div></div></div>"},"62513":{"type":"graphic_figure","displayName":"Connected Roux-en-O misconstruction depiction","title":"Connected Roux-en-O misconstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Connected Roux-en-O misconstruction</div><div class=\"cntnt\"><img style=\"width:398px; height:443px;\" src=\"images/SURG/62513_ConnectedRouxenO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the miscontruction of the Roux-en-Y gastric bypass procedure, resulting in the formation of an &quot;O&quot; connencting to the stomach</div><div id=\"graphicVersion\">Graphic 62513 Version 1.0</div></div></div>"},"62514":{"type":"graphic_diagnosticimage","displayName":"Paget disease of the L hemipelvis and L proximal femur","title":"Paget disease of the L hemipelvis and L proximal femur","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paget disease of the L hemipelvis and L proximal femur</div><div class=\"cntnt\"><img style=\"width:504px; height:433px;\" src=\"images/RHEUM/62514_Paget_L_hemipel_L_prox_fem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paget disease of the L hemipelvis and L proximal femur (sparing the R) with coarse remodeling of bone, enlargement, and deformity of the pelvis. There is thickening of the iliopectineal line so characteristic of PDB, with accentuated trabeculae and thickened cortices. Protrusio and loss of joint space are present on the left.</div><div class=\"graphic_footnotes\">PDG: Paget disease of bone.</div><div class=\"graphic_reference\">Courtesy of Margaret Seton, MD.</div><div id=\"graphicVersion\">Graphic 62514 Version 3.0</div></div></div>"},"62515":{"type":"graphic_picture","displayName":"Ectopic pregnancy 2","title":"Six-week ectopic pregnancy","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Six-week ectopic pregnancy</div><div class=\"cntnt\"><img style=\"width:468px; height:312px;\" src=\"images/OBGYN/62515_Ectopicpregnancy2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fallopian tube has been opened to reveal the gestational sac.</div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. Copyright Â© Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 62515 Version 2.0</div></div></div>"},"62517":{"type":"graphic_table","displayName":"Mechanisms of globin mutations","title":"Molecular mechanisms underlying globin mutations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular mechanisms underlying globin mutations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Mechanisms</td>\n\n      <td class=\"subtitle1\">Examples</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\">Single base substitution leading to amino acid replacement </td>\n\n      <td>Hemoglobin S</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>Hemoglobin C </td>\n    </tr>\n    <tr>\n      \n      <td>Hemoglobin E</td>\n    </tr>\n    <tr>\n\n      <td>Two replacements in same subunit</td>\n\n      <td>Hemoglobin C-Harlem</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"4\">Fusion hemoglobins </td>\n\n      <td>Hemoglobin Lepore (delta-beta)</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>Hemoglobin Miyada (beta-delta) </td>\n    </tr>\n    <tr>\n      \n      <td>Hemoglobin Parchman (delta-beta-delta)</td>\n    </tr>\n    <tr>\n      \n      <td>Hemoglobin Kenya (gamma-beta)</td>\n    </tr>\n    <tr>\n\n      <td>Deletion or insertion</td>\n\n      <td>Hemoglobin Gun Hill</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Insertion </td>\n\n      <td>Hemoglobin Grady</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>Hemoglobin Catonsville</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Deletion and insertion</td>\n\n      <td>Hemoglobin Montreal</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>Hemoglobin Galicia</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"sublist1_start\">Extended subunit</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Termination codon mutation</td>\n\n      <td class=\"sublist_other\">Hemoglobin Constant Spring</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\" colspan=\"1\" rowspan=\"2\">Frameshift mutation</td>\n      <td class=\"sublist_other\">Hemoglobin Wayne</td>\n    </tr>\n    <tr>\n      \n      <td>Hemoglobin Cranston</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1\" colspan=\"1\" rowspan=\"2\">N-terminal mutation leading to retention of initiator methionine</td>\n\n      <td class=\"sublist_other\">Hemoglobin Long Island</td>\n\n    </tr>\n    <tr>\n      \n      <td>Hemoglobin Marseille</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62517 Version 1.0</div></div></div>"},"62518":{"type":"graphic_picture","displayName":"Nasolacrimal duct obstruction","title":"Nasolacrimal duct obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasolacrimal duct obstruction</div><div class=\"cntnt\"><img style=\"width:360px; height:150px;\" src=\"images/PEDS/62518_Nasolacrimal_duct_obstructi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infants with nasolacrimal duct obstruction present with a history of chronic or intermittent tearing, and debris on the eyelashes. Conjunctival erythema is not typical, although chronic rubbing of the eyes may cause redness of the lower eyelid.</div><div class=\"graphic_reference\">Adapted with permission from: Paysse EA, Coats DK, Cassidy M. Refinements Volume III/Number 2. San Francisco: American Academy of Opthalmology, 1999.</div><div id=\"graphicVersion\">Graphic 62518 Version 4.0</div></div></div>"},"62519":{"type":"graphic_table","displayName":"PCV and PPSV23 in high-risk","title":"Recommendations for pneumococcal immunization with PCV13 and PPSV23 for children at high risk* of pneumococcal disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for pneumococcal immunization with PCV13 and PPSV23 for children at high risk* of pneumococcal disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Previous doses</td> <td class=\"subtitle1\">Recommendations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Any high-risk condition*</td> </tr> <tr> <td class=\"indent1\">&#8804;23 months</td> <td>None</td> <td>PCV13 per schedule for healthy children</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"10\">24 through 71 months</td> <td rowspan=\"2\">4 doses of PCV13</td> <td>1 dose of PPSV23, at least 8 weeks after last dose of PCV13</td> </tr> <tr> <td>Second dose<sup>&#182;</sup> of PPSV23,&nbsp;3 or 5 years<sup>&#916;</sup> after the first dose for children with sickle cell disease, 5 years after the first dose for children who have other types of functional or anatomic asplenia or are immunocompromised<sup>&#9674;</sup></td> </tr> <tr> <td rowspan=\"3\">Any incomplete schedule of 3 doses of PCV13</td> <td>1 dose of PCV13, at least 8 weeks after last dose of PCV13</td> </tr> <tr> <td>1 dose of PPSV23, 8 weeks after the last dose of PCV13</td> </tr> <tr> <td>Second dose<sup>&#182;</sup> of PPSV23, 3 or 5 years<sup>&#916;</sup> after the first dose for children with sickle cell disease,&nbsp;5 years after the first dose for children who have other types of functional or anatomic asplenia or are immunocompromised<sup>&#9674;</sup></td> </tr> <tr> <td rowspan=\"3\">Unvaccinated or any incomplete schedule of PCV13 and no doses of PPSV23</td> <td>2 doses of PCV13, 8 weeks apart, beginning at least 8 weeks after the last dose of PCV13</td> </tr> <tr> <td>1 dose of PPSV23, 8 weeks after the last dose of PCV13</td> </tr> <tr> <td>Second dose<sup>&#182;</sup> of PPSV23, 3 or 5 years<sup>&#916;</sup> after the first dose for children with sickle cell disease, 5 years after the first dose&nbsp;for children who have other types of functional or anatomic asplenia or are immunocompromised<sup>&#9674;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">1 dose of PPSV23</td> <td>2 doses of PCV13, 8 weeks apart, beginning at least 8 weeks after first dose of PPSV23</td> </tr> <tr class=\"divider_bottom\"> <td>Second dose<sup>&#182;</sup> of PPSV23 (at least 8 weeks after the last PCV13), 3 or 5 years<sup>&#916;</sup> after the first dose for children with sickle cell disease, 5 years after the first dose for children&nbsp;who have&nbsp;other types of functional or anatomic asplenia or&nbsp;are immunocompromised<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Anatomic or functional asplenia (including sickle cell disease), immunocompromising condition (including HIV, chronic renal failure, nephrotic syndrome), cochlear implant, or cerebrospinal fluid leak</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\">6 through 18 years</td> <td rowspan=\"3\">No doses of PPSV23 or PCV13 (0 to 4 doses of PCV7)</td> <td>1 dose of PCV13</td> </tr> <tr> <td>1 dose of PPSV23, at least 8 weeks after PCV13</td> </tr> <tr> <td>Second dose<sup>&#182;</sup> of PPSV23, 3 or 5 years<sup>&#916;</sup> after the first dose for children with sickle cell disease, 5 years after the first dose for children who have other types of functional or anatomic asplenia or are immunocompromised<sup>&#9674;</sup></td> </tr> <tr> <td rowspan=\"2\">1 dose of PCV13 and no doses of PPSV23</td> <td>1 dose of PPSV23, at least 8 weeks after PCV13</td> </tr> <tr> <td>Second dose<sup>&#182;</sup> of PPSV23, 3 or 5 years<sup>&#916;</sup> after the first dose for children with sickle cell disease, 5 years after the first dose for children who have other types of functional or anatomic asplenia or&nbsp;are immunocompromised<sup>&#9674;</sup></td> </tr> <tr> <td rowspan=\"2\">1 dose of PPSV23 and no doses of PCV13 (0 to 4 doses of PCV7)</td> <td>1 dose of PCV13, at least 8 weeks after first dose of PPSV23</td> </tr> <tr> <td>Second dose<sup>&#182;</sup> of PPSV23, 3 or 5 years<sup>&#916;</sup> after the first dose for children with sickle cell disease, 5 years after the first dose for children who have other types of functional or anatomic asplenia or are&nbsp;immunocompromised<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>2 doses of PPSV23 and no doses of PCV13 (0 to 4 doses of PCV7)</td> <td>1 dose of PCV13, at least 8 weeks after second dose<sup>&#182;</sup> of PPSV23</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Chronic heart disease, chronic lung disease, diabetes mellitus</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">6 through 18 years</td> <td>No doses of PPSV23 or PCV13 (0 to 4 doses of PCV7)</td> <td>1 dose of PPSV23, at least 8 weeks after last dose of PCV7</td> </tr> <tr> <td>1 dose of PPSV23 and no doses of PCV13 (0 to 4 doses of PCV7)</td> <td>No additional immunization</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCV13: 13-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine; HIV: human immunodeficiency virus; PCV7: 7-valent pneumococcal conjugate vaccine.<br />* High-risk children include those with sickle cell disease, asplenia, immunodeficiency, chronic heart or lung disease, cerebrospinal fluid leaks, diabetes mellitus, and cochlear implants<SUP innerHtml>â</SUP>.<br />Â¶ No more than two doses of PPSV23 are recommended.<br />Î For patients with sickle cell disease, some experts recommend an interval of three years between the first and second dose of PPSV23<SUP innerHtml>[1,2]</SUP>, whereas others recommend an interval&nbsp;of five years<SUP innerHtml>[3-5]</SUP>.<br />â A second dose of PPSV23 is <STRONG>not</STRONG> recommended for immunocompetent children with cochlear implants or chronic illness, including chronic heart disease, chronic lung disease, diabetes mellitus, or cerebrospinal fluid leaks.</div><div class=\"graphic_reference\">Based on recommendations from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Pneumococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases (30<SUP>th</SUP> ed),&nbsp;Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.626.</LI>&#xD;&#xA;<LI>National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease. Expert Panel Report, 2014. Available at: <A spellcheck=true href=\"http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines\" target=_blank>www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines</A>&nbsp;(Accessed on June 12, 2015).</LI>&#xD;&#xA;<LI>Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and childrenâuse of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccineârecommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013; 62:521.</LI>&#xD;&#xA;<LI>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</LI></OL></div><div id=\"graphicVersion\">Graphic 62519 Version 23.0</div></div></div>"},"62522":{"type":"graphic_diagnosticimage","displayName":"SARS CXR","title":"Severe acute respiratory syndrome (SARS) coronavirus pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe acute respiratory syndrome (SARS) coronavirus pneumonia</div><div class=\"cntnt\"><img style=\"width:400px; height:386px;\" src=\"images/ID/62522_SARSCXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows asymmatric bilateral consolidation involving mainly the middle lung zones.</div><div class=\"graphic_reference\">Reproduced with permission from: Viruses, Mycoplasma, and Chlamydia. In: Imaging of pulmonary infections. MÃ¼ller NL, Franquet T, Kyung SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62522 Version 8.0</div></div></div>"},"62523":{"type":"graphic_picture","displayName":"Candidal intertrigo neck folds","title":"Candidal intertrigo in the neck folds of an infant","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Candidal intertrigo in the neck folds of an infant</div><div class=\"cntnt\"><img style=\"width:549px; height:280px;\" src=\"images/PEDS/62523_Candidal_intertr_neck_folds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Symmetric, erythematous, weepy, and peeling skin folds of an infant with candidal intertrigo.</div><div class=\"graphic_reference\">Reproduced with permission from: Panagiotis Mitropoulos, DO. Originally published in: Mitropoulos P. Infant with red, peeling rashes. Am Fam Physician 2008; 77:1015. Copyright Â© 2008.</div><div id=\"graphicVersion\">Graphic 62523 Version 3.0</div></div></div>"},"62524":{"type":"graphic_figure","displayName":"Blood pressure and kidney-related mortality in blacks","title":"Blood pressure and kidney-related mortality in blacks","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Blood pressure and kidney-related mortality in blacks</div><div class=\"cntnt\"><img style=\"width:469px; height:235px;\" src=\"images/NEPH/62524_BP_race_and_nephrosclerosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relative risk of death from all causes of renal disease in blacks and whites according to systolic blood pressure in almost 350,000 men screened for the Multiple Risk Factor Intervention Trial. Patients with higher systolic pressures and blacks were at increased risk. A similar trend was seen for increasing diastolic pressures.</div><div class=\"graphic_reference\">Data from Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis 1993; 21 Suppl 1:31.</div><div id=\"graphicVersion\">Graphic 62524 Version 4.0</div></div></div>"},"62525":{"type":"graphic_table","displayName":"DRI infants","title":"Dietary reference intakes of selected nutrients for infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary reference intakes of selected nutrients for infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">0 to 6 months</td> <td class=\"subtitle1\">7 to 12 months</td> </tr> <tr> <td><strong>Carbohydrate</strong></td> <td>60 g/day</td> <td>95 g/day</td> </tr> <tr> <td><strong>Fat</strong></td> <td>31 g/day</td> <td>30 g/day</td> </tr> <tr> <td><strong>Protein</strong></td> <td>1.52 g/kg per day</td> <td>1.2 g/kg per day</td> </tr> <tr> <td><strong>Calcium</strong></td> <td>200 mg/day*</td> <td>260 mg/day*</td> </tr> <tr> <td><strong>Iron</strong></td> <td>0.27 mg/day<sup>&#182;</sup></td> <td>11 mg/day</td> </tr> <tr> <td><strong>Zinc</strong></td> <td>2 mg/day</td> <td>3 mg/day</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These values represent the Adequate Intake for calcium; there was insufficient scientific data to calculate a recommended dietary allowance (RDA).<br />&#182; The iron stores of full-term infants whose birth weight was appropriate for gestational age meet their iron requirement until four to six months of age.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Committee on Nutrition American Academy of Pediatrics. Appendix E-1. Dietary Reference Intakes: Recommended Intakes for Individuals, Food and Nutrition Board, Institute of Medicine. In: Pediatric Nutrition Handbook, 7<SUP>th</SUP> ed, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2014. p.1355. </LI>&#xD;&#xA;<LI>National Academies Press. Dietary Reference Intakes for Calcium and Vitamin D (2010). Available at http://books.nap.edu/openbook.php?record_id=13050&amp;page=291. Accessed on January 15, 2011. </LI></OL></div><div id=\"graphicVersion\">Graphic 62525 Version 8.0</div></div></div>"},"62526":{"type":"graphic_figure","displayName":"Omphalomesenteric anomalies","title":"Anomalies of the omphalomesenteric duct","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Anomalies of the omphalomesenteric duct</div><div class=\"cntnt\"><img style=\"width:538px; height:447px;\" src=\"images/PEDS/62526_Omphalomesenteric_anomalies.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62526 Version 2.0</div></div></div>"},"62528":{"type":"graphic_table","displayName":"Collecting family history","title":"Resources for collecting family history information","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for collecting family history information</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Resource\n   </td>\n   <td  class=\"subtitle1\">\n   URL\n   </td>\n   <td  class=\"subtitle1\">\n   Content\n   </td>\n   </tr>\n   <tr>\n   <td>US Surgeon General:My Family Health Portrait</td>\n   <td>\t<p>https://familyhistory.hhs.gov/</p>\n\t<p>https://familyhistory.hhs.gov/fhh-web/home.action?request_locale=es</p>\n</td>\n   <td>Tool for patients to create their own family tree (Available in English and Spanish).</td>\n   </tr>\n   <tr>\n   <td>National Society of Genetic Counselors: Your Family History - Your Future</td>\n   <td>http://www.nsgc.org/consumer/familytree/index.cfm</td>\n   <td>Guidelines on how to gather and record family history information.</td>\n   </tr>\n   <tr>\n   <td>American Medical Association: Family History Tools</td>\n   <td>http://www.ama-assn.org/go/familyhistory</td>\n   <td>Tools for collecting family history in prenatal, pediatric, and adult settings.</td>\n   </tr>\n   <tr>\n   <td>American Academy of Family Physicians: Family History Program</td>\n   <td>http://www.aafp.org</td>\n   <td>Guidance on efficient approaches for collecting and evaluating family history information.</td>\n   </tr>\n   <tr>\n   <td>Utah Department of Health</td>\n   <td>http://health.utah.gov/genomics/familyhistory/toolkit.html</td>\n   <td>Resource to help patients collect their own family histories.</td>\n   </tr>\n   <tr>\n   <td>American Heart Association</td>\n   <td>http://www.americanheart.org/presenter.jhtml?identifier=3044889</td>\n   <td>Resource for patients to collect family history information pertinent to heart disease and diabetes.</td>\n   </tr>\n   <tr>\n   <td>Ohio State University Comprehensive Cancer Center - James Cancer Hospital</td>\n   <td>http://www.jamesline.com/patientsandvisitors/prevention/</td>\n   <td>Online resource which provides cancer risk assessment based on family history.</td>\n   </tr>\n   <tr>\n   <td>March of Dimes</td>\n   <td>http://www.marchofdimes.com/pnhec/4439_1109.asp</td>\n   <td>Printable preconception/prenatal family and medical history questionnaire.</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58003&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Collecting_family_history.htm</title></head></div><div id=\"graphicVersion\">Graphic 62528 Version 1.0</div></div></div>"},"62529":{"type":"graphic_picture","displayName":"Peripheral IV placement 2","title":"Peripheral IV placement: Preparation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral IV placement: Preparation</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/EM/62529_Peripheral_IV_placement_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Place a tourniquet proximal to the venipuncture site and clean the involved area thoroughly.</div><div class=\"graphic_reference\">Courtesy of Robert Frank, MD.</div><div id=\"graphicVersion\">Graphic 62529 Version 2.0</div></div></div>"},"62531":{"type":"graphic_picture","displayName":"Atypical fibroxanthoma","title":"Atypical fibroxanthoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atypical fibroxanthoma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62531_Atypical_fibroxanthoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous, dome-shaped papule is present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62531 Version 3.0</div></div></div>"},"62532":{"type":"graphic_algorithm","displayName":"Two-step algorithm","title":"The two-step algorithm","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">The two-step algorithm</div><div class=\"cntnt\"><img style=\"width:540px; height:190px;\" src=\"images/DERM/62532_Two-step_algo_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 62532 Version 6.0</div></div></div>"},"62533":{"type":"graphic_movie","displayName":"FAST subxiphoid normal cardiac motion","title":"FAST: Subxiphoid view of normal cardiac motion","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">FAST: Subxiphoid view of normal cardiac motion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/62533_FASTsubxiphoidnormmovie.mp4\" style=\"width:496px;height:320px\"></div><img style=\"width:504px; height:389px;\" src=\"images/EM/62533_FASTsubxiphoidnormimage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip, obtained as part of a FAST examination, shows normal cardiac motion and no pericardial effusion.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 62533 Version 1.0</div></div></div>"},"62534":{"type":"graphic_figure","displayName":"Ileocolic anastomosis - anvil and spike of circular stapler","title":"Ileocolic anastomosis - anvil and spike of circular stapler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ileocolic anastomosis - anvil and spike of circular stapler</div><div class=\"cntnt\"><img style=\"width:363px; height:357px;\" src=\"images/SURG/62534_Circular-stapler-anvil-spike.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62534 Version 1.0</div></div></div>"},"62535":{"type":"graphic_figure","displayName":"Circulating hot water ablation","title":"Circulating hot water system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circulating hot water system</div><div class=\"cntnt\"><img style=\"width:389px; height:263px;\" src=\"images/OBGYN/62535_Circulating_hot_water_ablat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hot water circulated throughout an abnormal cavity is able to make contact with all surfaces, potentially providing better endometrial ablation than with a nonconforming system, such as a balloon.</div><div id=\"graphicVersion\">Graphic 62535 Version 1.0</div></div></div>"},"62536":{"type":"graphic_picture","displayName":"Bone marrow sideroblasts","title":"Bone marrow - ring sideroblasts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow - ring sideroblasts</div><div class=\"cntnt\"><img style=\"width:329px; height:454px;\" src=\"images/HEME/62536_Bone_marrow_sideroblasts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper panel: bone marrow aspirate stained with Prussian blue to show red cell precursors with numerous iron- positive granules surrounding the nucleus, in some cases forming a complete ring (arrows). Lower panel: Electron micrograph of a single erythroblast with iron-laden (electron dense deposits) mitochondia (red arrows) clustered&nbsp;near its nucleus.</div><div class=\"graphic_reference\">Courtesy of Sylvia Bottomley, MD.</div><div id=\"graphicVersion\">Graphic 62536 Version 2.0</div></div></div>"},"62537":{"type":"graphic_table","displayName":"Travelers' diarrhea pathogens","title":"Pathogens causing travelers' diarrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathogens causing travelers' diarrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bacteria</td> </tr> <tr> <td>Enterotoxigenic Escherichia coli</td> </tr> <tr> <td>Enteroaggregative E. coli</td> </tr> <tr> <td>Campylobacter jejuni</td> </tr> <tr> <td>Salmonella species</td> </tr> <tr> <td>Shigella species</td> </tr> <tr> <td>Clostridium difficile</td> </tr> <tr> <td>Vibrio parahaemolyticus (V. cholerae less common)</td> </tr> <tr> <td>Aeromonas hydrophilia</td> </tr> <tr> <td>Plesiomonas shigelloides</td> </tr> <tr> <td>Yersinia enterocolitica</td> </tr> <tr> <td class=\"subtitle1_single\">Viruses</td> </tr> <tr> <td>Rotavirus</td> </tr> <tr> <td>Norovirus&nbsp;</td> </tr> <tr> <td>Enteric adenovirus</td> </tr> <tr> <td class=\"subtitle1_single\">Parasites</td> </tr> <tr> <td>Giardia lamblia</td> </tr> <tr> <td>Cryptosporidium parvum</td> </tr> <tr> <td>Cyclospora cayetanensis</td> </tr> <tr> <td>Microsporidia</td> </tr> <tr> <td>Cystoisospora belli</td> </tr> <tr> <td>Entamoeba histolytica (not common)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62537 Version 3.0</div></div></div>"},"62538":{"type":"graphic_figure","displayName":"Beta blocker and potassium load","title":"Beta blocker enhances kalemic response to a potassium load","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Beta blocker enhances kalemic response to a potassium load</div><div class=\"cntnt\"><img style=\"width:425px; height:262px;\" src=\"images/NEPH/62538_Beta_blocker_potassium_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Change in the plasma potassium concentration after a potassium chloride infusion in control subjects (dashed line) and those treated with a beta blocker (solid line). The rise in the plasma potassium concentration was signficantly greater in the presence of beta blockade.</div><div class=\"graphic_reference\">Data from: Rosa RM, Silva P, Young JB, et al. N Engl J Med 1980; 302:431.</div><div id=\"graphicVersion\">Graphic 62538 Version 4.0</div></div></div>"},"62539":{"type":"graphic_figure","displayName":"Anatomy of the anus and rectum","title":"Anatomy of the anus and rectum","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Anatomy of the anus and rectum</div><div class=\"cntnt\"><img style=\"width:552px; height:363px;\" src=\"images/ONC/62539_Anatomyoftheanus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anal canal is 2.5 to 3.5 cm long and begins superiorly where the rectal ampulla is narrowed by the puborectalis sling (the levator ani muscle, which is palpable as the anorectal ring). It ends&nbsp;at the intersphincteric groove.&nbsp;Externally, the anal canal is surrounded by the internal and external anal sphincter muscles. <br />The superior half of the anal canal contains a series of longitudinal ridges called the anal columns (of Morgagni), which extend from the anorectal junction superiorly to the anal valves inferiorly. The anal valves form an irregular line called the dentate (or pectinate) line (colored purple in the diagram), which&nbsp;is an important anatomical landmark. The portions of the anal canal superior and inferior to it have different origins of arterial supply, nerve innervation, venous/lymphatic drainage, and epithelial lining. <br />The anal canal is internally lined with mucus membrane above the dentate line and anoderm below it. The upper portion of the anoderm (anal verge) consists of smooth, hairless skin; the lower portion of the anoderm (perianal skin)&nbsp;contains pigmented skin containing hair follicles and glands.</div><div id=\"graphicVersion\">Graphic 62539 Version 12.0</div></div></div>"},"62540":{"type":"graphic_picture","displayName":"Histology superficial spreading melanoma","title":"Superficial spreading melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial spreading melanoma</div><div class=\"cntnt\"><img style=\"width:368px; height:280px;\" src=\"images/ONC/62540_Histol_superfic_spread_mela.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium-power light photomicrograph of a superficial spreading melanoma, demonstrating intraepidermal and dermal growth of atypical, hyperchromatic cells. Note the highly disorganized architecture of the lesion.</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD, and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 62540 Version 4.0</div></div></div>"},"62543":{"type":"graphic_picture","displayName":"EtCO2 monitor photo","title":"End tidal CO2 (EtCO2) monitor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">End tidal CO2 (EtCO2) monitor</div><div class=\"cntnt\"><img style=\"width:432px; height:578px;\" src=\"images/EM/62543_EtCO2_monitor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo shows a child being monitored with capnography: 29 is the end tidal CO<sub>2</sub>. The capnographic waveform appears in the screen adjacent to the number. The nasal prongs and the bladder that extends from the front of the mouth detect exhaled CO<sub>2</sub>.</div><div class=\"graphic_reference\">Photo courtesy of Mark Waltzman, MD.</div><div id=\"graphicVersion\">Graphic 62543 Version 5.0</div></div></div>"},"62544":{"type":"graphic_picture","displayName":"Binding injured pelvis with sheet","title":"Binding injured pelvis with sheet","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Binding injured pelvis with sheet</div><div class=\"cntnt\"><img style=\"width:515px; height:391px;\" src=\"images/EM/62544_Pelvissheetwrap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Circumferential pelvic antishock sheeting is applied. The patient's clothing should be removed before application. The sheet is positioned beneath the patient's pelvis, being careful to avoid wrinkles that can create pressure sores. (B) The ends of the sheet are crossed in an overlapping manner anteriorly and (C) are pulled taut. (D) Clamps secure the smooth and snug sheet. The sheet pictured above is longer than that used in some instances; a sheet length limited to the pelvis is suitable.</div><div class=\"graphic_reference\">Reproduced with permission from: Routt ML, Falicov A, Woodhouse E, Schildhauer TA. Circumferential pelvic antishock sheeting: a temporary resuscitation aid. J Orthop Trauma 2002; 16:45. Copyright Â© 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62544 Version 13.0</div></div></div>"},"62546":{"type":"graphic_picture","displayName":"Rash in Henoch Schonlein purpura IgA vasculitis","title":"Skin lesions in Henoch-SchÃ¶nlein purpura (IgA vasculitis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin lesions in Henoch-SchÃ¶nlein purpura (IgA vasculitis)</div><div class=\"cntnt\"><img style=\"width:247px; height:369px;\" src=\"images/HEME/62546_Petechiae_in_HS_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clusters of palpable, pruritic&nbsp;lesions on the thigh of a patient with Henoch-SchÃ¶nlein purpura (IgA vasculitis). These lesions could be mistaken for thrombocytopenic petechiae.</div><div class=\"graphic_footnotes\">IgA: immunoglobulin A.</div><div id=\"graphicVersion\">Graphic 62546 Version 5.0</div></div></div>"},"62549":{"type":"graphic_diagnosticimage","displayName":"Misplaced nasogastric tube","title":"Misplaced nasogastric tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Misplaced nasogastric tube</div><div class=\"cntnt\"><img style=\"width:432px; height:385px;\" src=\"images/SURG/62549_Misplaced_nasogastric_tube.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This adolescent had a nasogastric tube placed after a polydrug ingestion. Charcoal was administered, and the patient's respiratory status deteriorated. The chest radiograph shows the nasogastric tube in the left lower lung (arrow) and alveolar opacification (asterisk).</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62549 Version 4.0</div></div></div>"},"62551":{"type":"graphic_picture","displayName":"Juvenile plantar dermatosis","title":"Juvenile plantar dermatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile plantar dermatosis</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/62551_Juvplantardermat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shiny-appearing plantar skin with accentuation of the skin folds and fissures in a teenager with juvenile plantar dermatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62551 Version 5.0</div></div></div>"},"62555":{"type":"graphic_table","displayName":"Lung abscess bacteriology","title":"Bacteriology of lung abscess","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bacteriology of lung abscess</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organisms</td> <td class=\"subtitle1\">Number of cases (percent)</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Total cases</td> </tr> <tr> <td class=\"indent1\">Aerobic bacteria only</td> <td>10 (11)</td> </tr> <tr> <td class=\"indent1\">Anaerobes only</td> <td>43 (46)</td> </tr> <tr> <td class=\"indent1\">Mixed aerobes and anaerobes</td> <td>40 (43)</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Predominant isolates</td> </tr> <tr> <td class=\"subtitle3\" colspan=\"2\">Aerobes</td> </tr> <tr> <td class=\"indent2\"><em>Staphylococcus aureus</em></td> <td>13 (4)</td> </tr> <tr> <td class=\"indent2\"><em>Escherichia coli</em></td> <td>9 (0)</td> </tr> <tr> <td class=\"indent2\"><em>Klebsiella pneumoniae</em></td> <td>7 (3)</td> </tr> <tr> <td class=\"indent2\"><em>Pseudomonas aeruginosa</em></td> <td>7 (1)</td> </tr> <tr> <td class=\"indent2\"><em>Streptococcus pneumoniae</em></td> <td>6 (1)</td> </tr> <tr> <td class=\"subtitle3\" colspan=\"2\">Anaerobes</td> </tr> <tr> <td class=\"indent2\"><em>Peptostreptococcus</em></td> <td>40 (12)</td> </tr> <tr> <td class=\"indent2\"><em>Fusobacterium nucleatum</em></td> <td>34 (5)</td> </tr> <tr> <td class=\"indent2\"><em>Prevotella</em> (black-pigmented)</td> <td>32 (1)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Bartlett JG. Chest 1987; 91:901.</div><div id=\"graphicVersion\">Graphic 62555 Version 4.0</div></div></div>"},"62557":{"type":"graphic_figure","displayName":"Anatomy female genitalia","title":"Anatomy of the female genitalia","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Anatomy of the female genitalia</div><div class=\"cntnt\"><img style=\"width:467px; height:391px;\" src=\"images/PEDS/62557_Anatomy_female_genitalia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Important landmarks of the female genitalia are depicted above.</div><div id=\"graphicVersion\">Graphic 62557 Version 1.0</div></div></div>"},"62558":{"type":"graphic_table","displayName":"Bulb syringe instructions","title":"Instructions on using a bulb syringe","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Instructions on using a bulb syringe</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Nasal congestion from a cold can make it difficult for a young infant to breathe while eating. Mucus can be removed from the infant's nose with a bulb syringe.</td> </tr> <tr> <td class=\"sublist1_start\">Before using a bulb syringe, saline nose drops can be used to thin the mucus. Saline nose drops can be purchased in most pharmacies or can be made at home by adding 1/4 teaspoon salt to 8 ounces (1 cup) of warm (not hot) water. Stir to dissolve the salt, and store the solution for up to&nbsp;one week in a clean container with a cover. </td> </tr> <tr> <td class=\"sublist1\">Place the infant on his or her back. Using a clean nose dropper, place 1 to 2 drops of saline solution in each nostril. Wait a short period. </td> </tr> <tr> <td class=\"sublist1\">Squeeze and hold the bulb syringe to remove the air. Gently insert the tip of the bulb syringe into one nostril, and release the bulb. The suction will draw mucus out of the nostril into the bulb. </td> </tr> <tr> <td class=\"sublist1\">Squeeze the mucus out of the bulb into a tissue. </td> </tr> <tr> <td class=\"sublist1\">Repeat suction process several times in each nostril until most mucus is removed. </td> </tr> <tr> <td class=\"sublist1\">Wash the dropper and bulb syringe in warm, soapy water. Rinse well, and squeeze to remove any water. </td> </tr> <tr> <td>The bulb syringe can be used two to three times per day as needed to remove mucus. It is best to do this before feeding; the saline and suction process can cause vomiting after feeding.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Information from <A href=\"http://www.cincinnatichildrens.org/health/info/newborn/home/suction.htm\">www.cincinnatichildrens.org/health/info/newborn/home/suction.htm</A>.</div><div id=\"graphicVersion\">Graphic 62558 Version 3.0</div></div></div>"},"62560":{"type":"graphic_diagnosticimage","displayName":"Pelvic anteroposterior compression fracture type II","title":"Pelvic anteroposterior compression fracture: Type II","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelvic anteroposterior compression fracture: Type II</div><div class=\"cntnt\"><img style=\"width:299px; height:489px;\" src=\"images/EM/62560_Pelvic_ant_post_fx2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Type II anteroposterior compression fracture with pubic symphysis diastasis, rami fractures, and widening of the right sacroiliac joint.<br />(B) CT scan showing the injury to the anterior portion of the sacroiliac ligaments.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jim Fiechtl, MD.</div><div id=\"graphicVersion\">Graphic 62560 Version 6.0</div></div></div>"},"62561":{"type":"graphic_picture","displayName":"Hypertrophic lichen planus","title":"Hypertrophic lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrophic lichen planus</div><div class=\"cntnt\"><img style=\"width:259px; height:395px;\" src=\"images/OBGYN/62561_Hypertrophic_lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Ridley CM, Neill SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright Â© 1999 Blackwell Science. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 62561 Version 3.0</div></div></div>"},"62565":{"type":"graphic_figure","displayName":"Tendon sheath","title":"Tendon anatomy","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Tendon anatomy</div><div class=\"cntnt\"><img style=\"width:531px; height:228px;\" src=\"images/RHEUM/62565_Tendon_sheath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tendon sheaths, like bursae, develop in response to motion as tendons pull and transmit power. The visceral sheath has a flat synovial lining, and the parietal layer has vesicular and granular patches. There is no basement membrane, only a fatty or collagenous connective tissue. Tendon healing is facilitated by an intact tendon sheath. Snapping or triggering of joint movement can be due to nodular enlargement of the tendon, stenosis of the sheath, or both. Enthesitis involves the area of the tendon that inserts into bone, tendinitis typically involves the area of the tendon closer to the enthesis,&nbsp;peritendonitis involves the area that inserts into muscle, and tenosynovitis represents inflammation of the tendon and its enveloping sheath.</div><div class=\"graphic_reference\">Modified with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 62565 Version 3.0</div></div></div>"},"62566":{"type":"graphic_picture","displayName":"Verrucous sarcoidosis","title":"Verrucous sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Verrucous sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/62566_Verrucous_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous sarcoidosis consisting of discrete hyperkeratotic, thick, hyperpigmented plaques. These types of lesions may be misdiagnosed as lichenified psoriasis, prurigo nodularis, or hypertrophic lichen planus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62566 Version 3.0</div></div></div>"},"62567":{"type":"graphic_diagnosticimage","displayName":"Lateral radiograph of the adult elbow","title":"Lateral radiograph of the adult elbow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral radiograph of the adult elbow</div><div class=\"cntnt\"><img style=\"width:360px; height:266px;\" src=\"images/EM/62567_Elbow_XR_lateral_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph shows normal elbow alignment. A line extended along the anterior border of the humerus (8) or through the middle of the shaft of the radius would bisect the capitellum (2). The structures shown include: humerus (1), olecranon (3), coronoid process (4), radial head (5), radial neck (6), radial tuberosity (7), and the olecranon fossa (9), which is not well seen on the lateral view.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum, TR, Rowe, LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62567 Version 3.0</div></div></div>"},"62568":{"type":"graphic_picture","displayName":"Cutaneous nocardiosis","title":"Cutaneous lesions of nocardiosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous lesions of nocardiosis</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/ID/62568_Cutaneous_nocardiosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin lesions were the presenting clinical manifestation of disseminated nocardiosis in a patient with systemic lupus erythematosus treated with glucocorticoids.</div><div class=\"graphic_reference\">Courtesy of Stanley W Chapman, MD.</div><div id=\"graphicVersion\">Graphic 62568 Version 3.0</div></div></div>"},"62571":{"type":"graphic_table","displayName":"TOAST classification","title":"TOAST classification of subtypes of acute ischemic stroke","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TOAST classification of subtypes of acute ischemic stroke</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Large-artery atherosclerosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardioembolism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Small-vessel occlusion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stroke of other determined etiology</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Stroke of undetermined etiology&nbsp;</td>\n\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Two or more causes identified </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Negative evaluation</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Incomplete evaluation</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62571 Version 1.0</div></div></div>"},"62573":{"type":"graphic_picture","displayName":"Intermediate anorectal malformation","title":"Rectal shelf in a three-month-old girl with an intermediate anorectal anomaly ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rectal shelf in a three-month-old girl with an intermediate anorectal anomaly </div><div class=\"cntnt\"><img style=\"width:396px; height:312px;\" src=\"images/PEDS/62573_Anorectal_malform.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A)&nbsp;The anal opening is excentrically located in pigmented skin of perineum. The opening is not stenotic. B)&nbsp;To demonstrate the posterior shelf, a&nbsp;surgical clamp&nbsp;is inserted&nbsp;into the anal opening, pulling outward on the posterior lip of anorectal canal.</div><div class=\"graphic_reference\">Reproduced with permission from: Hendren WH. Pediatric rectal and perineal problems. Pediatr Clin North Am 1998; 45:1353. Copyright Â©1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 62573 Version 3.0</div></div></div>"},"62574":{"type":"graphic_movie","displayName":"Muscular VSD multiple color","title":"Muscular VSD multiple color","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Muscular VSD multiple color</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/62574_MuscularVSDmultmovie.mp4\" style=\"width:496px;height:400px\"></div><img style=\"width:548px; height:377px;\" src=\"images/CARD/62574_MuscularVSDmultposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With color flow mapping, three jets of flow can be seen crossing the intraventricular septum. The apical jets share a common origin of the left ventricular aspect of the septum but enter the right ventricle via separate orifices.</div><div class=\"graphic_footnotes\">LA: left atrium; RA: right atrium; LV: left ventricle; RV: right ventricle; arrows: multiple muscular VSDs.</div><div id=\"graphicVersion\">Graphic 62574 Version 2.0</div></div></div>"},"62575":{"type":"graphic_waveform","displayName":"Tremor artifact tutorial","title":"Tremor artifact","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Tremor artifact</div><div class=\"cntnt\"><img style=\"width:462px; height:186px;\" src=\"images/CARD/62575_Tremor_artifact_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This dramatic example of tremor artifact demonstrates complexes which simulate a run of ventricular tachycardia. However, QRS complexes (arrows) can clearly be seen marching through the rhythm strip.</div><div id=\"graphicVersion\">Graphic 62575 Version 2.0</div></div></div>"},"62576":{"type":"graphic_figure","displayName":"Hypothalamic pituitary axis","title":"Hypothalamic-pituitary axis","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Hypothalamic-pituitary axis</div><div class=\"cntnt\"><img style=\"width:515px; height:258px;\" src=\"images/ENDO/62576_Hypothalamic_pituitary_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomic relationships of the hypothalamic-pituitary axis. Hormones released from the hypothalamus are released into the median eminence and then move down the pituitary stalk to the pituitary gland. Antidiuretic hormone and corticotropin-releasing hormone are secreted by the paraventricular and supraoptic nuclei, gonadotropin-releasing hormone by the preoptic area, and thyrotropin-releasing hormone by the anterior hypothalamus.</div><div class=\"graphic_reference\">Adapted from: Krieger DT, in: Neuroendocrinology, Krieger DT, Hughes JC (Eds), Sinauer Associates, Sunderland, MA, 1980, chap. 2.</div><div id=\"graphicVersion\">Graphic 62576 Version 4.0</div></div></div>"},"62577":{"type":"graphic_waveform","displayName":"Gastrointestinal manometry in amyloidosis","title":"Gastrointestinal manometry in amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Gastrointestinal manometry in amyloidosis</div><div class=\"cntnt\"><img style=\"width:492px; height:281px;\" src=\"images/GAST/62577_Amyloid_motility_study.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gastrointestinal manometric tracing during fasting in a 60-year-old patient with primary amyloidosis. There are low amplitude contractions at all levels.</div><div class=\"graphic_reference\">Reproduced with permission from: Malagelada JR, Camilleri M, Stanghellini V. Manometric Diagnosis of Gastrointestinal Motility Disorders. Thieme Medical Publishers, New York 1986.</div><div id=\"graphicVersion\">Graphic 62577 Version 4.0</div></div></div>"},"62578":{"type":"graphic_picture","displayName":"Boston brace","title":"Boston brace","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Boston brace</div><div class=\"cntnt\"><img style=\"width:270px; height:408px;\" src=\"images/PEDS/62578_Boston_brace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Boston brace is an underarm thoraco-lumbar-sacral orthosis (TLSO). Such braces can be camouflaged relatively easily under loose-fitting clothes.</div><div class=\"graphic_reference\">Courtesy of Susan A&nbsp;Scherl, MD.</div><div id=\"graphicVersion\">Graphic 62578 Version 2.0</div></div></div>"},"62581":{"type":"graphic_picture","displayName":"Destructive arthritis in MCTD","title":"Destructive arthritis in mixed connective tissue disease (MCTD)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Destructive arthritis in mixed connective tissue disease (MCTD)</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/RHEUM/62581_Destructive_arthritis_in_MC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Destructive arthritis, including &quot;telescoping&quot; of several digits, is a rare complication of mixed connective tissue disease.</div><div class=\"graphic_reference\">Courtesy of Robert M Bennett, MD.</div><div id=\"graphicVersion\">Graphic 62581 Version 2.0</div></div></div>"},"62582":{"type":"graphic_picture","displayName":"Palmoplantar pustulosis - heel","title":"Palmoplantar pustulosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palmoplantar pustulosis</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/62582_Palm_pustulosis_heel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustules are present within an erythematous, scaly plaque.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62582 Version 3.0</div></div></div>"},"62583":{"type":"graphic_figure","displayName":"Healing by primary and secondary intention","title":"Healing by primary and secondary intention","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Healing by primary and secondary intention</div><div class=\"cntnt\"><img style=\"width:524px; height:702px;\" src=\"images/SURG/62583_Healing_prim_second_intent.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: McConnell TH. The Nature Of Disease: Pathology for the Health Professions, Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62583 Version 2.0</div></div></div>"},"62585":{"type":"graphic_figure","displayName":"Age distribution in HL","title":"Bimodal age distribution of Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Bimodal age distribution of Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:562px; height:504px;\" src=\"images/ONC/62585_Age_distribution_in_HL_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age-specific average annual incidence rates of Hodgkin lymphoma for all races by sex per 100,000 population, 2004 to 2008, in the SEER program. Two peaks are noted: a larger peak in young adults, and a second peak in older adults.</div><div class=\"graphic_reference\">Data from: National Cancer Institute. SEER Cancer Statistics Review 1975-2008. Surveillance Epidemiology and End Results. http://seer.cancer.gov/csr/1975_2008/index.html (Accessed February 16, 2012).</div><div id=\"graphicVersion\">Graphic 62585 Version 6.0</div></div></div>"},"62586":{"type":"graphic_diagnosticimage","displayName":"Melanoma renal metastasis","title":"Renal metastasis from melanoma","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Renal metastasis from melanoma</div><div class=\"cntnt\"><img style=\"width:475px; height:215px;\" src=\"images/ONC/62586_Melanoma_renal_metastasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel is an axial CT image at the level of the renal veins showing a low density rounded lesion involving the posterior cortex of the right kidney (arrow). Right panel is an ultrasound of the right kidney showing this to be a solid noncystic mass (outlined by cursors).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Kevin Donohoe, MD.</div><div id=\"graphicVersion\">Graphic 62586 Version 3.0</div></div></div>"},"62589":{"type":"graphic_table","displayName":"Signs and symptoms of volatile inhalant abuse","title":"Signs and symptoms of volatile inhalant abuse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms of volatile inhalant abuse</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">General</td></tr>\n\t\t\t\t\t\t<tr><td>Mood swings</td></tr>\n\t\t\t\t\t\t<tr><td>Increased irritability and anger</td></tr>\n\t\t\t\t\t\t<tr><td>Uncontrolled laughter or violent outbursts</td></tr>\n\t\t\t\t\t\t<tr><td>Risk-taking</td></tr>\n\t\t\t\t\t\t<tr><td>Grandiose or hostile speech</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">HEENT</td></tr>\n\t\t\t\t\t\t<tr><td>Nosebleeds</td></tr>\n\t\t\t\t\t\t<tr><td>Increased salivation</td></tr>\n\t\t\t\t\t\t<tr><td>Facial rash or flushing</td></tr>\n\t\t\t\t\t\t<tr><td>Dilated pupils, conjunctival injection</td></tr>\n\t\t\t\t\t\t<tr><td>Nystagmus, diplopia</td></tr>\n\t\t\t\t\t\t<tr><td>Blisters near nose, mouth</td></tr>\n\t\t\t\t\t\t<tr><td>Unusual breath odor</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Gastrointestinal</td></tr>\n\t\t\t\t\t\t<tr><td>Nausea, vomiting, anorexia</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Respiratory</td></tr>\n\t\t\t\t\t\t<tr><td>Coughing or sneezing</td></tr>\n\t\t\t\t\t\t<tr><td>Wheezing</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">CNS</td></tr>\n\t\t\t\t\t\t<tr><td>Headache</td></tr>\n\t\t\t\t\t\t<tr><td>Decrease or loss of sense of smell</td></tr>\n\t\t\t\t\t\t<tr><td>Numbness and tingling of hands and feet</td></tr>\n\t\t\t\t\t\t<tr><td>Slurred speech</td></tr>\n\t\t\t\t\t\t<tr><td>Hallucinations</td></tr>\n\t\t\t\t\t\t<tr><td>Tinnitus</td></tr>\n\t\t\t\t\t\t<tr><td>Disorientation</td></tr>\n\t\t\t\t\t\t<tr><td>Convulsions</td></tr>\n\t\t\t\t\t\t<tr><td>Ataxia</td></tr>\n\t\t\t\t\t\t<tr><td>Hand tremor</td></tr>\n\t\t\t\t\t\t<tr><td>Muscle weakness</td></tr>\n\t\t\t\t\t\t<tr><td>Decreased reflexes</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62589 Version 2.0</div></div></div>"},"62590":{"type":"graphic_picture","displayName":"Giant molluscum contagiosum","title":"Molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62590_Giant_moll_contag.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large nodule is present on the face of this patient with molluscum contagiosum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62590 Version 3.0</div></div></div>"},"62591":{"type":"graphic_figure","displayName":"HRT and CHD HERS II","title":"Estrogen therapy not beneficial for secondary prevention of coronary heart disease","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Estrogen therapy not beneficial for secondary prevention of coronary heart disease</div><div class=\"cntnt\"><img style=\"width:460px; height:262px;\" src=\"images/ENDO/62591_HRT_and_CHD_HERS_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the HERS-II trial on the incidence of coronary heart disease events (death or nonfatal myocardial infarction) in 2763 postmenopausal women with a prior history of myocardial infarction or interventional procedure who were treated with combined HRT or placebo. There was no difference between the two groups. The curves are truncated at year 7 when less than half of the cohort remained in follow-up.</div><div class=\"graphic_footnotes\">HERS II: Heart and Estrogen/progestin Replacement Study follow-up; HRT: hormone replacement therapy.</div><div class=\"graphic_reference\">Data from: Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).&nbsp;JAMA 2002; 288:49.</div><div id=\"graphicVersion\">Graphic 62591 Version 6.0</div></div></div>"},"62592":{"type":"graphic_diagnosticimage","displayName":"SIS tamoxifen patient","title":"Saline infusion sonohysterography of a patient on tamoxifen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saline infusion sonohysterography of a patient on tamoxifen</div><div class=\"cntnt\"><img style=\"width:394px; height:260px;\" src=\"images/OBGYN/62592_SIS_tamoxifen_patient.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The endometrium surrounding the fluid is thin and atrophic and small sonolucent microcystic changes (marked by calipers) are seen under the superficial epithelium.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 62592 Version 3.0</div></div></div>"},"62593":{"type":"graphic_table","displayName":"Psychosocial burden past thalassemia","title":"Psychosocial burden of thalassemia in the past","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Psychosocial burden of thalassemia in the past</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n<tr>\n<td>Stigmatization</td>\n</tr>\n<tr>\n<td>Secrecy about the illness</td>\n</tr>\n<tr>\n<td>Isolation of patient and family</td>\n</tr>\n<tr>\n<td>Physical handicap</td>\n</tr>\n<tr>\n<td>Absence of sexual development</td>\n</tr>\n<tr>\n<td>Fear of dying before adulthood</td>\n</tr>\n<tr>\n<td>Fear of social rejection</td>\n</tr>\n<tr>\n<td>Dependency</td>\n</tr>\n</table></div><div class=\"graphic_reference\">Data from: Politis C. The psychosocial impact of chronic illness. Ann N Y Acad Sci 1998; 850:349.</div><div id=\"graphicVersion\">Graphic 62593 Version 2.0</div></div></div>"},"62594":{"type":"graphic_figure","displayName":"Imatinib mechanism of action","title":"Schematic representation of the mechanism of action of imatinib","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Schematic representation of the mechanism of action of imatinib</div><div class=\"cntnt\"><img style=\"width:461px; height:332px;\" src=\"images/HEME/62594_STI571_Gleevec_in_CML.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bcr-abl tyrosine kinase is a constituitively active kinase which functions by binding ATP and transferring phosphate from ATP to tyrosine residues on various substrates. This causes the excess proliferation of myeloid cells characteristic of CML. Imatinib (STI571,Gleevec) functions by blocking the binding of ATP to the bcr-abl tyrosine kinase, inhibiting its activity. In the absence of tyrosine kinase activity, substrates required for bcr-abl function cannot be phosphorylated and subsequent cellular events are abrogated.</div><div class=\"graphic_reference\">Reproduced with permission from Mauro, MJ, Drucker, BJ. STI571: Targeting BCR-ABL as therapy for CML. Oncologist 2001; 6:233. Copyright &#169; 2001 AlphaMed Press.</div><div id=\"graphicVersion\">Graphic 62594 Version 2.0</div></div></div>"},"62597":{"type":"graphic_table","displayName":"Differential monoarthritis","title":"Differential diagnosis of acute monoarthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of acute monoarthritis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td>Bacterial</td> </tr> <tr> <td>Fungal</td> </tr> <tr> <td>Mycobacterial</td> </tr> <tr> <td>Viral</td> </tr> <tr> <td>Spirochete</td> </tr> <tr> <td class=\"subtitle1_single\">Crystal induced</td> </tr> <tr> <td>Monosodium urate</td> </tr> <tr> <td>Calcium pyrophosphate dihydrate</td> </tr> <tr> <td>Hydroxyapatite</td> </tr> <tr> <td>Calcium oxalate</td> </tr> <tr> <td>Lipid</td> </tr> <tr> <td class=\"subtitle1_single\">Hemarthrosis</td> </tr> <tr> <td>Trauma</td> </tr> <tr> <td>Anticoagulation</td> </tr> <tr> <td>Clotting disorders</td> </tr> <tr> <td>Fracture</td> </tr> <tr> <td>Pigmented villonodular synovitis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Tumor</td> </tr> <tr> <td>Tenosynovial giant cell tumor (formerly pigmented villonodular synovitis)</td> </tr> <tr> <td>Chondrosarcoma</td> </tr> <tr> <td>Osteoid osteoma</td> </tr> <tr> <td>Metastatic disease</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic rheumatic disease</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Spondyloarthritis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Osteoarthritis</td> </tr> <tr> <td>Erosive variant</td> </tr> <tr> <td class=\"subtitle1_single\">Intraarticular derangement</td> </tr> <tr> <td>Meniscal tear</td> </tr> <tr> <td>Osteonecrosis</td> </tr> <tr> <td>Fracture</td> </tr> <tr> <td class=\"subtitle1_left\">Other</td> </tr> <tr> <td>Plant thorn synovitis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62597 Version 5.0</div></div></div>"},"62598":{"type":"graphic_picture","displayName":"Granuloma annulare on hand","title":"Localized granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Localized granuloma annulare</div><div class=\"cntnt\"><img style=\"width:432px; height:306px;\" src=\"images/DERM/62598_Granuloma_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 65-year-old presented with a 14-month history of annular lesions of granuloma annulare on the backs of each hand and left dorsum foot. The periphery of the lesion on the right hand demonstrates papules in some foci and a rope-like rim in other areas. The central area of clearing is hypopigmented.</div><div id=\"graphicVersion\">Graphic 62598 Version 2.0</div></div></div>"},"62599":{"type":"graphic_picture","displayName":"Acromioclavicular joint palpation","title":"Acromioclavicular joint palpation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular joint palpation</div><div class=\"cntnt\"><img style=\"width:432px; height:301px;\" src=\"images/EM/62599_AC_joint_palpation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Careful, systematic palpation of the clavicle, acromioclavicular joint, and acromion can help to identify the source of pain.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 62599 Version 2.0</div></div></div>"},"62602":{"type":"graphic_diagnosticimage","displayName":"Color flow Doppler moderate AR","title":"Color flow Doppler of aortic regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Color flow Doppler of aortic regurgitation</div><div class=\"cntnt\"><img style=\"width:351px; height:230px;\" src=\"images/CARD/62602_Color_flow_Doppler_moderate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The color flow Doppler from the long axis precordial view shows moderate aortic regurgitation (AR) with a jet width at its origin (vena contracta) about half of the left ventricular outflow tract (LVOT) diameter (arrow). Panel A is an M-mode echocardiogram with color flow Doppler, obtained from the two dimensional echocardiogram in the plane indicated by the dotted line (M-line); the AR jet is seen within the left ventricle (LV).</div><div class=\"graphic_footnotes\">Ao: aorta.</div><div id=\"graphicVersion\">Graphic 62602 Version 2.0</div></div></div>"},"62604":{"type":"graphic_figure","displayName":"PET rapid vs slow transporters","title":"Peritoneal equilibration test in rapid versus slow transporters","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peritoneal equilibration test in rapid versus slow transporters</div><div class=\"cntnt\"><img style=\"width:276px; height:332px;\" src=\"images/NEPH/62604_PD_Rapid_v_slow_transporter.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Differences between rapid and slow transporters during PD. Rapid transporters reach creatinine equilibration more quickly (dialysate-to-plasma creatinine equals one, top panel); have a gradual reduction in dialysate volume after two hours due to glucose absorption (middle panel); and have a reduction in CCr after four hours due to absorption of creatinine with the glucose and fluid (lower panel). Thus, short dwell times are most efficient in these patients.</div><div class=\"graphic_footnotes\">PD: peritoneal dialysis; CCr: creatinine clearance.</div><div class=\"graphic_reference\">Data from Twardowsky ZJ. Nightly peritoneal dialysis: Why, who, how, and when?&nbsp;ASAIO Trans 1990; 36:8.</div><div id=\"graphicVersion\">Graphic 62604 Version 6.0</div></div></div>"},"62605":{"type":"graphic_picture","displayName":"Pharmacologic mydriasis","title":"Pharmacologic mydriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pharmacologic mydriasis</div><div class=\"cntnt\"><img style=\"width:360px; height:244px;\" src=\"images/NEURO/62605_Pharmacologic_mydriasis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62605 Version 1.0</div></div></div>"},"62607":{"type":"graphic_picture","displayName":"Beau lines","title":"Beau lines","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Beau lines</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/62607_Beaulines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse grooves representing Beau lines are present on the nail plates.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62607 Version 6.0</div></div></div>"},"62608":{"type":"graphic_figure","displayName":"Technique end to side grafting","title":"Technique of end-to-side anastomosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Technique of end-to-side anastomosis</div><div class=\"cntnt\"><img style=\"width:335px; height:434px;\" src=\"images/CARD/62608_Technique_end_to_side_graft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stitches 1 to 6 are placed in the left internal mammary artery (LIMA) while elevated off the coronary artery (CA) (A). After stitch 6, the suture line is tightened (B) and the remaining sutures are placed (C,D).</div><div id=\"graphicVersion\">Graphic 62608 Version 1.0</div></div></div>"},"62609":{"type":"graphic_picture","displayName":"Milch technique for shoulder reduction","title":"Milch technique for shoulder reduction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Milch technique for shoulder reduction</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/EM/62609_Milch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arm is abducted and the physician's thumb is used to push the humeral head into its proper position. Gentle traction in line with the humerus is provided with the physician's opposite hand.</div><div class=\"graphic_reference\">Courtesy of Scott C Sherman, MD.</div><div id=\"graphicVersion\">Graphic 62609 Version 6.0</div></div></div>"},"62611":{"type":"graphic_table","displayName":"MAP chemo osteosarcoma","title":"Doxorubicin, cisplatin, and high-dose methotrexate (MAP) followed by surgery and MAP for nonmetastatic osteosarcoma (control arm, COG AOST 0331)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doxorubicin, cisplatin, and high-dose methotrexate (MAP) followed by surgery and MAP for nonmetastatic osteosarcoma (control arm, COG AOST 0331)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Weeks</td> <td class=\"subtitle1\">Agents</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Induction MAP (weeks 1 through 10)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" rowspan=\"2\">1, 6</td> <td>Doxorubicin</td> <td>37.5 mg/m<sup>2</sup> per day by continuous IV infusion or IV push</td> <td>1 and 2</td> </tr> <tr class=\"highlight_gray_text\"> <td>Cisplatin</td> <td>60 mg/m<sup>2</sup> per day IV over four hours</td> <td>1 and 2</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">4, 5, 9, 10</td> <td>High-dose methotrexate</td> <td>12 grams/m<sup>2</sup> IV over four hours*</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Leucovorin rescue</td> <td>15 mg (approximately 10 mg/m<sup>2</sup>) every six hours IV or orally for 10 doses<sup>&#182;</sup></td> <td>Starting 24 hours after beginning high-dose methotrexate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Surgery (week 11)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\">11</td> <td colspan=\"3\">Resection or amputation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Postoperative MAP (weeks 12 through 29)</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" rowspan=\"2\">12, 17</td> <td>Doxorubicin<sup>&#916;</sup></td> <td>37.5 mg/m<sup>2</sup> per day by continuous IV infusion or IV push</td> <td>1 and 2</td> </tr> <tr class=\"highlight_gray_text\"> <td>Cisplatin</td> <td>60 mg/m<sup>2</sup> per day IV over four hours</td> <td>1 and 2</td> </tr> <tr> <td class=\"indent1\">22, 26</td> <td>Doxorubicin<sup>&#916;</sup></td> <td>37.5 mg/m<sup>2</sup> per day IV over 24 hours</td> <td>1 and 2</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" rowspan=\"2\">15, 16, 20, 21, 24, 25, 28, 29</td> <td>High-dose methotrexate</td> <td>12 grams/m<sup>2</sup> IV over four hours</td> <td>1</td> </tr> <tr class=\"highlight_gray_text\"> <td>Leucovorin rescue</td> <td>15 mg (approximately 10 mg/m<sup>2</sup>) every six hours IV or orally for 10 doses</td> <td>Starting 24 hours after beginning high-dose methotrexate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Some pediatric oncologists limit the methotrexate dose to 20 grams total (Meyers, PA, et al. J Clin Oncol 2005; 23:2004).<br />&para; Leucovorin doses adjusted depending on blood methotrexate levels.<br />&Delta; Dexrazoxane can be given with doxorubicin, although osteosarcoma-specific data are not available.</div><div class=\"graphic_reference\">Created with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>National Cancer Institute Clinical Trials. Phase III randomized study of neoadjuvant induction therapy comprising doxorubicin, cisplatin, and high-dose methotrexate (MAP) followed by surgery and adjuvant maintenance therapy comprising map alone versus map and peg-interferon alfa-2b or MAP combined with ifosfamide and etoposide in patients with resectable high-grade osteosarcoma; available at: <a href=\"https://clinicaltrials.gov/ct2/show/NCT00134030?term=AOST+0331&amp;rank=1\" target=\"_blank\">https://clinicaltrials.gov/ct2/show/NCT00134030?term=AOST+0331&amp;rank=1</a>, accessed February 26, 2016.</li>&#xD;&#xA;    <li>Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003; 21:1574.</li>&#xD;&#xA;    <li>Geller DS, Goorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 2010; 8:705.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 62611 Version 6.0</div></div></div>"},"62612":{"type":"graphic_figure","displayName":"Modified Epley Right","title":"Modified Epley maneuver for self-treatment of benign positional vertigo (right)","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Modified Epley maneuver for self-treatment of benign positional vertigo (right)</div><div class=\"cntnt\"><img style=\"width:519px; height:443px;\" src=\"images/PC/62612_Modified_Epleys_Right.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This maneuver should be carried out three times a day. Repeat this daily until you are free from positional vertigo for 24 hours.</div><div class=\"graphic_reference\">Reproduced from <A href=\"http://www.charite.de/ch/neuro/englishL.htm\">http://www.charite.de/ch/neuro/englishL.htm</A></div><div id=\"graphicVersion\">Graphic 62612 Version 2.0</div></div></div>"},"62613":{"type":"graphic_picture","displayName":"Metered dose inhaler","title":"Metered dose inhaler","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Metered dose inhaler</div><div class=\"cntnt\"><img style=\"width:490px; height:259px;\" src=\"images/PULM/62613_Metered_dose_inhaler_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medication is stored under pressure in the canister and released from the dosing chamber when the canister is pressed downward.</div><div id=\"graphicVersion\">Graphic 62613 Version 4.0</div></div></div>"},"62615":{"type":"graphic_figure","displayName":"Eye anatomy","title":"Anatomy of the episclera and sclera","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Anatomy of the episclera and sclera</div><div class=\"cntnt\"><img style=\"width:535px; height:312px;\" src=\"images/RHEUM/62615_Eye-anatomy-edit-2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the location of the cornea, conjunctiva, episclera, and sclera.</div><div id=\"graphicVersion\">Graphic 62615 Version 3.0</div></div></div>"},"62616":{"type":"graphic_picture","displayName":"Skin biopsy scleroderma","title":"Skin biopsy of scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin biopsy of scleroderma</div><div class=\"cntnt\"><img style=\"width:360px; height:258px;\" src=\"images/RHEUM/62616_Skin_biopsy_scleroderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pauciinflammatory pandermal fibrosis with subcuticular and marked adnexal inflammation.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 62616 Version 3.0</div></div></div>"},"62622":{"type":"graphic_figure","displayName":"Subclavian steal","title":"Subclavian steal","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Subclavian steal</div><div class=\"cntnt\"><img style=\"width:511px; height:482px;\" src=\"images/SURG/62622_Subclavian_steal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subclavian artery occlusion or a hemodynamically significant stenosis proximal to the origin of the vertebral artery results in lower pressure in the distal subclavian artery. As a result, blood is &quot;stolen&quot; from the cerebral circulation to perfuse the arm. Blood flows up the contralateral vertebral artery to the basilar artery, and retrograde down the ipsilateral vertebral artery away from the brainstem.</div><div id=\"graphicVersion\">Graphic 62622 Version 5.0</div></div></div>"},"62623":{"type":"graphic_diagnosticimage","displayName":"TEE modified apical 4 chamber","title":"Modified apical four chamber view transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Modified apical four chamber view transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:466px; height:310px;\" src=\"images/CARD/62623_TEE_modified_apical_4_chamb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Horizontal (0Âº) imaging from the fundus of the stomach with maximum flexion results in a modified &quot;apical four chamber&quot; view of the heart. Seen are the right ventricle (RV), mitral valve (MV), left ventricle (LV), right atrium (RA), and left atrium. Panel A: Slight anterior rotation of the probe permits imaging of the left ventricular outflow tract (LVOT) and the aortic valve (AoV). Continuous wave, pulsed, or color Doppler examination may also be performed from this orientation. Panel C: In some patients, extensive portions of the ascending aorta (AAo) may be seen.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 62623 Version 2.0</div></div></div>"},"62625":{"type":"graphic_picture","displayName":"Narrow band imaging Endosc II","title":"Narrow band imaging in early esophageal cancer","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Narrow band imaging in early esophageal cancer</div><div class=\"cntnt\"><img style=\"width:540px; height:228px;\" src=\"images/GAST/62625_Narrow_band_imaging_Endos1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A detailed view of an early cancer area in a Barrett's esophagus imaged with high resolution endoscopy and magnification (left) and with narrow band imaging with magnification (right).</div><div class=\"graphic_reference\">Reproduced with permission from: www.Barrett.nl. Copyright &#169; Amsterdam Esophageal Research Foundation.</div><div id=\"graphicVersion\">Graphic 62625 Version 2.0</div></div></div>"},"62628":{"type":"graphic_picture","displayName":"Linear gingival erythema","title":"Generalized linear gingival erythema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Generalized linear gingival erythema</div><div class=\"cntnt\"><img style=\"width:432px; height:301px;\" src=\"images/PC/62628_Linear_gingival_erythema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HIV-positive individual with pronounced and defined redness at the gingival margins.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 62628 Version 2.0</div></div></div>"},"62629":{"type":"graphic_table","displayName":"Muscle innervation part C","title":"Function and peripheral and segmental innervation of muscles: part C","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Function and peripheral and segmental innervation of muscles: part C</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">Function</td>\n\n\n      <td class=\"subtitle1\">Muscle</td>\n\n\n      <td class=\"subtitle1\">Nerve</td>\n\n\n    </tr>\n\n\n    <tr><td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Plexus lumbalis: T12-L4</td></tr><tr>\n\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n\n      \n\n\n      <td class=\"subtitle2_left\">Femoral nerve</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Flexion and outward rotation of hip</td>\n\n\n      <td>Iliopsoas</td>\n\n\n      <td>L1-L3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Flexion and inward rotation of lower leg</td>\n\n\n      <td>Sartorius</td>\n\n\n      <td>L2-L3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Extension of lower leg in knee joint</td>\n\n\n      <td>Quadriceps femoris</td>\n\n\n      <td>L2-L4</td>\n\n\n    </tr>\n\n\n    \n\n\n    <tr>\n\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;</td>\n\n\n      \n\n\n      <td class=\"subtitle2_left\">Obturator nerve</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\" colspan=\"1\" rowspan=\"5\">Adduction of thigh</td>\n\n\n      <td>Pectineus</td>\n\n\n      <td>L2-L3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>Adductor longus</td>\n\n\n      <td>L2-L3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>Adductor brevis</td>\n\n\n      <td>L2-L4</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>Adductor magnus</td>\n\n\n      <td>L3-L4</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>Gracilis</td>\n\n\n      <td>L2-L4</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Adduction and outward rotation of thigh</td>\n\n\n      <td>Obturatorius externus</td>\n\n\n      <td>L3-L4</td>\n\n\n    </tr>\n\n\n    <tr><td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Plexus sacralis: L5-S1</td></tr><tr>\n\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;</td>\n\n\n      \n\n\n      <td class=\"subtitle2_left\">Superior gluteal nerve</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">Abduction and inward rotation of thigh</td>\n\n\n      <td colspan=\"1\" rowspan=\"2\">Gluteus medius and minimus</td>\n\n\n      <td>L4-S1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      \n\n\n      <td>L4-L5</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Flexion of upper leg in hip; abduction and inward rotation</td>\n\n\n      <td>Tensor fasciae latae</td>\n\n\n      <td colspan=\"1\" rowspan=\"2\">L5-S1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Outward rotation of thigh and abduction</td>\n\n\n      <td>Piriformis</td>\n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;</td>\n\n\n      <td class=\"subtitle2_left\">Inferior gluteal nerve</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Extension of thigh in hip</td>\n\n\n      <td>Gluteus maximus</td>\n\n\n      <td>L4-S2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">Outward rotation of thigh</td>\n\n\n      <td>Obturatorius internus</td>\n\n\n      <td>L5-S1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>Gemelli</td>\n\n\n      <td>L4-S1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>Quadratus</td>\n\n\n      <td>L4-S1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n\n      \n\n\n      <td class=\"subtitle2_left\">Sciatic nerve</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">Flexion of lower leg</td>\n\n\n      <td>Biceps femoris</td>\n\n\n      <td>L4-S2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>Semitendinosus</td>\n\n\n      <td>L4-S2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>Semimembranosus</td>\n\n\n      <td>L4-S1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n\n      \n\n\n      <td class=\"subtitle2_left\">Deep peroneal nerve</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Dorsiflexion and supination of foot</td>\n\n\n      <td>Tibialis anterior</td>\n\n\n      <td>L4-L5</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Extension of toes and foot</td>\n\n\n      <td>Extensor digitorum longus</td>\n\n\n      <td>L4-S1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Extension of toes II-V</td>\n\n\n      <td>Extensor digitorum brevis</td>\n\n\n      <td>L4-S1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Extension of large toe</td>\n\n\n      <td>Extensor hallucis longus</td>\n\n\n      <td>L4-S1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Extension of large toe</td>\n\n\n      <td>Extensor hallucis brevis</td>\n\n\n      <td>L4-S1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n\n      \n\n\n      <td class=\"subtitle2_left\">Superficial peronealnerve</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Lifting and pronation of outer portion of foot</td>\n\n\n      <td>Peronei</td>\n\n\n      <td>L5-S1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n\n      \n\n\n      <td class=\"subtitle2_left\">Tibial nerve</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Plantar flexion of foot in supination</td>\n\n\n      <td><p>Gastrocnemius</p>\n\t\t\t<p>Triceps surae</p>\n\t\t\t<p>Soleus</p></td>\n\n\n      <td>L5-S2</td>\n\n\n    </tr>\n\n\n    \n\n\n    \n\n\n    <tr>\n\n\n      <td class=\"indent1\">Supination and plantar flexion of foot</td>\n\n\n      <td>Tibialis posterior</td>\n\n\n      <td>L4-L5</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Flexion of distal phalanges of toes II-V (plantar flexion of foot in supination)</td>\n\n\n      <td>Flexor digitorum longus</td>\n\n\n      <td>L5-S2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Flexion of distal phalanx of big toe</td>\n\n\n      <td>Flexor hallucis longus</td>\n\n\n      <td>L5-S2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Flexion of middle phalanges of toes II-V</td>\n\n\n      <td>Flexor digitorum brevis</td>\n\n\n      <td>S1-S3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Spreading, closing, and flexing of proximal phalanges of toes</td>\n\n\n      <td>Plantaris pedis</td>\n\n\n      <td>S1-S3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n\n      \n\n\n      <td class=\"subtitle2_left\">Pudendal nerve</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Closing of sphincters of bladder and rectum</td>\n\n\n      <td>Perineal and sphincter musculature</td>\n\n\n      <td>S2-S4</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table>\n\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">3/23/99-Perm requested. 5/18/99-Perm granted for 1 edition. 11/18/99-perm requested for 8.1. 2/23/00-perm granted for 8.2 and 8.3 (put back in gold). \r\n10/16/2000-may not be in gold. 11/29/2000-renewal sent. 12/4/2000-perm granted 9.1-9.3; 11/7/2001 -renewal requested -jm;  11/13/2001 -renewal granted -jm; 5/14/2002 - received invoice for figure 1 - $85.00.  Gave to ajeah -jm\r\n10/4/2002 - renewal requested -jm; 10/9/2002 -renewal granted, no charge.   CD-Rom granted for 1 year, and internet perm expires after 2 years -jm\r\n10/8/2003 perm granted for 2 years\r\n11/14/2005 renewal requested 11/17/2005 granted - they will send invoice 1/10/2006 invoice to susan\r\n10/10/2006 renewal requested 1/9/2007 renewal granted (online perm until 2008) - invoice to come\r\n2/23/2007 - Inovice to Tammy.mt\r\n11/28/2007--renewal requested. EM\r\n1/8/2008--renewal granted, invoice to Tammy. EM\r\n\r\n1/13/2009--Requested renewal (JD).\r\n2/9/2009--Renewal granted via permissions agreement, awaiting formal invoice (JD).\r\n4/8/2009--Formal invoice received, to Catherine for payment (JD).\r\n\r\n The total fee of $&amp;quot;120.00&amp;quot;was originally charged to\r\nMuscle_innervation_part_A\r\nMuscle_innervation_part_B\r\nMuscle_innervation_part_C</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=59941&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Muscle_innervation_part_C.htm</title></head></div><div class=\"graphic_reference\">Data from Duus, P. Topical Diagnosis in Neurology, 2nd ed. Thieme Medical Publishers, New York, 1989.</div><div id=\"graphicVersion\">Graphic 62629 Version 2.0</div></div></div>"},"62630":{"type":"graphic_picture","displayName":"Constrictive bronchiolitis High","title":"Constrictive bronchiolitis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Constrictive bronchiolitis</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/PULM/62630_Constrictive_bronchioliti1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of constrictive bronchiolitis in a patient with severe progressive airflow obstruction following toxic fume exposure. There is complete obliteration of the bronchiole by submucosal scarring. The surrounding alveolar spaces are spared. Pentachrome stain.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 62630 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Section through a bronchiole</div><div class=\"cntnt\"><img style=\"width:220px; height:251px;\" src=\"images/PULM/74793_Normal_bronchiole.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchioles are distinguished from bronchi by a lack of glands and cartilage. Hematoxylin and eosin stain.</div><div class=\"graphic_reference\">From: Corrin, B. Development and structure of the normal lung. In: Clinical Atlas Respiratory Diseases, Turner-Warwick, M, Hodson, ME, Corrin, B, Kerr, IH (Eds), JB Lippincott, London, 1989.</div><div id=\"graphicVersion\">Graphic 74793 Version 1.0</div></div></div>"},"62632":{"type":"graphic_diagnosticimage","displayName":"CT scan showing pancreatic necrosis","title":"CT scan showing pancreatic necrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan showing pancreatic necrosis</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/SURG/62632_CT_scan_pancreatic_necrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced computed tomography (CECT) scan showing perfused pancreatic tissue (arrow) and nonperfused pancreatic necrosis (star) with associated peripancreatic necrosis (triangle) in the transverse mesocolon of a patient with severe acute pancreatitis.</div><div id=\"graphicVersion\">Graphic 62632 Version 3.0</div></div></div>"},"62633":{"type":"graphic_figure","displayName":"Carvedilol in HF I","title":"Survival benefit of carvedilol in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival benefit of carvedilol in heart failure</div><div class=\"cntnt\"><img style=\"width:422px; height:265px;\" src=\"images/CARD/62633_Carvedilol_in_HF_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier analysis of survival in patients with chronic heart failure (HF) who were maintained on digoxin, diuretics, and an angiotensin converting enzyme inhibitor and then treated with carvedilol or placebo. Therapy with carvedilol was associated with a significant improvement in survival (p &lt;0.001).</div><div class=\"graphic_reference\">Data from: Packer M, Bristow MR, Cohn JN, et al for the US Carvedilol Heart Failure Study Group, N Engl J Med 1996; 334:1349.</div><div id=\"graphicVersion\">Graphic 62633 Version 3.0</div></div></div>"},"62637":{"type":"graphic_diagnosticimage","displayName":"Normal first-trimester nuchal translucency","title":"Normal first-trimester nuchal translucency","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Normal first-trimester nuchal translucency</div><div class=\"cntnt\"><img style=\"width:720px; height:534px;\" src=\"images/OBGYN/62637_Firsttrimesnuchallucency.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nuchal translucency is the lucent zone observed sonographically at the posterior fetal neck. This 11-week fetus has a normal nuchal translucency of 1.2 mm as well as a normal nasal bone. The area of nuchal translucency is clearly separate from the underlying amnion (arrows).</div><div class=\"graphic_footnotes\">NB: nasal bone</div><div id=\"graphicVersion\">Graphic 62637 Version 6.0</div></div></div>"},"62639":{"type":"graphic_picture","displayName":"Child with severe Noma","title":"Child with severe Noma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Child with severe Noma</div><div class=\"cntnt\"><img style=\"width:385px; height:396px;\" src=\"images/ID/62639_Child_with_severe_Noma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Photo courtesy of Dr. Cyril O. Enwonwu. Originally published in: Scarlett M, Enwonwu CO. Noma: Poverty and oral health linked to orofacial gangrene. Medscape 2011. Available at: <a href=\"http://www.medscape.com/viewarticle/745088\" target=\"_blank\">http://www.medscape.com/viewarticle/745088</a> (Accessed on July 18, 2016).</div><div id=\"graphicVersion\">Graphic 62639 Version 4.0</div></div></div>"},"62641":{"type":"graphic_figure","displayName":"Schematic diagram of neuromuscular motor function","title":"Schematic diagram of neuromuscular motor function","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Schematic diagram of neuromuscular motor function</div><div class=\"cntnt\"><img style=\"width:531px; height:697px;\" src=\"images/EM/62641_Neuromusc_motor_unit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The motor unit (neuromuscular apparatus). Voluntary muscle control begins with a nerve impulse from the brain, which is relayed by an upper motor neuron to muscle by a lower motor neuron. A) Detail of the motor end plate, where nerve meets muscle. A nerve impulse causes discharge of acetylcholine into the synaptic space, where it attaches to receptors on muscle cells and causes muscle fiber contraction. B) Detail of skeletal muscle. In this microscopic depiction, type 1 (slow twitch) fibers are pale and type 2 (fast twitch) are dark.</div><div class=\"graphic_reference\">Reproduced with permission from: McConnell, TH. The nature of disease pathology for the health professions, Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62641 Version 2.0</div></div></div>"},"62643":{"type":"graphic_diagnosticimage","displayName":"Ewings sarcoma left tibia","title":"Ewing sarcoma in the left tibia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ewing sarcoma in the left tibia</div><div class=\"cntnt\"><img style=\"width:198px; height:519px;\" src=\"images/ONC/62643_Ewings_sarcoma_left_tibia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph of a Ewing sarcoma of the distal left tibia in a nine year old girl, demonstrating extensive cortical destruction.</div><div class=\"graphic_reference\">Courtesy of Thomas DeLaney, MD.</div><div id=\"graphicVersion\">Graphic 62643 Version 3.0</div></div></div>"},"62644":{"type":"graphic_table","displayName":"Categories of pulmonary nodules","title":"Causes of solitary pulmonary nodules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of solitary pulmonary nodules</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Malignant</td> </tr> <tr> <td class=\"subtitle2_single\">Bronchogenic carcinoma</td> </tr> <tr> <td class=\"indent1\">Adenocarcinoma</td> </tr> <tr> <td class=\"indent1\">Squamous cell carcinoma</td> </tr> <tr> <td class=\"indent1\">Large cell carcinoma</td> </tr> <tr> <td class=\"indent1\">Small cell carcinoma</td> </tr> <tr> <td class=\"subtitle2_single\">Metastatic lesions</td> </tr> <tr> <td class=\"indent1\">Breast</td> </tr> <tr> <td class=\"indent1\">Head and neck</td> </tr> <tr> <td class=\"indent1\">Melanoma</td> </tr> <tr> <td class=\"indent1\">Colon</td> </tr> <tr> <td class=\"indent1\">Kidney</td> </tr> <tr> <td class=\"indent1\">Sarcoma</td> </tr> <tr> <td class=\"indent1\">Germ cell tumor</td> </tr> <tr> <td class=\"indent1\">Others</td> </tr> <tr> <td class=\"subtitle2_single\">Pulmonary carcinoid</td> </tr> <tr> <td class=\"subtitle2_single\">Extranodal lymphoma</td> </tr> <tr> <td class=\"subtitle2_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Plasmacytoma</td> </tr> <tr> <td class=\"indent1\">Schwannoma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Benign</td> </tr> <tr> <td class=\"subtitle2_single\">Infectious granuloma</td> </tr> <tr> <td class=\"indent1\">Histoplasmosis</td> </tr> <tr> <td class=\"indent1\">Coccidioidomycosis</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Atypical mycobacteria</td> </tr> <tr> <td class=\"indent1\">Cryptococcosis</td> </tr> <tr> <td class=\"indent1\">Blastomycosis</td> </tr> <tr> <td class=\"subtitle2_single\">Other infections</td> </tr> <tr> <td class=\"indent1\">Bacterial abscess</td> </tr> <tr> <td class=\"indent1\">Dirofilaria immitis</td> </tr> <tr> <td class=\"indent1\">Echinococcus cyst</td> </tr> <tr> <td class=\"indent1\">Ascariasis</td> </tr> <tr> <td class=\"indent1\">Pneumocystis jirovecii</td> </tr> <tr> <td class=\"indent1\">Aspergillus</td> </tr> <tr> <td class=\"subtitle2_single\">Benign neoplasms</td> </tr> <tr> <td class=\"indent1\">Hamartoma</td> </tr> <tr> <td class=\"indent1\">Lipoma</td> </tr> <tr> <td class=\"indent1\">Fibroma</td> </tr> <tr> <td class=\"indent1\">Neurofibroma</td> </tr> <tr> <td class=\"indent1\">Leiomyoma</td> </tr> <tr> <td class=\"indent1\">Angioma</td> </tr> <tr> <td class=\"subtitle2_single\">Vascular</td> </tr> <tr> <td class=\"indent1\">Arteriovenous malformation</td> </tr> <tr> <td class=\"indent1\">Pulmonary varix</td> </tr> <tr> <td class=\"indent1\">Hematoma</td> </tr> <tr> <td class=\"indent1\">Pulmonary infarct</td> </tr> <tr> <td class=\"subtitle2_single\">Developmental</td> </tr> <tr> <td class=\"indent1\">Bronchogenic cyst</td> </tr> <tr> <td class=\"subtitle2_single\">Inflammatory</td> </tr> <tr> <td class=\"indent1\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"indent1\">Rheumatoid nodule</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"subtitle2_single\">Other</td> </tr> <tr> <td class=\"indent1\">Amyloidoma</td> </tr> <tr> <td class=\"indent1\">Rounded atelectasis</td> </tr> <tr> <td class=\"indent1\">Intrapulmonary lymph nodes</td> </tr> <tr> <td class=\"indent1\">Pseudotumor (loculated fluid)</td> </tr> <tr> <td class=\"indent1\">Mucoid impaction</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62644 Version 5.0</div></div></div>"},"62645":{"type":"graphic_figure","displayName":"PEEP and pulmonary hemodynamics","title":"Effect of positive end-expiratory pressure (PEEP) on pulmonary hemodynamics","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of positive end-expiratory pressure (PEEP) on pulmonary hemodynamics</div><div class=\"cntnt\"><img style=\"width:398px; height:326px;\" src=\"images/PULM/62645_PEEP_and_pulmonary_hemodyna.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure tracings from the same patient recorded at different levels of positive end-expiratory pressure (PEEP). The top panel shows 0 PEEP, the middle panel PEEP = 15 cm H<sub>2</sub>O, and the bottom panel PEEP = 20 cm H<sub>2</sub>O. Pulmonary artery pressure (P<sub>pa</sub>) is shown at the left of the tracing. The right side of the tracing shows wedge (pulmonary artery occlusion) pressure (P<sub>paO</sub>). The red bars indicate the degree of respiratory (or respirophasic) variation (I, E) exhibited at each level of PEEP in pulmonary artery pressure and wedge pressure. The ratio of respiratory variation in pulmonary artery pressure divided by respiratory variation in the wedge pressure was close to 1 when PEEP = 0 or 15 cm H<sub>2</sub>O PEEP. This increased to 2.3 at a level of 20 cm H<sub>2</sub>O PEEP. This suggests a shift from zone three to a non-zone three condition, where airway pressure has exceeded intravascular pressure at the balloon occluded pulmonary artery catheter tip. The end-expiratory wedge pressure value during PEEP = 20 cm H<sub>2</sub>O is markedly higher than during PEEP = 15 cm H<sub>2</sub>O (18 versus 10 mmHg), a change that cannot solely be explained by the increase in PEEP.</div><div class=\"graphic_footnotes\">I: inspiration; E: expiration.</div><div class=\"graphic_reference\">Original figure modified for this publication. Teboul JL, Besbes M, Andrivet P, et al. J Crit Care 1992; 7:22. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 62645 Version 3.0</div></div></div>"},"62646":{"type":"graphic_diagnosticimage","displayName":"Arthrogram full thickness cuff tear MR","title":"Full thickness rotator cuff tear on magnetic resonance arthrography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Full thickness rotator cuff tear on magnetic resonance arthrography</div><div class=\"cntnt\"><img style=\"width:328px; height:605px;\" src=\"images/RHEUM/62646_Arthrogram_small_cuff_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance&nbsp;arthrography&nbsp;of the right shoulder utilizing fat-suppressed T1 weighting and intraarticular injection of gadolinium. In the oblique coronal view (upper panel), there is contrast within the distal supraspinatus tendon, indicative of a tear (arrow). In the axial view (lower panel), contrast has traveled through the tear into the subdeltoid bursa (arrow).</div><div class=\"graphic_reference\">Courtesy of Douglas H Brown, MD.</div><div id=\"graphicVersion\">Graphic 62646 Version 4.0</div></div></div>"},"62649":{"type":"graphic_picture","displayName":"Trichiasis and sequelae","title":"Cicatricial disease: Trichiasis and its sequelae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cicatricial disease: Trichiasis and its sequelae</div><div class=\"cntnt\"><img style=\"width:271px; height:539px;\" src=\"images/ID/62649_Trichiasis_and_sequelae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) World Health Organizaion (WHO) grade TT. To make a diagnosis of TT, there must be evidence of at least one ingrown eyelash touching the globe, or evidence of epilation (eyelash removal). Trichiasis occurs when eyelid conjunctiva scar tissue contracts, distorting the lid margin and causing the eyelashes to rub on the cornea.&nbsp;<br />(B) Pannus. Pannus is the growth of vascular tissue over the cornea as a result of edema and ulceration due to eyelash abrasion on the cornea. It is a hallmark of trachoma but is not assessed in the current grading system.&nbsp;<br />(C) WHO grade CO. To make a diagnosis of CO, there must be evidence of corneal opacity blurring part of the pupil margin.</div><div id=\"graphicVersion\">Graphic 62649 Version 3.0</div></div></div>"},"62652":{"type":"graphic_table","displayName":"Hemicrania continua diagnostic criteria","title":"Hemicrania continua diagnostic criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemicrania continua diagnostic criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Description:</td> </tr> <tr> <td class=\"indent1\">Persistent, strictly unilateral headache, associated with ipsilateral conjunctival injection, lacrimation, nasal congestion, rhinorrhea, forehead and facial sweating, miosis, ptosis and/or eyelid edema, and/or with restlessness or agitation. The headache is absolutely sensitive to indomethacin.</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic criteria:</td> </tr> <tr> <td class=\"indent1\">A. Unilateral headache fulfilling criteria B to D</td> </tr> <tr> <td class=\"indent1\">B. Present for more than three months, with exacerbations of moderate or greater intensity</td> </tr> <tr> <td class=\"sublist2_start\">C. Either or both of the following:</td> </tr> <tr> <td class=\"sublist3_start\">1. At least one of the following symptoms or signs, ipsilateral to the headache:</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Conjunctival injection and/or lacrimation </li> <li>Nasal congestion and/or rhinorrhea </li> <li>Eyelid edema </li> <li>Forehead and facial sweating </li> <li>Forehead and facial flushing </li> <li>Sensation of fullness in the ear </li> <li>Miosis and/or ptosis </li> </ul> </td> </tr> <tr> <td class=\"indent2\">2. A sense of restlessness or agitation, or aggravation of the pain by movement</td> </tr> <tr> <td class=\"indent1\">D. Responds absolutely to therapeutic doses of indomethacin</td> </tr> <tr> <td class=\"indent1\">E. Not better accounted for by another ICHD-3 diagnosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICHD-3: International Classification of Headache Disorders, 3rd edition.</div><div class=\"graphic_reference\">Data from: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 62652 Version 3.0</div></div></div>"},"62653":{"type":"graphic_diagnosticimage","displayName":"Echogenic liver","title":"Echogenic liver mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echogenic liver mass</div><div class=\"cntnt\"><img style=\"width:380px; height:368px;\" src=\"images/OBGYN/62653_Echogenic_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse view of the liver in a fetus at 20 weeks gestational age shows a well-defined echogenic mass (calipers) consistent with a hemangioma. No other abnormalities were seen, and this did not change during gestation.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 62653 Version 2.0</div></div></div>"},"62656":{"type":"graphic_figure","displayName":"Child vs adult airway 2","title":"Child versus adult airway","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Child versus adult airway</div><div class=\"cntnt\"><img style=\"width:526px; height:406px;\" src=\"images/EM/62656_Child_vs_adult_airway_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anatomical differences particular to children are (a) higher, more anterior position of the glottic opening (note the relationship of the vocal cords to the chin/neck junction); (b) relatively larger tongue in the infant, which lies between the mouth and glottic opening; (c) relatively larger and more floppy epiglottis in the child; (d) the subglottic region as the functionally narrowest portion of the pediatric airway versus the vocal cords in the adult; (e) position and size of the cricothyroid membrane in the infant; (f) sharper, more difficult angle for blind nasotracheal intubation; and (g) larger relative size of the occiput in the infant.</div><div class=\"graphic_reference\">Reproduced with permission from: Luten RC, McAllister JD. Approach to the pediatric airway. In: Manual of Emergency Airway Management, 3rd edition, Walls RM, Murphy MF (Eds), Lippincott Wilkins and Williams, Philadelphia 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62656 Version 10.0</div></div></div>"},"62658":{"type":"graphic_figure","displayName":"Thyroid hormone action part A","title":"Mediation of thyroid hormone action","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Mediation of thyroid hormone action</div><div class=\"cntnt\"><img style=\"width:515px; height:205px;\" src=\"images/ENDO/62658_Thyr_horm_act_part_A.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the absence of T3,&nbsp;TR heterodimerizes with RXR, binds to a TRE and recruits CoR, resulting in gene silencing.</div><div class=\"graphic_footnotes\">CoR: co-repressor; RXR: retinoid X receptor; TR: thyroid hormone receptor; TRE: thyroid hormone response element; T3: triiodothyronine.</div><div class=\"graphic_reference\">Modified from: Refetoff S, Weiss RE. Resistance to thyroid hormone. In: Molecular Genetics of Endocrine Disorders, Thakker TV (Ed), Chapman &amp; Hill, London, 1997, p.89.</div><div id=\"graphicVersion\">Graphic 62658 Version 3.0</div></div></div>"},"62659":{"type":"graphic_table","displayName":"Periop cardiovascular agents","title":"Perioperative management of cardiovascular agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perioperative management of cardiovascular agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name or class of drug</td> <td class=\"subtitle1\">Clinical considerations</td> <td class=\"subtitle1\">Recommended strategy for surgery with brief NPO state</td> <td class=\"subtitle1\">Recommended strategy for surgery with prolonged NPO state</td> </tr> <tr> <td>Beta blockers</td> <td> <p>Abrupt withdrawal can result in hypertension, tachycardia, and myocardial ischemia.</p> <p>Perioperative initiation can prevent postoperative myocardial ischemic events in patients with significantly-increased cardiac risk but may increase risk for stroke.</p> <p>Perioperative initiation of beta blockers is: recommended in patients with CAD or ischemia on stress testing who are undergoing vascular surgery; and reasonable in patients with at least one cardiac risk factor who are undergoing vascular surgery, or with CAD or &#62;1 cardiac risk factor undergoing intermediate risk surgery.</p> Perioperative initiation of beta blockers is not recommended in patients with baseline heart rate &#60;60 beats per minute, systolic blood pressure &#60;90 mmHg, or when time is not sufficient for titration.</td> <td>Continue therapy up to and including day of surgery.</td> <td>Continue therapy up to and including day of surgery. Substitute IV propranolol, metoprolol, or labetalol during NPO state.</td> </tr> <tr> <td>Alpha 2 agonists</td> <td>Withdrawal can cause extreme hypertension and myocardial ischemia.</td> <td>Continue therapy up to and including day of surgery.</td> <td>Continue therapy up to and including day of surgery. Substitute transdermal clonidine.</td> </tr> <tr> <td>Calcium channel blockers</td> <td>Conflicting evidence on whether there is an increased risk of bleeding.</td> <td>Continue therapy up to and including day of surgery.</td> <td>Continue therapy up to and including day of surgery. No IV substitution necessary unless poor hemodynamics (hypertension or arrhythmia).</td> </tr> <tr> <td>ACE inhibitors and angiotensin receptor blockers</td> <td>Continuation can result in hypotension.</td> <td>Discontinue night before surgery unless using for HF and baseline blood pressure is adequate.</td> <td>Discontinue on night before surgery unless using for HF and baseline blood pressure is not low. Use parenteral enalaprilat as needed in postoperative period.</td> </tr> <tr> <td>Diuretics</td> <td>Continuation can result in hypovolemia and hypotension.</td> <td>Continue therapy up to day of surgery but discontinue morning dose.</td> <td>Continue therapy up to day of surgery but discontinue morning dose. Use parenteral forms as needed in postoperative period.</td> </tr> <tr> <td>Statins</td> <td>Continuation may elevate risk of myopathy, but provides cardiovascular protection.</td> <td>Continue statins.</td> <td>Continue statins up to and including day of surgery.</td> </tr> <tr> <td>Non-statin lipid-lowering agents</td> <td>Niacin and fibric acid derivatives may cause rhabdomyolysis. Bile acid sequestrants interfere with absorption of other medications.</td> <td>Discontinue day before surgery.</td> <td>Discontinue day before surgery. Resume with oral intake.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NPO: nil per os (nothing by mouth); CAD: coronary artery disease; IV: intravenous; ACE: angiotensin-converting enzyme; HF: heart failure.</div><div id=\"graphicVersion\">Graphic 62659 Version 5.0</div></div></div>"},"62660":{"type":"graphic_table","displayName":"Blood flow at rest and exercise","title":"Blood flow distribution at rest and at maximal exercise","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blood flow distribution at rest and at maximal exercise</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Rest (percent total)</td>\n\n      <td class=\"subtitle1\">Maximal exercise (percent total)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Splanchnic</td>\n\n      <td>24</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Skeletal muscle</td>\n\n      <td>21</td>\n\n      <td>88</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Kidneys</td>\n\n      <td>19</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Brain</td>\n\n      <td>13</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Skin</td>\n\n      <td>8</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Heart</td>\n\n      <td>3</td>\n\n      <td>4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Other organs</td>\n\n      <td>10</td>\n\n      <td>1</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62660 Version 1.0</div></div></div>"},"62662":{"type":"graphic_table","displayName":"Signs of lung disease in scleroderma","title":"Clinical manifestations of lung disease in scleroderma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of lung disease in scleroderma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Symptoms </td> <td class=\"subtitle1\">Signs</td> </tr> <tr> <td>Pulmonary fibrosis</td> <td> <p>Dyspnea</p> <p>Dry cough</p> </td> <td> <p>Chest expansion</p> <p>Basal crepitations (rales)</p> <p>Clubbing (late, very uncommon)</p> </td> </tr> <tr> <td>Pulmonary hypertension </td> <td> <p>Dyspnea</p> <p>Ankle edema</p> </td> <td> <p>Loud P2</p> <p>Right ventricular heave</p> </td> </tr> <tr> <td>Pleural involvement</td> <td> <p>Pleuritic chest pain</p> <p>Dyspnea</p> </td> <td> <p>Pleural rub</p> <p>Pleural effusion (rare)</p> </td> </tr> <tr> <td>Bronchiectasis</td> <td> <p>Cough with purulent sputum</p> <p>Dyspnea</p> </td> <td>Basal crepitations</td> </tr> <tr> <td>Spontaneous pneumothorax</td> <td> <p>Chest pain</p> <p>Dyspnea</p> </td> <td> <p>Resonant percussion</p> <p>Reduced breath sounds</p> </td> </tr> <tr> <td>Lung cancer (scar type), especially alveolar cell</td> <td> <p>Cough</p> <p>Hemoptysis</p> </td> <td>Possible signs of collapse</td> </tr> <tr> <td>Respiratory failure due to respiratory muscle involvement</td> <td> <p>Dyspnea</p> <p>Reduced chest expansion</p> </td> <td>Hypoventilation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62662 Version 3.0</div></div></div>"},"62663":{"type":"graphic_figure","displayName":"RA disease activity cutpoints","title":"Disease activity categories and respective cut-points for the CDAI, SDAI and DAS28","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Disease activity categories and respective cut-points for the CDAI, SDAI and DAS28</div><div class=\"cntnt\"><img style=\"width:550px; height:325px;\" src=\"images/RHEUM/62663_RA_disease_activity_cutpoin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ranges: CDAI = 0 to &#8764;76; SDAI = &#8764;0 to &#8764;90; DAS28 = &#8764;0.5 to &#8764;9.</div><div class=\"graphic_footnotes\">HDA: High Dose Activity; MDA: Moderate Dose Activity; LDA: Low Dose Activity; CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity Index; Rem: Remission; DAS 28: 28 Joint Disease Activity Score.</div><div id=\"graphicVersion\">Graphic 62663 Version 1.0</div></div></div>"},"62664":{"type":"graphic_waveform","displayName":"Pressures variable obstr HCM","title":"Pressure tracing in variably obstructive hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Pressure tracing in variably obstructive hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:458px; height:366px;\" src=\"images/CARD/62664_Pressures_variable_obstr_HC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top tracing shows simultaneously recorded left ventricular (LV) and aortic (Ao) pressures. The systolic LV and Ao pressures are equivalent and no gradient is present, even after a ventricular premature beat (VPB). Valsalva induces more frequent VPBs and an intraventricular gradient is provoked; the beat following the VPB results in a LV pressure that is significantly greater than the Ao pressure (arrows).</div><div class=\"graphic_reference\">Courtesy of Morton Kern, MD.</div><div id=\"graphicVersion\">Graphic 62664 Version 2.0</div></div></div>"},"62665":{"type":"graphic_picture","displayName":"Gas gangrene in muscle","title":"Necrotic muscle with clostridial gas gangrene","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrotic muscle with clostridial gas gangrene</div><div class=\"cntnt\"><img style=\"width:377px; height:240px;\" src=\"images/ID/62665_Gas_gangrene_in_muscle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin-stained biopsy of muscle (x400) from a patient with clostridial gas gangrene shows extensive necrosis.</div><div class=\"graphic_reference\">Courtesy of Stephen Calderwood, MD.</div><div id=\"graphicVersion\">Graphic 62665 Version 2.0</div></div></div>"},"62666":{"type":"graphic_figure","displayName":"Middle ear anatomy","title":"Anatomy of the ear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the ear</div><div class=\"cntnt\"><img style=\"width:431px; height:312px;\" src=\"images/ID/62666_Middle_ear_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This diagram illustrates the relationship of the middle ear to the external auditory canal and inner ear.</div><div class=\"graphic_reference\">Reproduced with permission from Bluestone CD, Klein JO. Otitis Media in Infants and Children. WB Saunders, Philadelphia, 2001.</div><div id=\"graphicVersion\">Graphic 62666 Version 3.0</div></div></div>"},"62670":{"type":"graphic_table","displayName":"Tissue process soft tissue mass","title":"Procedure for optimal tissue processing for a soft tissue mass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Procedure for optimal tissue processing for a soft tissue mass</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Tissue preparation</td> <td class=\"subtitle1\">Studies</td> </tr> <tr> <td rowspan=\"2\">Intraoperative samples</td> <td>Frozen tissue with cryopreservative</td> </tr> <tr> <td>Cytological, touch preparations, scrape and squash imprints for histologic diagnosis and FISH</td> </tr> <tr> <td rowspan=\"4\">Formalin-fixed tissue</td> <td>Routine histopathology</td> </tr> <tr> <td>Immunohistochemical staining</td> </tr> <tr> <td>RT-PCR </td> </tr> <tr> <td>FISH&nbsp;for cytogenetics (tissue sections)</td> </tr> <tr> <td>Glutaraldehyde-fixed tissue </td> <td>Electron microscopy</td> </tr> <tr> <td rowspan=\"3\">Fresh tissue (tissue culture media)</td> <td>Cytogenetics</td> </tr> <tr> <td>Molecular studies (FISH, RT-PCR for translocations)</td> </tr> <tr> <td>Tissue culture</td> </tr> <tr> <td>Fresh tissue </td> <td>Flow cytometry (DNA ploidy, cell surface markers)</td> </tr> <tr> <td>Frozen tissue (no cryopreservative)</td> <td>Molecular studies, gene rearrangement (FISH, RT-PCR), immunocytochemistry, microarray gene analysis, next-generation sequencing, precision medicine for tumor gene fusion and gene mutation panels</td> </tr> <tr> <td rowspan=\"3\">Alcohol-fixed tissue</td> <td>Immunocytochemistry (if required improved cytoplasmic preservation)</td> </tr> <tr> <td>Microarray gene analysis</td> </tr> <tr> <td>Cytologic imprinting for FISH studies</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FISH: fluorescence in situ hybridization; RT-PCR: reverse transcriptase polymerase chain reaction.</div><div id=\"graphicVersion\">Graphic 62670 Version 4.0</div></div></div>"},"62671":{"type":"graphic_picture","displayName":"Perforating folliculitis - hand","title":"Perforating folliculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perforating folliculitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/62671_Perfor_folliculitis_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules with central hyperkeratosis were present on the extremities of this woman with perforating folliculitis and renal failure. Perforating folliculitis most often occurs in the setting of renal failure or diabetes.</div><div class=\"graphic_reference\">Copyright Â© Patrick Keehan, D.O. and Greg Hosler, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 62671 Version 5.0</div></div></div>"},"62672":{"type":"graphic_diagnosticimage","displayName":"Severe tricuspid regurgitation","title":"Severe tricuspid regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe tricuspid regurgitation</div><div class=\"cntnt\"><img style=\"width:382px; height:266px;\" src=\"images/CARD/62672_Severe_tricuspid_regurgitat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four chamber view in a patient with severe tricuspid regurgitation (TR) shows right atrial (RA) enlargement (panel A); the RA, usually similar in size to the left atrium (LA), is larger and more spherical. With color flow Doppler imaging, the TR jet fills much of the RA (panel B); as the jet crosses the valve plane it is broad, suggesting a significant lesion. Panel C shows the continuous wave Doppler (CW) tracing from across the tricuspid valve (TV). The systolic portion of the tracing shows a dense waveform that is almost triangular in shape; this is in contrast to the parabolic waveform seen in milder degrees of TR. The sharp deceleration producing this characteristic waveform is known as the v-wave cut off sign, which is one of the most consistently reliable signs of TR severity. Also favoring a more severe lesion is the E point of the tricuspid inflow signal which reaches a velocity of over 1.3 meter/sec, a value that is twice the normal TV velocity Panel D is from a patient with mixed TR and tricuspid stenosis (TS); the v-wave cut-off suggests severe TR and the slow deceleration and high velocity of the inflow signal suggests an element of TS.</div><div id=\"graphicVersion\">Graphic 62672 Version 2.0</div></div></div>"},"62673":{"type":"graphic_table","displayName":"FOUR score","title":"FOUR score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FOUR score</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Eye response</td> </tr> <tr> <td>4 = eyelids open or opened, tracking, or blinking to command</td> </tr> <tr> <td>3 = eyelids open but not tracking</td> </tr> <tr> <td>2 = eyelids closed but open to loud voice</td> </tr> <tr> <td>1 = eyelids closed but open to pain</td> </tr> <tr> <td>0 = eyelids remain closed with pain</td> </tr> <tr> <td class=\"subtitle1_single\">Motor response</td> </tr> <tr> <td>4 = thumbs-up, fist, or peace sign</td> </tr> <tr> <td>3 = localizing to pain</td> </tr> <tr> <td>2 = flexion response to pain</td> </tr> <tr> <td>1 = extension response to pain</td> </tr> <tr> <td>0 = no response to pain or generalized myoclonus status</td> </tr> <tr> <td class=\"subtitle1_single\">Brainstem reflexes</td> </tr> <tr> <td>4 = pupil and corneal reflexes present</td> </tr> <tr> <td>3 = one pupil wide and fixed</td> </tr> <tr> <td>2 = pupil or corneal reflexes absent</td> </tr> <tr> <td>1 = pupil and corneal reflexes absent</td> </tr> <tr> <td>0 = absent pupil, corneal, and cough reflex</td> </tr> <tr> <td class=\"subtitle1_single\">Respiration</td> </tr> <tr> <td>4 = not intubated, regular breathing pattern</td> </tr> <tr> <td>3 = not intubated, Cheyne-Stokes breathing pattern</td> </tr> <tr> <td>2 = not intubated, irregular breathing</td> </tr> <tr> <td>1 = breathes above ventilator rate</td> </tr> <tr> <td>0 = breathes at ventilator rate or apnea</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FOUR score: Full Outline of UnResponsiveness.</div><div class=\"graphic_reference\">Reproduced from: Fischer M, Ruegg S, Czaplinski A, et al. Inter-rater reliability of the Full Outline of UnResponsiveness score and the Glasgow Coma Scale in critically ill patients: a prospective observational study. Crit Care 2010; 14:R64. Copyright Â© 2010 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 62673 Version 4.0</div></div></div>"},"62674":{"type":"graphic_picture","displayName":"Porokeratosis multiple lesions","title":"Porokeratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Porokeratosis</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/62674_Porokeratosis_mult_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple porokeratosis of Mibelli lesions are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62674 Version 3.0</div></div></div>"},"62676":{"type":"graphic_table","displayName":"Major symptoms and signs of hypothyroidism","title":"Major symptoms and signs of hypothyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major symptoms and signs of hypothyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Signs</td> </tr> <tr> <td>Slowing of metabolic processes</td> <td> <p>Fatigue and weakness</p> <p>Cold intolerance</p> <p>Dyspnea on exertion</p> <p>Weight gain</p> <p>Cognitive dysfunction</p> <p>Mental retardation (infantile onset)</p> <p>Constipation</p> <p>Growth failure</p> </td> <td> <p>Slow movement and slow speech</p> <p>Delayed relaxation of tendon reflexes</p> <p>Bradycardia</p> <p>Carotenemia</p> </td> </tr> <tr> <td>Accumulation of matrix substances</td> <td> <p>Dry skin</p> <p>Hoarseness</p> <p>Edema</p> </td> <td> <p>Coarse skin</p> <p>Puffy facies and loss of eyebrows</p> <p>Periorbital edema</p> <p>Enlargement of the tongue</p> </td> </tr> <tr> <td>Other</td> <td> <p>Decreased hearing</p> <p>Myalgia and paresthesia</p> <p>Depression</p> <p>Menorrhagia</p> <p>Arthralgia</p> <p>Pubertal delay</p> </td> <td> <p>Diastolic hypertension</p> <p>Pleural and pericardial effusions</p> <p>Ascites</p> <p>Galactorrhea</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62676 Version 4.0</div></div></div>"},"62677":{"type":"graphic_picture","displayName":"Periungual warts PI","title":"Warts around the nails (periungual warts)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Warts around the nails (periungual warts)</div><div class=\"cntnt\"><img style=\"width:273px; height:288px;\" src=\"images/PI/62677_Warts_around_nails_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 62677 Version 1.0</div></div></div>"},"62680":{"type":"graphic_diagnosticimage","displayName":"M mode scan II","title":"M mode echocardiogram scan of the heart","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">M mode echocardiogram scan of the heart</div><div class=\"cntnt\"><img style=\"width:468px; height:194px;\" src=\"images/CARD/62680_M_mode_scan_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transducer is positioned at the left parasternal area and is moved from the base to the apex. The scan that is obtained shows the aorta (Ao), aortic valve, the mitral valve, interventricular septum, the left ventricular (LV) chamber and the apex of the LV.</div><div id=\"graphicVersion\">Graphic 62680 Version 2.0</div></div></div>"},"62681":{"type":"graphic_picture","displayName":"LE cell","title":"CIrculating \"LE Cell\" in systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CIrculating \"LE Cell\" in systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/RHEUM/62681_LE_cell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood smear from a patient with systemic lupus erythematosus showing a classical LE cell in which a viable neutrophil has ingested nuclear material. Note the nuclear debris and an adjacent normal neutrophil and the nuclear debris.</div><div class=\"graphic_reference\">Courtesy of the American College of Rheumatology.</div><div id=\"graphicVersion\">Graphic 62681 Version 2.0</div></div></div>"},"62682":{"type":"graphic_figure","displayName":"Anterior view of upper abdominal structures","title":"Anterior view of upper abdominal structures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior view of upper abdominal structures</div><div class=\"cntnt\"><img style=\"width:360px; height:207px;\" src=\"images/SURG/62682_Ant_view_upper_abd_struct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The spleen is located in the left upper quandrant of the abdomen beneath the left hemidiaphragm and lateral to the greater curvature of the stomach.</div><div class=\"graphic_reference\">Reproduced with permission from: Bickley, LS, Szilagyl, P. Bates' Guide to Physical Examination and History Taking, 8th Ed. Philadelphia: Lippincott Williams &amp; Wilkins 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62682 Version 2.0</div></div></div>"},"62683":{"type":"graphic_algorithm","displayName":"Classification jaundice II","title":"Classification of jaundice due to both conjugated and unconjugated hyperbilirubinemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classification of jaundice due to both conjugated and unconjugated hyperbilirubinemia</div><div class=\"cntnt\"><img style=\"width:416px; height:304px;\" src=\"images/GAST/62683_Classification_jaundice_II.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62683 Version 6.0</div></div></div>"},"62686":{"type":"graphic_table","displayName":"Healthy weight nutrition tips B","title":"Tips for maintaining a healthy weight: nutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for maintaining a healthy weight: nutrition</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  colspan=\"3\" class=\"subtitle1_single\">\r\n  \r\n   Phase II\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"3\" class=\"subtitle2_single\">\r\n  \r\n   Eat a variety of foods.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"3\" class=\"indent1\">\r\n  \r\n   Eat fruits, vegetables, whole grain breads, cereals, rice, and pastas; low-fat and fat-free dairy products; lean chicken, turkey, fish, and legumes; and healthy fats. Use a small amount of added fats and sugars. Avoid fried foods. See the Low-fat, Low-Sugar Eating Guidelines for a list of food choices and sample menus.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"3\" class=\"subtitle2_single\">\r\n  \r\n   Eat proper portion sizes.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"3\" class=\"indent1\">\r\n  \r\n   Young children and inactive girls should choose the lower number of servings from each food group. Most active school-aged children and teen girls, as well as inactive teen boys should choose the middle number of servings. Active teen boys and some very active teen girls should choose the higher number of servings from each food group.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Group\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Number of servings per day\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Serving size\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bread, cereal, rice, pasta and starchy vegetable</td>\r\n  \r\n   <td>6 to 11</td>\r\n  \r\n   <td>1 slice whole wheat bread; 1/2 cup cooked whole-grain cereal, brown rice, or whole wheat pasta</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Fruit</td>\r\n  \r\n   <td>2 to 4</td>\r\n  \r\n   <td>1 small piece fruit or 1/2 banana; 1 cup fresh fruit such as melon or berries; 1/2 cup canned fruit; four ounces juice; two tablespoons dried fruit</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Vegetable</td>\r\n  \r\n   <td>3 to 5</td>\r\n  \r\n   <td>1/2 cup cooked vegetables or vegetable juice; 1 cup raw vegetables</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Milk, yogurt, and cheese</td>\r\n  \r\n   <td>2 to 4</td>\r\n  \r\n   <td>1 cup skim or 1 percent milk; 1 cup fat-free or low-fat yogurt; 1 ounce fat-free or reduced fat cheese</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Meat, poultry, fish, dry beans, eggs and nuts</td>\r\n  \r\n   <td>2 to 3</td>\r\n  \r\n   <td>2 to 3 ounces of skinless chicken, turkey, or fish; 1/2 cup beans or tofu; 1/4 cup nuts; 2 tablespoons nut butter; 1/4 cup egg whites or egg substitute</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Fats, oils, sweets</td>\r\n  \r\n   <td>Use a small amount</td>\r\n  \r\n   <td>1 teaspoon butter, margarine, mayonnaise, oil, or sugar; 1 tablespoon salad dressing</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"3\" class=\"subtitle2_single\">\r\n  \r\n   Stock your house with healthful food choices.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"3\" class=\"indent1\">\r\n  \r\n   Eliminate unhealthful food choices from your house including low-fat cookies, cakes and ice cream as these foods are often enriched with sugar. Instead, stock your house with fresh fruit, cut up vegetables and fat-free or low-fat yogurt. Children can choose between an apple or yogurt for a snack, not an apple or potato chips.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"3\" class=\"subtitle2_single\">\r\n  \r\n   Limit restaurant eating to 1 time per week.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"3\" class=\"indent1\">\r\n  \r\n   Restaurants provide large food portions. Split entrees or plan to take half home. If time is an issue, choose low-fat frozen dinners with bagged salad and/or a side of frozen vegetables.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"3\" class=\"subtitle2_single\">\r\n  \r\n   Take your lunch to school.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"3\" class=\"indent1\">\r\n  \r\n   Pack a lunch with 2 ounces of lean meat or 1 ounce low-fat or fat-free cheese on whole grain bread with one serving of fruit, vegetables and fat-free milk or yogurt. Avoid eating breakfast at school. Instead, choose a bowl of whole grain cereal at home.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Courtesy of Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 62686 Version 1.0</div></div></div>"},"62687":{"type":"graphic_table","displayName":"Muscles of larynx","title":"Muscles of the larynx","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscles of the larynx</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Muscle\n   </td>\n   <td  class=\"subtitle1\">\n   Innervation\n   </td>\n   <td  class=\"subtitle1\">\n   Action\n   </td>\n   </tr>\n   <tr>\n   <td>Cricothyrioid</td>\n   <td>External branch of superior laryngeal</td>\n   <td>Elongates, thins, and lowers the vocal fold</td>\n   </tr>\n   <tr>\n   <td>Posterior cricoarytenoid</td>\n   <td>Recurrent laryngeal</td>\n   <td>Sole abductor of the larynx; elevates, elongates, and thins the vocal fold</td>\n   </tr>\n   <tr>\n   <td>Lateral cricoarytenoid</td>\n   <td>Recurrent laryngeal</td>\n   <td>Elongates, thins, and adducts the vocal fold</td>\n   </tr>\n   <tr>\n   <td>Interarytenoid</td>\n   <td>Recurrent laryngeal and branches of the superior laryngeal</td>\n   <td>Adducts the vocal fold</td>\n   </tr>\n   <tr>\n   <td>Aryepiglottic</td>\n   <td>Recurrent laryngeal</td>\n   <td>Adducts the vocal fold and aryepiglottic fold</td>\n   </tr>\n   <tr>\n   <td>Thyroarytenoid</td>\n   <td>Recurrent laryngeal</td>\n   <td>Adducts the vocal fold</td>\n   </tr>\n   <tr>\n   <td>Vocalis (part of the thyroarytenoid)</td>\n   <td>Recurrent laryngeal</td>\n   <td>Adducts and thickens the vocal fold</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 62687 Version 1.0</div></div></div>"},"62688":{"type":"graphic_waveform","displayName":"Intermediate case 14 answer","title":"Ventricular aneurysm","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Ventricular aneurysm</div><div class=\"cntnt\"><img style=\"width:505px; height:211px;\" src=\"images/CARD/62688_Intermediate_case_14_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing anterior wall myocardial infarction with probable ventricular aneurysm. Persistent ST segment elevation in leads V1 to V4 three or more weeks after a Q-wave myocardial infarction is a relatively specific but not highly sensitive sign of severe ventricular motion abnormality and sometimes frank aneurysm formation. Note also that the rhythm is sinus. There is borderline left axis deviation (about -30Â°) with an intraventricular conduction delay.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 62688 Version 3.0</div></div></div>"},"62689":{"type":"graphic_picture","displayName":"Barretts pre PDT","title":"Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:311px; height:329px;\" src=\"images/GAST/62689_Barretts_pre_PDT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of Barrett's esophagus prior to treatment. The salmon-colored tongues of Barrett's mucosa are visible in the background of the the pale, pink squamous mucosa.</div><div class=\"graphic_reference\">Courtesy of Marta Davila, MD and Jacques Van Dam, MD, PhD.</div><div id=\"graphicVersion\">Graphic 62689 Version 1.0</div></div></div>"},"62690":{"type":"graphic_picture","displayName":"Mixed cell versus lymphocyte depletion HL","title":"Hodgkin lymphoma variants","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Hodgkin lymphoma variants</div><div class=\"cntnt\"><img style=\"width:508px; height:286px;\" src=\"images/HEME/62690_Mixed_cell_vs_lymph_depl_HL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Mixed cellularity variant. The characteristic background infiltrate of reactive cells (eosinophils, lymphocytes) and uninucleate Reed-Sternberg cells is present in this field (red arrow). Right panel: Lymphocyte depletion variant. Diffuse fibrosis is seen, and a diagnostic binucleate Reed-Sternberg cell is present (blue arrow).</div><div class=\"graphic_reference\">From: Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 62690 Version 2.0</div></div></div>"},"62691":{"type":"graphic_figure","displayName":"Asthma daily diary I","title":"Asthma Diary","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Asthma Diary</div><div class=\"cntnt\"><img style=\"width:599px; height:771px;\" src=\"images/PULM/62691_Asthma_daily_diary_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Use the symptom severity key to give a numerical value to the severity of your asthma. In the notes section, note any triggers that seem to affect your asthma on the day it occurs. Triggers can include colds or infections, exercise, irritants, allergens, and cold air.</div><div id=\"graphicVersion\">Graphic 62691 Version 1.0</div></div></div>"},"62694":{"type":"graphic_figure","displayName":"Normal neuromuscular junction","title":"Normal neuromuscular junction","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Normal neuromuscular junction</div><div class=\"cntnt\"><img style=\"width:519px; height:424px;\" src=\"images/NEURO/62694_Normal-nm-junction.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62694 Version 5.0</div></div></div>"},"62695":{"type":"graphic_picture","displayName":"Hymenolepis nana eggs","title":"<EM>Hymenolepis nana</EM>Â eggs","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\"><EM>Hymenolepis nana</EM>&nbsp;eggs</div><div class=\"cntnt\"><img style=\"width:586px; height:586px;\" src=\"images/ID/62695_Hymenolepiasis_nana_eggs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A-D) Eggs of <em>Hymenolepis nana</em>. These eggs are oval and smaller than those of <em>H. diminuta</em>, with a size range of 30 to 50 micrometers. On the inner membrane are two poles, from which four to eight polar filaments spread out between the two membranes. The oncosphere has six hooks.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Hymenolepiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/hymenolepiasis/index.html\">http://www.cdc.gov/dpdx/hymenolepiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 62695 Version 7.0</div></div></div>"},"62696":{"type":"graphic_figure","displayName":"Presentation of hyperparathyroidism","title":"Changing presentation of primary hyperparathyroidism","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Changing presentation of primary hyperparathyroidism</div><div class=\"cntnt\"><img style=\"width:514px; height:256px;\" src=\"images/ENDO/62696_Presentation_of_hyperpara.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Different patterns of presentation of primary hyperparathyroidism in three different time periods. The latest survey shows that 80 percent&nbsp;of patients are asymptomatic and discovered incidentally on routine blood screening; bone disease (osteitis fibrosa cystica), on the other hand, has virtually disappeared as a presenting symptom. Bone disease was assessed by radiographs and bone densitometry; patients with skeletal involvement by bone density measurement were not included.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Cope O. The study of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med 1966; 274:1174.</li>&#xD;&#xA;    <li>Heath H III, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 1980; 302:189.</li>&#xD;&#xA;    <li>Silverberg SJ, Shane E, Jacobs TP, et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990; 89:327.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 62696 Version 6.0</div></div></div>"},"62697":{"type":"graphic_table","displayName":"Warfarin drug interactions","title":"Medications that interfere with the effect of warfarin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications that interfere with the effect of warfarin</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">May increase INR</td> </tr> <tr> <td class=\"indent1\">Acetaminophen</td> </tr> <tr> <td class=\"indent1\">Allopurinol</td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> </tr> <tr> <td class=\"indent1\">Androgens (eg, methyltestosterone, oxandrolone, testosterone)</td> </tr> <tr> <td class=\"indent1\">Antibiotics</td> </tr> <tr> <td class=\"indent2\"> <ul> <li> <p>Penicillins (eg, amoxicillin, amoxicillin-clavulanate)</p> Exceptions: Dicloxacillin and nafcillin may decrease the INR </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Doxycycline </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Cephalosporins </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Fluoroquinolones (eg, ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Macrolides (eg, azithromycin, erythromycin, clarithromycin) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Metronidazole </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Trimethoprim-sulfamethoxazole </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Azole antifungals (eg, fluconazole, miconazole [oral], voriconazole)*</td> </tr> <tr> <td class=\"indent1\">Cancer therapies</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Capecitabine </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Fluorouracil (5-FU) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Imatinib </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Tamoxifen </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>Cholesterol-lowering agents (eg, gemfibrozil, fenofibrate, fluvastatin, lovastatin, rosuvastatin, simvastatin)</p> Exception: Cholestyramine may decrease the INR</td> </tr> <tr> <td class=\"indent1\">Cimetidine</td> </tr> <tr> <td class=\"indent1\">Glucocorticoids (eg, prednisone, methylprednisolone)</td> </tr> <tr> <td class=\"indent1\">Omeprazole (case reports with other proton pump inhibitors)</td> </tr> <tr> <td class=\"indent1\">Serotonin reuptake inhibitors (eg, duloxetine, fluoxetine, fluvoxamine, sertraline, venlafaxine)</td> </tr> <tr> <td class=\"indent1\">Sitaxentan (not available in United States)</td> </tr> <tr> <td class=\"indent1\">Tramadol</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">May decrease INR</td> </tr> <tr> <td class=\"indent1\">Antibiotics</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Dicloxacillin </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Griseofulvin </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Nafcillin </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Rifampin </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> </tr> <tr> <td class=\"indent1\">Enzyme-inducing antiepileptic drugs (eg, carbamazepine, phenobarbital, phenytoin [mixed effects described])</td> </tr> <tr> <td class=\"indent1\">Cholestyramine</td> </tr> <tr> <td class=\"indent1\">Ritonavir</td> </tr> <tr> <td class=\"indent1\">Sucralfate</td> </tr> <tr> <td class=\"indent1\">Saint John's wort</td> </tr> <tr> <td class=\"indent1\">Vitamin K</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This is a partial list of medications that may increase or decrease warfarin effect on the INR. The patient's medications should be analyzed closely for drug interactions with warfarin, especially when initiating or altering therapy. The effect of a drug interaction can be unpredictable; thus, individuals receiving interacting medications are likely to require increased INR monitoring. Additional medications may increase bleeding risk independent of (or in addition to) effects on the INR (eg, NSAIDs, antiplatelet medications). Refer to UpToDate content on warfarin use for additional details. Drug interactions may be evaluated using the Lexi-interact program included with UpToDate.</div><div class=\"graphic_footnotes\">INR: international normalized ratio; NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* A more moderate effect on INR control may also be seen with posaconazole and itraconazole.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Greenblatt DJ, von Moltke L. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005; 45:127.</LI>&#xD;&#xA;<LI>Holbrook A, Schulman S, Witt D, et al. Evidenced-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed. Chest 2012; 141:e152S.</LI>&#xD;&#xA;<LI>Hazlewood KA, Fugate SE, Harrison DL. Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother 2006; 40:2101.</LI>&#xD;&#xA;<LI>Lexi-Interact. Copyright Â© 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 62697 Version 7.0</div></div></div>"},"62698":{"type":"graphic_waveform","displayName":"Atrial fibrillation tutorial","title":"Atrial fibrillation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:279px; height:121px;\" src=\"images/CARD/62698_Atrial_fibrillation_tutoria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial fibrillation is an irregularly irregular rhythm without regular or organized atrial activity. Atrial activation is rapid (generally greater than 320 beats per minute) and of various amplitudes. No discrete P waves are seen on this tracing. Instead, rapid, irregular, variable and low amplitude oscillating fibrillatory waves are observed between the QRS complexes. When the arrhythmia is of long duration, the fibrillatory waves may be inapparent.</div><div id=\"graphicVersion\">Graphic 62698 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"62701":{"type":"graphic_figure","displayName":"Breech extraction4","title":"Delivery of the head","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Delivery of the head</div><div class=\"cntnt\"><img style=\"width:454px; height:314px;\" src=\"images/OBGYN/62701_Breech_extraction4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mauriceau maneuver to deliver the after coming head.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART, Obstetrics &amp; Gynecology. Copyright &#169;2009 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 62701 Version 1.0</div></div></div>"},"62702":{"type":"graphic_picture","displayName":"Umbilical cord knot","title":"Umbilical cord knot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Umbilical cord knot</div><div class=\"cntnt\"><img style=\"width:432px; height:322px;\" src=\"images/OBGYN/62702_Umbilical_cord_knot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loose, true knot of the umbilical cord.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 62702 Version 1.0</div></div></div>"},"62705":{"type":"graphic_picture","displayName":"Perioral dermatitis papulopustular","title":"Perioral dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Perioral dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62705_Perioral_derma_papulopust.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tiny papules and pustules grouped on the chin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62705 Version 3.0</div></div></div>"},"62706":{"type":"graphic_figure","displayName":"Seldinger cricothyrotomy step 3","title":"Seldinger cricothyrotomy technique: Step 3","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seldinger cricothyrotomy technique: Step 3</div><div class=\"cntnt\"><img style=\"width:425px; height:506px;\" src=\"images/EM/62706_Cric_Seldinger_step_three.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thread the guidewire through the catheter into the trachea. Remove the catheter, sliding it over the guidewire.</div><div id=\"graphicVersion\">Graphic 62706 Version 4.0</div></div></div>"},"62707":{"type":"graphic_figure","displayName":"Inguinal hernia reduction 2","title":"Alternate method for bimanual reduction of an inguinal hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alternate method for bimanual reduction of an inguinal hernia</div><div class=\"cntnt\"><img style=\"width:446px; height:588px;\" src=\"images/EM/62707_Inguinalherniareduction2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Anatomy of an indirect inguinal hernia. Note the position in the groin of the hernia &quot;neck&quot; extending through the internal and external inguinal rings. B) The fingers of one hand are first used to sweep along the inguinal canal from the anterior iliac crest to the distal scrotum. The same hand is then used to grasp the testicle, hernia mass, or scrotal skin and apply gentle pressure. C) The index finger and thumb of the opposite hand are used to apply &quot;upward&quot; and lateral traction over the hernia neck to help in keeping the internal and external inguinal rings open. D) The fingers of the hand on the scrotum are then used to &quot;walk&quot; the bottom of the hernia sac progressively up toward the inguinal rings until the hernia is reduced.</div><div class=\"graphic_reference\">Reproduced with permission from: King C, Henretig FM. Inguinal hernia reduction. In: Textbook of pediatric emergency medicine procedures, 2nd ed, Lippincott Williams &amp; Wilkins 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62707 Version 11.0</div></div></div>"},"62708":{"type":"graphic_diagnosticimage","displayName":"Malignant gastric ulcer UGI","title":"Malignant and benign gastric ulcer as seen on upper gastrointestinal (UGI) series","html":"<div class=\"graphic normal\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Malignant and benign gastric ulcer as seen on upper gastrointestinal (UGI) series</div><div class=\"cntnt\"><img style=\"width:583px; height:312px;\" src=\"images/GAST/62708_Malignant_gastric_ulcer_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper GI series showing the differences between a malignant and benign gastric ulcer.<br />(A) Malignant gastric ulcer of the distal lesser curvature. There is the biconvex meniscus sign with a nodular ulcer mound (arrow).<br />(B) Benign gastric ulcer of the lesser curvature. The ulcer crater has smooth margins and projects beyond the gastric wall (arrow).</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy, III, MD.</div><div id=\"graphicVersion\">Graphic 62708 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal upper GI series</div><div class=\"cntnt\"><img style=\"width:286px; height:330px;\" src=\"images/GAST/81537_Normal_upper_GI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal air-contrast upper gastrointestinal (GI)&nbsp;study showing normal gastric folds and small intestinal anatomy, and no masses.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 81537 Version 4.0</div></div></div>"},"62709":{"type":"graphic_diagnosticimage","displayName":"Hypoplasia lymphoid tissue","title":"Normal adenoid (left); absent adenoid in agammaglobulinemia (right)","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Normal adenoid (left); absent adenoid in agammaglobulinemia (right)</div><div class=\"cntnt\"><img style=\"width:474px; height:216px;\" src=\"images/PEDS/62709_Hypoplasia_lymphoid_tissue.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Douglas J Barrett, MD.</div><div id=\"graphicVersion\">Graphic 62709 Version 2.0</div></div></div>"},"62711":{"type":"graphic_diagnosticimage","displayName":"Ultrasound appearance of a breast abscess","title":"Ultrasound appearance of a breast abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound appearance of a breast abscess</div><div class=\"cntnt\"><img style=\"width:307px; height:296px;\" src=\"images/PC/62711_Ultrasound_appearance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows an abscess in the breast using ultrasound.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 62711 Version 3.0</div></div></div>"},"62712":{"type":"graphic_figure","displayName":"Dyspnea in asthmatics","title":"Perception of dyspnea in asthmatics","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Perception of dyspnea in asthmatics</div><div class=\"cntnt\"><img style=\"width:555px; height:279px;\" src=\"images/PULM/62712_Dyspnea_in_asthmatics.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perception of dyspnea (Borg Score) (mean &plusmn;SE) during breathing at six levels of resistance in 12 normal subjects, 11 patients with asthma but no near fatal attacks, and 11 patients with near fatal asthma.</div><div class=\"graphic_reference\">Redrawn from: Kikuchi Y, Okabe S, Tamura G, et al, N Engl J Med 1994; 330:1329.</div><div id=\"graphicVersion\">Graphic 62712 Version 2.0</div></div></div>"},"62714":{"type":"graphic_algorithm","displayName":"Adult tachycardia algorithm","title":"Adult tachycardia algorithm","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Adult tachycardia algorithm</div><div class=\"cntnt\"><img style=\"width:535px; height:794px;\" src=\"images/EM/62714_Adult_tachycardia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The algorithm presented above has been modified to make it more consistent with the 2015 update to the ACLS Guidelines while we await permission from the AHA to reproduce the latest version.</div><div class=\"graphic_footnotes\">CHF: congestive heart failure; ECG: electrocardiogram; IV: intravenous; J: joules; NS: normal (isotonic) saline; VT: ventricular tachycardia.</div><div class=\"graphic_reference\">Reprinted with permission. Adult Advanced Cardiovascular Life Support: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. &copy; 2010 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 62714 Version 14.0</div></div></div>"},"62717":{"type":"graphic_table","displayName":"Rhabdomyosarcoma TNM staging","title":"TNM staging system for rhabdomyosarcoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging system for rhabdomyosarcoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage </td> <td class=\"subtitle1\">Sites </td> <td class=\"subtitle1\">Tumor stage invasiveness </td> <td class=\"subtitle1\">T stage size </td> <td class=\"subtitle1\">N </td> <td class=\"subtitle1\">M </td> </tr> <tr> <td>1</td> <td> <p>Orbit</p> <p>Head and neck<sup>*</sup></p> <p>Genitourinary<sup>&#182;</sup></p> <p>Biliary tract</p> </td> <td>T<sub>1</sub> or T<sub>2</sub></td> <td>a or b</td> <td>Any N</td> <td>M<sub>0</sub></td> </tr> <tr> <td>2</td> <td> <p>Bladder/prostate</p> <p>Extremity</p> <p>Cranial parameningeal</p> <p>Other<sup>&#916;</sup></p> </td> <td>T<sub>1</sub> or T<sub>2</sub></td> <td>a</td> <td>N<sub>0</sub> or N<sub>X</sub></td> <td>M<sub>0</sub></td> </tr> <tr> <td rowspan=\"2\">3 </td> <td rowspan=\"2\"> <p>Bladder/prostate</p> <p>Extremity</p> <p>Cranial parameningeal</p> <p>Other<sup>&#916;</sup></p> </td> <td rowspan=\"2\">T<sub>1</sub> or T<sub>2</sub> </td> <td>a</td> <td>N1</td> <td rowspan=\"2\">M<sub>0</sub> </td> </tr> <tr> <td>b</td> <td>Any N</td> </tr> <tr> <td>4</td> <td>All</td> <td>T<sub>1</sub> or T<sub>2</sub></td> <td>a or b</td> <td>N<sub>0</sub> or N<sub>1</sub></td> <td>M<sub>1</sub></td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">T: Tumor stage </td> <td class=\"subtitle1\">N: Regional nodes </td> <td class=\"subtitle1\" colspan=\"3\">M: Metastases </td> </tr> <tr> <td colspan=\"2\"> <p>T<sub>1</sub>: Confined to anatomic site of origin</p> <p>T<sub>2</sub>: Extension</p> <p>a: &#8804;5 cm in diameter</p> <p>b: &#62;5 cm in diameter</p> </td> <td> <p>N<sub>0</sub>: Not clinically involved</p> <p>N<sub>1</sub>: Clinically involved</p> <p>N<sub>X</sub>: Clinical status unknown</p> </td> <td colspan=\"3\"> <p>M<sub>0</sub>: No distant metastases</p> <p>M<sub>1</sub>: Distant metastases present</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Excluding parameningeal.<br />Â¶&nbsp;Nonbladder/nonprostate.<br />Î Includes trunk, retroperitoneum, etc, excluding biliary tract.</div><div class=\"graphic_reference\">Adapted from Lawrence W, Gehan EA, Hays DM, et al. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 1987; 5:46; and Lawrence W, Anderson JR, Gehan EA, et al. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Cancer 1997; 80:1165.</div><div id=\"graphicVersion\">Graphic 62717 Version 3.0</div></div></div>"},"62718":{"type":"graphic_table","displayName":"Congenital anomalies associated with stridor","title":"Congenital anomalies associated with stridor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Congenital anomalies associated with stridor</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Malformation</td> <td class=\"subtitle1\">Characteristics</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Nose</strong>*</td> <td>Nasal deformities</td> <td>Choanal atresia or agenesis, septum deformities, turbinate hypertrophy, vestibular atresia, or stenosis.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Pharynx</strong>*</td> <td>Craniofacial anomalies</td> <td>Anomalies causing facial retrusion are associated with upper airway obstruction, including Crouzon, Pierre Robin, and Apert syndromes.</td> </tr> <tr> <td class=\"divider_bottom\">Tongue</td> <td class=\"divider_bottom\">Macroglossia and glossoptosis.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\"><strong>Larynx</strong></td> <td>Laryngomalacia</td> <td>Most common cause of chronic stridor in infants. Almost all patients present by six weeks of age. Symptoms are more pronounced after upper respiratory infections.</td> </tr> <tr> <td>Laryngeal webs</td> <td>75 percent located in the glottic area. Complete webs cause respiratory distress at birth, partial webs produce stridor, weak cry, and different degrees of respiratory distress. Associated anomalies are common.</td> </tr> <tr> <td>Laryngeal cysts</td> <td>Located in supraglottic area may cause respiratory distress and stridor.</td> </tr> <tr> <td>Laryngeal clefts</td> <td>Characterized by abnormal communication between the larynx and pharynx, sometimes extending downward between the trachea and esophagus. Patients may present with aspiration, cough, swallowing difficulties, respiratory distress, hoarse cry, or occasionally with stridor; often associated with other congenital anomalies.</td> </tr> <tr> <td>Subglottic hemangioma</td> <td>Presents as with stridor and respiratory distress, usually worsening during the first few months of life. Often associated with cutaneous hemangiomas.</td> </tr> <tr> <td>Subglottic stenosis</td> <td>May be congenital but more often acquired secondary to intubation. Usually located 2 to 3 mm below the glottis.</td> </tr> <tr> <td class=\"divider_bottom\">Vocal cord paralysis</td> <td class=\"divider_bottom\">Idiopathic, or secondary to a neurologic disorder (including Chiari II malformation, hydrocephalus, meningomyelocele, hypoxic cerebral palsy, and cerebral hemorrhage).<sup>[1,2]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Trachea<sup>&#182;</sup></strong></td> <td>Tracheal stenosis</td> <td>Usually presents with stridor or both stridor and wheezing. If stenosis is significant, respiratory distress occurs.</td> </tr> <tr> <td>Vascular rings or slings</td> <td>74 percent of vascular rings are symptomatic. The airway compression usually is intrathoracic, causing expiratory stridor. Associated anomalies are common.</td> </tr> <tr> <td class=\"divider_bottom\">Tracheomalacia</td> <td class=\"divider_bottom\">Often associated with other congenital anomalies. May be secondary to a vascular ring or cysts. Worsens with upper respiratory infections, crying, coughing, or feeding. May cause severe spells with cyanosis.</td> </tr> <tr> <td><strong>Bronchi and distal airways<sup>&#182;</sup></strong></td> <td>Bronchogenic cyst</td> <td>May occur at any point throughout the tracheobronchial tree. Typically present during childhood with recurrent coughing, wheezing, or pneumonia, but may become symptomatic during infancy or adulthood, or present as an incidental finding on chest radiographs.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Noise generated from the nose or pharynx is typically low in pitch and is referred to as snoring or stertor.<br />&para; Noise generated from the trachea, bronchi or distal airways is mostly wheezing.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Nisa L, Holtz F, Sandu K. Paralyzed neonatal larynx in adduction. Case series, systematic review and analysis. Int J Pediatr Otorhinolaryngol 2013; 77:13.</li>&#xD;&#xA;    <li>Holinger LD, Holinger PC, Holinger PH. Etiology of bilateral abductor vocal cord paralysis: a review of 389 cases. Ann Otol Rhinol Laryngol 1976; 85:428.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 62718 Version 7.0</div></div></div>"},"62720":{"type":"graphic_picture","displayName":"Herpes simplex virus hand","title":"Herpes simplex virus infection of the hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes simplex virus infection of the hand</div><div class=\"cntnt\"><img style=\"width:389px; height:261px;\" src=\"images/PC/62720_Herpes_simplex_virus_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Close-up view of vesicles on an erythematous base.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 62720 Version 2.0</div></div></div>"},"62721":{"type":"graphic_figure","displayName":"Radial echoendoscope","title":"Radial echoendoscope tip entering the stomach","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Radial echoendoscope tip entering the stomach</div><div class=\"cntnt\"><img style=\"width:456px; height:388px;\" src=\"images/GAST/62721_Radial_echoendoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The scanning plane (arrows) is perpendicular to the axis of the echoendoscope, providing cross-sectional views of the abdominal structures.</div><div class=\"graphic_reference\">Courtesy of Lyndon V. Hernandez, MD and Manoop S. Bhutani, MD.</div><div id=\"graphicVersion\">Graphic 62721 Version 1.0</div></div></div>"},"62722":{"type":"graphic_picture","displayName":"Polyp forceps-Kevorkian curette","title":"Uterine polyp forceps and Kevorkian curette","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterine polyp forceps and Kevorkian curette</div><div class=\"cntnt\"><img style=\"width:450px; height:216px;\" src=\"images/OBGYN/62722_Polyp_forceps-Kevorkian_cur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Kevorkian-Younge curette. (B) Randall-Stone polyp forceps.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 62722 Version 3.0</div></div></div>"},"62723":{"type":"graphic_figure","displayName":"Physiologic anemia of pregnancy","title":"Physiologic anemia of pregnancy","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Physiologic anemia of pregnancy</div><div class=\"cntnt\"><img style=\"width:500px; height:304px;\" src=\"images/PULM/62723_Physiologic_anemia_preg_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representations of the increases in intravascular volume that occur during pregnancy. Plasma volume increases more than the total red cell volume (50% versus 25%), resulting in a 40% rise in blood volume and a dilutional fall in the hematocrit.</div><div id=\"graphicVersion\">Graphic 62723 Version 3.0</div></div></div>"},"62724":{"type":"graphic_table","displayName":"Catastrophic APS criteria","title":"Classification criteria for catastrophic antiphospholipid antibody syndrome (CAPS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification criteria for catastrophic antiphospholipid antibody syndrome (CAPS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Criteria</td> </tr> <tr> <td>1. Evidence of involvement of three or more organs, systems, and/or tissues</td> </tr> <tr> <td>2. Development of manifestations simultaneously or in less than a week</td> </tr> <tr> <td>3. Confirmation by histopathology of small vessel occlusion in at least one organ or tissue</td> </tr> <tr> <td>4. Laboratory confirmation of the presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, and/or anti-beta2-glycoprotein I antibodies)</td> </tr> <tr> <td class=\"subtitle1_single\">Classification</td> </tr> <tr> <td class=\"subtitle2_single\">Definite catastrophic APS</td> </tr> <tr> <td class=\"indent1\">Requires all four criteria</td> </tr> <tr> <td class=\"subtitle2_single\">Probable catastrophic APS</td> </tr> <tr> <td class=\"indent1\">All four criteria, except for only two organs, systems, and/or sites of tissue involvement <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">All four criteria, except for the laboratory confirmation at least six weeks apart due to the early death of a patient never tested for aPL before the catastrophic APS <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">Criteria 1, 2, and 4 above <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">1, 3, and 4 and the development of a third event in more than a week but less than a month, despite anticoagulation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">aPL: antiphospholipid antibodies.</div><div class=\"graphic_reference\">Adapted from: Asherson, RA, Cervera, R, de Groot, PG, et al. Lupus 2003; 12:530.</div><div id=\"graphicVersion\">Graphic 62724 Version 6.0</div></div></div>"},"62726":{"type":"graphic_table","displayName":"FOLFIRI plus cetuximab for colorectal cancer","title":"FOLFIRI plus cetuximab chemotherapy for K-ras wild-type metastatic colorectal cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FOLFIRI plus cetuximab chemotherapy for K-ras wild-type metastatic colorectal cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 28 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Cetuximab</strong></td> <td>400 mg/m<sup>2</sup> IV</td> <td>The appropriate dose should be withdrawn from the vials (supplied in a concentration of 2 mg/mL) and aseptically transferred into an empty sterile IV bag without further dilution. The initial dose should be infused over 120 minutes*<sup>&#916;</sup>.</td> <td>Day 1</td> </tr> <tr> <td><strong>Cetuximab</strong></td> <td>250 mg/m<sup>2</sup> IV</td> <td>If Day 1 cetuximab is tolerated, subsequent doses may be administered over 60 minutes.</td> <td>Weekly, beginning Day 8<sup>&#9674;</sup></td> </tr> <tr> <td><strong>Irinotecan</strong></td> <td>180<sup>&#167;</sup> mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL 5 percent dextrose in water (D5W)<sup>&#165;</sup> and administer over 90 minutes after cetuximab; may be given concurrently with leucovorin via y-site connection.</td> <td>Days 1 and 15</td> </tr> <tr> <td><strong>Leucovorin</strong><sup>&#135;</sup></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL D5W and administer over two hours; may give concurrent with irinotecan via y-site connection.</td> <td>Days 1 and 15</td> </tr> <tr> <td><strong>Fluorouracil (FU)</strong></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Slow intravenous push over five minutes (administer immediately after leucovorin).</td> <td>Days 1 and 15</td> </tr> <tr> <td><strong>Fluorouracil (FU)</strong></td> <td>2400<sup>&#134;</sup> mg/m<sup>2</sup> IV</td> <td>Dilute in 500 to 1000 mL D5W and administer over 46 hours (begin immediately after FU bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL normal saline.</td> <td>Days 1 and 15</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> MODERATE (30 to 60 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Premedicate with diphenhydramine with or without a glucocorticoid at least prior to the first infusion of cetuximab<sup>[2]</sup>. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with granulocyte colony stimulating factors is not justified (risk of febrile neutropenia with this regimen was 3 percent<sup>[1]</sup>). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> A lower starting dose of FU and irinotecan may be needed for patients with liver impairment. A lower starting dose of irinotecan may be needed for patients with severe renal impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramps and/or diarrhea within 24 hours of treatment, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea. <strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Obtain CBC with differential and platelet count prior to each treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes (including magnesium, calcium, and potassium) and liver and renal function prior to each dose. Monitor serum calcium, magnesium, and potassium levels weekly for eight weeks after completion of therapy<sup>[3]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Delay treatment until absolute neutrophil count is &#62;1500 cells/microL and the platelet count is &#62;100,000/microL. United States Prescribing Information suggests irinotecan dose reduction for grade 3 or worse hematologic toxicity during a prior cycle<sup>[2]</sup>. A different approach is used by some clinicians. If treatment is delayed for two weeks or delayed for one week on two separate occasions, the Day 1 FU bolus is eliminated. With the second occurrence, reduce the FU infusion dose by 20 percent and reduce irinotecan dose to 150 mg/m<sup>2</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Withhold treatment until resolution of diarrhea for at least 24 hours off antidiarrheal medications. Reduce irinotecan dose for patients with grade 2 or worse diarrhea during a prior treatment cycle<sup>[2]</sup>. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dermatologic toxicity:</strong> Severe dermatologic reactions, such as acneiform rash, require delayed administration of cetuximab and/or dose reduction. Refer to UpToDate topic on \"Acneiform eruption secondary to epidermal growth factor receptor&nbsp;(EGFR) inhibitors\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Other toxicity:</strong> If grade 2, hold treatment until less than or equal to grade 1; if grade 3 or 4, hold treatment until less than or equal to grade 2<sup>[2]</sup>. Withhold FU for grade 2 or worse diarrhea, and restart at a lower dose after complete resolution<sup>[4]</sup>. Reduce irinotecan dose for patients with grade 3 or worse other non-hematologic toxicities during a prior treatment cycle<sup>[2]</sup>. For grade 3 mucositis, eliminate FU bolus dose; prophylactic ice chips may be beneficial. Refer to UpToDate topic on \"Oral toxicity associated with chemotherapy\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.<br />* Cetuximab should be administered with an infusion or syringe pump, using a low protein-binding 0.22 micron in line filter. Do not shake or dilute. Flush line with normal saline.<br />Î A slower infusion rate should be considered in areas with a high incidence of infusion reactions (such as the Southeast United States). Refer to UpToDate topic on \"Infusion reactions to the therapeutic monoclonal antibodies used in cancer therapy\".<br /><FONT class=lozenge>â</FONT> Results from a nonrandomized phase II trial<SUP>[5]</SUP> and a multicenter retrospective analysis<SUP>[6]</SUP> suggest that cetuximab at a dose of 500 mg/m<SUP>2</SUP> every two weeks results in similar plasma <SPAN style=\"COLOR: black\">concentrations and single-agent activity as does weekly dosing.<br />Â§ A lower initial starting dose of irinotecan may be considered for patients with poor performance status, prior pelvic or abdominal radiotherapy, or increased bilirubin levels<SUP>[2]</SUP>. Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether </SPAN>testing for this allele should be carried out prior to starting irinotecan&nbsp;are controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".<br />Â¥ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />â¡ Leucovorin dose is given for d,l-racemic mixture<SUP>[7]</SUP>. Use half the dose for LEVOleucovorin (l-leucovorin).<br />â  If there is no grade 1 or worse toxicity 1 in cycles 1 and 2, some clinicians increase the dose to 3000 mg/m<SUP>2</SUP> starting with cycle 3<SUP>[1]</SUP>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Van Cutsem E, et al. N Engl J Med 2009; 360:1408. </LI>&#xD;&#xA;<LI>Irinotecan hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016). </LI>&#xD;&#xA;<LI>Cetuximab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016). </LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016). </LI>&#xD;&#xA;<LI>Pfeiffer P, et al. Ann Oncol 2008; 19:1141. </LI>&#xD;&#xA;<LI>Bouchahda M, et al. Med Oncol 2011; 28 Suppl1:253. </LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016). </LI></OL></div><div id=\"graphicVersion\">Graphic 62726 Version 11.0</div></div></div>"},"62727":{"type":"graphic_figure","displayName":"Lat distal radius volar tilt","title":"Distal radius anatomy, lateral view","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Distal radius anatomy, lateral view</div><div class=\"cntnt\"><img style=\"width:541px; height:615px;\" src=\"images/EM/62727_Lat_distal_radius_volar_til.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measurements performed on lateral radiographs include volar tilt and AP distance. Note the normal linear alignment of the capitate, lunate, and radius. Also, note how the curvature of the articular surfaces of these bones corresponds.</div><div id=\"graphicVersion\">Graphic 62727 Version 2.0</div></div></div>"},"62730":{"type":"graphic_movie","displayName":"Robot-assisted rad hyst 1","title":"Dissection of the right uterine artery during robot-assisted radical hysterectomy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dissection of the right uterine artery during robot-assisted radical hysterectomy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/62730_Disrightuterartconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:396px; height:304px;\" src=\"images/CARD/62730_Dissectionrightuterart.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Colleen M Feltmate, MD.</div><div id=\"graphicVersion\">Graphic 62730 Version 4.0</div></div></div>"},"62731":{"type":"graphic_diagnosticimage","displayName":"Chromosomal transloc Ewing FISH","title":"Typical chromosomal translocation seen in Ewing sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical chromosomal translocation seen in Ewing sarcoma</div><div class=\"cntnt\"><img style=\"width:443px; height:231px;\" src=\"images/ONC/62731_Chromosomal_transloc_Ewing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluorescence in situ hybridization (FISH) study demonstrating the (11;22)(q24;q12) translocation [der(22)] found in Ewing sarcoma and primitive peripheral neuroectodermal tumors (PNET).</div><div class=\"graphic_reference\">Courtesy of Andrew L Rosenberg, MD.</div><div id=\"graphicVersion\">Graphic 62731 Version 3.0</div></div></div>"},"62732":{"type":"graphic_algorithm","displayName":"Algorithm for evaluating an infant with frequent regurgitation","title":"Algorithm for evaluating an infant with frequent regurgitation","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluating an infant with frequent regurgitation</div><div class=\"cntnt\"><img style=\"width:630px; height:900px;\" src=\"images/PEDS/62732_Algorithm_infn_frequ_regurg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dotted line denotes alternate pathway, depending on results of clinical assessment.</div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease; CBC: complete blood count; BUN: blood urea nitrogen; tTG-IgA: immunoglobulin A antibodies to tissue transglutaminase; PPI: proton pump inhibitor.<br />* Warning signals include bilious vomiting, consistently forceful vomiting, abdominal tenderness or distension, fever, or other systemic signs (see text).<br />Â¶ Trials of both thickened feeds and a cow's milk- and soy-free diet should generally be performed before a trial of acid suppression. If neither of these trials is successful, the next step is a trial of acid suppression.</div><div id=\"graphicVersion\">Graphic 62732 Version 7.0</div></div></div>"},"62735":{"type":"graphic_picture","displayName":"Infantile perianal pyramidal protrusion","title":"Infantile perianal pyramidal protrusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infantile perianal pyramidal protrusion</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/62735_Inf_perianal_pyramid_protru.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infantile perianal pyramidal protrusion is a pedunculated perineal lesion, typically located in the midline, just anterior to the anus. It occurs almost exclusively in girls.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62735 Version 3.0</div></div></div>"},"62736":{"type":"graphic_picture","displayName":"IPMN pancreatoscopy","title":"Intraductal papillary mucinous neoplasm of the pancreas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraductal papillary mucinous neoplasm of the pancreas</div><div class=\"cntnt\"><img style=\"width:384px; height:373px;\" src=\"images/GAST/62736_IPMN_pancreatoscopy_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreatoscopy showing villous projections associated with an intraductal papillary mucinous neoplasm of the pancreas.</div><div id=\"graphicVersion\">Graphic 62736 Version 2.0</div></div></div>"},"62737":{"type":"graphic_algorithm","displayName":"Pediatric acute hip pain and limp diagnostic algorithm","title":"Diagnostic approach to a child with limp and acute hip pain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to a child with limp and acute hip pain</div><div class=\"cntnt\"><img style=\"width:414px; height:702px;\" src=\"images/EM/62737_Act_hip_pain_limp_algo_chld.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SCFE: slipped capital femoral epiphysis; ESR: erythrocyte sedimentation rate; WBC: white blood cell; CRP: C-reactive protein.<br />* White blood cell count &gt;50,000/microL or positive Gram stain. Children may have septic arthritis without either of these findings.</div><div id=\"graphicVersion\">Graphic 62737 Version 3.0</div></div></div>"},"62738":{"type":"graphic_table","displayName":"Features of acute small bowel versus acute colonic ischemia","title":"Features of acute small bowel versus acute colonic ischemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of acute small bowel versus acute colonic ischemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Acute small bowel ischemia</td> <td class=\"subtitle1\">Acute colonic ischemia</td> </tr> <tr> <td>Age varies with etiology of ischemia</td> <td>90 percent of patients over age 60 years</td> </tr> <tr> <td>Acute precipitating cause is typical</td> <td>Acute precipitating cause is rare</td> </tr> <tr> <td>Patients appear severely ill</td> <td>Patients do not appear severely ill</td> </tr> <tr> <td>Pain is usually severe, tenderness is not prominent early</td> <td>Mild abdominal pain, tenderness present</td> </tr> <tr> <td>Bleeding uncommon until very late</td> <td>Rectal bleeding, bloody diarrhea typical</td> </tr> <tr> <td>MRA or MDCT angiography may be considered as the initial diagnostic test; angiography is recommended if there is strong clinical suspicion</td> <td>Colonoscopy is procedure of choice</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRA: magnetic resonance angiography; MDCT: multidetector row computed tomography.</div><div class=\"graphic_reference\">Data from: Reinus JF, Brandt LJ, Boley SJ. Ischemic diseases of the bowel.&nbsp;Gastroenterol Clin North Am 1990; 19:319.</div><div id=\"graphicVersion\">Graphic 62738 Version 8.0</div></div></div>"},"62739":{"type":"graphic_figure","displayName":"Obturator fossa nodes","title":"Obturator fossa node dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Obturator fossa node dissection</div><div class=\"cntnt\"><img style=\"width:427px; height:363px;\" src=\"images/OBGYN/62739_Obturator_fossa_nodes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lymphatic tissue of the obturator fossa is freed from the lateral pelvic sidewall by bluntly dissecting lateral to the external iliac artery and vein. The obturator nerve is then identified coursing through the obturator fossa and freed of lymphatic tissue by running the Metzenbaum scissors parallel to the nerve. The lymphatic tissue can now be lifted out of the obturator fossa carefully to avoid damaging the internal iliac artery and vein.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 62739 Version 1.0</div></div></div>"},"62742":{"type":"graphic_table","displayName":"Hormone replacement for Turner syndrome","title":"Turner syndrome: Pubertal induction and maintenance therapy using transdermal estrogens â A protocol using low growth-promoting doses for the first 18 to 24 months","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Turner syndrome: Pubertal induction and maintenance therapy using transdermal estrogens â A protocol using low growth-promoting doses for the first 18 to 24 months</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Typical age range</td> <td class=\"subtitle1\">Time from start of treatment&nbsp;</td> <td class=\"subtitle1\">Target E2 concentration*<sup>&#182;</sup> </td> <td class=\"subtitle1\">E2 dose&nbsp;</td> <td class=\"subtitle1\">Progestin dose&nbsp;</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td>11-12 years</td> <td>&nbsp;0-12 months</td> <td>3-4 pg/mL</td> <td>~0.1 micrograms/kg</td> <td>&nbsp;--</td> <td> <ul> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #000000;\">Start estrogen to initiate puberty at age 11 to 12 years if there is no breast development.</span> </li> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #000000;\">Start by cutting&nbsp;a portion (one-sixth to one-eighth) of a matrix estrogen patch, calculated&nbsp;to deliver 0.1 micrograms/kg E2 daily<span style=\"font-size: 13px; font-family: Calibri;\">.<sup>&#916;</sup></span> </span></li> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #000000;\">At first, apply this patch in the evening and remove in the morning<span style=\"color: #0000ff;\">.</span></span> </li> <li>After four to six months, start wearing the same portion of the patch continuously. </li> <li>Change the patch as directed (once or twice weekly). </li> <li>Check&nbsp;E2&nbsp;concentration to ensure that E2 is in the target range.<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td>12-12.5 years</td> <td>12-18 months&nbsp;</td> <td>6-8 pg/mL</td> <td>0.2 micrograms/kg&nbsp;</td> <td>&nbsp;--</td> <td> <ul id=\"_telerik_insertedList_id\"> <li>The timing of when to advance the E2 dose varies, based on the individual patient's&nbsp;clinical response. </li> </ul> </td> </tr> <tr> <td>12.5-13&nbsp;years</td> <td>18-24 months&nbsp;</td> <td>12 pg/mL</td> <td>12.5 micrograms</td> <td>--&nbsp;</td> <td> <ul> <li>E2&nbsp;concentrations below this threshold (12 pg/mL) may accelerate growth more than bone maturation. </li> <li>Some patients who have already achieved an acceptable adult height may benefit from a more rapid advancement to 25 and 37.5 microgram/day dosing. </li> </ul> </td> </tr> <tr> <td>13-13.5 years</td> <td>24-30 months</td> <td>25 pg/mL</td> <td>25 micrograms</td> <td>Give progestins 12 days/month:<br /> <ul> <li>100 to 200 mg micronized oral progesterone<sup>&#9674;</sup> </li> <li><strong>or</strong>&nbsp;5 mg oral medroxyprogesterone </li> </ul> </td> <td> <ul> <li>Progestin therapy should be begun after approximately two years of estrogen monotherapy (typically around 13 or 14 years of age), or when vaginal breakthrough bleeding first occurs. </li> <li>Spontaneous&nbsp;vaginal&nbsp;breakthrough bleeding&nbsp;usually coincides with an E2 dose of 37.5 to 50 micrograms/day, which is usually reached after 30 to 36 months of escalating&nbsp;E2 therapy. </li> </ul> </td> </tr> <tr> <td>13.5-14 years&nbsp;</td> <td>30-36 months&nbsp;</td> <td>37 pg/mL</td> <td>37.5 micrograms&nbsp;</td> <td>Continue as above&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>14.5-15 years</td> <td>36-42 months</td> <td>50 pg/mL</td> <td>50 micrograms&nbsp;</td> <td>Continue as above</td> <td>&nbsp;</td> </tr> <tr> <td>15-15.5 years</td> <td>42-48 months</td> <td>75 pg/mL</td> <td>75 micrograms</td> <td>Continue as above</td> <td>&nbsp;</td> </tr> <tr> <td>15 years and thereafter&nbsp;</td> <td>48 months and thereafter</td> <td>100&nbsp;pg/mL</td> <td>100 micrograms&nbsp;</td> <td>Continue as above</td> <td>These are typical doses&nbsp;for treatment of primary ovarian insufficiency in adults. Further details are available in the UpToDate topic on Management of spontaneous primary ovarian insufficiency (premature ovarian failure).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This protocol is but one of many that can be used. This specific protocol is used in the author's clinic and is individualized depending on patient circumstances and desires. For example, older girls may prefer to start at 25 micrograms of estrogen. The estrogen-progestin replacement should be continued until about age 50 years, the average age of menopause, to mimic the hormonal patterns of women with functioning ovaries. As of 2016, a group of experts&nbsp;is working on a revised set of recommendations for the estrogen/progestin replacement therapy in Turner syndrome. We expect and will update on the recommendations in this table&nbsp;when the&nbsp;evidence-based review and consensus statement are available.</div><div class=\"graphic_footnotes\">E2: 17-beta estradiol.<br />* To convert picograms per milliliter to picomoles per liter, multiply by 3.671. E2 levels should be monitored using liquid chromatography/tandem mass spectrometry technology.<br />Â¶ We typically check E2 concentrations after each dosing change, testing&nbsp;six or more hours after applying a new patch.&nbsp;We adjust the dose as needed to keep the E2 concentration&nbsp;near the target range. <br />Î Vivelle Dot, matrix transdermal patch, is small and tends to adhere well. One-sixth to one-eighth of a 25 microgram patch&nbsp;delivers approximately 0.1 micrograms/k<FONT color=black>g/</FONT><FONT color=red><FONT color=black>day&nbsp;if worn<FONT color=black> continuously</FONT></FONT><FONT color=black>.</FONT><FONT color=black> The cutting&nbsp;technique cannot be used&nbsp;for a reservoir-type patch, as this would make the entire dose available at once.<br />â Give micronized oral progesterone before bedtime, because it may cause drowsiness.</FONT></FONT><br />â</div><div class=\"graphic_reference\">Modified from: Davenport ML. Approach to the patient with Turner syndrome. J Clin Endocrinol Metab 2010; 95:1487.</div><div id=\"graphicVersion\">Graphic 62742 Version 11.0</div></div></div>"},"62743":{"type":"graphic_table","displayName":"Egg substitutes","title":"Substitutions for egg in recipes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Substitutions for egg in recipes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>2 tablespoons of fruit puree (binding only)</td> </tr> <tr> <td>1 tablespoon of ground flax seeds, 3 tablespoons water (binding only)</td> </tr> <tr> <td>1&#189; tablespoons water, 1&#189; tablespoons oil, 1 teaspoon baking powder (leavening and binding)</td> </tr> <tr> <td>1 teaspoon baking powder, 1 tablespoon liquid, 1 tablespoon vinegar (leavening and binding)</td> </tr> <tr> <td>Commercial, powdered, egg-free egg replacer (leavening and binding)</td> </tr> <tr> <td>1 packet of gelatin, 2 tablespoons warm water - Mix when ready to use (leavening and binding)</td> </tr> <tr> <td>1 teaspoon yeast dissolved in &#188; cup warm water (leavening and binding)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62743 Version 3.0</div></div></div>"},"62745":{"type":"graphic_figure","displayName":"Pelvic organ prolapse","title":"Anatomic sites of pelvic organ prolapse","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Anatomic sites of pelvic organ prolapse</div><div class=\"cntnt\"><img style=\"width:490px; height:478px;\" src=\"images/OBGYN/62745_Pelvic_organ_prolapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pelvic support disorders.<br> (A) Cystocele.<br> (B) Rectocele.<br> (C) Enterocele.</div><div class=\"graphic_reference\">Modified with permission from: Smeltzer, S, Bare, B. Brunner and Suddarth's Textbook of Medical-Surgical Nursing, Ninth Edition. Philadelphia: Lippincott Williams &amp; Wilkins. Copyright &#169; 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62745 Version 2.0</div></div></div>"},"62746":{"type":"graphic_figure","displayName":"Intraoperative PTH dynamics","title":"Intraoperative parathyroid hormone (PTH) dynamics during parathyroidectomy for sporadic primary hyperparathyroidism in two successfully treated patients","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Intraoperative parathyroid hormone (PTH) dynamics during parathyroidectomy for sporadic primary hyperparathyroidism in two successfully treated patients</div><div class=\"cntnt\"><img style=\"width:519px; height:364px;\" src=\"images/SURG/62746_Intrao_PTH_dyn_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The pre-excision PTH level has increased when compared with the pre-incision sample due to manipulation of the abnormal gland during dissection. In this case, if the pre-excision sample was not collected, the intraoperative parathyroid hormone monitoring (IPM) criterion would not have been met in 10 minutes.<br />(B) The pre-excision PTH level has already decreased when compared with the pre-incision sample due to early devascularization of the abnormal gland. In this case, if the pre-incision sample was not collected, the IPM criterion would not have been met in 10 minutes.</div><div id=\"graphicVersion\">Graphic 62746 Version 5.0</div></div></div>"},"62748":{"type":"graphic_movie","displayName":"Mitral stenosis apical long axis echocardiogram 1","title":"Mitral stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/62748_aplaxms1conv.mp4\" style=\"width:312px;height:224px\"></div><img style=\"width:236px; height:369px;\" src=\"images/CARD/62748_aplaxms1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical long axis view from a 2-D echocardiogram shows thickened mitral valve leaflets which have marked limitation of mobility and show doming, with failure to open normally during diastole.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 62748 Version 2.0</div></div></div>"},"62749":{"type":"graphic_diagnosticimage","displayName":"CW Doppler pulmonary vein MR","title":"Pulmonary vein flow in severe mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary vein flow in severe mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:346px; height:254px;\" src=\"images/CARD/62749_CW_Doppler_pulmonary_vein_M.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The continuous wave Doppler, obtained from the pulmonary vein (PV), shows systolic flow reversal or retrograde systolic flow, which is the hallmark of severe mitral regurgitation (MR) and is the flow analogue of the v-wave seen on the pulmonary artery catheter wedge pressure tracing.</div><div id=\"graphicVersion\">Graphic 62749 Version 2.0</div></div></div>"},"62750":{"type":"graphic_table","displayName":"CUP immunostaining","title":"Characteristic immunohistochemical staining patterns for undifferentiated neoplasms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristic immunohistochemical staining patterns for undifferentiated neoplasms</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Neoplasm\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Cytokeratin\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   EMA\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   LCA\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   S-100\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Desmin/ vimentin*\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   OCT 4/ HCG/ AFP/ PLAP*\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Chromogranin/ synaptophysin\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Carcinoma</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>S</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>S</td>\r\n  \r\n   <td>S</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Melanoma</td>\r\n  \r\n   <td>-, R</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sarcoma</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>S</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lymphoma</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-, R</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Neuroendocrine carcinoma</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Germ cell tumor</td>\r\n  \r\n   <td>-, R</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">EMA: Epithelial membrane antigen; LCA: Leukocyte common antigen; S-100: S-100 protein; HCG: Human chorionic gonadotrophin; AFP: Alpha-fetoprotein; PLAP: Placental leukocyte alkaline phosphatase; +: Positive; -: Negative; S: Sometimes positive; R: Rare positive cells.<br>* Positive for one or more of these markers.</div><div class=\"graphic_reference\">Modified from: Dabbs DJ. Immunohistology of metastatic carcinoma of unknown primary. In: Diagnostic Immunohistochemistry, 2nd ed, Dabbs DJ (Ed), Churchill Livingstone, Pittsburgh 2006. p.180.</div><div id=\"graphicVersion\">Graphic 62750 Version 2.0</div></div></div>"},"62751":{"type":"graphic_table","displayName":"Causes abnormal vaginal bleeding teen","title":"Causes of abnormal vaginal bleeding in the nonpregnant adolescent","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of abnormal vaginal bleeding in the nonpregnant adolescent</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Comments/associated clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\"><span style=\"color: black;\">Causes of bleeding from the uterus</span></td> </tr> <tr> <td class=\"indent1\">Anovulatory uterine bleeding related to immature HPO axis at the onset of menarche*</td> <td>Most common cause in adolescents; unpredictable timing of bleeding and variable amounts of flow</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Other causes of ovulatory dysfunction</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>PCOS* or other causes of hyperandrogenism (eg, adrenal tumor, CAH) </li> </ul> </td> <td>Hyperandrogenism (acne, hirsutism, clitoromegaly)</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Thyroid disease </li> </ul> </td> <td>Weight loss or gain; heat or cold intolerance; fatigue</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Hyperprolactinemia </li> </ul> </td> <td>Galactorrhea, vision change, headaches</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Hypothalamic dysfunction </li> </ul> </td> <td>Stress, intense exercise, change in weight (loss or gain)</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Estrogen-secreting ovarian tumor </li> </ul> </td> <td>Ovarian enlargement or mass</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Hypercortisolism (Cushing syndrome) </li> </ul> </td> <td>Central obesity, proximal muscle weakness, purplish striae</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Pituitary disease (tumor, infarction) </li> </ul> </td> <td>Impaired vision, headache, pituitary hormone deficiencies (eg, fatigue, cold intolerance, decreased appetite) or excess (eg, hyperprolactinemia)</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Diabetes mellitus </li> </ul> </td> <td>Polyuria, polydipsia, nocturia</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Primary ovarian insufficiency (premature ovarian failure) </li> </ul> </td> <td> <p><span style=\"color: #ff0000;\"><span style=\"color: black;\">Primary ovarian insufficiency in adolescents can be associated with chromosomal abnormalities (eg, Turner syndrome), thyroid or adrenal abnormalities, and fragile X syndrome.<sup>&#182;[1]</sup></span>&nbsp;</span></p> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Medications: <ul> <li>Hormonal contraception </li> <li>Androgens </li> <li>Spironolactone </li> <li>Antipsychotics and antidepressants </li> <li>Corticosteroids </li> <li>Chemotherapeutic agents </li> </ul> </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Infection</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Pelvic inflammatory disease* </li> </ul> </td> <td><span style=\"color: black;\">Fever, mucopurulent discharge</span>, lower abdominal or pelvic pain, pelvic organ tenderness (eg, cervical motion tenderness, adnexal tenderness), inflammation of the genital tract</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Endometritis unrelated to pregnancy </li> </ul> </td> <td> <p>Vague, crampy, lower abdominal pain</p> <p>Intrauterine foreign objects</p> Uterine radiation</td> </tr> <tr> <td class=\"indent1\">Endometriosis</td> <td><span style=\"color: black;\">Cyclic pain with menses that may progress to acyclic pain</span>; bowel symptoms (rectal pain, constipation, painful defecation, rectal bleeding); bladder symptoms (dysuria, urgency, hematuria)</td> </tr> <tr> <td class=\"indent1\">Bleeding disorders (coagulopathy)* <ul class=\"decimal_heading\"> <li>Thrombocytopenia (eg, ITP, leukemia, aplastic anemia) </li> <li>Coagulation disorders (eg, von Willebrand disease, liver dysfunction, vitamin K deficiency) </li> <li>Associated with systemic disease (eg, systemic lupus erythematosus, liver disease, chronic renal disease) </li> <li>Associated with medications (eg, anticoagulants, platelet inhibitors) </li> </ul> </td> <td>Suggested by one of the following:<sup>[2]</sup> <ul class=\"decimal_heading\"> <li>Heavy menstrual bleeding since menarche </li> <li>&#8805;1 of the following: <ul> <li>Postpartum hemorrhage </li> <li>Surgery-related bleeding </li> <li>Bleeding associated with dental work </li> </ul> </li> <li>&#8805;2 of the following: <ul> <li>Bruising one to two times per month </li> <li>Epistaxis one to two times per month </li> <li>Frequent gum bleeding </li> <li>Family history of bleeding symptoms </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Structural uterine problems <ul class=\"decimal_heading\"> <li>Polyp </li> <li>Adenomyosis </li> <li>Leiomyoma (fibroid) </li> <li>Malignancy and hyperplasia </li> <li>Congenital uterine anomalies (eg, septate/arcuate, unicornuate, etc) </li> </ul> </td> <td>May be identified through imaging or histopathology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">IUD-related bleeding</td> <td> <p>Intermenstrual: All IUDs</p> <p>Excessive volume: Primarily copper IUD</p> <p>Irregular bleeding: Primarily levonorgestrel IUDs</p> Amenorrhea: Primarily IUDs containing 52 mg levonorgestrel</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\"><span style=\"color: black;\">Causes of vaginal bleeding from sites other than the uterus</span></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Ovary: Cyst, tumor</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Cervix: Carcinoma, cervicitis, ectropion, hemangioma, polyp</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Vagina: Carcinoma/sarcoma, foreign body (eg, retained tampon), trauma, vaginitis</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Vulva: Trauma, sexually transmitted diseases (eg, ulcers), dermatologic conditions</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Gastrointestinal tract: Hemorrhoids, infectious colitis, inflammatory bowel disease, vascular malformation, rectal prolapse</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Urinary tract: Urinary tract infection, irritation of the urethral meatus, urethral trauma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPO: hypothalamic-pituitary-ovarian; PCOS: polycystic ovary syndrome; CAH: congenital adrenal hyperplasia; ITP: immune thrombocytopenic purpura; IUD: intrauterine device.<br />* Most common causes in adolescents.<br /><SPAN style=\"COLOR: black\">Â¶ Refer to UpToDate content on primary ovarian insufficiency for additional information</SPAN><SPAN style=\"COLOR: black\">.</SPAN></div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">ACOG Committee Opinion No. 605: Primary ovarian insufficiency in adolescents and young women. Obstet Gynecol 2014: 124:193.</SPAN></LI>&#xD;&#xA;<LI><FONT color=black>Kouides PA, Conard J, Peyvandi F, et al. Hemostasis and menstruation: Appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertil Steril 2005; 84:1345.</FONT></LI></OL>Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>ACOG Committee Opinion No. 651: Menstruation in girls and adolescents: Using the menstrual cycle as a vital sign. Obstet Gynecol 2015; 126:e143.</LI>&#xD;&#xA;<LI>Gray SH, Emans SJ. Abnormal vaginal bleeding in the adolescent. In: Emans, Laufer, Goldstein's Pediatric &amp; Adolescent Gynecology, 6<SUP>th</SUP> ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.159.</LI>&#xD;&#xA;<LI>Munro MG, Critchley HO, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011; 113:3.</LI></OL></div><div id=\"graphicVersion\">Graphic 62751 Version 7.0</div></div></div>"},"62752":{"type":"graphic_picture","displayName":"RTT late deterioration","title":"Rett syndrome, late deterioration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rett syndrome, late deterioration</div><div class=\"cntnt\"><img style=\"width:252px; height:378px;\" src=\"images/PEDS/62752_RS_stage_IVA_late_deteriora.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This woman with RTT no longer ambulated and had severe motor dysfunction: scoliosis, dystonia, lack of facial expression are characteristic of this phase.</div><div class=\"graphic_reference\">Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright Â© 1997 Medscape.</div><div id=\"graphicVersion\">Graphic 62752 Version 4.0</div></div></div>"},"62753":{"type":"graphic_picture","displayName":"Lichen sclerosus perianal","title":"Perianal lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perianal lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:258px; height:396px;\" src=\"images/OBGYN/62753_Lichen_sclerosus_perianal.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Ridley CM, Neill SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright Â© 1999 Blackwell Science. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 62753 Version 3.0</div></div></div>"},"62754":{"type":"graphic_picture","displayName":"Uterus bicollis","title":"Uterus with two cervices (bicollis)","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Uterus with two cervices (bicollis)</div><div class=\"cntnt\"><img style=\"width:468px; height:308px;\" src=\"images/OBGYN/62754_Uterusbicollis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two cervical os from uterus didelphys are visible (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62754 Version 13.0</div></div></div>"},"62755":{"type":"graphic_table","displayName":"Vitamins lactation","title":"Recommended dietary allowances for vitamins during lactation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended dietary allowances for vitamins during lactation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">RDA women</td> <td class=\"subtitle1\">Milk secretion</td> <td class=\"subtitle1\">Efficiency</td> <td class=\"subtitle1\">RDA lactation</td> </tr> <tr> <td><strong>Vitamin C</strong></td> <td>75 mg/d</td> <td>40 mg/d</td> <td>85 percent</td> <td>120 mg/d</td> </tr> <tr> <td><strong>Thiamine</strong></td> <td>1.1 mg/d</td> <td>0.16 mg/d</td> <td>0.1 mg/d</td> <td>1.4 mg/d</td> </tr> <tr> <td><strong>Riboflavin</strong></td> <td>1.1 mg/d</td> <td>0.3 mg/d</td> <td>0.1 mg/d</td> <td>1.6 mg/d</td> </tr> <tr> <td><strong>Niacin</strong></td> <td>14 mg/d</td> <td>1.4 mg/d</td> <td>1 mg/d</td> <td>17 mg/d</td> </tr> <tr> <td><strong>Vitamin B6</strong></td> <td>1.3 mg/d</td> <td>0.1 mg/d</td> <td>0.48 mg/d</td> <td>2 mg/d</td> </tr> <tr> <td><strong>Folic acid</strong></td> <td>400 mcg/d</td> <td>66 mcg/d</td> <td>66 mcg/d</td> <td>500 mcg/d</td> </tr> <tr> <td><strong>Vitamin B12</strong></td> <td>2 mcg/d</td> <td>0.33 mcg/d</td> <td>&nbsp;</td> <td>2.8 mcg/d</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RDA: recommended dietary allowance.</div><div class=\"graphic_reference\">Data from: Dietary Reference Intakes. The Essential Guide to Nutrient Requirements. Otten JJ, Hellwig JP, Meyers LD (Eds), IoM, Washington, DC 2006.</div><div id=\"graphicVersion\">Graphic 62755 Version 4.0</div></div></div>"},"62757":{"type":"graphic_table","displayName":"Common solutions for rehydration","title":"Composition (mEq/L) of common solutions used for rehydration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composition (mEq/L) of common solutions used for rehydration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Solution</td> <td class=\"subtitle1\">Na+</td> <td class=\"subtitle1\">K+</td> <td class=\"subtitle1\">Cl-</td> <td class=\"subtitle1\">HCO3-</td> <td class=\"subtitle1\">Citrate</td> <td class=\"subtitle1\">Ca++</td> <td class=\"subtitle1\">Glucose/carbohydrate</td> </tr> <tr> <td rowspan=\"4\">Intravenous</td> <td>Normal saline</td> <td>154</td> <td>-</td> <td>154</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Ringer's Lactate</td> <td>130</td> <td>4</td> <td>111</td> <td>28</td> <td>-</td> <td>3</td> <td>-</td> </tr> <tr> <td>Ringer's Lactate + 5 percent dextrose</td> <td>130</td> <td>4</td> <td>109</td> <td>28</td> <td>-</td> <td>3</td> <td>278</td> </tr> <tr> <td>Cholera saline (\"Dhaka solution\")</td> <td>133</td> <td>13</td> <td>98</td> <td>48</td> <td>-</td> <td>-</td> <td>140</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Oral</td> <td>Standard ORS</td> <td>90</td> <td>20</td> <td>80</td> <td>-</td> <td>10</td> <td>-</td> <td>111</td> </tr> <tr> <td>Hypo-osmolar ORS</td> <td>75</td> <td>20</td> <td>65</td> <td>-</td> <td>10</td> <td>-</td> <td>75</td> </tr> <tr> <td>ReSoMal* (Reduced Osmolarity ORS for Malnourished Children)</td> <td>45</td> <td>40</td> <td>76</td> <td>-</td> <td>7</td> <td>-</td> <td>125</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ORS is reviewed in detail separately. (See &quot;Oral rehydration therapy&quot;).</div><div class=\"graphic_footnotes\">ORS: oral rehydration solution(s).<br> * Also contains Mg 6 mmol/L, Zn 300 umol/L, Cu 45 umol/L.</div><div class=\"graphic_reference\">Data from: World Health Organization. The treatment of diarrhea: A manual for physicians and other senior health workers - 4th revision. World Health Organization, Geneva 2005. Available at: <a href=\"http://whqlibdoc.who.int/publications/2005/9241593180.pdf\" target=\"_blank\">http://whqlibdoc.who.int/publications/2005/9241593180.pdf</a>.</div><div id=\"graphicVersion\">Graphic 62757 Version 2.0</div></div></div>"},"62758":{"type":"graphic_picture","displayName":"Terminal villi","title":"Term placenta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Term placenta</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/OBGYN/62758_Terminal_villi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal term placenta showing a spectrum of villous sizes with terminal villi predominating.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 62758 Version 1.0</div></div></div>"},"62759":{"type":"graphic_picture","displayName":"Pyogenic granuloma multiple","title":"Multiple pyogenic granulomas","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Multiple pyogenic granulomas</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62759_Pyogenic_granuloma_multi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient, multiple pyogenic granulomas developed at the site of a previously excised solitary pyogenic granuloma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62759 Version 4.0</div></div></div>"},"62760":{"type":"graphic_algorithm","displayName":"Diagnosis and initial management of intestinal ischemia","title":"Diagnosis and initial management of intestinal ischemia","html":"<div class=\"graphic\"><div style=\"width: 886px\" class=\"figure\"><div class=\"ttl\">Diagnosis and initial management of intestinal ischemia</div><div class=\"cntnt\"><img style=\"width:866px; height:609px;\" src=\"images/SURG/62760_DXinitmgmtintstnlischem.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* Patients ultimately identified with nonocclusive mesenteric ischemia will not benefit from anticoagulation, at which point it can be discontinued.<br />Â¶ Imaging signs associated with mesenteric ischemia include focal or segmental bowel wall thickening, intestinal pneumatosis, portal vein gas, portomesenteric thrombosis, mesenteric arterial calcification, and mesenteric artery occlusion.<br />Î Medically fit patients.<br /><FONT class=lozenge>â</FONT> Refer to associated UpToDate algorithms on mesenteric ischemia (acute or chronic, occlusive or nonocclusive, arterial or venous).</div><div id=\"graphicVersion\">Graphic 62760 Version 6.0</div></div></div>"},"62761":{"type":"graphic_picture","displayName":"Xerocytosis","title":"Xerocytosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xerocytosis</div><div class=\"cntnt\"><img style=\"width:389px; height:252px;\" src=\"images/HEME/62761_Xerocytosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear from a patient with hereditary xerocytosis shows many hyperchromic red cells with hemoglogin puddled at the periphery of the cell (eccentrocytes, arrows). There is also marked anisocytosis, poikilocytosis, and target cells.</div><div class=\"graphic_reference\">Courtesy of Carlo Brugnara, MD.</div><div id=\"graphicVersion\">Graphic 62761 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"62762":{"type":"graphic_table","displayName":"Drug Rx arrhythmias WPW","title":"Medical therapy of arrhythmias associated with Wolff-Parkinson-White syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical therapy of arrhythmias associated with Wolff-Parkinson-White syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Arrhythmia</td> <td class=\"subtitle1\">Treatment options</td> <td class=\"subtitle1\">Contraindicated therapies</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Orthodromic AV reentrant tachycardia</td> </tr> <tr> <td class=\"indent1\">Acute termination*</td> <td> <p><strong>Unstable patients:</strong> Synchronized cardioversion</p> <p><strong>Stable patients:<span class=\"indent2\"></span></strong></p> <ul> <li><span class=\"indent2\"><strong>First line</strong>: Vagal maneuvers</span> </li> <li><span class=\"indent2\"><strong>Second line</strong>: IV adenosine</span> </li> <li><span class=\"indent2\"><strong>Third line</strong>: IV verapamil OR IV diltiazem</span> </li> <li><span class=\"indent2\"><strong>Other therapies</strong>: IV procainamide OR IV beta blocker; synchronized cardioversion if other therapies are ineffective or not feasible</span> </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chronic prevention<sup>&#182;</sup> </td> <td> <p><strong>First line</strong>: Catheter ablation of the accessory pathway</p> <p><strong>Second line</strong>: Oral&nbsp;flecainide or propafenone in the absence of structural or ischemic heart disease</p> <strong>Third line</strong>: Oral IA antiarrhythmic agent OR oral amiodarone</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antidromic AV reentrant tachycardia</td> </tr> <tr> <td class=\"indent1\">Acute termination*</td> <td> <p><strong>Unstable patients:</strong> Synchronized cardioversion</p> <p><strong>Stable patients (if CERTAIN of the diagnosis)</strong>: Same progression of therapies as acute termination of orthodromic AVRT<sup>&#916;</sup></p> <p><strong>Stable patients (if NOT certain of the diagnosis)</strong>: IV procainamide, synchronized cardioversion if procainamide is ineffective or not available<sup>&#916;</sup></p> </td> <td>Adenosine, verapamil, diltiazem, beta blockers, digoxin should all be avoided if NOT certain of diagnosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chronic prevention<sup>&#182;</sup></td> <td> <p><strong>First line</strong>: Catheter ablation of the accessory pathway</p> <p><strong>Second line</strong>: Oral flecainide or propafenone in the absence of structural or ischemic heart disease</p> <p><strong>Other therapies</strong>: Oral IA antiarrhythmic agent OR oral amiodarone</p> </td> <td> <p>Digoxin</p> <p>Beta blockers</p> <p>Verapamil, diltiazem</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"3\">Pre-excited atrial fibrillation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;Acute termination*</td> <td><strong>Unstable patients:</strong> Synchronized cardioversion <p><strong>Stable patients:<span class=\"indent2\"></span></strong></p> <ul> <li><span class=\"indent2\"><strong>First line</strong>: IV ibutilide or IV procainamide</span> </li> <li><span class=\"indent2\"><strong>Other therapies</strong>: IC antiarrhythmic agent or dofetilide; synchronized cardioversion if other therapies are ineffective or not available</span> </li> </ul> </td> <td> <p>Amiodarone</p> <p>Digoxin</p> <p>Beta blockers</p> <p>Adenosine</p> <p>Verapamil, diltiazem</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;Chronic prevention<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> <td> <p><strong>First line</strong>: Catheter ablation or the accessory pathway</p> <p><strong>Second line</strong>: Oral flecainide or propafenone in the absence of structural or ischemic heart disease</p> <p><strong>Third line</strong>: Oral IA antiarrhythmic agent OR oral amiodarone</p> </td> <td>Oral digoxin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AVRT: atrioventricular reciprocating tachycardia; IV: intravenous; class IC: flecainide, propafenone; class IA: quinidine, procainamide, disopyramide.<br />* Cardioversion is indicated if hemodynamically unstable or drugs are ineffective.<br />Â¶ Ablation of the accessory pathway is generally preferred to cure the arrhythmia.<br />Î Procainamide is the intravenous drug of choice for acute termination of suspected antidromic AVRT. If the tachycardia is definitely known to be&nbsp;antidromic AVRT, and it has been verified that the AV node (rather than a second accessory pathway) is acting as the retrograde limb of the circuit, one could consider&nbsp;treatment with an agent such as adenosine similar to therapy for orthodromic AVRT, but it is rare to have&nbsp;all of&nbsp;the necessary data in the acute setting to justify use of AV nodal blocking agents.</div><div id=\"graphicVersion\">Graphic 62762 Version 7.0</div></div></div>"},"62764":{"type":"graphic_table","displayName":"Fibromyalgia CFS/SEID PI","title":"Clinical similarities between fibromyalgia and chronic fatigue syndrome (CFS), salso known as systemic exertion intolerance disease (SEID)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical similarities between fibromyalgia and chronic fatigue syndrome (CFS), salso known as systemic exertion intolerance disease (SEID)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>80 to 90% women, usual age 20 to 55 years</td> </tr> <tr> <td>Myalgias and fatigue in more than 90%</td> </tr> <tr> <td class=\"sublist1_start\">Associated common symptoms</td> </tr> <tr> <td class=\"sublist1\">Neurocognitive and mood disturbances</td> </tr> <tr> <td class=\"sublist1\">Headaches</td> </tr> <tr> <td class=\"sublist1\">Sleep disturbances</td> </tr> <tr> <td>No identifiable cause</td> </tr> <tr> <td class=\"sublist1_start\">Testing not helpful</td> </tr> <tr> <td class=\"sublist1\">Physical examination usually normal except for tender points which are present in most patients with both conditions</td> </tr> <tr> <td class=\"sublist1\">Normal laboratory and radiologic tests</td> </tr> <tr> <td>Chronic symptoms, no highly effective therapy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62764 Version 5.0</div></div></div>"},"62765":{"type":"graphic_picture","displayName":"Duane syndrome type 3","title":"Duane syndrome of the left eye (type 3)","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Duane syndrome of the left eye (type 3)</div><div class=\"cntnt\"><img style=\"width:465px; height:310px;\" src=\"images/PEDS/62765_Duane_syndrome_type_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adduction and abduction of the involved left eye are limited.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62765 Version 1.0</div></div></div>"},"62766":{"type":"graphic_figure","displayName":"Osteoblastoma sites","title":"Skeletal distribution of osteoblastoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skeletal distribution of osteoblastoma</div><div class=\"cntnt\"><img style=\"width:247px; height:605px;\" src=\"images/PEDS/62766_Osteoblastoma_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62766 Version 2.0</div></div></div>"},"62767":{"type":"graphic_table","displayName":"Tests of anovulation","title":"Diagnostic tests suggesting ovulatory dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic tests suggesting ovulatory dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Absence of a 0.5&#176;F&nbsp;rise on measurement of basal body temperature</td> </tr> <tr> <td>Low value (&#60;2 ng/mL) of midluteal phase serum progesterone concentration</td> </tr> <tr> <td>Lack of an LH surge on monitoring urinary LH excretion</td> </tr> <tr> <td>Out of phase timed endometrial biopsy</td> </tr> <tr> <td>Lack of a periovulatory follicle on serial transvaginal sonography</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LH: luteinizing hormone.</div><div class=\"graphic_reference\">Source: Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil Steril 2003; 80:1302.</div><div id=\"graphicVersion\">Graphic 62767 Version 4.0</div></div></div>"},"62769":{"type":"graphic_figure","displayName":"Division of liver tissue during hepatic resection","title":"Division of liver tissue during hepatic resection","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Division of liver tissue during hepatic resection</div><div class=\"cntnt\"><img style=\"width:487px; height:653px;\" src=\"images/SURG/62769_Divisionoflivertissue.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62769 Version 1.0</div></div></div>"},"62770":{"type":"graphic_table","displayName":"Short acting bronchodilators adult","title":"Short-acting inhaled bronchodilators for asthma treatment in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Short-acting inhaled bronchodilators for asthma treatment in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug and trade names in United States</td> <td class=\"subtitle1\">Preparations</td> <td class=\"subtitle1\">Adult dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Albuterol (salbutamol)</td> </tr> <tr> <td class=\"indent1\">ProAir-HFA, Proventil-HFA, and Ventolin-HFA MDIs</td> <td>MDI: 90 mcg/puff</td> <td>2 puffs every 4 to 6 hours as needed*</td> </tr> <tr> <td class=\"indent1\">ProAir RespiClick DPI</td> <td>Aerosol: 90 mcg/inhalation</td> <td>2 inhalations every 4 to&nbsp;6 hours as needed*</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Albuterol solution for nebulization (generic)</td> <td class=\"sublist1_start\" colspan=\"2\">Nebulizer solution:</td> </tr> <tr> <td class=\"indent1\">0.63 mg/3 mL unit dose (0.021%)</td> <td class=\"divider_bottom\" rowspan=\"4\">1.25 to 2.5 mg every 4 to 8 hours as needed<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">1.25 mg per 3 mL unit dose (0.042%)</td> </tr> <tr> <td class=\"indent1\">2.5 mg per 3 mL unit dose (0.083%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">2.5 mg per 0.5 mL concentrate (0.5%) to be diluted to a total volume of 3 mL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Levalbuterol (Levosalbutamol)</td> </tr> <tr> <td class=\"indent1\">Xopenex-HFA metered MDI</td> <td>MDI: 45 mcg/puff</td> <td>2 puffs every 4 to 6 hours as needed*</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Xopenex solution for nebulization or generic</td> <td class=\"sublist1_start\" colspan=\"2\">Nebulizer solution:</td> </tr> <tr> <td class=\"indent1\">0.31/3 mL unit dose</td> <td rowspan=\"2\">0.63 mg every 6 to 8 hours as needed<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">0.63 mg/3 mL unit dose</td> </tr> <tr> <td class=\"indent1\">1.25 mg/3 mL unit dose</td> <td class=\"divider_bottom\" rowspan=\"2\">1.25 mg every 8 hours as needed<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">1.25 mg/0.5 mL concentrate to be diluted to a total volume of 3 mL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Combination short-acting bronchodilators<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Albuterol (salbutamol) with ipratropium bromide</td> </tr> <tr> <td class=\"indent2\">Combivent Respimat inhalation</td> <td>Spray: 100 mcg albuterol with 20 mcg ipratropium per inhalation</td> <td>1 inhalation every 4 to 6 hours as needed</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Albuterol with ipratropium solution for nebulization (generic)</td> <td class=\"sublist1_start\" colspan=\"2\">Nebulizer solution:</td> </tr> <tr> <td class=\"indent1\">2.5 mg albuterol with 0.5 mg ipratropium/3 mL</td> <td>3 mL every 6 hours as needed<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Fenoterol with ipratropium bromide</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\"> <p>Duovent UDV solution for nebulization</p> <p>Not available in US; available in Canada and other countries</p> </td> <td class=\"sublist1_start\" colspan=\"2\">Nebulizer solution:</td> </tr> <tr> <td class=\"indent1\">1.25 mg fenoterol with 0.5 mg ipratropium/4 mL</td> <td>4 mL every 6 hours as needed</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Product strengths shown are according to United States (US) official prescribing information. For available strengths and dosing of non US products, consult local prescribing information.</div><div class=\"graphic_footnotes\">MDI: metered dose inhaler; HFA: hydrofluoroalkane; DPI: dry powder inhaler; UDV: unit dose vial.<br />* Short-acting beta agonists can also be administered&nbsp;10 to&nbsp;20 minutes prior to exercise and more frequently than every 4 hours when patients are in a <FONT color=red><FONT color=black>medically</FONT></FONT> supervised, urgent care setting. The use of short-acting inhaled bronchodilator MDIs in intubated, mechanically ventilated&nbsp;patients is discussed in the UpToDate topic on the delivery of inhaled medications in adults.<br />Â¶ Nebulizer treatments can be given every 20 minutes during an acute exacerbation, if the patient is in a monitored setting. Alternatively, for severe acute exacerbations, short-acting beta agonists can be given by continuous nebulization (eg, albuterol 10 to 15 mg/hour). Continuous nebulization&nbsp;requires&nbsp;specialized equipment which is described separately&nbsp;in the UpToDate topic on the delivery of inhaled medication&nbsp;in adults.<br />Î For patients with asthma, use of combination beta-2 agonist and anticholinergic (ipratropium) treatment is generally reserved for early treatment of patients with severe acute exacerbations.</div><div id=\"graphicVersion\">Graphic 62770 Version 9.0</div></div></div>"},"62772":{"type":"graphic_diagnosticimage","displayName":"Main pancreatic duct stricture","title":"Pancreatic duct stricture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic duct stricture</div><div class=\"cntnt\"><img style=\"width:383px; height:252px;\" src=\"images/GAST/62772_Main_pancreatic_duct_strict.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreatogram shows a dominant stricture (arrow) in the head of the pancreas following pancreatic duct stenting.</div><div class=\"graphic_reference\">Courtesy of Marc Catalano, MD.</div><div id=\"graphicVersion\">Graphic 62772 Version 2.0</div></div></div>"},"62774":{"type":"graphic_figure","displayName":"Free estradiol and cognition","title":"Free estradiol and cognitive function","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Free estradiol and cognitive function</div><div class=\"cntnt\"><img style=\"width:473px; height:356px;\" src=\"images/ENDO/62774_Free_estradiol_and_cognitio.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Six-year decrease in mean&nbsp;MMSE score according to tertile of estradiol concentration in older women not taking hormone replacement therapy. Women with the highest levels of free estradiol and bioavailable estradiol (perhaps representing estradiol available to the brain) showed less cognitive decline over time.</div><div class=\"graphic_footnotes\">MMSE: Mini-Mental State Examination.</div><div class=\"graphic_reference\">Data from: Yaffe K, Browner W, Cauley J, et al. Association between bone mineral density and cognitive decline in older women.&nbsp;J Am Geriatr Soc 1999; 47:1176.</div><div id=\"graphicVersion\">Graphic 62774 Version 2.0</div></div></div>"},"62775":{"type":"graphic_table","displayName":"Arozullah index","title":"Arozullah respiratory failure index","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Arozullah respiratory failure index</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Preoperative predictor</td> <td class=\"subtitle1\">Point value</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Type of surgery</td> </tr> <tr> <td class=\"sublist1\">Abdominal aortic aneurysm</td> <td class=\"sublist_other\">27</td> </tr> <tr> <td class=\"sublist1\">Thoracic</td> <td class=\"sublist_other\">21</td> </tr> <tr> <td class=\"sublist1\">Neurosurgery, upper abdominal, peripheral vascular</td> <td class=\"sublist_other\">14</td> </tr> <tr> <td class=\"sublist1\">Neck</td> <td class=\"sublist_other\">11</td> </tr> <tr> <td>Emergency surgery</td> <td>11</td> </tr> <tr> <td>Albumin &#60;3.0 g/dL</td> <td>9</td> </tr> <tr> <td>BUN &#62;30 mg/dL</td> <td>8</td> </tr> <tr> <td>Partially or fully dependent functional status</td> <td>7</td> </tr> <tr> <td>History of chronic obstructive pulmonary disease</td> <td>6</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Age</td> </tr> <tr> <td class=\"sublist1\">&#8805;70 years</td> <td class=\"sublist_other\">6</td> </tr> <tr> <td class=\"sublist1\">60 to 69 years</td> <td class=\"sublist_other\">4</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Arozulla AM, Daley J, Henderson WG, Khuri SF. Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. Ann Surg 2000; 232:242. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright Â© 2000 American Surgical Association and European Surgical Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 62775 Version 3.0</div></div></div>"},"62776":{"type":"graphic_picture","displayName":"Palpation of anserine bursa","title":"Palpation of the anserine bursa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the anserine bursa</div><div class=\"cntnt\"><img style=\"width:351px; height:287px;\" src=\"images/EM/62776_Palpation_of_anserine_bursa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anserine bursa is located between the medial collateral ligament and the conjoined tendon formed by the gracilis, sartorius, and semitendinosis tendons. The entire tibial plateau is palpated to distinguish the localized tenderness of anserine bursitis from the more extensive tenderness of the medial collateral ligament. The patella and the tibial tubercle are marked with a pen. Tenderness at the level of the tibial tubercle is compared with tenderness at the medial joint line and the medial femoral condyle.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 62776 Version 2.0</div></div></div>"},"62777":{"type":"graphic_picture","displayName":"Nonmelanoma PI","title":"Nonmelanoma skin cancer","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Nonmelanoma skin cancer</div><div class=\"cntnt\"><img style=\"width:514px; height:388px;\" src=\"images/PI/62777_Nonmelanom_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A raised or flat area of the skin with a sore that won't heal can be a sign of a basal cell skin cancer.<br> (B) Some basal cell skin cancers can look like flat, pink spots on the skin that do not go away.<br> (C) This red scaly spot is a squamous cell skin cancer.<br> (D) This pink, scaly bump is a squamous cell skin cancer.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62777 Version 5.0</div></div></div>"},"62778":{"type":"graphic_figure","displayName":"US trends in childhood obesity","title":"Trends in obesity among children and adolescents aged 2â19 years, by age: United States, 1963â1965 through 2013â2014","html":"<div class=\"graphic\"><div style=\"width: 756px\" class=\"figure\"><div class=\"ttl\">Trends in obesity among children and adolescents aged 2â19 years, by age: United States, 1963â1965 through 2013â2014</div><div class=\"cntnt\"><img style=\"width:736px; height:404px;\" src=\"images/PEDS/62778_US_trnds_chldhd_obsty_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the United States Health and Nutrition Examination Surveys (NHANES). Obesity is defined as a body mass index (BMI) â¥95th percentile for age and gender. This figure does not distinguish between groups with mild versus severe obesity.</div><div class=\"graphic_reference\">Fryar CD, Carroll MD, and Ogden CL. Prevalence of Overweight and Obesity Among Children and Adolescents Aged 2â19 Years: United States, 1963â1965 Through 2013â2014. Health E-Stats July 2016. Available at: <A href=\"http://www.cdc.gov/nchs/data/hestat/obesity_child_13_14/obesity_child_13_14.htm\" target=_blank>http://www.cdc.gov/nchs/data/hestat/obesity_child_13_14/obesity_child_13_14.htm</A></div><div id=\"graphicVersion\">Graphic 62778 Version 4.0</div></div></div>"},"62779":{"type":"graphic_picture","displayName":"Eczema herpeticum","title":"Eczema herpeticum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eczema herpeticum</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/ID/62779_Eczema_herpeticum.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62779 Version 4.0</div></div></div>"},"62781":{"type":"graphic_diagnosticimage","displayName":"Postop CBD stricture resolved","title":"Cholecystectomy-associated stricture following stenting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholecystectomy-associated stricture following stenting</div><div class=\"cntnt\"><img style=\"width:277px; height:358px;\" src=\"images/GAST/62781_Postop_CBD_stricture_resolv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiogram 12 months after stent removal demonstrates near complete stricture resolution.</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 62781 Version 4.0</div></div></div>"},"62784":{"type":"graphic_picture","displayName":"Nickel allergy PI","title":"Nickel allergy PI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nickel allergy PI</div><div class=\"cntnt\"><img style=\"width:402px; height:255px;\" src=\"images/PI/62784_Nickel_allergy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subumbilical allergic contact dermatitis from metal fasteners in pants (nickel allergy).</div><div class=\"graphic_reference\">Courtesy of William L Weston, MD.</div><div id=\"graphicVersion\">Graphic 62784 Version 1.0</div></div></div>"},"62785":{"type":"graphic_algorithm","displayName":"EPDWG clinical algorithm","title":"Clinical algorithm for treatment of elevated calcium phosphorus product in children with chronic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Clinical algorithm for treatment of elevated calcium phosphorus product in children with chronic kidney disease</div><div class=\"cntnt\"><img style=\"width:604px; height:444px;\" src=\"images/PEDS/62785_EPDWG_clinical_algo_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Pi: phosphorus; Ca-cont: calcium-containing; Ca-free: calcium-free; phos-binder: phosphate binder; vit. D: vitamin D; ADBD: adynamic bone disease; PTH: parathyroid hormone.</div><div class=\"graphic_reference\">Reproduced from: Klaus G, Watson A, Edefonti A, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21:151; with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2006.</div><div id=\"graphicVersion\">Graphic 62785 Version 15.0</div></div></div>"},"62787":{"type":"graphic_figure","displayName":"Division of sartorius muscle","title":"Division of sartorius muscle for transposition at time of groin node dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Division of sartorius muscle for transposition at time of groin node dissection</div><div class=\"cntnt\"><img style=\"width:315px; height:314px;\" src=\"images/OBGYN/62787_Division_of_sartorius_muscl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sartorius muscle is divided close to its origin at the anterior superior iliac spine.</div><div id=\"graphicVersion\">Graphic 62787 Version 3.0</div></div></div>"},"62789":{"type":"graphic_figure","displayName":"Chemical structure DNA and RNA","title":"Chemical structure of DNA and RNA","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Chemical structure of DNA and RNA</div><div class=\"cntnt\"><img style=\"width:531px; height:324px;\" src=\"images/PC/62789_Building_blocks_of_life.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62789 Version 2.0</div></div></div>"},"62790":{"type":"graphic_figure","displayName":"Physiology normal micturition","title":"Diagram showing neural circuits controlling continence and micturition","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Diagram showing neural circuits controlling continence and micturition</div><div class=\"cntnt\"><img style=\"width:492px; height:456px;\" src=\"images/PC/62790_Physiology_normal_micturiti.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Urine storage reflexes. During the storage of urine, distention of the bladder produces low level vesical afferent firing, which in turn stimulates (1) the sympathetic outflow to the bladder outlet (base and urethra) and (2) pudendal outflow to the external urethral sphincter. These responses occur by spinal reflex pathways and represent &quot;guarding reflexes,&quot; which promote continence. Sympathetic firing also inhibits detrusor muscle and modulates transmission in bladder ganglia. A region in the rostral pons (the pontine storage center, or &quot;L&quot; region) increases external urethral sphincter activity. (B) Voiding reflexes. During elimination of urine, intense bladder afferent firing activates spinobulbospinal reflex pathways passing through the pontine micturition center, which stimulate the parasympathetic outflow to the bladder and internal sphincter smooth muscle and inhibit the sympathetic and pudendal outflow to the urethral outlet. Ascending afferent input from the spinal cord may pass through relay neurons in the periaqueductal gray (PAG) before reaching the pontine micturition center.</div><div class=\"graphic_reference\">Reproduced with permission from: Abrams P, Cardozo L, Wein A (Eds). Incontinence: 2nd ed International Consultation on Incontinence, Health Publications Ltd. 2002. p.88. Copyright Â© Health Publications.</div><div id=\"graphicVersion\">Graphic 62790 Version 2.0</div></div></div>"},"62791":{"type":"graphic_picture","displayName":"Amelanotic melanoma 2","title":"Amelanotic melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amelanotic melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/62791_Amelanotic_melanoma_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amelanotic melanoma presenting as a red, excoriated, papular lesion.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62791 Version 5.0</div></div></div>"},"62792":{"type":"graphic_picture","displayName":"Warfarin-induced skin necrosis on extremity","title":"Warfarin-induced skin necrosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Warfarin-induced skin necrosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62792_Warfarin_skin_necr_extrem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A retiform purpuric lesion with bullae and skin necrosis is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62792 Version 3.0</div></div></div>"},"62793":{"type":"graphic_table","displayName":"Survival small bowel carcinoid tumor by stage and resection type","title":"Disease-specific and overall survival for 135 surgically treated patients with small bowel carcinoid tumors, stratified by stage and resection type","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disease-specific and overall survival for 135 surgically treated patients with small bowel carcinoid tumors, stratified by stage and resection type</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\" colspan=\"3\">Disease-specific survival, percent<br /> (95% CI)</td> <td class=\"subtitle1\" colspan=\"3\">Overall survival, percent<br /> (95% CI)</td> </tr> <tr> <td class=\"subtitle2\">5-year</td> <td class=\"subtitle2\">10-year</td> <td class=\"subtitle2\">15-year</td> <td class=\"subtitle2\">5-year</td> <td class=\"subtitle2\">10-year</td> <td class=\"subtitle2\">15-year</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Stage</td> </tr> <tr> <td class=\"indent1\">Localized</td> <td>25</td> <td>100</td> <td>100</td> <td>89 (70-100)</td> <td>72 (54-90)</td> <td>59 (39-79)</td> <td>42 (21-63)</td> </tr> <tr> <td class=\"indent1\">Regional</td> <td>62</td> <td>86 (77-95)</td> <td>81 (70-92)</td> <td>66 (50-82)</td> <td>68 (56-79)</td> <td>47 (34-59)</td> <td>24 (13-35)</td> </tr> <tr> <td class=\"indent1\">Distant metastatic</td> <td>48</td> <td>51 (36-65)</td> <td>28 (14-41)</td> <td>12 (2-23)</td> <td>46 (32-60)</td> <td>23 (11-36)</td> <td>10 (1-20)</td> </tr> <tr> <td class=\"indent1\">Total</td> <td>135</td> <td>75 (67-83)</td> <td>63 (54-72)</td> <td>48 (37-59)</td> <td>61 (53-69)</td> <td>41 (32-49)</td> <td>22 (15-30)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Resection type</td> </tr> <tr> <td class=\"indent1\">R0 (complete)</td> <td>68</td> <td>93 (87-100)</td> <td>91 (84-99)</td> <td>78 (65-92)</td> <td>72 (61-83)</td> <td>55 (43-67)</td> <td>33 (21-45)</td> </tr> <tr> <td class=\"indent1\">R1, R2</td> <td>60</td> <td>53 (40-66)</td> <td>31 (18-44)</td> <td>12 (2-23)</td> <td>45 (32-58)</td> <td>22 (11-33)</td> <td>6 (0-13)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CI: confidence interval; R0: complete tumor resection; R1: margins microscopically positive; R2: margins macroscopically positive.</div><div class=\"graphic_reference\">Data from: Landerholm K, et al. Br J Surg 2011; 98:1217.</div><div id=\"graphicVersion\">Graphic 62793 Version 3.0</div></div></div>"},"62794":{"type":"graphic_diagnosticimage","displayName":"Infiltrating gastric cancer UGI","title":"Infiltrating gastric carcinoma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infiltrating gastric carcinoma</div><div class=\"cntnt\"><img style=\"width:284px; height:341px;\" src=\"images/GAST/62794_Infiltrating_gastric_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper GI series showing infiltrating gastric carcinoma in the region of the incisura. There is irregular narrowing affecting both the lesser and greater curvatures (arrow).</div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 62794 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal upper GI series</div><div class=\"cntnt\"><img style=\"width:286px; height:330px;\" src=\"images/GAST/81537_Normal_upper_GI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal air-contrast upper gastrointestinal (GI)&nbsp;study showing normal gastric folds and small intestinal anatomy, and no masses.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 81537 Version 4.0</div></div></div>"},"62797":{"type":"graphic_figure","displayName":"Baseline FHR by gestational age","title":"Graph of baseline FHR according to gestational age, weeks","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Graph of baseline FHR according to gestational age, weeks</div><div class=\"cntnt\"><img style=\"width:505px; height:215px;\" src=\"images/OBGYN/62797_Baseline_FHR_by_gestational.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Bpm: beats per minute; FHR: fetal heart rate.</div><div class=\"graphic_reference\">Adapted from: Park MI, Hwang JG, Cha KJ, et al. Computerized analysis of fetal heart rate&nbsp;parameters by gestational age.&nbsp;Int J Gynaecol Obstet 2001; 74:157.</div><div id=\"graphicVersion\">Graphic 62797 Version 2.0</div></div></div>"},"62798":{"type":"graphic_diagnosticimage","displayName":"Fetal ascites transverse view","title":"Transverse view of fetal abdomen showing anechoic rim of abdominal fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse view of fetal abdomen showing anechoic rim of abdominal fluid</div><div class=\"cntnt\"><img style=\"width:425px; height:286px;\" src=\"images/OBGYN/62798_Fetal_ascites_trnsvrs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rim of ascites. Transverse image of the fetal abdomen. Arrows point to the skin surface. The echolucent area beneath the abdominal wall&nbsp;in this area is ascites.</div><div class=\"graphic_reference\">Courtesy of Svena Julien, MD.</div><div id=\"graphicVersion\">Graphic 62798 Version 3.0</div></div></div>"},"62799":{"type":"graphic_figure","displayName":"ECG grid","title":"Grid lines and standardization of the ECG","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grid lines and standardization of the ECG</div><div class=\"cntnt\"><img style=\"width:318px; height:392px;\" src=\"images/CARD/62799_ECG_grid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The electrocardiogam is recorded on paper that has large boxes (heavy lines) of 0.5 cm sides. On the horizontal axis, each large box, which represents 0.2 seconds at a typical paper speed of 25mm/sec, is divided into five smaller boxes, each one representing 0.04 seconds. On the vertical axis, the large box also has five subdivisions, each 1 mm in height; 10 mm equals 1 mV with standard calibration.</div><div id=\"graphicVersion\">Graphic 62799 Version 1.0</div></div></div>"},"62800":{"type":"graphic_table","displayName":"Breast MRI mam occult breast CA","title":"Utility of breast MRI for mammographically-occult breast cancer in patients presenting with metastatic axillary lymphadenopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Utility of breast MRI for mammographically-occult breast cancer in patients presenting with metastatic axillary lymphadenopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">MRI-positive, percent</td> <td class=\"subtitle1\">Histologic diagnosis of breast cancer</td> </tr> <tr> <td>Morris, E; 1997</td> <td>12</td> <td>9 (75)</td> <td>8</td> </tr> <tr> <td>Brenner, R; 1997</td> <td>4</td> <td>4 (100)</td> <td>4</td> </tr> <tr> <td>Tilanus-Linthorst, M; 1997</td> <td>4</td> <td>4 (100)</td> <td>4</td> </tr> <tr> <td>Schorn, C; 1999</td> <td>14<sup>&#182;</sup></td> <td>9 (64)</td> <td>6/9</td> </tr> <tr> <td>Henry-Tillman, R; 1999</td> <td>10</td> <td>8 (80)</td> <td>8</td> </tr> <tr> <td>Olson, J; 2000</td> <td>40</td> <td>28 (70)</td> <td>21/22*</td> </tr> <tr> <td>Obdeijn, I; 2000</td> <td>20</td> <td>8 (40)</td> <td>8</td> </tr> <tr> <td>Fourquet, A; 2004</td> <td>15</td> <td>14 (93)</td> <td>9/11</td> </tr> <tr> <td rowspan=\"2\">Buchanan, C; 2005</td> <td rowspan=\"2\">69</td> <td rowspan=\"2\">42 (76)</td> <td>26/42 MRI+</td> </tr> <tr> <td>4/12 MRI&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Number of patients with confirmed MRI findings at the time of surgery.<br />&para; Included six axillary nodal metastases, one supraclavicular nodal metastases, three bone metastases, three liver metastases, and one lung metastases with an unknown primary.</div><div id=\"graphicVersion\">Graphic 62800 Version 2.0</div></div></div>"},"62801":{"type":"graphic_figure","displayName":"Insulin relatives at risk","title":"Kalan-Meier curves: insulin therapy does not prevent type 1 diabetes in high risk family members","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Kalan-Meier curves: insulin therapy does not prevent type 1 diabetes in high risk family members</div><div class=\"cntnt\"><img style=\"width:453px; height:317px;\" src=\"images/ENDO/62801_Insulin_relatives_at_risk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Diabetes Prevention Trial, insulin therapy did not prevent type 1 diabetes in siblings of diabetic patients with high serum islet-cell antibody concentrations and low acute insulin responses to glucose. Subjects received close observation or low-dose subcutaneous insulin (ultralente insulin administered twice daily; total daily dose 0.25 units/kg) plus annual four-day continuous insulin infusions. After median follow-up of 3.7 years, 69 of 169 subjects in the intervention group and 70 of 170 subjects (42 versus 41 percent, respectively) in the observation group were diagnosed with diabetes.</div><div class=\"graphic_reference\">Data from: Diabetes Prevention Trial - Type&nbsp;1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus.&nbsp;N Engl J Med 2002; 346:1685.</div><div id=\"graphicVersion\">Graphic 62801 Version 2.0</div></div></div>"},"62804":{"type":"graphic_picture","displayName":"Resectoscope assembly 2","title":"Hysteroscopy: Resectoscope assembly 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopy: Resectoscope assembly 2</div><div class=\"cntnt\"><img style=\"width:432px; height:276px;\" src=\"images/OBGYN/62804_Resectoscope_assembly_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Linda D Bradley, MD.</div><div id=\"graphicVersion\">Graphic 62804 Version 2.0</div></div></div>"},"62805":{"type":"graphic_table","displayName":"Radiation tox cutaneous","title":"Radiation toxicity: cutaneous system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiation toxicity: cutaneous system</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Symptom/sign</td>\n\n      <td class=\"subtitle1\">Degree1</td>\n\n      <td class=\"subtitle1\"> Degree 2</td>\n\n      <td class=\"subtitle1\"> Degree 3</td>\n\n      <td class=\"subtitle1\"> Degree 4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Erythema</td>\n\n      <td>Minimal, transient</td>\n\n      <td>Moderate &#60;10 percent BSA</td>\n\n      <td>Marked 10-40 percent BSA</td>\n\n      <td>Severe &#62;40 percent BSA</td>\n\n    </tr>\n\n    \n\n    <tr>\n\n      <td>Sensation/itching</td>\n\n      <td>Pruritus</td>\n\n      <td>Slight, int. pain</td>\n\n      <td>Moderate persistent pain</td>\n\n      <td>Severe persistent pain</td>\n\n    </tr>\n\n    \n\n    <tr>\n\n      <td>Blistering</td>\n\n      <td>Rare</td>\n\n      <td>Rare hemorrhage</td>\n\n      <td>Bullae</td>\n\n      <td>Bullae hemorrhage</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Desquamation</td>\n\n      <td>Absent</td>\n\n      <td>Patchy, dry</td>\n\n      <td>Patchy, moist</td>\n\n      <td>Confluent, moist</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ulcer/necrosis</td>\n\n      <td>Epidermal only</td>\n\n      <td>Dermal</td>\n\n      <td>Subcutaneous</td>\n\n      <td>Muscle or bone</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Onycholysis</td>\n\n      <td>Absent</td>\n\n      <td>Partial</td>\n\n      <td>Partial</td>\n\n      <td>Complete</td>\n\n    </tr>\n\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26434&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Radiation_tox_cutaneous.htm</title></head></div><div class=\"graphic_footnotes\">BSA: body surface area; Int: intermittent.</div><div class=\"graphic_reference\">Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Intern Med 2004; 140:1037. Copyright Â© 2004 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 62805 Version 4.0</div></div></div>"},"62807":{"type":"graphic_diagnosticimage","displayName":"Pulmonary hypertension PA I","title":"Idiopathic pulmonary arterial hypertension (IPAH)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic pulmonary arterial hypertension (IPAH)</div><div class=\"cntnt\"><img style=\"width:334px; height:344px;\" src=\"images/PULM/62807_Pulmonary_hypertension_PA_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows centralization of pulmonary vascular flow. The main pulmonary artery segment and the central, hilar pulmonary arteries are dilated. The peripheral pulmonary vasculature is &quot;pruned.&quot;</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 62807 Version 4.0</div></div></div>"},"62808":{"type":"graphic_picture","displayName":"Emergency thoracotomy pericardiotomy","title":"Emergency thoracotomy showing pericardiotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Emergency thoracotomy showing pericardiotomy</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/62808_Emerg_thora_pericardio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forceps grasping cut surface of the pericardium. Scissors pointing at the left phrenic nerve.</div><div id=\"graphicVersion\">Graphic 62808 Version 1.0</div></div></div>"},"62809":{"type":"graphic_figure","displayName":"Heller myotomy with Toupet fundoplication","title":"Heller myotomy with Toupet fundoplication","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heller myotomy with Toupet fundoplication</div><div class=\"cntnt\"><img style=\"width:374px; height:432px;\" src=\"images/SURG/62809_Heller_myo_toupet_fundo_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright Â© University of Washington.</div><div id=\"graphicVersion\">Graphic 62809 Version 3.0</div></div></div>"},"62810":{"type":"graphic_picture","displayName":"Honey bee 2","title":"Honey bee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Honey bee</div><div class=\"cntnt\"><img style=\"width:432px; height:344px;\" src=\"images/ALLRG/62810_Honey_bee_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 62810 Version 1.0</div></div></div>"},"62814":{"type":"graphic_picture","displayName":"Extramammary Pagets disease","title":"Extramammary Paget disease of the vulva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extramammary Paget disease of the vulva</div><div class=\"cntnt\"><img style=\"width:400px; height:300px;\" src=\"images/OBGYN/62814_Extramammary_Paget_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 62814 Version 1.0</div></div></div>"},"62816":{"type":"graphic_picture","displayName":"Acne closed comedones","title":"Mild acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mild acne</div><div class=\"cntnt\"><img style=\"width:432px; height:322px;\" src=\"images/DERM/62816_Acne_closed_comedones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 14-year-old girl has multiple closed comedones and scattered, small inflammatory papules and pustules on the forehead.</div><div class=\"graphic_reference\">Courtesy of Douglas Hoffman, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 62816 Version 7.0</div></div></div>"},"62817":{"type":"graphic_diagnosticimage","displayName":"Postop fat necrosis","title":"Post operative fat necrosis presenting as a palpable lump","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Post operative fat necrosis presenting as a palpable lump</div><div class=\"cntnt\"><img style=\"width:314px; height:423px;\" src=\"images/PC/62817_Post_operative_necrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral MLO views of TRAM flap reconstructed breasts. Coarse, lucent centered dystrophic calcifications are seen in a bizarre pattern in both breasts consistent with bilateral fat necrosis presenting as a palpable lump.</div><div class=\"graphic_footnotes\">MLO: mediolateral oblique; TRAM: transverse rectus abdominis myocutaneous.</div><div id=\"graphicVersion\">Graphic 62817 Version 2.0</div></div></div>"},"62818":{"type":"graphic_table","displayName":"Preseptal and orbital cellulitis studies","title":"Clinical manifestations of preseptal and orbital cellulitis studies on admission","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of preseptal and orbital cellulitis studies on admission</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup span=\"10\" width=\"8%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" rowspan=\"4\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"10\">Study: Study design, patient population</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Nageswaran, et al<sup>[1]</sup>:<br /> Retrospective, children</td> <td class=\"subtitle2\" colspan=\"2\">Botting, et al<sup>[2]</sup>:<br /> Retrospective, children</td> <td class=\"subtitle2\" colspan=\"2\">Chaudhry, et al<sup>[3]</sup>:<br /> Retrospective<sup>&#182;</sup>, children and adults</td> <td class=\"subtitle2\" colspan=\"2\">Sobol, et al<sup>[4]</sup>:<br /> Retrospective, children</td> <td class=\"subtitle2\" colspan=\"2\">Seltz, et al<sup>[5]</sup>:<br /> Retrospective, children</td> </tr> <tr> <td class=\"subtitle3\" colspan=\"2\">Type of cellulitis</td> <td class=\"subtitle3\" colspan=\"2\">Type of cellulitis</td> <td class=\"subtitle3\" colspan=\"2\">Type of cellulitis</td> <td class=\"subtitle3\" colspan=\"2\">Type of cellulitis</td> <td class=\"subtitle3\" colspan=\"2\">Type of cellulitis</td> </tr> <tr class=\"divider_bottom\"> <td>Preseptal</td> <td>Orbital (n = 41)</td> <td>Preseptal (n = 227)</td> <td>Orbital (n = 35)</td> <td>Preseptal (n = 104)</td> <td>Orbital</td> <td>Preseptal (n = 101)</td> <td>Orbital (n = 26)<sup>&#916;</sup></td> <td>Preseptal</td> <td>Orbital (n = 94)</td> </tr> <tr> <td><strong>Age (yrs)<sup>&#9674;</sup></strong></td> <td>&nbsp;</td> <td>7.5 (range 0-16)</td> <td>3.9</td> <td>7.5</td> <td>19 (range 0-75)</td> <td>&nbsp;</td> <td>3.8 (range 0-16)</td> <td>6.4 (range 0-13)</td> <td>&nbsp;</td> <td>6 (range 0-18)</td> </tr> <tr> <td><strong>History of trauma*</strong></td> <td>&nbsp;</td> <td>Excluded</td> <td>89 (39)</td> <td>4 (11)</td> <td>28</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Excluded</td> </tr> <tr> <td><strong>Eye pain and/or tenderness</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>64 (62)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Eyelid swelling +/&ndash; erythema</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>104 (100)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Proptosis</strong></td> <td>&nbsp;</td> <td>25 (61)</td> <td>2 (0.9)</td> <td>33 (94)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1 (1)</td> <td>20 (77)</td> <td>&nbsp;</td> <td>36 (38)</td> </tr> <tr> <td><strong>Ophthalmoplegia</strong></td> <td>&nbsp;</td> <td>19 (46)</td> <td>1 (0.4)</td> <td>4 (11)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1 (1)</td> <td>20 (77)</td> <td>&nbsp;</td> <td>45 (48)</td> </tr> <tr> <td><strong>Diplopia</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2 (0.9)</td> <td>19 (54)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Vision impaired</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>0</td> <td>1 (3)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>3 (3)</td> <td>3 (11)</td> <td>&nbsp;</td> <td>11 (12)</td> </tr> <tr> <td><strong>No ophthalmologic signs (proptosis, ophthalmoplegia, visual loss)</strong></td> <td>&nbsp;</td> <td>11 (27)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Chemosis</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>10 (11)</td> </tr> <tr> <td><strong>Fever</strong></td> <td>&nbsp;</td> <td>27 (66)</td> <td>106 (47)</td> <td>33 (94)</td> <td>Children 52 percent; adults 10 percent</td> <td>&nbsp;</td> <td>59 (59)</td> <td>18 (69)</td> <td>&nbsp;</td> <td>63 (67)</td> </tr> <tr> <td><strong>White blood cell count &#62;15,000</strong></td> <td>&nbsp;</td> <td>19 (46)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Sinusitis<sup>&#167;</sup></strong></td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">21 (9)</td> <td class=\"sublist_other_start\">32 (91)</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"><strong>Ethmoid sinusitis</strong></td> <td>&nbsp;</td> <td>40 (98)</td> <td>&nbsp;</td> <td>30 (86)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>22 (86)</td> <td>&nbsp;</td> <td>87 (93)</td> </tr> <tr> <td class=\"indent1\"><strong>Maxillary sinusitis</strong></td> <td>&nbsp;</td> <td>29 (71)</td> <td>&nbsp;</td> <td>21 (60)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>22 (86)</td> <td>&nbsp;</td> <td>84 (89)</td> </tr> <tr> <td><strong>Subperiosteal abscess</strong></td> <td>&nbsp;</td> <td>24 (59)</td> <td>&nbsp;</td> <td>12 (34)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#916;</td> <td>&nbsp;</td> <td>44 (47)</td> </tr> <tr> <td><strong>Orbital abscess</strong></td> <td>&nbsp;</td> <td>10 (24)</td> <td>&nbsp;</td> <td>2 (6)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>0</td> <td>&nbsp;</td> <td>8 (8)</td> </tr> <tr> <td><strong>&#62;Surgical procedure</strong></td> <td>&nbsp;</td> <td>29 (71)</td> <td>11 (5)</td> <td>8 (23)</td> <td>52 (50)<sup>&#182;</sup></td> <td>&nbsp;</td> <td>0</td> <td>6 (23)<sup>&#916;</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Results are reported as number of patients with a given finding (percent).</div><div class=\"graphic_footnotes\">* Eg, insect bites, scratches.<br />Â¶ This study involved patients referred to a tertiary care hospital in Saudi Arabia. 38.5 percent of patients were &gt;16 years of age. Many had acute dacryocystitis, trauma, or recent surgery, which is probably why such a large proportion of patients underwent surgical procedures.<br />Î In this study, 12 cases of children with subperiosteal abscess were evaluated separately; these cases are not shown in the table, but the findings were similar to those with simple orbital cellulitis. Of patients with orbital cellulitis or subperiosteal abscess, 12 of 38 (32 percent) had a subperiosteal abscess; 66 percent of patients with subperiosteal abscess underwent surgery.<br /><FONT class=lozenge>â</FONT> The mean age is reported for all studies except for Seltz et al<SUP>[5]</SUP>; this study reported the median age.<br />Â§ The ethmoid and maxillary sinuses were involved most commonly, but some patients had frontal sinusitis and/or sphenoid sinusitis; many patients had involvement of multiple sinuses.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Nageswaran S, Woods CR, Benjamin DK Jr, et al. Orbital cellulitis in children. Pediatr Infect Dis J 2006; 25:695. </LI>&#xD;&#xA;<LI>Botting AM, McIntosh D, Mahadevan M. Paediatric pre- and post-septal peri-orbital infections are different diseases - A retrospective review of 262 cases. Int J Pediatr Otorhinolaryngol 2008; 72:377. </LI>&#xD;&#xA;<LI>Chaudhry IA, Shamsi FA, Elzaridi E, et al. Inpatient preseptal cellulitis: experience from a tertiary eye care centre. Br J Ophthalmol 2008; 92:1337. </LI>&#xD;&#xA;<LI>Sobol SE, Marchand J, Tewfik TL, et al. Orbital complications of sinusitis in children. J Otolaryngol 2002; 31:131. </LI>&#xD;&#xA;<LI>Seltz LB, Smith J, Durairaj VD, et al. Microbiology and antibiotic management of orbital cellulitis. Pediatrics 2011; 127:e566. </LI></OL></div><div id=\"graphicVersion\">Graphic 62818 Version 3.0</div></div></div>"},"62819":{"type":"graphic_figure","displayName":"Glove technique","title":"Glove method of ring removal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glove method of ring removal</div><div class=\"cntnt\"><img style=\"width:306px; height:465px;\" src=\"images/EM/62819_Glovetechnique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This technique has the advantage of causing minimal additional pain, and can be used with finger fractures or soft tissue injuries and lacerations. Cut one finger from a surgical glove to form a cylindrical sleeve. <br />(A) Place this sleeve on the involved digit and slip the proximal end circumferentially under the ring using a hemostat. <br />(B) Once in place, pull the proximal end back over the ring and toward the tip of the digit in a twisting motion, advancing the ring distally. Avoid pulling so hard that the glove rips or pulls out from under the ring.</div><div class=\"graphic_reference\">Reproduced with permission from: Fuchs SM. Ring removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62819 Version 10.0</div></div></div>"},"62820":{"type":"graphic_figure","displayName":"Oropharyngeal airway insertion","title":"Oropharyngeal airway insertion","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Oropharyngeal airway insertion</div><div class=\"cntnt\"><img style=\"width:542px; height:323px;\" src=\"images/EM/62820_Oropharyn_airway_insert.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When inserting an oropharyngeal airway (OPA), the clinician must avoid pushing the tongue into the posterior pharynx. This can be accomplished by starting with the curve of the OPA inverted (ie, directed cephalad) and then rotating it 180 degrees as its tip reaches the posterior pharynx.</div><div id=\"graphicVersion\">Graphic 62820 Version 3.0</div></div></div>"},"62821":{"type":"graphic_table","displayName":"Laboratory evaluation postmenopausal osteoporosis","title":"Laboratory evaluation for postmenopausal osteoporosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory evaluation for postmenopausal osteoporosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Initial laboratory tests</td> </tr> <tr> <td>Complete chemistry profile (including alkaline phosphatase)</td> </tr> <tr> <td>Complete blood count</td> </tr> <tr> <td>Calcium, phosphorus</td> </tr> <tr> <td>25-hydroxyvitamin D</td> </tr> <tr> <td class=\"subtitle1_single\">Additional laboratory tests if indicated</td> </tr> <tr> <td>24-hour urine for calcium and creatinine</td> </tr> <tr> <td>24-hour urine for free cortisol</td> </tr> <tr> <td>Estradiol</td> </tr> <tr> <td>FSH, LH</td> </tr> <tr> <td>Prolactin</td> </tr> <tr> <td>Magnesium</td> </tr> <tr> <td>1,25-dihydroxyvitamin D</td> </tr> <tr> <td>Intact PTH</td> </tr> <tr> <td>TSH</td> </tr> <tr> <td>Celiac screen</td> </tr> <tr> <td>Serum protein electrophoresis/urine protein electrophoresis</td> </tr> <tr> <td>Erythrocyte sedimentation rate</td> </tr> <tr> <td>Rheumatoid factor</td> </tr> <tr> <td>Ferritin and carotene levels</td> </tr> <tr> <td>Iron and total iron binding capacity</td> </tr> <tr> <td>Serum tryptase and histamine levels</td> </tr> <tr> <td>Homocysteine</td> </tr> <tr> <td>Skin biopsy for connective tissue disorders</td> </tr> <tr> <td>COL1A genetic testing for osteogenesis imperfecta</td> </tr> <tr> <td>Serum and urine markers of bone turnover</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone; LH: luteinizing hormone; PTH: parathyroid hormone; TSH: thyroid stimulating hormone.</div><div id=\"graphicVersion\">Graphic 62821 Version 5.0</div></div></div>"},"62822":{"type":"graphic_diagnosticimage","displayName":"Pancreatic duct EUS","title":"Pancreatic duct seen on endoscopic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic duct seen on endoscopic ultrasound</div><div class=\"cntnt\"><img style=\"width:335px; height:613px;\" src=\"images/GAST/62822_Pancreatic_duct_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top: Radial endoscopic ultrasound image showing the pancreatic duct (PD) almost parallel with the common bile duct (CBD), and converging into the ampulla.<br />Bottom: Simplification of top image.</div><div class=\"graphic_reference\">Courtesy of Lyndon V. Hernandez, MD and Manoop S. Bhutani, MD.</div><div id=\"graphicVersion\">Graphic 62822 Version 4.0</div></div></div>"},"62823":{"type":"graphic_picture","displayName":"Rape2","title":"Traumatic rape of child","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Traumatic rape of child</div><div class=\"cntnt\"><img style=\"width:504px; height:341px;\" src=\"images/EM/62823_Rape2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note 3rd degree laceration which was repaired in layers.</div><div class=\"graphic_reference\">Courtesy of Marc R.&nbsp;Laufer, MD.</div><div id=\"graphicVersion\">Graphic 62823 Version 4.0</div></div></div>"},"62824":{"type":"graphic_picture","displayName":"Severe dry eye","title":"Dry eye disease with conjunctival injection, associated neovascularization of the cornea, and a central corneal opacity/scarring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dry eye disease with conjunctival injection, associated neovascularization of the cornea, and a central corneal opacity/scarring</div><div class=\"cntnt\"><img style=\"width:432px; height:306px;\" src=\"images/PC/62824_Severe_dry_eye.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62824 Version 1.0</div></div></div>"},"62825":{"type":"graphic_figure","displayName":"Circadian lung function asthma","title":"Circadian lung function in asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circadian lung function in asthma</div><div class=\"cntnt\"><img style=\"width:423px; height:260px;\" src=\"images/PULM/62825_Circadian_lung_function_ast.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circadian alterations in lung function (as assessed by peak expiratory flow rate or FEV1) in normal subjects and asthmatics. The nadir occurs at approximately 4 AM in both groups, but the amplitude of the peak-to-trough swings is much larger in asthma.</div><div class=\"graphic_reference\">Adapted from Hetzel, MR, Clark, TJ, Thorax 1980; 35:732.</div><div id=\"graphicVersion\">Graphic 62825 Version 1.0</div></div></div>"},"62826":{"type":"graphic_picture","displayName":"Oral lichen planus - erosive","title":"Erosive oral lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erosive oral lichen planus</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/62826_Oral_lichen_planus_erosive.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcers are present on the tongue in this patient with erosive oral lichen planus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62826 Version 3.0</div></div></div>"},"62827":{"type":"graphic_picture","displayName":"Collodion baby","title":"Collodion baby","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Collodion baby</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/62827_Collodion_baby.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This infant appears encased in a taut, shiny stratum corneum, with underlying generalized erythroderma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62827 Version 4.0</div></div></div>"},"62828":{"type":"graphic_picture","displayName":"Fusarium paranasal cellulitis and skin nodules","title":"<EM>Fusarium</EM> paranasal cellulitis and skin nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Fusarium</EM> paranasal cellulitis and skin nodules</div><div class=\"cntnt\"><img style=\"width:396px; height:366px;\" src=\"images/ID/62828_Fusarium_paranas_cell_nod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paranasal cellulitis in a 15-year-old girl with aplastic anemia who presented with <EM>Fusarium </EM>sinusitis with subsequent development of cutaneous nodules on the face, extremities, and chest caused by <EM>Fusarium</EM> species.</div><div class=\"graphic_reference\">Reproduced from: Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immuncompromised hosts: Implications for diagnosis and management. Clin Infect Dis 2002; 35:909 by permission of Oxford University Press. Copyright Â© 2002.</div><div id=\"graphicVersion\">Graphic 62828 Version 3.0</div></div></div>"},"62829":{"type":"graphic_figure","displayName":"Web space abscess","title":"Web space abscess","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Web space abscess</div><div class=\"cntnt\"><img style=\"width:560px; height:380px;\" src=\"images/SURG/62829_Web_space_abscess_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A web space abscess requires a combined palmar and dorsal approach for adequate drainage and debridement. Note that the incisions are not connected to each other.</div><div id=\"graphicVersion\">Graphic 62829 Version 2.0</div></div></div>"},"62831":{"type":"graphic_algorithm","displayName":"Revised El Escorial schema","title":"Revised El Escorial schema for the clinical diagnosis of amyotrophic lateral sclerosis (ALS)","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Revised El Escorial schema for the clinical diagnosis of amyotrophic lateral sclerosis (ALS)</div><div class=\"cntnt\"><img style=\"width:462px; height:373px;\" src=\"images/NEURO/62831_RevisedElEscorialschema.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The body is divided into four regions: cranial, cervical, thoracic, and lumbosacral.<br /><STRONG>Clinically definite ALS</STRONG> is defined on clinical evidence alone by the presence of UMN, as well as LMN signs, in three regions.<br /><STRONG>Clinically probable ALS</STRONG> is defined on clinical evidence alone by UMN and LMN signs in at least two regions with some UMN signs necessarily rostral to (above) the LMN signs.<br /><STRONG>Clinically probable&nbsp;laboratory supported ALS</STRONG> is defined when clinical signs of UMN and LMN dysfunction are in only one region, or when UMN signs alone are present in one region, and LMN signs defined by EMG criteria are present in at least two limbs, with proper application of neuroimaging and clinical laboratory protocols to exclude other causes.<br /><STRONG>Clinically possible ALS</STRONG> is defined when clinical signs of UMN and LMN dysfunction are found together in only one region or UMN signs are found alone in two or more regions; or LMN signs are found rostral to UMN signs and the diagnosis of <EM>clinically probable laboratory supported ALS</EM> cannot be proven by evidence on clinical grounds in conjunction with electrodiagnostic, neurophysiologic, neuroimaging, or clinical laboratory studies. Other diagnoses must have been excluded to accept a diagnosis of <EM>clinically possible ALS</EM>.<br /><STRONG>Clinically suspected ALS</STRONG> is a pure LMN syndrome, wherein the diagnosis of ALS could not be regarded as sufficiently certain to include the patient in a research study.</div><div class=\"graphic_footnotes\">ALS: amyotrophic lateral sclerosis; EMG: electromyography; LMN: lower motor neuron sign(s); NCV: nerve conduction velocity; UMN: upper motor neuron sign(s).</div><div class=\"graphic_reference\">Reproduced with permission from: Brooks, BR, Miller, RG, Swash, M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1:293. Copyright Â©2000 Taylor &amp; Francis.</div><div id=\"graphicVersion\">Graphic 62831 Version 4.0</div></div></div>"},"62833":{"type":"graphic_figure","displayName":"Event rates in SPAF III","title":"Increased stroke risk with low dose warfarin plus aspirin in AF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increased stroke risk with low dose warfarin plus aspirin in AF</div><div class=\"cntnt\"><img style=\"width:427px; height:306px;\" src=\"images/CARD/62833_Event_rates_in_SPAF_III.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results from the SPAF III trial of high-risk patients showing significantly higher event rates for intracranial hemorrhage and ischemic stroke in patients treated with fixed low dose warfarin plus aspirin compared with standard adjusted-dose warfarin. The risk was greater in those with a previous thromboembolic event.</div><div class=\"graphic_reference\">Data from Stroke Prevention in Atrial Fibrillation Investigators. Lancet 1996; 348:633.</div><div id=\"graphicVersion\">Graphic 62833 Version 1.0</div></div></div>"},"62834":{"type":"graphic_diagnosticimage","displayName":"Avulsion ischial tuberosity","title":"Apophyseal avulsion injury of the left ischial tuberosity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apophyseal avulsion injury of the left ischial tuberosity</div><div class=\"cntnt\"><img style=\"width:432px; height:340px;\" src=\"images/PEDS/62834_Avulsion_ischial_tuberosity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apophyseal avulsion injury of the left ischial tuberosity at the site of insertion of the hamstring muscles (arrow).</div><div class=\"graphic_reference\">Courtesy of Rajvee Shah, MD.</div><div id=\"graphicVersion\">Graphic 62834 Version 2.0</div></div></div>"},"62835":{"type":"graphic_figure","displayName":"Genu varum and valgum","title":"Genu varum and genu valgum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Genu varum and genu valgum</div><div class=\"cntnt\"><img style=\"width:379px; height:656px;\" src=\"images/PEDS/62835_Genu_varum_and_valgum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Genu varum (upper panel) is a varus alignment of the knee. In varus deformities, the apex of the angle formed by the bones on both sides of a joint points away from the body. Genu valgum (lower panel) is a valgus alignment of the knee. In valgus deformities, the apex of the angle formed by the bones on both sides of a joint points toward the body.</div><div id=\"graphicVersion\">Graphic 62835 Version 1.0</div></div></div>"},"62838":{"type":"graphic_picture","displayName":"Large horizontal overjet","title":"Large horizontal overjet","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Large horizontal overjet</div><div class=\"cntnt\"><img style=\"width:504px; height:358px;\" src=\"images/PEDS/62838_Large_horizontal_overjet.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: McTigue, DJ. Managing traumatic injuries in the young permanent dentition. In: Pediatric Dentistry: Infancy through adolescence, 4th ed, WB Saunders, Philadelphia 2005. Copyright &#169; Elsevier.</div><div id=\"graphicVersion\">Graphic 62838 Version 1.0</div></div></div>"},"62839":{"type":"graphic_table","displayName":"Peak expiratory flow in women","title":"Predicted average peak expiratory flow (PEF) for normalÂ women (liters/minute)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predicted average peak expiratory flow (PEF) for normal&nbsp;women (liters/minute)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age</td> <td class=\"subtitle1\" colspan=\"6\">Height (inches/centimeters)</td> </tr> <tr> <td class=\"subtitle2\">55/140</td> <td class=\"subtitle2\">60/152</td> <td class=\"subtitle2\">65/165</td> <td class=\"subtitle2\">70/178</td> <td class=\"subtitle2\">75/190</td> </tr> <tr> <td>20</td> <td>390</td> <td>423</td> <td>460</td> <td>496</td> <td>529</td> </tr> <tr> <td>25</td> <td>385</td> <td>418</td> <td>454</td> <td>490</td> <td>523</td> </tr> <tr> <td>30</td> <td>380</td> <td>413</td> <td>448</td> <td>483</td> <td>516</td> </tr> <tr> <td>35</td> <td>375</td> <td>408</td> <td>442</td> <td>476</td> <td>509</td> </tr> <tr> <td>40</td> <td>370</td> <td>402</td> <td>436</td> <td>470</td> <td>502</td> </tr> <tr> <td>45</td> <td>365</td> <td>397</td> <td>430</td> <td>464</td> <td>495</td> </tr> <tr> <td>50</td> <td>360</td> <td>391</td> <td>424</td> <td>457</td> <td>488</td> </tr> <tr> <td>55</td> <td>355</td> <td>386</td> <td>418</td> <td>451</td> <td>482</td> </tr> <tr> <td>60</td> <td>350</td> <td>380</td> <td>412</td> <td>445</td> <td>475</td> </tr> <tr> <td>65</td> <td>345</td> <td>375</td> <td>406</td> <td>439</td> <td>468</td> </tr> <tr> <td>70</td> <td>340</td> <td>369</td> <td>400</td> <td>432</td> <td>461</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These values represent average normal values within 80 liters/minute. Predicted values for African American and Hispanic minorities are approximately 10 percent lower.</div><div class=\"graphic_reference\">Data from: Leiner GC, Abramowitz S, Small MJ, et al. Expiratory Peak Flow Rate. Standard Values for Normal Subjects. Use as a Clinical Test of Ventilatory Function. Am Rev Respir Dis 1963; 88:644.</div><div id=\"graphicVersion\">Graphic 62839 Version 7.0</div></div></div>"},"62841":{"type":"graphic_picture","displayName":"Elbow hypermobility","title":"Elbow hypermobility","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elbow hypermobility</div><div class=\"cntnt\"><img style=\"width:274px; height:189px;\" src=\"images/RHEUM/62841_Elbow_hypermobility.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laxity of the elbow with greater than 10 degrees of joint extension.</div><div class=\"graphic_reference\">Reproduced with permission from: Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed. Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 62841 Version 1.0</div></div></div>"},"62842":{"type":"graphic_figure","displayName":"Regulation SR function","title":"Regulation of excitation-contraction coupling","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Regulation of excitation-contraction coupling</div><div class=\"cntnt\"><img style=\"width:542px; height:348px;\" src=\"images/CARD/62842_Regulation_SR_function_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the factors responsible for regulation of the calcium transient at the sarcoplasmic reticulum (top) and of the regulation of excitation-contraction coupling by the binding of calcium to troponin C.</div><div class=\"graphic_footnotes\">SERCA: sarco/endoplasmic reticulum&#160;calcium transporting<sup>&#160;</sup>ATPase; RyR2: Ryanodine receptor 2;&#160;DAG: diacylglycerol; IP3: inositol triphosphate.</div><div class=\"graphic_reference\">Courtesy of Timothy W Smith, MD, PhD.</div><div id=\"graphicVersion\">Graphic 62842 Version 3.0</div></div></div>"},"62843":{"type":"graphic_picture","displayName":"Lateral segmentectomy","title":"Lateral segmentectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral segmentectomy</div><div class=\"cntnt\"><img style=\"width:439px; height:584px;\" src=\"images/SURG/62843_Lateralsegmentectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parallelogram partial mastectomy, lateral segment (&quot;lateral segmentectomy&quot;), preoperative, and intraoperative images.<br> (A) Intraoperative marking with patient in supine position demonstrating the tangential approach of the parallelogram skin marking to the nipple-areolar complex.<br> (B) Full-thickness ï¬broglandular resection.<br> (C) Final skin closure.</div><div class=\"graphic_reference\">Reproduced with permission from: Calhoun KE, Anderson BO. Oncoplastic surgery: Segmental resection for lumpectomies. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62843 Version 8.0</div></div></div>"},"62845":{"type":"graphic_figure","displayName":"Arterial supply of the spinal cord","title":"Arterial supply of the spinal cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arterial supply of the spinal cord</div><div class=\"cntnt\"><img style=\"width:448px; height:540px;\" src=\"images/NEURO/62845_SC_vasculature.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Prasad S, Price RS, Kranick SM, et al. Clinical Reasoning: A 59-year-old woman with acute paraplegia. Neurology 2007; 69:E41. Copyright Â© 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62845 Version 10.0</div></div></div>"},"62846":{"type":"graphic_table","displayName":"Common cold treatments in pregnancy 1","title":"Agents used to treat the common cold and its symptoms, efficacy and safety in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents used to treat the common cold and its symptoms, efficacy and safety in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Effect in randomly controlled trial<br /> (not pregnant)</td> <td class=\"subtitle1\">Pregnancy data</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Rhinorrhea, sneezing, throat pain</td> </tr> <tr> <td class=\"indent1\">Ipratropium bromide 0.06 percent nasal spray</td> <td>Mild improvement in rhinorrhea and sneezing</td> <td>It is presumed that the agent can be used nasally in pregnancy because of the small systemic absorption and reassuring animal data.</td> </tr> <tr> <td class=\"indent1\"> <p>Cromolyn sodium* aqueous nasal spray (5.2 mg per spray)</p> <p><strong>OR</strong></p> <p>Cromolyn sodium* as dry powder (20 mg per inhalation in spincaps). Note: Not available in the United States.</p> Other cromolyn inhalation preparations*: solution for nebulization 20 mg/2 mL (available in United States) and metered dose inhaler (MDI) 5 mg/puff (not available in United States)</td> <td>Mildly shortens the duration and severity of cold symptoms including sneezing and sore throat</td> <td> <p>Less than 10 percent of an inhaled dose of cromolyn is believed to be absorbed systemically.</p> <p>Animal data are reassuring.</p> The published data with respect to the use of this agent to treat asthma in pregnancy&nbsp;are very reassuring.</td> </tr> <tr> <td class=\"indent1\">Saline nasal irrigation or spray</td> <td> <p>Buffered normal and hypertonic saline irrigation or spray modestly improve symptoms of rhinitis and chronic rhinosinusitis</p> Benefit in acute URI not established</td> <td> <p>Systemic absorption is expected to be low with proper use.</p> The published data with respect to the use of this agent to treat chronic rhinosinusitis and pregnancy rhinitis is very reassuring.</td> </tr> <tr> <td class=\"indent1\">Anesthetic lozenges or sprays</td> <td> <p>Small studies of benzocaine or lidocaine lozenges and sprays demonstrate benefit in relief of sore throat pain</p> Data are lacking for most other&nbsp;over-the-counter preparations such as dyclonine and phenol lozenges and sprays</td> <td> <p>Systemic absorption of lidocaine and benzocaine occurs via mucous membranes of oral cavity.</p> Over-the-counter anesthetic lozenges and sprays (dyclonine, phenol): Fetal harm appears to be unlikely when used appropriately. Limited data from a study in rats and two epidemiologic studies in humans did not show an increased risk of teratogenesis from use of throat lozenges made from cetylpyridinium chloride (eg, Cepacol). Since human and animal data are lacking for most agents, we prefer acetaminophen based upon availability of pregnancy safety data.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antipyretics and simple analgesics</td> </tr> <tr> <td class=\"indent1\">Acetaminophen</td> <td>Antipyretic and symptomatic relief of associated myalgias, headaches and sore throat</td> <td>Extensive animal data and population-based studies are very reassuring regarding the safety of this agent in pregnancy.</td> </tr> <tr> <td class=\"indent1\">Nonsteroidal anti-inflammatory drugs (NSAIDs)</td> <td>Reductions in headache, malaise, myalgia with a 29 percent reduction in the total (five-day) symptom score. Has no effect on nasal symptoms.</td> <td>NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies, cleft palate, and gastroschisis have been observed following NSAID exposure in some studies. The absolute risk appears to be low. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. When used in the third trimester, NSAIDs have been associated with oligohydramnios, pulmonary hypertension, intracranial hemorrhage, and necrotizing enterocolitis in infants. Their use in pregnancy is <strong>not </strong>appropriate for the treatment of common cold symptoms. Acetaminophen will offer similar relief in this setting without placing the fetus at increased risk.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Cromolyn (sodium chromoglycate) inhalation may cause transient bronchospasm, throat irritation, or cough.</div><div id=\"graphicVersion\">Graphic 62846 Version 9.0</div></div></div>"},"62847":{"type":"graphic_diagnosticimage","displayName":"Battery versus coin AP radiograph","title":"Battery versus coin ingestion","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Battery versus coin ingestion</div><div class=\"cntnt\"><img style=\"width:467px; height:219px;\" src=\"images/PEDS/62847_Battery_vs_coin_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enlarged radiographic comparison between the camera battery ingestion (left) and the coin ingestion (right) will show the subtle but characteristic differences between the two foreign bodies. The bilaminar structure of the button battery gives it a double-ring or halo appearance on plain radiograph, whereas the appearance of the coin is homogeneous.</div><div class=\"graphic_reference\">Courtesy of Barbara Specter, MD.</div><div id=\"graphicVersion\">Graphic 62847 Version 3.0</div></div></div>"},"62849":{"type":"graphic_figure","displayName":"Stool diary sample","title":"Stool diary (sample)","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Stool diary (sample)</div><div class=\"cntnt\"><img style=\"width:542px; height:602px;\" src=\"images/PEDS/62849_Stool_diary_sample.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62849 Version 1.0</div></div></div>"},"62850":{"type":"graphic_diagnosticimage","displayName":"Oblique fracture of the great toe: AP and oblique views","title":"Oblique fracture of the great toe: AP and oblique views","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique fracture of the great toe: AP and oblique views</div><div class=\"cntnt\"><img style=\"width:325px; height:568px;\" src=\"images/EM/62850_Oblique_fx_prox_phalanx_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This fracture is subtle: There is no clear break in the cortex, and the fracture line is less apparent. However, in a patient with point tenderness and the appropriate history, the irregular lucent line seen on two views (arrows) confirms the presence of a fracture.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 62850 Version 5.0</div></div></div>"},"62852":{"type":"graphic_figure","displayName":"Red cell ion transport mechanisms","title":"Red blood cell ion transport mechanisms","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Red blood cell ion transport mechanisms</div><div class=\"cntnt\"><img style=\"width:567px; height:328px;\" src=\"images/HEME/62852_Red_cell_transporters.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the transport mechanisms regulating red cell hydration. The extracellular concentrations of sodium and calcium are higher than those within the cell, creating favorable gradients for entry, while the intracellular concentration of potassium is higher than that in the extracellular fluid, creating a favorable gradient for potassium exit by the K-Cl cotransporter or the calcium-activated (Gardos) potassium channel. The red transporters are active, the blue transporters are passive. Band 3 protein primarily functions as a Cl-HCO3 exchanger. Its primary physiological function is to facilitate CO2 transport from tissues to alveoli; it also plays an important role in defining red cell shape and membrane stability. Water movement passively follows that of cations and anions, or changes in tonicity of the red cell's environment. Transport of water can occur at a much faster rate via water channels (aquaporin-1, Aqp-1).</div><div id=\"graphicVersion\">Graphic 62852 Version 3.0</div></div></div>"},"62853":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM PA gram I","title":"Arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:295px; height:468px;\" src=\"images/PULM/62853_Pulm_AVM_PA_gram_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pulmonary arteriogram shows an arteriovenous malformation supplied by a pulmonary artery branch.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 62853 Version 2.0</div></div></div>"},"62854":{"type":"graphic_picture","displayName":"Duodenum in scleroderma Light","title":"Duodenum in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duodenum in scleroderma</div><div class=\"cntnt\"><img style=\"width:352px; height:240px;\" src=\"images/RHEUM/62854_Duodenum_in_scleroderma_Lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Section of duodenum from a patient with scleroderma (Masson trichrome stain). There is normal villus structure and epithelial cell morphology (right side), a mild inflammatory cell infiltrate in the lamina propria, collagen (seen in dark blue) encapsulating Brunner's glands, and fibrous replacement of the muscularis.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 62854 Version 1.0</div></div></div>"},"62855":{"type":"graphic_picture","displayName":"Nail changes in psoriasis","title":"Sequential nail changes in psoriasis","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Sequential nail changes in psoriasis</div><div class=\"cntnt\"><img style=\"width:464px; height:128px;\" src=\"images/RHEUM/62855_Nail_changes_in_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Mild nail involvement characterized by discrete pits in the nail plate and early onycholytic separation of the lateral edges of the nail plate from the nail bed. These nail changes are the earliest and the most common in psoriasis. Panel B: Moderate nail involvement manifested by the combination of nail plate pitting and more advanced distal onycholysis; the distal third of the nail plate is now separated from the nail bed. Panel C: The most severe and the least common type of psoriatic nail involvement, in which the normal nail plates have been replaced by thickened hyperkeratotic masses.</div><div class=\"graphic_reference\">Reproduced with permission from Richard D Sontheimer, DM. In: Resource Materials in Rheumatology, number 19: Nail changes in rheumatic diseases.</div><div id=\"graphicVersion\">Graphic 62855 Version 1.0</div></div></div>"},"62856":{"type":"graphic_table","displayName":"Cincinnati Prehospital Stroke Scale","title":"Cincinnati Prehospital Stroke Scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cincinnati Prehospital Stroke Scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>The CPSS evaluates for facial palsy, arm weakness, and speech abnormalities. Items are scored as either normal or abnormal.</td> </tr> <tr> <td class=\"subtitle1_single\">Facial droop</td> </tr> <tr> <td>The patient shows teeth or smiles</td> </tr> <tr> <td class=\"indent1\"><strong>Normal:</strong> Both sides of face move equally.</td> </tr> <tr> <td class=\"indent1\"><strong>Abnormal:</strong> One side of face does not move as well as the other.</td> </tr> <tr> <td class=\"subtitle1_single\">Arm drift</td> </tr> <tr> <td>The patient closes their eyes and extends both arms straight out for 10 seconds</td> </tr> <tr> <td class=\"indent1\"><strong>Normal:</strong> Both arms move the same, or both arms do not move at all.</td> </tr> <tr> <td class=\"indent1\"><strong>Abnormal:</strong> One arm either does not move, or one arm drifts down compared to the other.</td> </tr> <tr> <td class=\"subtitle1_single\">Speech</td> </tr> <tr> <td>The patient repeats \"The sky is blue in Cincinnati\"</td> </tr> <tr> <td class=\"indent1\"><strong>Normal:</strong> The patient says correct words with no slurring of words.</td> </tr> <tr> <td class=\"indent1\"><strong>Abnormal:</strong> The patient slurs words, says the wrong words, or is unable to speak.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Kothari RU, Pancioli A, Liu T, et al. Cincinnati Prehospital Stroke Scale: reproducibility and validity. Ann Emerg Med 1999; 33:373. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 62856 Version 1.0</div></div></div>"},"62857":{"type":"graphic_figure","displayName":"Increased C1 to C2 spinous process distance","title":"Increased C1 to C2 spinous process distance","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Increased C1 to C2 spinous process distance</div><div class=\"cntnt\"><img style=\"width:535px; height:406px;\" src=\"images/EM/62857_Increased-C1-to-C2-spinous-process-distance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This figure demonstrates an example of an enlarged C1&ndash;2:C2&ndash;3 ratio (20:6) in a patient with tectorial membrane disruption as the bones would appear on lateral cervical spine radiograph or sagittal computed tomography cervical spine reconstruction.<br />(B) Disrupted. The enlarged C1&ndash;2:C2&ndash;3 ratio in tectorial membrane disruption may be created by the vectors illustrated on this sagittal figure. The craniocervical junction is flexed in an supine young child on a flat surface (long curved arrow). Without an intact tectorial membrane firmly strapping the flexed cranium to C-2, the occipital condyles push down on the anterior rim of cup-shaped C-1 articulation (red arrow) and rotate the posterior ring of C-1 superiorly (straight black arrow). This enlarges the C1&ndash;2 interspace relative to the C2&ndash;3 interspace to create the abnormal C1&ndash;2:C2&ndash;3 ratio.<br />(C) Normal. The entire Oc&mdash;C2 complex moves up as a unit with an intact tectorial membrane (solid black line). Movement of the occipital condyle is limited to rotation within the cup-shaped C-1 articulation (curved black arrow), and the joint relationship is maintained (straight black arrow).</div><div id=\"graphicVersion\">Graphic 62857 Version 6.0</div></div></div>"},"62858":{"type":"graphic_picture","displayName":"HSTCL liver biopsy","title":"Hepatosplenic T-cell lymphoma liver involvement","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hepatosplenic T-cell lymphoma liver involvement</div><div class=\"cntnt\"><img style=\"width:504px; height:369px;\" src=\"images/HEME/62858_HSTCLsinusoidalinfiltrat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy shows sinusoidal infiltration by lymphoma cells, whereas the portal areas are devoid of tumor cell infiltration. Hematoxylin and eosin, 10x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry and Immunochemistry for Hematologic Neoplasms, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 62858 Version 7.0</div></div></div>"},"62862":{"type":"graphic_waveform","displayName":"EEG Small sharp spikes or BETS","title":"Small sharp spikes also known as benign epileptiform transients of sleep (BETS)","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Small sharp spikes also known as benign epileptiform transients of sleep (BETS)</div><div class=\"cntnt\"><img style=\"width:544px; height:403px;\" src=\"images/NEURO/62862_SSS_BETS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small sharp spikes (also known as benign epileptiform transients of sleep, or BETS; see boxed area). This is a normal variant.</div><div class=\"graphic_reference\">Courtesy of Drs. Lawrence Hirsch and Hiba Arif.</div><div id=\"graphicVersion\">Graphic 62862 Version 2.0</div></div></div>"},"62863":{"type":"graphic_table","displayName":"Cryosurg BCC advant disadvant","title":"Cryosurgery for BCC: advantages and disadvantages","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cryosurgery for BCC: advantages and disadvantages</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Advantages</td> </tr> <tr> <td>Relatively quick office procedure</td> </tr> <tr> <td>Requires little (if any) anesthesia</td> </tr> <tr> <td>Does not require sedation or general anesthesia</td> </tr> <tr> <td>Offers good-to-excellent cosmetic results</td> </tr> <tr> <td>Offers excellent cure rates for primary BCCs</td> </tr> <tr> <td>Can be performed on large superficial tumors</td> </tr> <tr> <td>Can be performed on multiple tumors</td> </tr> <tr> <td>Can be used on BCCs fixed to cartilage</td> </tr> <tr> <td>Can be used on BCCs located on the lips, eyelids, nose, ears, dorsa of the hands, scalp, trunk, and extremities</td> </tr> <tr> <td>Well tolerated even by medically complicated patients</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Disadvantages</td> </tr> <tr> <td>Creates an ulcerative wound that is exudative and requires active participation in wound care</td> </tr> <tr> <td>Commonly causes long-lasting pigmentary changes</td> </tr> <tr> <td>Rarely causes nerve damage, anatomic and functional impairment (ectropion, stenosis of the ear canal), alopecia, and tendon rupture</td> </tr> <tr> <td>Requires a great deal of clinician experience in its use for successful outcome</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62863 Version 2.0</div></div></div>"},"62866":{"type":"graphic_table","displayName":"Osteoporosis screening recommendations","title":"Osteoporosis screening recommendations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Osteoporosis screening recommendations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td rowspan=\"5\">National Osteoporosis Foundation (NOF)</td> <td class=\"sublist1_start\">The NOF recommends measurement of BMD (DXA of the hip and spine) in<sup>[1]</sup>:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Women age 65 years and older and men age 70 years&nbsp;and older, regardless of clinical risk factors</td> </tr> <tr> <td class=\"sublist1\">&#8226; Younger postmenopausal women, women in the menopausal transition, and men age 50 to 69 years&nbsp;with clinical risk factors for fracture</td> </tr> <tr> <td class=\"sublist1\">&#8226; Adults who have a fracture after age 50 years</td> </tr> <tr> <td class=\"sublist1\">&#8226; Adults with a condition (eg, rheumatoid arthritis) or taking a medication (eg, glucocorticoids in a daily dose &#8805;5 mg prednisone or equivalent for &#8805;3 months) associated with low bone mass or bone loss</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"14\">International Society for Clinical Densitometry (ISCD)</td> <td class=\"sublist1_start\">The ISCD recommends measurement of BMD (DXA of the hip and spine) in<sup>[2]</sup>:</td> </tr> <tr> <td class=\"sublist1\">&#8226; All women age 65 years and older and men age 70 years&nbsp;and older regardless of risk factors</td> </tr> <tr> <td class=\"sublist1\">&#8226; Postmenopausal women and men age 50 to 70 years when risk factors are present</td> </tr> <tr> <td class=\"sublist1\">&#8226; Adults with a fragility fracture</td> </tr> <tr> <td class=\"sublist1\">&#8226; Adults with a condition or taking a medication associated with low bone mass or bone loss</td> </tr> <tr> <td class=\"sublist1\">&#8226; Anyone being considered for pharmacologic therapy for osteoporosis</td> </tr> <tr> <td class=\"sublist1\">&#8226; Anyone being treated for osteoporosis to monitor response to therapy</td> </tr> <tr> <td class=\"sublist1\">&#8226; Anyone not receiving therapy when evidence of bone loss would lead to treatment</td> </tr> <tr> <td class=\"sublist1\">&#8226; Women in the menopausal transition if there is a specific risk factor associated with increased fracture, such as low body weight, prior low-trauma fracture, or high-risk medication</td> </tr> <tr> <td class=\"sublist1\">&#8226; Postmenopausal women discontinuing estrogen should be considered for bone density testing</td> </tr> <tr> <td class=\"sublist1\">&#8226; The 33 percent forearm (1/3 radius) site is recommended in the following cases:</td> </tr> <tr> <td class=\"sublist2\">- If hip and/or spine cannot be measured or interpreted</td> </tr> <tr> <td class=\"sublist2\">- Hyperparathyroidism</td> </tr> <tr> <td class=\"sublist2\">- Severe obesity (over the weight limit of DXA table)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Association of Clinical Endocrinologists (AACE)</td> <td class=\"sublist1_start\">AACE recommends measurement of BMD (DXA) in<sup>[3]</sup>:</td> </tr> <tr> <td class=\"sublist1\">&#8226; All women age 65 years and older</td> </tr> <tr> <td class=\"sublist1\">&#8226; Any adult with a history of fracture not caused by severe trauma</td> </tr> <tr> <td class=\"sublist1\">&#8226; Younger postmenopausal women with clinical risk factors for fracture</td> </tr> <tr> <td class=\"sublist1\">&#8226; The lumbar spine (PA) and proximal femur are recommended sites of measurement</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">United States Preventive Services Task Force (USPSTF)</td> <td class=\"sublist1_start\">USPSTF recommends measurements of BMD in<sup>[4]</sup>:</td> </tr> <tr> <td class=\"sublist1\">&#8226; All women age 65 years&nbsp;and older</td> </tr> <tr> <td class=\"sublist1\">&#8226; In addition, they recommend screening in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors</td> </tr> <tr> <td class=\"sublist1\">&#8226; The best site to screen is not mentioned, although the report agrees that DXA of the hip is the best predictor of hip fracture</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">American Academy of Family Physicians (AAFP)</td> <td class=\"sublist1_start\">The AAFP recommends measurement of BMD in<sup>[5]</sup>:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Women age 65 years and older</td> </tr> <tr> <td class=\"sublist1\">&#8226; Women age 60 years and older at increased risk for osteoporotic fracture</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">National Institutes of Health (NIH)</td> <td class=\"sublist1_start\">The NIH recommends<sup>[6]</sup>:</td> </tr> <tr> <td class=\"sublist1\">&#8226; BMD measurements for individuals at high risk for osteoporosis. They do not recommend universal screening.</td> </tr> <tr class=\"divider_top\"> <td>UK National Osteoporosis Guideline Group (NOGG)</td> <td>The NOGG does not recommend population screening. They are in favor of performing BMD measurements using a case-finding strategy based upon age-specific fracture probability thresholds<sup>[7]</sup>.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Canadian Osteoporosis Society</td> <td class=\"sublist1_start\">The Canadian Osteoporosis Society recommends BMD measurement in<sup>[8]</sup>:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Postmenopausal women age&nbsp;&#8805;65 years</td> </tr> <tr> <td class=\"sublist1\">&#8226; Men age&nbsp;&#8805;65 years</td> </tr> <tr> <td class=\"sublist1\">&#8226; Younger men and women with additional clinical risk factors for fracture</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMD: bone mineral density: DXA: dual-energy x-ray absorptiometry.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>National Ostoporosis Foundation. 2013 Clinician's Guide to Prevention and Treatment of Osteoporosis. http://nof/public/content/resource/913/files/580.pdf (Accessed on November 14, 2013).</LI>&#xD;&#xA;<LI>International Society for Clinical Densitometry. 2013 ISCD Official Positions - Adult. www.iscd.org/official-positions/2013-iscd-official-positions-adult/ (Accessed on November 14, 2013).</LI>&#xD;&#xA;<LI>American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis. www.aace.com/pub/pdf/guidelines/OsteoGuidelines2010.pdf (Accessed on January 10, 2011).</LI>&#xD;&#xA;<LI>US Preventive Services Task Force. Screening for Osteoporosis Recommendation Statement. www.uspreventiveservicestaskforce.org/uspstf10/osteoporosis/osteors.htm (Accessed on February 10, 2011).</LI>&#xD;&#xA;<LI>American Academy of Family Physicians. Recommendations for clinical preventative services. www.aafp.org/exam.xml (Accessed on January 10, 2011).</LI>&#xD;&#xA;<LI>www.consensus.nih.gov (Accessed on January 10, 2011).</LI>&#xD;&#xA;<LI>National Osteoporosis Guideline Group (NOGG). www.shef.ac.uk/NOGG/index.html (Accessed on June 29, 2011).</LI>&#xD;&#xA;<LI>Papaioannou A, Morin S, Cheung AM, et al. 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ 2010; 182:1864.</LI></OL></div><div id=\"graphicVersion\">Graphic 62866 Version 12.0</div></div></div>"},"62868":{"type":"graphic_figure","displayName":"Silicone band sterilization A","title":"Silicone bandÂ sterilization by laparoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Silicone band&nbsp;sterilization by laparoscopy</div><div class=\"cntnt\"><img style=\"width:331px; height:370px;\" src=\"images/OBGYN/62868_Tubal_ring_sterilization_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tube is grasped 2 to 3 cm distal to the tubal junction prior to releasing the Falope ring.</div><div class=\"graphic_reference\">Courtesy of William Mann, MD.</div><div id=\"graphicVersion\">Graphic 62868 Version 2.0</div></div></div>"},"62872":{"type":"graphic_table","displayName":"Screening tests for occlusive vascular syndromes","title":"Screening tests for occlusive vascular syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening tests for occlusive vascular syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Complete blood count with differential, platelet count, and blood smear</td> </tr> <tr> <td>Polycythemia or anemia, granulocytosis, thrombocytosis, poikilocytosis<br /> <ul> <li>May be sign of myeloproliferative or myelodysplastic diseases </li> </ul> </td> </tr> <tr> <td>Evidence of red cell fragmentation (schistocytes) and microangiopathy, consider:<br /> <ul> <li>TTP-hemolytic uremic syndrome </li> <li>Purpura fulminans with DIC, occasionally </li> <li>Antiphospholipid antibody syndrome, occasionally </li> </ul> </td> </tr> <tr> <td>Thrombocytopenia, consider:<br /> <ul> <li>Heparin necrosis, some patients </li> <li>Purpura fulminans with DIC </li> <li>TTP-hemolytic uremic syndrome </li> <li>Antiphospholipid antibody syndrome, some patients </li> </ul> </td> </tr> <tr> <td>Severe neutropenia<br /> <ul> <li>Immunocompromised; opportunistic infections very likely </li> </ul> </td> </tr> <tr> <td>Eosinophilia<br /> <ul> <li>Cholesterol emboli </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Partial thromboplastin time (PTT)</td> </tr> <tr> <td>Minimally prolonged in TTP-hemolytic uremic syndrome</td> </tr> <tr> <td>Prolonged in purpura fulminans and DIC</td> </tr> <tr> <td>Prolonged if lupus anticoagulant activity present, and assay sensitive</td> </tr> <tr> <td class=\"subtitle1_single\">Cryoglobulins (occasionally cryofibrinogen and cold agglutinins) when location and history suggest cold occlusion syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Biopsy</td> </tr> <tr> <td>Confirms occlusion versus other mechanisms of vessel injury</td> </tr> <tr> <td>May suggest platelet plugs instead of fibrin thrombi</td> </tr> <tr> <td>May suggest cryoglobulin gelling</td> </tr> <tr> <td>May diagnose calciphylaxis</td> </tr> <tr> <td>May suggest cholesterol, oxalate or crystal globulin occlusion</td> </tr> <tr> <td>Special stains for organisms in immunocompromised hosts, when appropriate</td> </tr> <tr> <td class=\"subtitle1_single\">Basic hepatic and renal function screens</td> </tr> <tr> <td>Hepatic function can affect vitamin K-dependent factors and warfarin (Coumadin&#174;) metabolism</td> </tr> <tr> <td>Renal disease moves cutaneous calciphylaxis higher in the differential diagnosis</td> </tr> <tr> <td class=\"subtitle1_single\">ANCA</td> </tr> <tr> <td>To reduce the likelihood of the uncommon non-inflammatory retiform purpura presentation of granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis</td> </tr> <tr> <td>ANCA may be available before permanent histologic sections</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Cutaneous manifestations of microvascular occlusion syndromes. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Elsevier Limited, Spain 2008. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 62872 Version 2.0</div></div></div>"},"62873":{"type":"graphic_diagnosticimage","displayName":"Acetabular posterior wall and column fractures","title":"Acetabular posterior wall and column fractures","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Acetabular posterior wall and column fractures</div><div class=\"cntnt\"><img style=\"width:514px; height:541px;\" src=\"images/EM/62873_Acetablar_fx_pt_wll_col.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The anteroposterior pelvis radiograph shows the disruption of the ilioischial (arrow) but not the iliopectineal lines (small arrowheads), and the ischial ramus fracture is present (large arrowhead). The posterior wall fragment can be appreciated overlying the roof of the acetabulum (dashed arrow).<br />(B) The obturator oblique view shows the displaced posterior wall fragment (arrow), the ischial ramus fracture (small arrowhead), and the intact iliopectineal line (large arrowhead).<br />(C) The iliac oblique demonstrates the disruption of the greater sciatic notch and the posterior wall fragment superimposed on the roof of the acetabulum (arrow).<br />(D) This computed tomography section shows the posterior wall fracture (arrow) with a column fracture line typical of a posterior column fracture (small arrowheads).</div><div class=\"graphic_reference\">Originally published in: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Reproduced with permission. Copyright &copy; Berton R. Moed, MD.</div><div id=\"graphicVersion\">Graphic 62873 Version 3.0</div></div></div>"},"62874":{"type":"graphic_algorithm","displayName":"BL diagnostic algorithm","title":"Diagnostic algorithm for Burkitt lymphoma","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for Burkitt lymphoma</div><div class=\"cntnt\"><img style=\"width:481px; height:545px;\" src=\"images/HEME/62874_BLdiagnosticalgorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BL: Burkitt lymphoma; FISH: fluorescence in situ hybridization; DLBCL: diffuse large B-cell lymphoma.</div><div class=\"graphic_reference\">Modified with permission from: Gascoyne RD, Magrath IT, Sehn L. Burkitt lymphoma. In: Non-Hodgkin Lymphomas, 2nd ed, Armitage JO, Mauch PM, Harris NL, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 62874 Version 7.0</div></div></div>"},"62875":{"type":"graphic_table","displayName":"Evaluation chronic HBV","title":"Evaluation of patients with chronic HBV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of patients with chronic HBV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Initial evaluation </td> </tr> <tr> <td>1. History and physical examination*</td> </tr> <tr> <td>2. Family history of HBV infection, liver disease, HCC</td> </tr> <tr> <td>3. Laboratory tests to assess liver disease - complete blood counts with platelets, aminotransferase levels, total bilirubin, alkaline phosphatase, albumin, and INR</td> </tr> <tr> <td>4. Tests for HBV replication - HBeAg, anti-HBe, HBV DNA</td> </tr> <tr> <td>5. Tests to rule out viral coinfections - anti-HCV, anti-HDV (in persons from countries where HDV infection is common and in those with history of injection drug use), and anti-HIV<sup>&#182;</sup></td> </tr> <tr> <td>6. Tests to screen for HCC<sup><span style=\"font-size: 13px;\">&#916;</span></sup> - (eg, ultrasound)</td> </tr> <tr> <td>7. Tests to screen for fibrosis<sup>&#9674;</sup> - vibration-controlled transient elastography, serum fibrosis panel, or liver biopsy<sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Suggested follow-up for patients not considered for treatment: HBeAg+, HBV DNA &#62;20,000 int. units/mL, and normal ALT without cirrhosis<sup>&#165;</sup></td> </tr> <tr> <td>ALT every 3-6 months and HBeAg every 6-12 months</td> </tr> <tr> <td> <p>If ALT levels&nbsp;increase between 1 to 2 x ULN<sup>&#135;</sup>:</p> <ul> <li>Recheck ALT every 1-3 months and HBeAg every 6 months. </li> <li>Consider liver biopsy or noninvasive assessment of fibrosis if ALT levels remain persistently elevated, age &#62;40, and/or family history of HCC.&nbsp;Recommend&nbsp;treatment if biopsy shows moderate/severe inflammation or significant fibrosis (eg, METAVIR score &#8805;F2). </li> </ul> </td> </tr> <tr> <td>If ALT increases to &#62;2 x&nbsp;<span style=\"font-size: 13px;\">ULN<sup>&#135; </sup></span>for 3-6 months and HBeAg+, HBV DNA &#62;20,000 int. units/mL,&nbsp;recommend treatment</td> </tr> <tr> <td>Screen for HCC in relevant population<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"subtitle1_single\">Suggested follow-up for patients not considered for treatment: HBeAg-, HBV DNA &#60;2000 int. units/mL, and normal ALT without cirrhosis<sup><span style=\"font-size: 13px;\">&#165;</span></sup></td> </tr> <tr> <td>ALT every 3 months for 1 year, if persistently normal, ALT every 6-12 months</td> </tr> <tr> <td> <p>If ALT increases between 1 to 2 x <span style=\"font-size: 13px;\">ULN<sup>&#135;</sup></span><span style=\"font-size: 13px;\">:</span></p> <ul> <li>Check serum HBV DNA level and exclude other causes of liver disease. </li> <li>Monitor ALT and HBV DNA every 3 months.</li> <li>Consider liver biopsy or noninvasive assessment of fibrosis if ALT remains elevated on serial tests or if HBV DNA persistently &#8805;2000 int. units/mL.&nbsp;Recommend treatment for patients with moderate/severe inflammation or significant fibrosis. </li> </ul> </td> </tr> <tr> <td>If ALT increases to&nbsp;&#62;2 x ULN, recommend treatment if HBV DNA &#62;2000 int. units/mL</td> </tr> <tr> <td>Screen&nbsp;for HCC in relevant population<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AFP: Alpha feto protein; ALT: alanine aminotransferase; anti-HBe: antibody to HBeAg; HBV: hepatitis B virus; HBeAg: hepatitis B e antigen; HCC: hepatocellular carcinoma; HCV:&nbsp;hepatitis C virus; HDV: hepatitis delta virus; ULN: upper limit of normal.<br />* Patient should be evaluated for signs and symptoms of cirrhosis, risk factors for coinfections, alcohol use, and information on vaccination status. <br />Â¶ In patients who have not undergone one-time screening and those with ongoing risk factors for HIV-infection.<br />Î Refer to the topic that discusses screening of hepatocellular carcinoma.&nbsp;<br />â&nbsp;Refer to the topics in UpToDate that discuss noninvasive assessment of hepatic fibrosis.<br />Â§ Liver biopsy can also assess severity of inflammation and help rule out other causes of liver disease, information that will not be provided by noninvasive assessment of liver fibrosis.<br />Â¥&nbsp;Cirrhosis is based upon findings from the initial evaluation. Patients with advanced fibrosis determined by noninvasive methods should be evaluated using a second method, and if results are concordant, consider managing the same way as patients with cirrhosis.&nbsp;<br />â¡ The AASLD recommends using an ALT &gt;30 U/L for men and &gt;19 U/L for women as the upper limit of normal rather than local laboratory values. <br /></div><div class=\"graphic_reference\">References:&nbsp;<br /><OL>&#xD;&#xA;<LI>Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at http://publish.aasld.org/Pages/Default.aspx. Accessed September 8th 2009. Copyright Â© 2009 American Association for the Study of Liver Diseases.</LI>&#xD;&#xA;<LI>Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan; 63(1):261-83.</LI></OL></div><div id=\"graphicVersion\">Graphic 62875 Version 10.0</div></div></div>"},"62878":{"type":"graphic_picture","displayName":"Ciprofloxacin crystals kidney bx","title":"Light micrograph of kidney biopsy with ciprofloxacin crystals within tubular lumen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph of kidney biopsy with ciprofloxacin crystals within tubular lumen</div><div class=\"cntnt\"><img style=\"width:359px; height:539px;\" src=\"images/NEPH/62878_Cipro_crystals_kidney_bx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hematoxylin and eosin staining shows needle-shaped stellate crystals.<br />(B) Ciprofloxacin crystals within the tubule polarize.</div><div class=\"graphic_reference\">Reproduced with permission from: Stratta, P, Lazzarich, E, Canavese, C, et al. Ciprofloxacin crystal nephropathy. Am J Kidney Dis 2007; 50:330. Copyright Â©2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 62878 Version 4.0</div></div></div>"},"62879":{"type":"graphic_figure","displayName":"Sympathetic input to pupil","title":"Sympathetic pathway for pupillary innervation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sympathetic pathway for pupillary innervation</div><div class=\"cntnt\"><img style=\"width:446px; height:663px;\" src=\"images/NEURO/62879_Sympathetic_input_to_pupil.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Trigeminal ganglion.</div><div class=\"graphic_reference\">Reproduced with permission from: Martin, TJ, Corbett, JJ. The Pupil. In: Neuro-ophthalmology: the requisites in ophthalmology, Krachmer, JH (Ed), Mosby, St. Louis 2000. Copyright &#169;2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 62879 Version 1.0</div></div></div>"},"62880":{"type":"graphic_table","displayName":"NSAIDs - Strength of COX-1 and COX-2 inhibition","title":"NSAIDs and aspirin cross-reactivity: Strength of COX-1 and COX-2 inhibition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NSAIDs and aspirin cross-reactivity: Strength of COX-1 and COX-2 inhibition</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">NSAIDs that preferentially inhibit COX-1 and cross-react with aspirin</td> </tr> <tr> <td class=\"indent1\">Diclofenac</td> </tr> <tr> <td class=\"indent1\">Etodolac</td> </tr> <tr> <td class=\"indent1\">Fenoprofen</td> </tr> <tr> <td class=\"indent1\">Floctafenine (available outside of the United States)</td> </tr> <tr> <td class=\"indent1\">Flurbiprofen</td> </tr> <tr> <td class=\"indent1\">Ibuprofen</td> </tr> <tr> <td class=\"indent1\">Indomethacin</td> </tr> <tr> <td class=\"indent1\">Ketoprofen</td> </tr> <tr> <td class=\"indent1\">Ketorolac</td> </tr> <tr> <td class=\"indent1\">Meclofenamate</td> </tr> <tr> <td class=\"indent1\">Mefenamic acid</td> </tr> <tr> <td class=\"indent1\">Naproxen</td> </tr> <tr> <td class=\"indent1\">Oxaprozin</td> </tr> <tr> <td class=\"indent1\">Piroxicam</td> </tr> <tr> <td class=\"indent1\">Sulindac</td> </tr> <tr> <td class=\"indent1\">Tiaprofenic acid (available outside of the United States)</td> </tr> <tr> <td class=\"indent1\">Tolmetin</td> </tr> <tr> <td class=\"subtitle1_single\">Nonopioid analgesics and nonacetylated salicylates that are poor inhibitors of COX-1 and only with higher concentrations of drug; cross-reactions with higher doses</td> </tr> <tr> <td class=\"indent1\">Acetaminophen (paracetamol)</td> </tr> <tr> <td class=\"indent1\">Choline magnesium trisalicylate</td> </tr> <tr> <td class=\"indent1\">Diflunisal</td> </tr> <tr> <td class=\"indent1\">Salsalate</td> </tr> <tr> <td class=\"indent1\">Bismuth subsalicylate, bismuth salicylate (NOTE: Absorption of salicylate occurs from oral bismuth salicylates [eg, as used for treatment of diarrhea and other gastrointestinal complaints])</td> </tr> <tr> <td class=\"subtitle1_single\">NSAIDs that preferentially inhibit COX-2 but also inhibit COX-1 when higher doses given; cross-reactions with higher doses</td> </tr> <tr> <td class=\"indent1\">Meloxicam</td> </tr> <tr> <td class=\"indent1\">Nabumetone</td> </tr> <tr> <td class=\"indent1\">Nimesulide (available outside of the United States)</td> </tr> <tr> <td class=\"subtitle1_single\">Highly selective COX-2 inhibitors that do not inhibit COX-1; cross-reactions are rare (may occur at the highest doses)</td> </tr> <tr> <td class=\"indent1\">Celecoxib</td> </tr> <tr> <td class=\"indent1\">Etoricoxib (available outside of the United States)</td> </tr> <tr> <td class=\"indent1\">Parecoxib (parenteral) (available outside of the United States)</td> </tr> <tr> <td class=\"indent1\">Lumiracoxib (limited availability outside of the United States)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs; COX-1: cyclooxygenase, isoform 1; COX-2: cyclooxygenase, isoform 2.</div><div class=\"graphic_reference\">Adapted with permission from: Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 2004; 24:491. Copyright &copy; 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 62880 Version 12.0</div></div></div>"},"62882":{"type":"graphic_table","displayName":"IgD mean by age","title":"Immunoglobulin D (IgD) normal and 95<SUP>th</SUP> percentile values by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunoglobulin D (IgD) normal and 95<SUP>th</SUP> percentile values by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Average normal IgD (mg/dL)</td> <td class=\"subtitle1\">Upper limit reference range IgD*</td> </tr> <tr> <td>0 to 0.5</td> <td>0.07</td> <td>0.21</td> </tr> <tr> <td>0.5 to 1</td> <td>0.34</td> <td>1.64</td> </tr> <tr> <td>1 to 2</td> <td>0.71</td> <td>6.58</td> </tr> <tr> <td>2 to 4</td> <td>1.60</td> <td>20.4</td> </tr> <tr> <td>4 to 6</td> <td>4.82</td> <td>29.1</td> </tr> <tr> <td>6 to 10</td> <td>4.49</td> <td>41.4</td> </tr> <tr> <td>10 to 15</td> <td>4.84</td> <td>23.6</td> </tr> <tr> <td>&#62;15</td> <td>1.95</td> <td>23.7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgD: immunoglobulin D.<br />* &gt;2 standard deviations above the mean for age.</div><div class=\"graphic_reference\">Data from: Haraldsson A, Weemaes CM, Jonasdottir S, et al. Serum immunoglobulin D in infants and children. Scand J Immunol 2000; 51:415.</div><div id=\"graphicVersion\">Graphic 62882 Version 4.0</div></div></div>"},"62883":{"type":"graphic_figure","displayName":"Diameters of the fetal head at term","title":"Diameters of the fetal head at term","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Diameters of the fetal head at term</div><div class=\"cntnt\"><img style=\"width:507px; height:430px;\" src=\"images/OBGYN/62883_Diameters-of-fetal-head-edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Measurements from: Williams Obstetrics, 23<SUP>rd</SUP>&nbsp;ed, Cunnigham FG, Leveno KJ, Bloom SL, et al (Eds), McGraw-Hill, New York 2010.</div><div id=\"graphicVersion\">Graphic 62883 Version 6.0</div></div></div>"},"62884":{"type":"graphic_figure","displayName":"Fibroid embolization 2a","title":"Fibroid embolization 2a","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibroid embolization 2a</div><div class=\"cntnt\"><img style=\"width:331px; height:303px;\" src=\"images/OBGYN/62884_Fibroid_embolization_2a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing superselective catheter position in the right uterine artery via left femoral arterial approach.</div><div id=\"graphicVersion\">Graphic 62884 Version 1.0</div></div></div>"},"62885":{"type":"graphic_table","displayName":"Etiology AV block","title":"Major causes of atrioventricular (AV) block","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of atrioventricular (AV) block</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Physiologic and pathophysiologic</td> </tr> <tr> <td>Increased vagal tone</td> </tr> <tr> <td>Fibrosis and sclerosis of the conduction system</td> </tr> <tr> <td>Ischemic heart disease</td> </tr> <tr> <td>Cardiomyopathy and myocarditis</td> </tr> <tr> <td>Congenital heart disease</td> </tr> <tr> <td>Familial AV block</td> </tr> <tr> <td class=\"sublist1_start\">Progressive cardiac conduction system disease</td> </tr> <tr> <td class=\"sublist1_start\">Other</td> </tr> <tr> <td class=\"sublist1\">Hyperkalemia, infiltrative malignancies, neonatal lupus syndrome, severe hypo- or hyperthyroidism, trauma, degenerative neuromuscular diseases</td> </tr> <tr> <td class=\"subtitle1_single\">Iatrogenic</td> </tr> <tr> <td class=\"sublist1_start\">Drugs</td> </tr> <tr> <td class=\"sublist1\">Beta blockers, calcium channel blockers, digoxin,&nbsp;adenosine, antiarrhythmic drugs</td> </tr> <tr> <td>Cardiac surgery</td> </tr> <tr> <td>Transcatheter aortic valve implantation</td> </tr> <tr> <td>Catheter ablation of arrhythmias</td> </tr> <tr> <td>Transcatheter closure of VSD</td> </tr> <tr> <td>Alcohol septal ablation for HCM</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VSD: ventricular septal defect; HCM: hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 62885 Version 5.0</div></div></div>"},"62886":{"type":"graphic_figure","displayName":"BMI chart PI","title":"Your body mass index (BMI)","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Your body mass index (BMI)</div><div class=\"cntnt\"><img style=\"width:604px; height:620px;\" src=\"images/PI/62886_BMI_chart_PI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Find your height (in feet and inches) in the top row. Then find your weight (in pounds) in the first column. Now find where the column for your height and the row for your weight meet. That is your BMI. For example, if you are 5-feet-9-inches tall and you weigh 260 pounds, your BMI is 38. You can also go online to www.uptodate.com/patients and search for &quot;BMI.&quot; There you will find a calculator that will tell you what your BMI is if you type in your height and weight.</div><div id=\"graphicVersion\">Graphic 62886 Version 3.0</div></div></div>"},"62887":{"type":"graphic_algorithm","displayName":"Eval proteinuria children","title":"Algorithm for evaluation of asymptomatic proteinuria in children","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of asymptomatic proteinuria in children</div><div class=\"cntnt\"><img style=\"width:548px; height:544px;\" src=\"images/PEDS/62887_Eval_proteinuria_children.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to&nbsp;UpToDate topics on the&nbsp;evaluation of proteinuria in children for further details.</div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen; C3: complement component 3; C4: complement component 4.<br />* For children between 6 and 24 months, the threshold value is 0.5 mg protein to mg creatinine.<br />Â¶ Persistent proteinuria, elevated blood pressure, and impaired renal function (elevated serum creatinine) are suggestive of renal parenchymal damage. Such patients should be referred to a pediatric nephrologist (or a clinician with expertise in the care of children with renal disease).</div><div class=\"graphic_reference\">Adapted with permission from: Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000; 105:1242.</div><div id=\"graphicVersion\">Graphic 62887 Version 3.0</div></div></div>"},"62888":{"type":"graphic_picture","displayName":"Mondini malformation","title":"Mondini malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mondini malformation</div><div class=\"cntnt\"><img style=\"width:358px; height:303px;\" src=\"images/PEDS/62888_Mondini_malformation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow indicates cochlea and vestibule reduced to a single cystic cavity.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 62888 Version 1.0</div></div></div>"},"62889":{"type":"graphic_table","displayName":"Diagnostic eval wheezing","title":"Approach to evaluation of wheezing in children based upon suspected diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to evaluation of wheezing in children based upon suspected diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Suspected diagnosis</td> <td class=\"subtitle1\">Signs and symptoms</td> <td class=\"subtitle1\">Diagnostic evaluation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Acute</td> </tr> <tr> <td class=\"indent1\">Asthma</td> <td>History of recurrent wheeze, cough, at least partial response to bronchodilator</td> <td>History, PFT with bronchodilators, empiric trial of bronchodilators, exercise or methacholine challenge testing, chest radiography only if atypical, skin (or in vitro) testing for aeroallergen sensitization if history suggests inhalant allergen triggers</td> </tr> <tr> <td class=\"indent1\">Viral bronchiolitis</td> <td>Prodrome with rhinitis, occurs in infancy and early childhood, seasonal pattern</td> <td>History, age, season, rapid antigen testing (RSV, influenza), viral cultures, chest radiography</td> </tr> <tr> <td class=\"indent1\">Foreign body</td> <td>Sudden onset of coughing and wheezing</td> <td>History, physical examination, chest radiography, bronchoscopy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Chronic</td> </tr> <tr> <td class=\"indent1\">Asthma</td> <td>As above</td> <td>As above</td> </tr> <tr> <td class=\"indent1\">Tracheomalacia</td> <td>Persistent wheeze, starts early in life, poor response to bronchodilators, varies with position and activity</td> <td>History, fluoroscopy, flexible bronchoscopy</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> <td>Chronic productive cough, crackles, with or without clubbing, failure to thrive, recurrent respiratory infections</td> <td>Sweat chloride test, genetic testing</td> </tr> <tr> <td class=\"indent1\">Swallowing dysfunction</td> <td>Neurologic abnormality (nonuniversal), choking with eating, symptoms exaggerated by feeding</td> <td><span style=\"color: black;\">Videofluoroscopic</span><span style=\"color: black;\">&nbsp;swallowing study (modified barium swallow)</span></td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux</td> <td>Symptoms sometimes related to eating, vomiting, refusal to eat, failure to thrive</td> <td><span style=\"color: black;\">24-hour esophageal pH monitoring, multichannel intraluminal impedance monitoring</span></td> </tr> <tr> <td class=\"indent1\">Vascular ring or sling</td> <td>Persistent symptoms, starts early in infancy, may be exaggerated by position, homophonous wheeze</td> <td>Barium swallow, MRI</td> </tr> <tr> <td class=\"indent1\">Tracheal stenosis</td> <td>Persistent symptoms, with or without stridor, homophonous wheeze</td> <td>Chest radiograph, CT scan, bronchoscopy</td> </tr> <tr> <td class=\"indent1\">Mediastinal nodes or mass</td> <td>Persistent symptoms, localized wheezing, no response to bronchodilator, systemic symptoms of underlying disease</td> <td>Chest radiograph, CT scan</td> </tr> <tr> <td class=\"indent1\">Immunodeficiency</td> <td>Recurrent sinopulmonary infections, crackles, FTT, clubbing</td> <td>Immunoglobulins, vaccine responses</td> </tr> <tr> <td class=\"indent1\">Primary ciliary dyskinesia</td> <td>Persistent sinusitis and otitis media with draining ears, recurrent respiratory infection, wet cough with sputum production, crackles, clubbing, FTT</td> <td>Ciliary biopsy, with or without genetic testing</td> </tr> <tr> <td class=\"indent1\">Vocal cord dysfunction</td> <td>Inspiratory stridor, poor response to bronchodilators, absent symptoms during sleep, teenage, exercise related</td> <td>Exercise testing, pulmonary function tests, laryngoscopy while symptomatic</td> </tr> <tr> <td class=\"indent1\">Bronchiolitis obliterans</td> <td>History of predisposing disease, ie, viral infection or transplantation, dyspnea, persistent wheezing</td> <td>Chest CT scan, lung biopsy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PFT: pulmonary function test; RSV: respiratory syncytial virus; MRI: magnetic resonance imaging; CT: computed tomography; FTT: failure to thrive.</div><div class=\"graphic_reference\">Data from: Dorkin HL. Noisy breathing. In: Respiratory Disease in Children: Diagnosis and Management, Loughlin GM, Eigen H (Eds), Williams and Wilkins 1994. p.171.</div><div id=\"graphicVersion\">Graphic 62889 Version 8.0</div></div></div>"},"62892":{"type":"graphic_table","displayName":"Causes of hypokalemia","title":"Major causes of hypokalemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of hypokalemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Decreased potassium intake</td> </tr> <tr> <td class=\"subtitle1_single\">Increased entry into cells</td> </tr> <tr> <td>An elevation in extracellular pH</td> </tr> <tr> <td>Increased availability of insulin</td> </tr> <tr> <td>Elevated &#946;-adrenergic activity - stress or administration of beta agonists</td> </tr> <tr> <td>Hypokalemic periodic paralysis</td> </tr> <tr> <td>Marked increase in blood cell production</td> </tr> <tr> <td>Hypothermia</td> </tr> <tr> <td>Chloroquine intoxication</td> </tr> <tr> <td class=\"subtitle1_single\">Increased gastrointestinal losses</td> </tr> <tr> <td>Vomiting</td> </tr> <tr> <td>Diarrhea</td> </tr> <tr> <td>Tube drainage</td> </tr> <tr> <td>Laxative abuse</td> </tr> <tr> <td class=\"subtitle1_single\">Increased urinary losses</td> </tr> <tr> <td>Diuretics</td> </tr> <tr> <td>Primary mineralocorticoid excess</td> </tr> <tr> <td>Loss of gastric secretions</td> </tr> <tr> <td>Nonreabsorbable anions</td> </tr> <tr> <td>Renal tubular acidosis</td> </tr> <tr> <td>Hypomagnesemia</td> </tr> <tr> <td>Amphotericin B</td> </tr> <tr> <td>Salt-wasting nephropathies - including Bartter's or Gitelman's syndrome</td> </tr> <tr> <td>Polyuria</td> </tr> <tr> <td class=\"subtitle1_single\">Increased sweat losses</td> </tr> <tr> <td class=\"subtitle1_single\">Dialysis</td> </tr> <tr> <td class=\"subtitle1_single\">Plasmapheresis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62892 Version 3.0</div></div></div>"},"62894":{"type":"graphic_table","displayName":"Comb modal tox HL","title":"Toxicities associated with combination chemotherapy and radiation therapy for Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toxicities associated with combination chemotherapy and radiation therapy for Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Acute toxicities</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Alopecia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nausea and vomiting</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diarrhea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mucositis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Paresthesias and neuropathy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>CNS confusion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anemia, leukopenia, and thrombocytopenia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Disulfiram-like reaction following alcohol while taking procarbazine</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Delayed toxicities</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Secondary malignancies</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Acute myelogenous leukemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Acute lymphoblastic leukemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Non-Hodgkin lymphoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Melanoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Sarcoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Breast, gastric, lung, and thyroid cancers</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Pulmonary complications</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Bleomycin lung toxicity</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Pulmonary fibrosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Cardiac complications</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Cardiomyopathy</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Accelerated atherosclerotic heart disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Pericardial fibrosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Endocrine complications</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Infertility</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hypothyroidism</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62894 Version 2.0</div></div></div>"},"62895":{"type":"graphic_table","displayName":"TNM staging esoph SCC","title":"TNM staging of esophageal squamous cell cancer (SCC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging of esophageal squamous cell cancer (SCC)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Primary tumor (T)<sup>*</sup></td> </tr> <tr> <td>TX</td> <td colspan=\"5\">Primary tumor cannot be assessed</td> </tr> <tr> <td>T0</td> <td colspan=\"5\">No evidence of primary tumor</td> </tr> <tr> <td>Tis</td> <td colspan=\"5\">High-grade dysplasia<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1_start\">T1 </td> <td class=\"sublist_other_start\" colspan=\"5\">Tumor invades lamina propria, muscularis mucosae, or submucosa </td> </tr> <tr> <td class=\"sublist1\">T1a </td> <td class=\"sublist_other\" colspan=\"5\">Tumor invades lamina propria or muscularis mucosae </td> </tr> <tr> <td class=\"sublist1\">T1b </td> <td class=\"sublist_other\" colspan=\"5\">Tumor invades submucosa </td> </tr> <tr> <td>T2 </td> <td colspan=\"5\">Tumor invades muscularis propria </td> </tr> <tr> <td>T3 </td> <td colspan=\"5\">Tumor invades adventitia </td> </tr> <tr> <td class=\"sublist1_start\">T4 </td> <td class=\"sublist_other_start\" colspan=\"5\">Tumor invades adjacent structures </td> </tr> <tr> <td class=\"sublist1\">T4a </td> <td class=\"sublist_other\" colspan=\"5\">Resectable tumor invading pleura, pericardium, or diaphragm </td> </tr> <tr> <td class=\"sublist1\">T4b </td> <td class=\"sublist_other\" colspan=\"5\">Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc. </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Regional lymph nodes (N)<sup>&#916;</sup> </td> </tr> <tr> <td>NX </td> <td colspan=\"5\">Regional lymph node(s) cannot be assessed </td> </tr> <tr> <td>N0 </td> <td colspan=\"5\">No regional lymph node metastasis </td> </tr> <tr> <td>N1 </td> <td colspan=\"5\">Metastasis in 1 to 2 regional lymph nodes </td> </tr> <tr> <td>N2 </td> <td colspan=\"5\">Metastasis in 3 to 6 regional lymph nodes </td> </tr> <tr> <td>N3 </td> <td colspan=\"5\">Metastasis in seven or more regional lymph nodes </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Distant metastasis (M) </td> </tr> <tr> <td>M0 </td> <td colspan=\"5\">No distant metastasis </td> </tr> <tr> <td>M1 </td> <td colspan=\"5\">Distant metastasis </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Histologic grade (G) </td> </tr> <tr> <td>GX </td> <td colspan=\"5\">Grade cannot be assessed - stage grouping as G1 </td> </tr> <tr> <td>G1 </td> <td colspan=\"5\">Well differentiated </td> </tr> <tr> <td>G2 </td> <td colspan=\"5\">Moderately differentiated </td> </tr> <tr> <td>G3 </td> <td colspan=\"5\">Poorly differentiated </td> </tr> <tr> <td>G4 </td> <td colspan=\"5\">Undifferentiated - stage grouping as G3 squamous </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Anatomic stage/prognostic groups </td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"6\">Squamous cell carcinoma<sup>&#9674; </sup></td> </tr> <tr> <td class=\"subtitle4\">Stage </td> <td class=\"subtitle4\">T </td> <td class=\"subtitle4\">N </td> <td class=\"subtitle4\">M </td> <td class=\"subtitle4\">Grade </td> <td class=\"subtitle4\">Tumor location<sup>&#167;</sup> </td> </tr> <tr> <td>0</td> <td>Tis (HGD)</td> <td>N0</td> <td>M0</td> <td>1, X</td> <td>Any</td> </tr> <tr> <td>IA</td> <td>T1</td> <td>N0</td> <td>M0</td> <td>1, X</td> <td>Any</td> </tr> <tr> <td rowspan=\"2\">IB </td> <td>T1</td> <td>N0</td> <td>M0</td> <td>2 to 3</td> <td>Any</td> </tr> <tr> <td>T2-3</td> <td>N0</td> <td>M0</td> <td>1, X</td> <td>Lower, X</td> </tr> <tr> <td rowspan=\"2\">IIA </td> <td>T2-3</td> <td>N0</td> <td>M0</td> <td>1, X</td> <td>Upper, middle</td> </tr> <tr> <td>T2-3</td> <td>N0</td> <td>M0</td> <td>2 to 3</td> <td>Lower, X</td> </tr> <tr> <td rowspan=\"2\">IIB </td> <td>T2-3</td> <td>N0</td> <td>M0</td> <td>2 to 3</td> <td>Upper, middle</td> </tr> <tr> <td>T1-2</td> <td>N1</td> <td>M0</td> <td>Any</td> <td>Any</td> </tr> <tr> <td rowspan=\"3\">IIIA </td> <td>T1-2</td> <td>N2</td> <td>M0</td> <td>Any</td> <td>Any</td> </tr> <tr> <td>T3</td> <td>N1</td> <td>M0</td> <td>Any</td> <td>Any</td> </tr> <tr> <td>T4a</td> <td>N0</td> <td>M0</td> <td>Any</td> <td>Any</td> </tr> <tr> <td>IIIB</td> <td>T3</td> <td>N2</td> <td>M0</td> <td>Any</td> <td>Any</td> </tr> <tr> <td rowspan=\"3\">IIIC </td> <td>T4a</td> <td>N1-2</td> <td>M0</td> <td>Any</td> <td>Any</td> </tr> <tr> <td>T4b</td> <td>Any</td> <td>M0</td> <td>Any</td> <td>Any</td> </tr> <tr> <td>Any</td> <td>N3</td> <td>M0</td> <td>Any</td> <td>Any</td> </tr> <tr> <td>IV</td> <td>Any</td> <td>Any</td> <td>M1</td> <td>Any</td> <td>Any</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_footnotes\">* At least maximal dimension of the tumor must be recorded and multiple tumors require the T(m) suffix.<br />Â¶&nbsp;High-grade dysplasia (HGD) includes all noninvasive neoplastic epithelia that were formerly called carcinoma in situ, a diagnosis that is no longer used for columnar mucosae anywhere in the gastrointestinal tract.<br />Î Number must be recorded for total number of regional nodes sampled and total number of reported nodes with metastasis.<br />â Or mixed histology including a squamous component or not&nbsp;otherwise specified&nbsp;(NOS).<br />Â§ Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 62895 Version 13.0</div></div></div>"},"62896":{"type":"graphic_figure","displayName":"Details of Ig gene rearrangement","title":"Details of immunoglobulin gene rearrangement","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Details of immunoglobulin gene rearrangement</div><div class=\"cntnt\"><img style=\"width:525px; height:343px;\" src=\"images/ALLRG/62896_Details_Ig_gene_rearrangeme.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) The heptamer and nonamer recombination signal sequences. The 3' flanking sequences of&nbsp;Vx genes have the palindromic heptamer recombination signal sequence, a 12 bp spacer, and the AT-rich nonamer signal sequence. The 5' flanking region of&nbsp;Jx genes contain the sequences in the reverse order, and separated by a 23 bp spacer. The immunoglobulin gene recombination mechanism only operates when one flanking sequence has a 12 bp spacer, and the other a 23 bp spacer (the 12 to 23 bp rule). The flanking sequences of&nbsp;lambda gene segments are identical, but transposed. VH genes have 3' 23 bp spacers, D genes are flanked both 5' and 3' with 12 bp spacers, and JH genes have 5' 23 bp spacers. <br />B) Genetic products of rearrangement. Rearrangement proceeds by deletion of intervening DNA. The two gene segments are joined, as are the two signal sequences in a separate circular piece of DNA. The excised circular DNA contains all of the sequence which stood between the gene segments before rearrangement. The arrow within the gene segments indicates the transcriptional orientation of the gene segment (the direction taken by RNA polymerase when synthesizing mRNA). The rearrangement break points are indicated by arrows marked \"X.\" <br />C) Consequences of imprecise gene segment joining. Ig gene segments need not always be spliced together at the same positions within their coding sequences. As long as the reading frame is maintained, a potentially functional protein may be generated. In the example here, four different in-frame splices are possible. Splicing at each position creates a codon for a different amino acid at the union of the two gene segments. Additional diversity may be generated by the random addition of nucleotides forming the N regions between the gene segments during splicing.</div><div class=\"graphic_footnotes\">Ig: immunoglobulin.</div><div class=\"graphic_reference\">Reproduced with permission from: Bona C, Bonilla FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright Â© 1996 Overseas Publishers Association, NV. Permission granted by Gordon and Breach Publishers.</div><div id=\"graphicVersion\">Graphic 62896 Version 6.0</div></div></div>"},"62897":{"type":"graphic_figure","displayName":"H6PDH deficiency","title":"Apparent cortisone reductase deficiency (H6PDH deficiency)","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Apparent cortisone reductase deficiency (H6PDH deficiency)</div><div class=\"cntnt\"><img style=\"width:602px; height:377px;\" src=\"images/ENDO/62897_H6PDH_deficiency.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62897 Version 3.0</div></div></div>"},"62898":{"type":"graphic_picture","displayName":"Tapetoretinal degeneration","title":"Tapetoretinal degeneration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tapetoretinal degeneration</div><div class=\"cntnt\"><img style=\"width:396px; height:273px;\" src=\"images/PEDS/62898_Tapetoretinal_degeneration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundoscopic appearance of a patient with Senior-Loken syndrome demonstrating tapetoretinal degeneration.</div><div id=\"graphicVersion\">Graphic 62898 Version 2.0</div></div></div>"},"62899":{"type":"graphic_table","displayName":"Major causes hypocalcemia","title":"Major causes of hypocalcemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of hypocalcemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Low PTH (hypoparathyroidism)</td> </tr> <tr> <td class=\"sublist2_start\">Genetic disorders</td> </tr> <tr> <td class=\"sublist2\">Abnormal parathyroid gland development</td> </tr> <tr> <td class=\"sublist2\">Abnormal PTH synthesis</td> </tr> <tr> <td class=\"sublist2\">Activating mutations of calcium-sensing receptor (autosomal dominant hypocalcemia or sporadic isolated hypoparathyroidism)</td> </tr> <tr> <td class=\"indent1\">Postsurgical (thyroidectomy, parathyroidectomy, radical neck dissection)</td> </tr> <tr> <td class=\"sublist2_start\">Autoimmune</td> </tr> <tr> <td class=\"sublist2\">Autoimmune polyglandular syndrome (associated with chronic mucocutaneous candidiasis and primary adrenal insufficiency)</td> </tr> <tr> <td class=\"sublist2\">Isolated hypoparathyroidism due to activating antibodies to calcium-sensing receptor</td> </tr> <tr> <td class=\"indent1\">Infiltration of the parathyroid gland (granulomatous, iron overload, metastases)</td> </tr> <tr> <td class=\"indent1\">Radiation-induced destruction parathyroid glands</td> </tr> <tr> <td class=\"indent1\">Hungry bone syndrome (post-parathyroidectomy)</td> </tr> <tr> <td class=\"indent1\">HIV infection</td> </tr> <tr> <td class=\"subtitle1_single\">High PTH (secondary hyperparathyroidism in response to hypocalcemia)</td> </tr> <tr> <td class=\"sublist2_start\">Vitamin D deficiency or resistance</td> </tr> <tr> <td class=\"sublist2\">Multiple causes</td> </tr> <tr> <td class=\"sublist2_start\">PTH&nbsp;resistance</td> </tr> <tr> <td class=\"sublist2\">Missense mutation in PTH</td> </tr> <tr> <td class=\"sublist2\">Pseudohypoparathyroidism</td> </tr> <tr> <td class=\"sublist2\">Hypomagnesemia</td> </tr> <tr> <td class=\"indent1\">Renal disease</td> </tr> <tr> <td class=\"sublist2_start\">Loss of calcium from the circulation</td> </tr> <tr> <td class=\"sublist2\">Hyperphosphatemia</td> </tr> <tr> <td class=\"sublist2\">Tumor lysis</td> </tr> <tr> <td class=\"sublist2\">Acute pancreatitis</td> </tr> <tr> <td class=\"sublist2\">Osteoblastic metastases</td> </tr> <tr> <td class=\"sublist2\">Acute respiratory alkalosis</td> </tr> <tr> <td class=\"sublist2\">Sepsis or acute severe illness</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td class=\"indent1\">Inhibitors of bone resorption (bisphosphonates, calcitonin, denosumab), especially in vitamin D deficiency</td> </tr> <tr> <td class=\"indent1\">Cinacalcet</td> </tr> <tr> <td class=\"indent1\">Calcium chelators (EDTA, citrate, phosphate)</td> </tr> <tr> <td class=\"indent1\">Foscarnet (due to intravascular complexing with calcium)</td> </tr> <tr> <td class=\"indent1\">Phenytoin (due to conversion of vitamin D to inactive metabolites)</td> </tr> <tr> <td class=\"indent1\">Fluoride poisoning</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of magnesium metabolism</td> </tr> <tr> <td class=\"indent1\">Hypomagnesemia can reduce PTH secretion or cause PTH resistance and is therefore associated with normal, low, or high PTH levels</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTH: parathyroid hormone; HIV: human immunodeficiency virus; EDTA: ethylenediaminetetraacetic acid.</div><div class=\"graphic_reference\">Data from: Thakker RV. Hypocalcemia: Pathogenesis, differential diagnosis, and management. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, sixth edition, American Society of Bone and Mineral Research 2006; 35:213.</div><div id=\"graphicVersion\">Graphic 62899 Version 7.0</div></div></div>"},"62903":{"type":"graphic_table","displayName":"Staging of pressure-induced skin and soft tissue injuries","title":"Staging of pressure-induced skin and soft tissueÂ injuries*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Staging of pressure-induced skin and soft tissue&nbsp;injuries*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage </td> <td class=\"subtitle1\">Description </td> </tr> <tr> <td>1</td> <td>Skin intact but with non-blanchable redness for &#62;1 hour after relief of pressure.</td> </tr> <tr> <td>2</td> <td>Blister or other break in the dermis with partial thickness loss of dermis, with or without infection.</td> </tr> <tr> <td>3</td> <td>Full thickness tissue loss. Subcutaneous fat may be visible; destruction extends into muscle with or without infection. Undermining and tunneling may be present.</td> </tr> <tr> <td>4</td> <td>Full thickness skin loss with involvement of bone, tendon, or joint, with or without infection. Often includes undermining and tunneling.</td> </tr> <tr> <td>Unstageable</td> <td>Full thickness tissue loss in which the base of the ulcer is covered by slough and/or eschar in the wound bed.</td> </tr> <tr> <td>Suspected deep tissue injury</td> <td>Purple or maroon localized area of discolored intact skin or blood-filled blister due to damage of underlying tissue from pressure and/or shear.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* From the National Pressure Ulcer Advisory Panel.</div><div id=\"graphicVersion\">Graphic 62903 Version 4.0</div></div></div>"},"62905":{"type":"graphic_table","displayName":"Intraarticular steroid indications","title":"Indications and relative contraindications for intraarticular corticosteroid injection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications and relative contraindications for intraarticular corticosteroid injection</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Indications</td> </tr> <tr> <td>Rheumatoid arthritis, persistent activity in large- or medium-sized joints in which injection may slow erosion</td> </tr> <tr> <td>Other inflammatory arthritides erosive or not, but particularly if oligoarticular, eg, Reiters, gout, psoriatic arthritis, other spondyloarthropathy</td> </tr> <tr> <td>Osteoarthritis of large weightbearing joint (knee) with bone on bone pain and eventual total joint arthroplasty planned or accepted already</td> </tr> <tr> <td>Small joint osteoarthritis, eg, of the first carpometacarpal, especially with slight inflammatory component on physical exam</td> </tr> <tr> <td>Subdeltoid bursitis or rotator cuff tendonitis, first presentation or already investigated radiologically</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Relative contraindications</td> </tr> <tr> <td>Rheumatoid arthritis in small joints of hand in which soft tissue support is necessary to prevent deformity is subject to atrophy</td> </tr> <tr> <td>Rheumatoid arthritis, one joint out of proportion to others; infection suspect, culture on first athrocentesis before injection</td> </tr> <tr> <td>Other monoarthritis suspected of sepsis, especially in diabetes</td> </tr> <tr> <td>Early osteoarthritis in which cartilage repair may be important</td> </tr> <tr> <td>Small joint osteoarthritis which failed to respond for six weeks to previous injection</td> </tr> <tr> <td>Subacute shoulder pain not responsive to previous injection</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62905 Version 3.0</div></div></div>"},"62906":{"type":"graphic_table","displayName":"S-LANSS","title":"S-LANSS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">S-LANSS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"2\"><strong>1.</strong> In the area where you have pain, do you also have 'pins and needles', tingling or prickling sensations?</td> </tr> <tr> <td class=\"indent1\">a) NO - I don't get these sensations</td> <td>(0)</td> </tr> <tr> <td class=\"indent1\">b) YES - I get these sensations often</td> <td>(5)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>2.</strong> Does the painful area change colour (perhaps looks mottled or more red) when the pain is particularly bad?</td> </tr> <tr> <td class=\"indent1\">a) NO - The pain does not affect the colour of my skin</td> <td>(0)</td> </tr> <tr> <td class=\"indent1\">b) YES - I have noticed that the pain does make my skin look different from normal</td> <td>(5)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>3.</strong> Does your pain make the affected skin abnormally sensitive to touch? Getting unpleasant sensations or pain when lightly stroking the skin might describe this.</td> </tr> <tr> <td class=\"indent1\">a) NO - The pain does not make my skin in that area abnormally sensitive to touch</td> <td>(0)</td> </tr> <tr> <td class=\"indent1\">b) YES - My skin in that area is particularly sensitive to touch</td> <td>(3)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>4.</strong> Does your pain come on suddenly and in bursts for no apparent reason when you are completely still? Words like 'electric shocks', jumping and bursting might describe this.</td> </tr> <tr> <td class=\"indent1\">a) NO - My pain doesn't really feel like this</td> <td>(0)</td> </tr> <tr> <td class=\"indent1\">b) YES - I get these sensations often</td> <td>(2)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>5.</strong> In the area where you have pain, does your skin feel unusually hot like a burning pain?</td> </tr> <tr> <td class=\"indent1\">a) NO - I don't have burning pain</td> <td>(0)</td> </tr> <tr> <td class=\"indent1\">b) YES - I get burning pain often</td> <td>(1)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>6.</strong> Gently <strong>rub</strong> the painful area with your index finger and then rub a non-painful area (for example, an area of skin further away or on the opposite side from the painful area). How does this rubbing feel in the painful area?</td> </tr> <tr> <td class=\"indent1\">a) The painful area feels no different from the non-painful area</td> <td>(0)</td> </tr> <tr> <td class=\"indent1\">b) I feel discomfort, like pins and needles, tingling or burning in the painful area that is different from the non-painful area</td> <td>(5)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>7.</strong> Gently <strong>press</strong> on the painful area with your finger tip then gently press in the same way onto a non-painful area (the same non-painful area that you chose in the last question). How does this feel in the painful area?</td> </tr> <tr> <td class=\"indent1\">a) The painful area does not feel different from the non-painful area</td> <td>(0)</td> </tr> <tr> <td class=\"indent1\">b) I feel numbness or tenderness in the painful area that is different from the non-painful area</td> <td>(3)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>SCORING: A score of 12 or more suggests pain of predominantly neuropathic origin.</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Bennet, MI, Smith, BH, Torrance, N, et al. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain 2005; 6:149. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 62906 Version 2.0</div></div></div>"},"62907":{"type":"graphic_table","displayName":"Isolation P marneffei","title":"Sources of isolation of organism in HIV-infected patients with <em>Penicillium marneffei</em> infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sources of isolation of organism in HIV-infected patients with <em>Penicillium marneffei</em> infection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n <tr>\n    <td class=\"subtitle1\" rowspan=\"2\">Specimen</td>\n    <td class=\"subtitle1\" colspan=\"2\">Number of cases/total</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2\">Thailand<sup>[1]</sup></td>\n    <td class=\"subtitle2\">India<sup>[2]</sup></td>\n  </tr>\n  <tr>\n    <td>Blood</td>\n    <td>59/78</td>\n    <td>&nbsp;</td>\n  </tr>\n  <tr>\n    <td>Skin</td>\n    <td>47/52</td>\n    <td>10/10</td>\n  </tr>\n  <tr>\n    <td>Lymph node</td>\n    <td>9/9</td>\n    <td>&nbsp;</td>\n  </tr>\n  <tr>\n    <td>Bone marrow</td>\n    <td>26/26</td>\n    <td>N/A</td>\n  </tr>\n  <tr>\n    <td>Sputum</td>\n    <td>14/41</td>\n    <td>1/1</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from:<br> 1. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344:110.<br> 2. Ranjana KH, Priyokumar K, Singh TJ, et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect Dis 2002; 45:268.</div><div id=\"graphicVersion\">Graphic 62907 Version 1.0</div></div></div>"},"62908":{"type":"graphic_movie","displayName":"Bronchial obstruction","title":"Central airway obstruction","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central airway obstruction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/62908_trachobsconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:338px; height:236px;\" src=\"images/CARD/62908_trachobs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Video shows severe, bilateral bronchial obstruction and widening of the main carina due to growth of bronchogenic adenocarcinoma into the lower third of the trachea.</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD and Praveen Mathur, MD.</div><div id=\"graphicVersion\">Graphic 62908 Version 2.0</div></div></div>"},"62909":{"type":"graphic_waveform","displayName":"Echo complex tutorial","title":"Reciprocal complex (echo beat","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reciprocal complex (echo beat</div><div class=\"cntnt\"><img style=\"width:320px; height:140px;\" src=\"images/CARD/62909_Echo_complex_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A ventricular premature beat is followed by a retrograde P wave due to retrograde conduction through the atrioventricular (AV) node. Subsequent antegrade conduction through the AV node results in a normal QRS complex after a long PR interval.</div><div id=\"graphicVersion\">Graphic 62909 Version 3.0</div></div></div>"},"62910":{"type":"graphic_picture","displayName":"Contralateral breast management","title":"Contralateral reduction mammoplasty for symmetry","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Contralateral reduction mammoplasty for symmetry</div><div class=\"cntnt\"><img style=\"width:550px; height:281px;\" src=\"images/ONC/62910_Contralateral_breast_manage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following right mastectomy, the patient had an immediate right breast reconstruction with an expander followed by an anatomic saline implant. Reduction mammoplasty of the contralateral side was performed to restore symmetry. Left panel: preoperative appearance; right panel: postoperative appearance.</div><div class=\"graphic_reference\">Courtesy of Jorge de la Pedraja, MD.</div><div id=\"graphicVersion\">Graphic 62910 Version 2.0</div></div></div>"},"62912":{"type":"graphic_table","displayName":"Treatment diarrhea pts on IFL","title":"Recommendations of an independent panel for management of diarrhea in patients receiving the IFL regimen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations of an independent panel for management of diarrhea in patients receiving the IFL regimen</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical presentation</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr> <td>Diarrhea, any grade</td> <td>Oral loperamide (2 mg every two hours) until diarrhea-free for &#8805;12 hours</td> </tr> <tr> <td>Diarrhea persists on loperamide &#62;24 hours</td> <td>Oral fluoroquinolone for seven days</td> </tr> <tr> <td>Diarrhea persists on loperamide &#62;48 hours</td> <td>Stop loperamide; hospitalize the patient, adminsiter IV fluids</td> </tr> <tr> <td>Neutropenic (ANC &#60;500 microL), even in the absence of fever or diarrhea</td> <td>Oral fluoroquinolone, continue until resolution of neutropenia</td> </tr> <tr> <td>Fever with persistent diarrhea, even in absence of neutropenia</td> <td>Oral fluoroquinolone, continue until resolution of fever and diarrhea</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IFL: irinotecan, fluorouracil, leucovorin; IV: intravenous; ANC: absolute neutrophil count.</div><div class=\"graphic_reference\">Rothenberg ML, Meropol NJ,&nbsp;Polin EA, et&nbsp;al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19:3801.</div><div id=\"graphicVersion\">Graphic 62912 Version 5.0</div></div></div>"},"62913":{"type":"graphic_form","displayName":"Patient data flow sheet","title":"Patient data flow sheet","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Patient data flow sheet</div><div class=\"cntnt\"><img style=\"width:589px; height:766px;\" src=\"images/ENDO/62913_Patient_data_flow_sheet.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* A: Alert; D: Drowsy; S: Stuporous; C: Comatose.<br> â¢ D: Deep; S: Shallow; N: Normal.<br>Î [2 x Na (meq/L)] + [glucose (mg/dL) Ã· 18].</div><div id=\"graphicVersion\">Graphic 62913 Version 2.0</div></div></div>"},"62914":{"type":"graphic_picture","displayName":"High cytokeratin stain","title":"Idiopathic adulthood ductopenia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic adulthood ductopenia</div><div class=\"cntnt\"><img style=\"width:432px; height:322px;\" src=\"images/GAST/62914_High_cytokeratin_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a portal triad from a liver biopsy using a CK7 cytokeratin immunostain specific for biliary epithelium from an adult with idiopathic ductopenia. The portal tract lacks a bile duct but is surrounded by brown staining, representing focal ductular proliferation.</div><div class=\"graphic_reference\">Courtesy of John Hart, MD.</div><div id=\"graphicVersion\">Graphic 62914 Version 2.0</div></div></div>"},"62916":{"type":"graphic_picture","displayName":"Scalp folliculitis","title":"Scalp folliculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scalp folliculitis</div><div class=\"cntnt\"><img style=\"width:389px; height:260px;\" src=\"images/DERM/62916_Scalp_folliculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustules are evident on the scalp.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 62916 Version 2.0</div></div></div>"},"62917":{"type":"graphic_figure","displayName":"Sural nerve","title":"Sural nerve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sural nerve</div><div class=\"cntnt\"><img style=\"width:392px; height:402px;\" src=\"images/SURG/62917_Sural_nerve_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sural nerve is a cutaneous nerve that is closely associated with the small saphenous vein as it travels distally to the lateral foot.</div><div id=\"graphicVersion\">Graphic 62917 Version 3.0</div></div></div>"},"62918":{"type":"graphic_diagnosticimage","displayName":"Resting myocardial perfusion imaging in ischemia","title":"Acute rest technetium 99m sestamibi myocardial perfusion imaging in myocardial ischemia","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Acute rest technetium 99m sestamibi myocardial perfusion imaging in myocardial ischemia</div><div class=\"cntnt\"><img style=\"width:570px; height:410px;\" src=\"images/CARD/62918_Resting_scan_in_ischemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute rest myocardial perfusion imaging (upper rows) in a 38-year-old white man evaluated in the emergency department for atypical chest pain and a nondiagnostic electrocardiogram. There is an inferior defect which resolves on rest images obtained after stabilization with medical therapy (arrow). Gated SPECT (panel A) revealed hypokinesis in the area of the defect and allowed rapid estimation of the systolic function. The patient underwent emergent coronary angiography for recurrence of chest pain with subsequent ST elevation in the inferior leads, and was found to have an occluded right coronary artery. Successful coronary angioplasty was performed.</div><div class=\"graphic_footnotes\">SPECT: single-photon emission computed tomography.</div><div class=\"graphic_reference\">Courtesy of Gary Heller, MD.</div><div id=\"graphicVersion\">Graphic 62918 Version 4.0</div></div></div>"},"62919":{"type":"graphic_table","displayName":"Differential diagnosis of BWS - Genetic disorders","title":"Differential diagnosis of Beckwith-Wiedemann syndrome - Genetic disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of Beckwith-Wiedemann syndrome - Genetic disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Diagnostic testing</td> <td class=\"subtitle1\">Main characteristics</td> </tr> <tr> <td>Simpson-Golabi-Behmel syndrome</td> <td>Yes</td> <td>Macrocephaly, coarse facies, ocular hypertelorism, broad flat nose, macrostomia, macroglossia, cleft lip, nail hypoplasia, macrosomia, visceromegaly, skeletal abnormalities, increased risk for embryonal tumor(s)</td> </tr> <tr> <td>Costello syndrome</td> <td>Yes</td> <td>Coarse facies, loose skin, diffuse hypotonia, joint laxity, sparse fine hair, failure to thrive, increased risk for malignant solid tumors</td> </tr> <tr> <td>Perlman syndrome</td> <td>Yes</td> <td>Macrosomia, unusual facies (depressed nasal bridge, anteverted upper lip, mild micrognathia), intellectual disability, increased risk for Wilms tumor</td> </tr> <tr> <td>Sotos syndrome (cerebral gigantism)</td> <td>Yes</td> <td>Macrosomia, macrocephaly, ventriculomegaly, typical facial appearance, advanced bone age, intellectual disability</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62919 Version 3.0</div></div></div>"},"62922":{"type":"graphic_table","displayName":"Stages hepatic encephalopathy","title":"Grading system for hepatic encephalopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading system for hepatic encephalopathy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Grade</td>\n\n      <td class=\"subtitle1\">Mental status</td>\n\n      <td class=\"subtitle1\">Asterixis</td>\n\n      <td class=\"subtitle1\">EEG</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"4\">I</td>\n\n      <td>Euphoria/depression</td>\n\n      <td colspan=\"1\" rowspan=\"4\">Yes/no</td>\n\n      <td colspan=\"1\" rowspan=\"4\">Usually normal</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>Mild confusion</td>\n      \n      \n    </tr>\n    <tr>\n      \n      <td>Slurred speech</td>\n      \n      \n    </tr>\n    <tr>\n      \n      <td>Disordered sleep</td>\n      \n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">II</td>\n\n      <td>Lethargy</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Yes</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Abnormal</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>Moderate confusion</td>\n      \n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\">III</td>\n\n      <td>Marked confusion&nbsp;</td>\n\n      <td colspan=\"1\" rowspan=\"3\">Yes</td>\n\n      <td colspan=\"1\" rowspan=\"3\">Abnormal</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>Incoherent</td>\n      \n      \n    </tr>\n    <tr>\n      \n      <td>Sleeping but arousable</td>\n      \n      \n    </tr>\n    <tr>\n\n      <td>IV</td>\n\n      <td>Coma</td>\n\n      <td>No</td>\n\n      <td>Abnormal</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62922 Version 1.0</div></div></div>"},"62925":{"type":"graphic_diagnosticimage","displayName":"Brain MRI age 13 years juvenile Alexander disease","title":"Brain MRI, T2-weighted images, of a 13-year-old with juvenile Alexander disease","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Brain MRI, T2-weighted images, of a 13-year-old with juvenile Alexander disease</div><div class=\"cntnt\"><img style=\"width:468px; height:212px;\" src=\"images/NEURO/62925_MRI_juv_13yr_Alex_Dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal: symmetric lesions in the medulla oblongata at the level of the vestibular nuclei and the corticospinal tract.<br />(B) Axial: symmetric intramedullary lesions extending from the craniocervical level down to the middle of the cervical spine.<br />(C) Axial: normal cerebral white matter and basal ganglia.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Probst EN, Hagel C, Weisz V, et al. Atypical focal MRI lesions in a case of juvenile Alexander's disease. Ann Neurol 2003; 53:118. Copyright &copy;2003 John Wiley and Sons, Inc.</div><div id=\"graphicVersion\">Graphic 62925 Version 3.0</div></div></div>"},"62926":{"type":"graphic_table","displayName":"Tumor vertebral pain synd","title":"Tumor-related vertebral pain syndromes in cancer patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tumor-related vertebral pain syndromes in cancer patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td class=\"subtitle1\">Syndrome</td>\n    <td class=\"subtitle1\">Characteristics</td>\n  </tr>\n  <tr>\n    <td rowspan=\"2\">Atlantoaxial destruction and odontoid fracture</td>\n    <td>Nuchal or occipital pain that often radiates over the posterior aspect of the skull</td>\n  </tr>\n  <tr>\n    <td>Patients usually present with insidious neurological deficits in one or more extremities</td>\n  </tr>\n  <tr>\n    <td>C7-T1 syndrome</td>\n    <td>Pain in the interscapular region caused by tumor invasion of a C7 or T1 vertebra</td>\n  </tr>\n  <tr>\n    <td>T12-L1 syndrome</td>\n    <td>Referred pain at the ipsilateral crest or sacroiliac joint caused by tumor invasion of a T12 or L1 vertebra</td>\n  </tr>\n  <tr>\n    <td rowspan=\"2\">Sacral syndrome</td>\n    <td>Pain radiating to buttocks, perineum, or posterior thighs</td>\n  </tr>\n  <tr>\n    <td>Intense pain with hip adduction and internal rotation due to stretching of pyriformis muscle</td>\n  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 62926 Version 1.0</div></div></div>"},"62927":{"type":"graphic_figure","displayName":"Ileal brake","title":"Peptide YY and the \"ileal brake\"","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Peptide YY and the &quot;ileal brake&quot;</div><div class=\"cntnt\"><img style=\"width:514px; height:434px;\" src=\"images/GAST/62927_Ileal_brake_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the ileal brake where exposure of the distal ileum to fat and/or unabsorbed nutrients decreases gastric emptying, pancreatic secretion, and bowel motility. This response is mediated, in part, by peptide YY.</div><div class=\"graphic_reference\">Modified from: Mannon P, Taylor IL. The Pancreatic Polypeptide Family. In: Gut Peptides, Biochemistry and Physiology, Walsh JH, Dockray JG (Eds), Raven Press Ltd, New York 1994. p.341.</div><div id=\"graphicVersion\">Graphic 62927 Version 3.0</div></div></div>"},"62928":{"type":"graphic_figure","displayName":"Heart rate variability HF","title":"Absence of heart rate variability predicts mortality in HF","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Absence of heart rate variability predicts mortality in HF</div><div class=\"cntnt\"><img style=\"width:458px; height:296px;\" src=\"images/CARD/62928_Heart_rate_variability_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among patients with heart failure (HF), the absence of heart rate variability, defined as a standard deviation of RR intervals (SDNN) less than 50 msec was associated with a 51.4 percent annual mortality compared to 5.5 percent in those who had an SDNN greater than 100 msec and 12.7 percent in those who had an SDNN of 50 to 100 msec (p&lt;0.0001).</div><div class=\"graphic_reference\">Data from: Nolan J, Batin PD, Andrews R, et al. Circulation 1998; 98:1510.</div><div id=\"graphicVersion\">Graphic 62928 Version 4.0</div></div></div>"},"62929":{"type":"graphic_diagnosticimage","displayName":"Tibial spine fracture","title":"Intraarticular fracture of the tibial spine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraarticular fracture of the tibial spine</div><div class=\"cntnt\"><img style=\"width:396px; height:387px;\" src=\"images/RHEUM/62929_Tibial_spine_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior view of the knee demonstrates an intraarticular fracture of the tibial spine (arrow).</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 62929 Version 2.0</div></div></div>"},"62930":{"type":"graphic_picture","displayName":"Folliculitis in dark skin","title":"Folliculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Folliculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/62930_Folliculitisdarkskin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small, inflammatory papules and pustules are present in this patient with folliculitis. Erythema is difficult to appreciate due to dark skin pigmentation. Postinflammatory hyperpigmentation is also present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62930 Version 4.0</div></div></div>"},"62931":{"type":"graphic_figure","displayName":"Lateral ligament of the rectum","title":"Lateral ligament of the rectum","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Lateral ligament of the rectum</div><div class=\"cntnt\"><img style=\"width:513px; height:486px;\" src=\"images/SURG/62931_lateral-ligament.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts&nbsp;a lateral ligament of the rectum, which is comprised of the fascia propria. Typically, this is an avascular structure, but it can contain small arterial and venous vessels.</div><div id=\"graphicVersion\">Graphic 62931 Version 3.0</div></div></div>"},"62933":{"type":"graphic_figure","displayName":"PTH effect skeletal architecture","title":"Effect of teriparatide PTH (20 mcg) on skeletal architecture","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Effect of teriparatide PTH (20 mcg) on skeletal architecture</div><div class=\"cntnt\"><img style=\"width:525px; height:237px;\" src=\"images/ENDO/62933_PTH_effect_skeletal_archit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Neer et al trial (NEJM 2001), one biopsy in one subject shows significant changes in bone architecture.</div><div class=\"graphic_footnotes\">PTH: parathyroid hormone.</div><div class=\"graphic_reference\">Reproduced from: Jiang, Y, Zhao, JJ, Mitlak, BH, Wang, O, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18:1932. Copyright Â©American Society for Bone and Mineral Research.</div><div id=\"graphicVersion\">Graphic 62933 Version 4.0</div></div></div>"},"62934":{"type":"graphic_table","displayName":"CSF drug conc with inflammation","title":"Peak CSF concentrations of cephalosporins in bacterial meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Peak CSF concentrations of cephalosporins in bacterial meningitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Cephalothin</td> <td>0.16-0.31 &#181;g/mL</td> </tr> <tr> <td>Cefoxitin</td> <td>&#60;1.56-12.5 &#181;g/mL</td> </tr> <tr> <td>Cefuroxime</td> <td>4.3-9.3 &#181;g/mL</td> </tr> <tr> <td>Cefotaxime</td> <td>6.8-27.2 &#181;g/mL</td> </tr> <tr> <td>Ceftriaxone</td> <td>2-42 &#181;g/mL</td> </tr> <tr> <td>Ceftazidime</td> <td>2.5-30 &#181;g/mL</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62934 Version 3.0</div></div></div>"},"62935":{"type":"graphic_movie","displayName":"MR post MI parasternal long axis echo with closeup","title":"Mitral regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/62935_palaxzmrconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:244px; height:360px;\" src=\"images/CARD/62935_palaxzmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal long axis view from a 2-D echocardiogram with a close up of the mitral valve (MV) shows a posterior leaflet that has limited mobility and fails to close properly with systole.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 62935 Version 2.0</div></div></div>"},"62937":{"type":"graphic_picture","displayName":"Stage III membranous nephropathy","title":"Electron micrograph in stage III membranous nephropathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph in stage III membranous nephropathy</div><div class=\"cntnt\"><img style=\"width:376px; height:255px;\" src=\"images/NEPH/62937_StgIII_membranous_nephrpthy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in stage III membranous nephropathy. The subepithelial immune deposits (asterisk) have a lucent, moth-eaten appearance and have been incorporated into the glomerular basement membrane (Î) as new basement membrane has grown around the deposits (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 62937 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"62939":{"type":"graphic_table","displayName":"Modified FOLFOX6 plus bevacizumab chemotherapy","title":"Modified FOLFOX6 plus bevacizumab chemotherapy for advanced colorectal cancer<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified FOLFOX6 plus bevacizumab chemotherapy for advanced colorectal cancer<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Bevacizumab</td> <td>5 mg/kg IV</td> <td>Dilute into a total volume of 100 mL normal saline (NS).* Administer first dose over 90 minutes following oxaliplatin and leucovorin. If well tolerated, the second infusion may be administered over 60 minutes after chemotherapy. If well tolerated, all subsequent doses may be administered over 10 to 30 minutes before chemotherapy.<sup>&#182;</sup><sup>[3,4]</sup></td> <td>Day 1</td> </tr> <tr> <td>Oxaliplatin</td> <td>85 mg/m<sup>2</sup> IV<sup>&#916;</sup></td> <td>Dilute with 500 mL 5% dextrose in water (D5W)* and administer over two hours (on days 1 and 15, oxaliplatin and leucovorin can be administered concurrently in separate bags using a Y-connector).</td> <td>Day 1</td> </tr> <tr> <td>Leucovorin<sup>&#9674;</sup></td> <td>400 mg/m<sup>2</sup> IV<sup>&#167;</sup></td> <td>Dilute with 250 mL D5W* and administer over two hours, concurrent with oxaliplatin.</td> <td>Day 1</td> </tr> <tr> <td>Fluorouracil (FU)</td> <td>400 mg/m<sup>2</sup> IV bolus</td> <td>Slow IV push over five minutes (administer immediately after leucovorin).</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>FU</td> <td>2400 mg/m<sup>2</sup> IV</td> <td>Dilute with 500 to 1000 mL D5W and administer over 46 hours (begin immediately after FU IV bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin and FU are classified as irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors not justified (estimated risk of febrile neutropenia &#60;5%<sup>[2]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of oxaliplatin may be needed for severe renal impairment.<sup>[5]</sup> A lower starting dose of FU may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in blood pressure, urine protein concentration, neurologic function, and risk for bleeding prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment cycle one week for total white blood cell count &#60;3000/microL, absolute neutrophil count &#60;1500/microL, or platelets &#60;75,000/microL on the day of treatment. If treatment is delayed for two weeks or delayed for one week on two separate occasions, eliminate FU bolus. With the second occurrence, reduce infusional FU by 20% and reduce oxaliplatin dose from 85 to 65 mg/m<sup>2</sup>. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For transient grade 3 paresthesias/dysesthesias or grade 2 symptoms lasting longer than seven days, decrease oxaliplatin dose by 25%. Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia.<sup>[2]</sup> The United States Prescribing Information recommends a dose reduction in oxaliplatin to 65 mg/m<sup>2</sup> for persistent grade 2 neurosensory events that do not resolve, and discontinuation for persistent grade 3 neurosensory events.<sup>[5]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Withhold FU for grade 2 or worse diarrhea, and restart at a lower dose after complete resolution.<sup>[6]</sup> The United States Prescribing Information recommends dose reduction of oxaliplatin to 65 mg/m<sup>2</sup> as well as a reduction of bolus FU and infusional FU after recovery from grade 3 or 4 diarrhea during the prior cycle.<sup>[5]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicities</strong></td> <td colspan=\"3\"> <ul> <li>Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy, serious hemorrhage, arterial thromboembolism, nephrotic syndrome, gastrointestinal perforation, fistula formation, or reversible posterior leukoencephalopathy syndrome (RPLS).<sup>[3]</sup> Do not administer bevacizumab within 28 days of surgery; suspend prior to elective surgery. </li> <li>Refer to UpToDate topics on \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\" and \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; ECG: electrocardiogram; CBC: complete blood count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Â¶ For the 5 mg/kg dose, many clinicians administer the first dose over 60 minutes and if well tolerated, subsequent doses are administered over 10 minutes.<SUP>[4]</SUP><br />Î Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.<br /><FONT class=lozenge>â</FONT> Leucovorin dose is given for d,l-racemic mixture.<SUP>[7]</SUP> Use half the dose for LEVOleucovorin (l-leucovorin).<br />Â§ The dose of leucovorin in the two trials of modified FOLFOX6 was 350 mg/m<SUP>2</SUP>. However, most clinicians use the standard 400 mg/m<SUP>2</SUP> doses as was used for original FOLFOX6.<SUP>[8]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cheeseman SL, et al. Br J Cancer 2002; 87:393.</LI>&#xD;&#xA;<LI>Hochster HS, et al. J Clin Oncol 2008; 26:3523.</LI>&#xD;&#xA;<LI>Bevacizumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Reidy DL, et al. J Clin Oncol 2007; 25:2691.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Tournigand C, et al. J Clin Oncol 2004; 22:229.</LI></OL></div><div id=\"graphicVersion\">Graphic 62939 Version 31.0</div></div></div>"},"62941":{"type":"graphic_table","displayName":"ASGE guideline personnel propaf","title":"Appropriate personnel and equipment for propofol use in an endoscopic procedure room","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Appropriate personnel and equipment for propofol use in an endoscopic procedure room</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>At least one person who is qualified in both basic and advanced life support skills (ie, tracheal intubation, defibrillation, use of resuscitation medications)</td>\n</tr>\n<tr>\n<td>Physiologic monitoring should include pulse oximetry, electrocardiography, and automated blood pressure measurement. Monitoring oxygenation by pulse oximetry is not a substitute for monitoring ventilatory function</td>\n</tr>\n<tr>\n<td>Equipment for airway management and resuscitation</td>\n</tr>\n<tr>\n<td>Trained personnel dedicated to the continuous and uninterrupted monitoring of the patient's physiologic parameters and administration of propofol</td>\n</tr>\n<tr>\n<td>Extended monitoring with capnography should be considered as it may decrease the risks during deep sedation</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Faigel DO, Baron TH, Goldstein JL, et al. Guidelines for the use of deep sedation and anesthesia for GI endoscopy. Gastrointest Endosc 2002; 56:613. Copyright Â© 2002 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 62941 Version 2.0</div></div></div>"},"62942":{"type":"graphic_figure","displayName":"Location colonic diverticula","title":"Location of colonic diverticula within the bowel wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Location of colonic diverticula within the bowel wall</div><div class=\"cntnt\"><img style=\"width:417px; height:312px;\" src=\"images/GAST/62942_Location_colonic_diverticul.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diverticula develop at four well-defined points around the circumference of the colon, the sites at which the vasa recta penetrate the circular muscle layer. These vessels enter the wall on each side of the mesenteric taenia and on the mesenteric border of the two antimesenteric taeniae. The insets represent the development of a diverticulum at one such point of weakness.</div><div class=\"graphic_reference\">Reproduced from: Pemberton JH, Armstrong DN, Dietzen CD. In: Textbook of Gastroenterology, 2nd ed, Yamada T (Ed), 1995. By permission of Mayo Foundation 1997.</div><div id=\"graphicVersion\">Graphic 62942 Version 4.0</div></div></div>"},"62943":{"type":"graphic_figure","displayName":"Pulmonary artery wedge tracing","title":"Pulmonary artery wedge pressure tracing","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Pulmonary artery wedge pressure tracing</div><div class=\"cntnt\"><img style=\"width:457px; height:302px;\" src=\"images/PULM/62943_Pulmonary_artery_wedge_trac.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic diagram shows the different components of the pulmonary artery wedge pressure tracing. A simultaneous ECG is shown to demonstrate the timing of the different components. The peak of the 'v' wave falls outside the peak of the electrocardiographic T wave.</div><div class=\"graphic_reference\">Redrawn from Gore, JM, Alpert, JS, Benotti, JR, et al. Handbook of hemodynamic monitoring, 1st ed, Boston, Little Brown &amp; Co, 1985.</div><div id=\"graphicVersion\">Graphic 62943 Version 1.0</div></div></div>"},"62945":{"type":"graphic_figure","displayName":"Montgomery-Asberg Depression Rating Scale - page 1","title":"Montgomery-Asberg Depression Rating Scale, page 1","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Montgomery-Asberg Depression Rating Scale, page 1</div><div class=\"cntnt\"><img style=\"width:611px; height:791px;\" src=\"images/PSYCH/62945_Montgomery.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Montgomery, SA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382.</div><div id=\"graphicVersion\">Graphic 62945 Version 2.0</div></div></div>"},"62946":{"type":"graphic_table","displayName":"Risk factors for intracranial hemorrhage with thrombolysis","title":"Cooperative cardiovascular project risk model for intracranial hemorrhage with thrombolytic therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cooperative cardiovascular project risk model for intracranial hemorrhage with thrombolytic therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Risk Factors*</td> </tr> <tr> <td colspan=\"2\">Age &#8805;75 years</td> </tr> <tr> <td colspan=\"2\">Black race</td> </tr> <tr> <td colspan=\"2\">Female sex</td> </tr> <tr> <td colspan=\"2\">Prior history of stroke</td> </tr> <tr> <td colspan=\"2\">Systolic blood pressure &#8805;160 mmHg</td> </tr> <tr> <td colspan=\"2\">Weight &#8804;65 kg for women or &#8804;80 kg for men</td> </tr> <tr> <td colspan=\"2\">INR &#62;4 or PT &#62;24<sup>&#182;</sup></td> </tr> <tr> <td colspan=\"2\">Use of alteplase (versus other thrombolytic agent)</td> </tr> <tr> <td class=\"subtitle1\">Risk score</td> <td class=\"subtitle1\">Rate of intracranial hemorrhage, percent</td> </tr> <tr> <td>0 or 1</td> <td>0.69</td> </tr> <tr> <td>2</td> <td>1.02</td> </tr> <tr> <td>3</td> <td>1.63</td> </tr> <tr> <td>4</td> <td>2.49</td> </tr> <tr> <td>&#8805;5</td> <td>4.11</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Each risk factor is worth 1 point if present, 0 points if absent. Points are added to determine the risk score.<br />Â¶ INR: international normalized ratio; PT: prothrombin time.</div><div class=\"graphic_reference\">Data from Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the cooperative cardiovascular project. Stroke 2000; 31:1802.</div><div id=\"graphicVersion\">Graphic 62946 Version 6.0</div></div></div>"},"62947":{"type":"graphic_table","displayName":"Hereditary renal cystic diseases and genes","title":"Hereditary renal cystic diseases and their underlying gene defect","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hereditary renal cystic diseases and their underlying gene defect</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Main features</td> <td class=\"subtitle1\">Genes involved</td> <td class=\"subtitle1\">Corresponding protein</td> <td class=\"subtitle1\">Protein localization</td> <td class=\"subtitle1\">Postulated functions</td> </tr> <tr> <td>Autosomal recessive PKD (ARPKD)</td> <td>Renal cyst, enlarged kidneys, hepatic fibrosis</td> <td><em>PKHD1</em></td> <td>Fibrocystin/polyductin (FPC)</td> <td>Cilia and secreted</td> <td>Calcium response; proliferation/differentiation</td> </tr> <tr class=\"divider_top\"> <td>Autosomal dominant PKD (ADPKD)</td> <td>Renal, hepatic, pancreatic and brain cysts</td> <td><em>PKD1</em>, <em>PKD2</em></td> <td>Polycystin 1 (PC1), Polycystin 2 (PC2)</td> <td>Cilia, Golgi apparatus, focal adhesions</td> <td>Calcium response; proliferation/differentiation</td> </tr> <tr class=\"divider_top\"> <td>Nephronophthisis (NPHP) and Senior L&oslash;ken Syndrome (SNLS)</td> <td>Renal fibrosis, renal cysts, tubular atrophy, retinal dystrophy (in SNLS)</td> <td><em>NPHP1-NPHP11</em></td> <td>Nephrocystin-1, 2/inversin, 3, 4, 5, 6/CEP290, 7/GLIS2, 8/RPGRIP1L, 9/NEK8, 11/Meckelin</td> <td>Cilia, basal bodies, centrosomes, focal adhesions</td> <td>Cell-cell and cell-matrix adhesion; actin cytoskeleton; cell division; Wnt and Shh signaling</td> </tr> <tr class=\"divider_top\"> <td>Joubert syndrome (JS)</td> <td>NPHP and cerebellar ataxia</td> <td><em>AHI1</em>, <em>NPHP1</em>, <em>CEP290</em>, <em>JBTS6/TMEM67</em>, <em>RPGRIP1L</em>, <em>ARL13B</em>, <em>CC2D2A</em>, <em>INPP5E</em>, <em>JBTS2/TMEM216</em></td> <td>Jouberin, Nephrocystin, CEP290, Meckelin, RPGRIP1L, ARL13B, CC2D2A, INPP5E, TMEM216</td> <td>Cilia, basal bodies, centrosomes, cell junctions</td> <td>Ciliogenesis, Sonic Hedgehog signaling</td> </tr> <tr class=\"divider_top\"> <td>Bardet-Biedl syndrome (BBS)</td> <td>Renal cysts, obesity, polydactyly, retinal dystrophy, mental retardation</td> <td><em>BBS1-12</em>, <em>MKS1</em>, <em>CEP290</em>, <em>FRITZ</em>, <em>SDCCAG8</em></td> <td>BBS1-12, MKS1, CEP290, FRITZ, SDCCAG8</td> <td>Centrosomes, basal bodies</td> <td>Pericentriolar organization, ciliogenesis, Wnt signaling</td> </tr> <tr class=\"divider_top\"> <td>Meckel-Gruber syndrome (MKS)</td> <td>Occipital meningoencephalocele, cystic kidneys, liver fibrosis, polydactyly</td> <td><em>MKS1</em>, <em>MKS3/TMEM67</em>, <em>NPHP3</em>, <em>CEP290</em>, <em>RPGRIP1L</em>, <em>CC2D2A</em>, <em>MKS2/TMEM216</em></td> <td>MKS1, Meckelin, Nephrocystin 3, CEP290, RPGRIP1L, CC2D2A, TMEM216</td> <td>Centrosomes, cilia, plasma membrane</td> <td>Basal body localization, ciliogenesis, Hedgehog signaling</td> </tr> <tr class=\"divider_top\"> <td>Oral-facial-digital syndrome 1 (OFD1)</td> <td>Malformations of face, oral cavity and digits, renal cysts, polydactyly</td> <td><em>OFD1</em></td> <td>OFD1</td> <td>Cilia, basal bodies, centrosomes, nucleus</td> <td>Ciliogenesis, L-R asymmetry, possibly gene regulation</td> </tr> <tr class=\"divider_top\"> <td>Short-Rib Polydactily (including Jeune Asphyxiating Thoracic Dystrophy)</td> <td>Renal cysts, shortened bones, polydactyly, situs inversus</td> <td><em>DYN2CH1</em>, <em>IFT80</em></td> <td>Cytoplasmic dynein 2 heavy chain, IFT80</td> <td>Chondrocyte cilia, basal bodies</td> <td>Intraflagelar transport, Hedgehog signaling</td> </tr> <tr class=\"divider_top\"> <td>Tuberous sclerosis complex</td> <td>Renal cysts, beningn tumors in multiple organs, dermatologic abnormalities inlcuding hypopigmented macules (ash-leaf spots), angiofibromas, shagreen patches, and brown fibrous plaque of the forehead</td> <td><em>TSC1, TSC2</em></td> <td>Hamartin (<em>TSC1</em>), Tuberin (<em>TSC2</em>)</td> <td>Centrosome, cytoplasm,</td> <td>Cellular signaling by regulating the mammalian target of rapamycin (mTOR) signaling pathway</td> </tr> <tr class=\"divider_top\"> <td>Uromodulin associated kidney diseases (MCKD2, FJHN, GCKD)</td> <td>Renal cysts, fibrosis, hypertension, hypoeruricemia</td> <td><em>UMOD</em>, <em>MCKD1</em>, <em>MCKD2</em></td> <td>Uromodulin</td> <td>Cilia, basal bodies, centrosomes, secreted</td> <td>Unknown ciliary role</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Hereditary cystic diseases of the kidney, their causal genes, encoded proteins, localization, and proposed function.</div><div class=\"graphic_footnotes\">PKD: polycystic kidney disease; MCKD2: medullary cystic kidney disease type 2; FJHN: familial juvenile hyperuricemic nephropathy; GCKD: glomerulocystic kidney disease.</div><div class=\"graphic_reference\">Reproduced from: Gascue C, Katsanis N, Badano JL. Cystic disease of the kidney: ciliary dysfucntion and cytogenetic mechanisms. Pediatr Nephrol 2011; 26:1181, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2011.</div><div id=\"graphicVersion\">Graphic 62947 Version 8.0</div></div></div>"},"62948":{"type":"graphic_picture","displayName":"Leukoplakia PI","title":"Leukoplakia","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Leukoplakia</div><div class=\"cntnt\"><img style=\"width:584px; height:336px;\" src=\"images/PI/62948_Leukoplakia_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leukoplakia causes white or gray patches in the mouth or on the tongue. Photo A shows leukoplakia on the inside on the cheek. Photo B shows leukoplakia on the tongue.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 62948 Version 4.0</div></div></div>"},"62949":{"type":"graphic_table","displayName":"Testicular tumors PI","title":"Classification of testicular tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of testicular tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Germ cell tumors</td> </tr> <tr> <td class=\"sublist1_start\">Seminoma</td> </tr> <tr> <td class=\"sublist1\">Seminoma with syncytiotrophoblastic cells</td> </tr> <tr> <td class=\"sublist1_start\">Spermatocytic seminoma</td> </tr> <tr> <td class=\"sublist1\">Spermatocytic seminoma with sarcoma</td> </tr> <tr> <td class=\"sublist1_start\">Nonseminomatous germ cell tumors</td> </tr> <tr> <td class=\"sublist1\">Embryonal carcinoma</td> </tr> <tr> <td class=\"sublist1\">Teratoma</td> </tr> <tr> <td class=\"sublist2\">Dermoid cyst</td> </tr> <tr> <td class=\"sublist2\">Monodermal teratoma</td> </tr> <tr> <td class=\"sublist2\">Teratoma with somatic type malignancy</td> </tr> <tr> <td class=\"sublist1\">Trophoblastic tumors (choriocarcinoma)</td> </tr> <tr> <td class=\"sublist1\">Yolk sac tumor (endodermal sinus tumor)</td> </tr> <tr> <td class=\"sublist1\">Mixed germ cell tumors</td> </tr> <tr> <td class=\"subtitle1_single\">Sex cord-stromal tumors</td> </tr> <tr> <td>Sertoli cell tumor</td> </tr> <tr> <td>Leydig cell tumor</td> </tr> <tr> <td>Granulosa cell tumor</td> </tr> <tr> <td>Mixed types (eg, Sertoli-Leydig cell tumor)</td> </tr> <tr> <td>Unclassified</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Tumours of the Urinary System and Male Genital Organs. Eble, JN, Sauter, G, Epstein, JI, Sesterhenn, IA (Eds). In: World Health Organization Classification of Tumours. Lyon 2004.</div><div id=\"graphicVersion\">Graphic 62949 Version 3.0</div></div></div>"},"62950":{"type":"graphic_picture","displayName":"MPS VII","title":"Mucopolysaccharidosis type VII (MPS VII, Sly syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucopolysaccharidosis type VII (MPS VII, Sly syndrome)</div><div class=\"cntnt\"><img style=\"width:253px; height:405px;\" src=\"images/PEDS/62950_Sly_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A three-year-old boy with Sly syndrome. Note the flared ribs, pigeon breast, hepatosplenomegaly, and umbilical hernia.</div><div class=\"graphic_reference\">Reproduced with permission from: Sly WS, Quinton BA, McAlister WH, Rimoin DL. J Pediatr 1973; 82:249. Copyright &copy; 1973 Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 62950 Version 3.0</div></div></div>"},"62951":{"type":"graphic_table","displayName":"Use antidepressants adol","title":"Use of antidepressants in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Use of antidepressants in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Evaluation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Consider antidepressant for patients with moderate to severe depression, or recurrent depressive episodes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Consider antidepressant for patients who have family members with positive response to SSRI antidepressant (and screen if family members had negative response/side effects to SSRIs)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\">Screen for potential bipolar disorder</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Family history of bipolar disorder, pressured speech, lack of sleep, impulsivity, patient initially presents suddenly very depressed out of the blue, excessive sleeping, very slowed down</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Review potential risk for increased agitation, suicidal ideation, and clarify importance of contacting physician if any thoughts of harm to self or others emerge</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Review SSRI Discontinuation syndrome if medication is stopped abruptly (dizziness, paresthesias, nausea, increased irritability)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Have patient and family sign consent (can obtain form from www.aacap.org)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Follow-Up</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>If not feasible to meet weekly, ensure patient and family know how to contact physician if any thoughts of harm to self or others emerge, or if patient becomes more agitated</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Review symptoms <strong>AND</strong> provide side effect scale (download free from www.schoolpsychiatry.org) and rating scales</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Create reasonable expectations (time line of medication response can take four to six weeks, if taken consistently)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Establish realistic outcome measures with patient (medication will improve sadness, ruminations, but will not make patient \"mind\" better, or no longer argue about curfew/bedtime)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Counsel adolescent about risks of substance use, especially alcohol, when depressed and on medication</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Consider safety issues in the home (availability of dangerous medications, weapons) and provide phone number to access emergency psychiatric services</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=56842&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Use_antidepressants_adol.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Rappaport, N, Bostic, JQ, Prince JB, Jellinek, M. Treating pediatric depression in primary care: Coping with the patients' blue mood and the FDA's black box. J Pediatr 2006; 148:567. Copyright Â©2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 62951 Version 1.0</div></div></div>"},"62952":{"type":"graphic_figure","displayName":"Internal and external validity","title":"Internal and external validity","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Internal and external validity</div><div class=\"cntnt\"><img style=\"width:536px; height:435px;\" src=\"images/PC/62952_Internal_and_external_valid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Internal validity addresses the question of whether the results of clinical research are correct for the patients in the study and is threatened by bias and chance. External validity addresses the question of whether the results of the research apply to patients outside of the study population.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher RH, Fletcher SW. Clinical Epidemiology: The Essentials, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 62952 Version 4.0</div></div></div>"},"62953":{"type":"graphic_diagnosticimage","displayName":"Suspicious calcifications","title":"Suspicious calcifications","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Suspicious calcifications</div><div class=\"cntnt\"><img style=\"width:499px; height:473px;\" src=\"images/PC/62953_Suspicious_calcifications.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clustered microcalcifications in three different cases. A loose group of varying sizes of calcifications are seen in Panel A. A small cluster of powdery calcifications are seen in a background of dense breast parenchyma in Panel B. Very faint microcalcifications are seen in between coarse larger calcifications in Panel C.</div><div id=\"graphicVersion\">Graphic 62953 Version 2.0</div></div></div>"},"62957":{"type":"graphic_table","displayName":"High fiber diet sample menu","title":"High fiber diet sample menu","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">High fiber diet sample menu</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Sample menu for a 7- to 10-year-old child, with approximate fiber content*<br /> (estimated fiber requirement for this age group: 25 to 31 grams per day)</td> </tr> <tr> <td class=\"subtitle2_single\">Breakfast (6.5 grams fiber)</td> </tr> <tr> <td class=\"indent1\">1 cup instant oatmeal (2 grams fiber)*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">1 slice whole-grain toast (1.5 grams fiber)</td> </tr> <tr> <td class=\"indent1\">1 teaspoon margarine or butter</td> </tr> <tr> <td class=\"indent1\">1 cup strawberries (3 grams fiber)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">8 ounces skim milk</td> </tr> <tr> <td class=\"subtitle2_single\">Lunch (10 grams fiber)</td> </tr> <tr> <td class=\"indent1\">Turkey sandwich on whole grain bread (3 grams fiber)</td> </tr> <tr> <td class=\"indent1\">1 teaspoon mustard</td> </tr> <tr> <td class=\"indent1\">1 ounce whole grain chips (2 grams fiber)</td> </tr> <tr> <td class=\"indent1\">1 medium apple (3 grams fiber)</td> </tr> <tr> <td class=\"indent1\">8 baby carrots (2 grams fiber)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bottled water</td> </tr> <tr> <td class=\"subtitle2_single\">Snack 1 (3 grams fiber)</td> </tr> <tr> <td class=\"indent1\">4 fig bar cookies (3 grams fiber)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">8 ounces skim milk</td> </tr> <tr> <td class=\"subtitle2_single\">Dinner (8.5 grams fiber)</td> </tr> <tr> <td class=\"indent1\">3 ounces pork tenderloin</td> </tr> <tr> <td class=\"indent1\">&#189; cup mashed sweet potatoes (4 grams fiber)</td> </tr> <tr> <td class=\"indent1\">&#189; cup green beans (1.5 grams fiber)</td> </tr> <tr> <td class=\"indent1\">&#188; cup baked beans (3 grams fiber)</td> </tr> <tr> <td class=\"indent1\">2 teaspoons margarine or butter</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">8 ounces skim milk</td> </tr> <tr> <td class=\"subtitle2_single\">Snack 2</td> </tr> <tr> <td class=\"indent1\">&#189; cup vanilla bean ice-cream</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Reflects insoluble fiber, which is the most relevant type of fiber for prevention and treatment of constipation. Soluble fiber has different health benefits.<br />&para; Some \"high fiber\" forms of instant oatmeal contain up to 10 grams of fiber. However, most of this additional fiber is soluble, which may not be as valuable as insoluble fiber for prevention and treatment of constipation.</div><div id=\"graphicVersion\">Graphic 62957 Version 6.0</div></div></div>"},"62959":{"type":"graphic_picture","displayName":"Systemic juvenile idiopathic arthritis rash","title":"Systemic juvenile idiopathic arthritis rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Systemic juvenile idiopathic arthritis rash</div><div class=\"cntnt\"><img style=\"width:351px; height:250px;\" src=\"images/PEDS/62959_SystonsetJRArash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A salmon-pink rash is characteristic of this juvenile idiopathic arthritis (JIA) subtype. The rash is brought out by heat and often can be found in the axillae and around the waist but may be present anywhere on the body.</div><div class=\"graphic_reference\">Courtesy of Robert Sundel, MD.</div><div id=\"graphicVersion\">Graphic 62959 Version 9.0</div></div></div>"},"62961":{"type":"graphic_table","displayName":"High PEEP vent","title":"Allowable combinations of positive end-expiratory pressure (PEEP) and fraction of inspired oxygen (FiO2) used in the high PEEP arm of the ALVEOLI trial","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Allowable combinations of positive end-expiratory pressure (PEEP) and fraction of inspired oxygen (FiO2) used in the high PEEP arm of the ALVEOLI trial</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\" colspan=\"8\">\n   High PEEP group\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   <strong>FiO2</strong>\n   </td>\n   <td>0.3</td>\n   <td>0.4</td>\n   <td>0.5</td>\n   <td>0.5-0.8</td>\n   <td>0.8</td>\n   <td>0.9</td>\n   <td>1.0</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   <strong>PEEP</strong>\n   </td>\n   <td>12-14</td>\n   <td>14-16</td>\n   <td>16-18</td>\n   <td>20</td>\n   <td>22</td>\n   <td>22</td>\n   <td>22-24</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Data from: Brower, RG, Lanken, PH, MacIntyre, N, et al. Higher versus Lower Positive End-Expiratory pressures in Patients with the Acute Respiratory Distress Syndrome. N Engl J Med 2004; 351:327.</div><div id=\"graphicVersion\">Graphic 62961 Version 1.0</div></div></div>"},"62962":{"type":"graphic_diagnosticimage","displayName":"Normal bone scan","title":"Hypertrophic pulmonary osteoarthropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrophic pulmonary osteoarthropathy</div><div class=\"cntnt\"><img style=\"width:152px; height:630px;\" src=\"images/PULM/62962_Nrml_bn_scn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal bone scan for comparison.</div><div id=\"graphicVersion\">Graphic 62962 Version 3.0</div></div></div>"},"62964":{"type":"graphic_figure","displayName":"Cervical flexion deformity AS","title":"Cervical flexion deformity in ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical flexion deformity in ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:194px; height:361px;\" src=\"images/RHEUM/62964_Cervical_flexion_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The severity of cervical flexion deformity in ankylosing spondylitis can be assessed by measuring the occiput to wall distance (Flesche test). With the patient standing erect, the heels and the buttocks are placed against a wall. The patient is then instructed to extend his or her neck maximally in an attempt to touch the wall with the occiput. The distance between the occiput and the wall is a measure of the degree of flexion deformity of the cervical spine.</div><div class=\"graphic_reference\">Courtesy of Craig W Wiesenhutter, MD.</div><div id=\"graphicVersion\">Graphic 62964 Version 3.0</div></div></div>"},"62966":{"type":"graphic_diagnosticimage","displayName":"Cervical extension teardrop fracture","title":"Radiograph ofÂ a cervical spine extensionÂ teardrop fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of&nbsp;a cervical spine extension&nbsp;teardrop fracture</div><div class=\"cntnt\"><img style=\"width:288px; height:406px;\" src=\"images/EM/62966_Cervicalextentearfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral radiograph of the cervical spine shows a fracture through the C2 vertebral body (arrow). The extension teardrop fracture occurs when abrupt neck extension causes the anterior longitudinal ligament to pull the anteroinferior&nbsp;portion of the vertebral body away from the remainder producing a triangular-shaped fracture fragment (teardrop).</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 62966 Version 3.0</div></div></div>"},"62967":{"type":"graphic_diagnosticimage","displayName":"Acute cholangitis ERCP","title":"ERCP in acute cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ERCP in acute cholangitis</div><div class=\"cntnt\"><img style=\"width:312px; height:352px;\" src=\"images/GAST/62967_Acute_cholangitis_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagnosis and treatment of acute cholangitis with ERCP.<br />(A): Multiple small stones in the lower common bile duct (arrow). Ultrasonography had shown borderline dilatation of the common bile duct but no stones.<br />(B): After sphincterotomy and stone extraction, the common bile duct is free of stones.</div><div class=\"graphic_footnotes\">ERCP: Endoscopic retrograde cholangiopancreatography.</div><div class=\"graphic_reference\">Courtesy of Nezam Afdhal, MD.</div><div id=\"graphicVersion\">Graphic 62967 Version 3.0</div></div></div>"},"62969":{"type":"graphic_table","displayName":"Lead exposure sources list","title":"Lead exposure sources list","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lead exposure sources list</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Lead mining</td> </tr> <tr> <td>Primary or secondary lead smelting or refining</td> </tr> <tr> <td>Scrap metal processing or recycling</td> </tr> <tr> <td>Radiator manufacturing or repair</td> </tr> <tr> <td>Lead glaze or frit manufacture or use, such as in pottery making</td> </tr> <tr> <td>Battery manufacture, recycling, or repair</td> </tr> <tr> <td class=\"sublist1_start\">Construction work on pre-1978 structures or on exterior structures such as bridges, ships, or water towers regardless of age</td> </tr> <tr> <td class=\"sublist1\">Welding on painted steel</td> </tr> <tr> <td class=\"sublist1\">Power operations, such as cutting or sanding, on painted structures</td> </tr> <tr> <td class=\"sublist1\">Abrasive blasting</td> </tr> <tr> <td class=\"sublist1\">Demolition work</td> </tr> <tr> <td class=\"sublist1\">Bridge maintenance and repair</td> </tr> <tr> <td class=\"sublist1\">Shipbuilding</td> </tr> <tr> <td>Paint removal on pre-1978 structures or on exterior structures of any age</td> </tr> <tr> <td>Lead abatement</td> </tr> <tr> <td>Rubber products and plastics industries using lead stabilizers</td> </tr> <tr> <td>Cable making, splicing, or stripping</td> </tr> <tr> <td>Burning lead-painted wood</td> </tr> <tr> <td>Auto body repair shops</td> </tr> <tr> <td>Automotive repair shop or junkyard work involving welding or other operations, such as power sanding or cutting, on lead painted surfaces or lead batteries</td> </tr> <tr> <td>Furniture refinishing if paint removal creates inhalable lead (eg, power sanding)</td> </tr> <tr> <td>Making lead fishing weights (sinkers), soldiers or bullets</td> </tr> <tr> <td>Indoor firing range instructors, custodial staff, inspectors in firearms manufacturing</td> </tr> <tr> <td>Lead bullet manufacturing</td> </tr> <tr> <td>Leaded solder use (welding, stained glass production, plumbing, valve and pipe fittings, jewelry making, electronics)</td> </tr> <tr> <td>Retained lead bullet</td> </tr> <tr> <td>Metal casting or other foundry work</td> </tr> <tr> <td>Lead grinding, polishing or buffing</td> </tr> <tr> <td class=\"subtitle1_single\">Potential for lead exposure from eating, drinking, or using any of the following:</td> </tr> <tr> <td>Imported or glazed pottery such as a Mexican bean pot</td> </tr> <tr> <td>Foods canned outside the US</td> </tr> <tr> <td>Imported candy (eg, tamarind or chili-based Mexican candies)</td> </tr> <tr> <td>Home-distilled alcoholic beverages (moonshine; liquor from homemade still)</td> </tr> <tr> <td>Imported lead-containing cosmetics, such as kohl eye make-up</td> </tr> <tr> <td>Pica (ingestion of lead-containing nonfood items, eg, ceramic, plaster or paint chips; soil; primarily considered in children, but sometimes occurs in pregnant women)</td> </tr> <tr> <td>Imported folk remedies</td> </tr> <tr> <td>Ayurvedic herbal medicine products</td> </tr> <tr> <td class=\"sublist1_start\">Mexican folk remedies such as those used to treat the colic-like illness \"empacho\"</td> </tr> <tr> <td class=\"sublist1\">Alarcon</td> </tr> <tr> <td class=\"sublist1\">Coral</td> </tr> <tr> <td class=\"sublist1\">Liga</td> </tr> <tr> <td class=\"sublist1\">Maria Luisa</td> </tr> <tr> <td class=\"sublist1\">Rueda</td> </tr> <tr> <td class=\"sublist1\">Azarcon</td> </tr> <tr> <td class=\"sublist1\">Greta</td> </tr> <tr> <td class=\"sublist1\">Alkohl</td> </tr> <tr> <td class=\"sublist1_start\">Nutritional pills other than vitamins</td> </tr> <tr> <td class=\"sublist1\">Hazard</td> </tr> <tr> <td class=\"sublist1\">Pay-loo-ah</td> </tr> <tr> <td class=\"sublist1_start\">Lead-containing remedies used in Asian communities including</td> </tr> <tr> <td class=\"sublist1\">Ba-baw-san</td> </tr> <tr> <td class=\"sublist1\">Bali goli</td> </tr> <tr> <td class=\"sublist1\">Chuifong</td> </tr> <tr> <td class=\"sublist1\">Ghasard</td> </tr> <tr> <td class=\"sublist1\">Kandu</td> </tr> <tr> <td class=\"sublist1\">Tokuwan</td> </tr> <tr> <td class=\"sublist1_start\">Middle Eastern remedies and cosmetics include</td> </tr> <tr> <td class=\"sublist1\">Alkohl</td> </tr> <tr> <td class=\"sublist1\">Cebagin</td> </tr> <tr> <td class=\"sublist1\">Saoott</td> </tr> <tr> <td>Immigrant from countries other than Europe and Canada</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Virginia M Weaver, MD, MPH and Bernard G Jaar, MD, MPH, FASN.</div><div id=\"graphicVersion\">Graphic 62969 Version 2.0</div></div></div>"},"62970":{"type":"graphic_picture","displayName":"Medium CMN","title":"Medium-sized congenital melanocytic nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medium-sized congenital melanocytic nevus</div><div class=\"cntnt\"><img style=\"width:432px; height:241px;\" src=\"images/PEDS/62970_Medium_CMN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the pebbly surface and mild hypertrichosis.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 62970 Version 1.0</div></div></div>"},"62973":{"type":"graphic_figure","displayName":"Transperineal fistula repair1","title":"Transverse transperineal approach to a rectovaginal fistula located at the sphincter complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse transperineal approach to a rectovaginal fistula located at the sphincter complex</div><div class=\"cntnt\"><img style=\"width:357px; height:540px;\" src=\"images/OBGYN/62973_Transperineal_fistula_repai.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A wire probe is used to identify the fistula tract. A transverse transperineal incision is made above the sphincter complex.</div><div id=\"graphicVersion\">Graphic 62973 Version 1.0</div></div></div>"},"62974":{"type":"graphic_figure","displayName":"Thrombin generation pathways","title":"Thrombin generation pathways","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Thrombin generation pathways</div><div class=\"cntnt\"><img style=\"width:522px; height:326px;\" src=\"images/HEME/62974_Thrombin_generation_pathway.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the two pathways of in vivo thrombin generation. Activation pathways are shown as black arrows while inhibitory pathways are shown here as interrupted red arrows. The left-hand pathway illustrates initial thrombin generation. Following injury, tissue factor (TF) is liberated, which binds to factor VIIa, activating both factor X and Factor IX (not shown). Tissue factor-dependent coagulation is rapidly inhibited by tissue factor pathway inhibitor (TFPI), such that only a limited amount of thrombin is generated. Although a fibrin clot is formed, it is susceptible to fibrinolysis. The right-hand pathway illustrates how coagulation is maintained through a feedback loop. The small amount of thrombin generated initially activates platelets and factors V, VIII, and XI, leading to a burst of thrombin-generating potential through activation of tenase and prothrombinase activity. These greater amounts of thrombin, in combination with thrombomodulin (TM), activate thrombin-activatable fibrinolysis inhibitor (TAFIa), increasing the resistance of the forming clot to fibrinolysis. Low levels of factor XI, VIII, or IX interfere with this feedback loop, resulting in a lessened production of thrombin as well as a fibrin clot that is susceptible to fibrinolysis.</div><div id=\"graphicVersion\">Graphic 62974 Version 3.0</div></div></div>"},"62975":{"type":"graphic_waveform","displayName":"Sick sinus syndrome tutorial","title":"Sick sinus syndrome","html":"<div class=\"graphic normal\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Sick sinus syndrome</div><div class=\"cntnt\"><img style=\"width:454px; height:199px;\" src=\"images/CARD/62975_Sick_sinus_syndrome_tutoria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tracing of sick sinus syndrome (tachycardia-bradycardia syndrome). The initial three beats show atrial fibrillation (AF) which terminates abruptly and is followed after a long offset pause by a junctional escape beat (J) and then a sinus beat (S).</div><div id=\"graphicVersion\">Graphic 62975 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"62976":{"type":"graphic_picture","displayName":"FAST hepatorenal right flank probe position","title":"FAST: Hepatorenal (right flank) probe position","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Hepatorenal (right flank) probe position</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/EM/62976_FAST_hepatoren_right_flank.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows proper probe position for obtaining a view of Morisons pouch (hepatorenal interface).</div><div class=\"graphic_reference\">Courtesy of Manoj Pariyadath, MD.</div><div id=\"graphicVersion\">Graphic 62976 Version 1.0</div></div></div>"},"62977":{"type":"graphic_diagnosticimage","displayName":"Distal tibia stress fracture","title":"Stress fracture of distal tibia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stress fracture of distal tibia</div><div class=\"cntnt\"><img style=\"width:304px; height:357px;\" src=\"images/EM/62977_Distal_tib_stress_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Periosteal reaction is evident at the site of this stress fracture (arrow).</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 62977 Version 3.0</div></div></div>"},"62978":{"type":"graphic_table","displayName":"Clinical findings by stage of hypothermia","title":"Clinical findings by stage of hypothermia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings by stage of hypothermia*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Core temperature</td> <td class=\"subtitle1\">Possible findings</td> </tr> <tr> <td rowspan=\"3\">Mild</td> <td rowspan=\"3\"> <p>32-35&#176;C</p> (90-95&#176;F)</td> <td>Shivering but conscious</td> </tr> <tr> <td>Cyanosis</td> </tr> <tr> <td>Prolonged capillary refill</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Moderate</td> <td rowspan=\"5\"> <p>28-32&#176;C</p> (82-90&#176;F)</td> <td>Shivering stops, impaired consciousness</td> </tr> <tr> <td>Clumsiness</td> </tr> <tr> <td>Confusion or delirium</td> </tr> <tr> <td>Slurred speech</td> </tr> <tr> <td>Decreasing BP</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"8\">Severe</td> <td rowspan=\"8\"> <p>&#60;28&#176;C</p> (&#60;82&#176;F)</td> <td>No shivering, unconscious, vital signs may or may not be present</td> </tr> <tr> <td>Muscle rigidity</td> </tr> <tr> <td>Erythema and edema</td> </tr> <tr> <td>Stupor or coma</td> </tr> <tr> <td>Absent pulses</td> </tr> <tr> <td>Fixed, dilated pupils</td> </tr> <tr> <td>Ventricular fibrillation</td> </tr> <tr> <td>Asystole</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* When present, findings are typical of the stage shown, but may vary in their presence and their temperature of onset.</div><div id=\"graphicVersion\">Graphic 62978 Version 5.0</div></div></div>"},"62980":{"type":"graphic_figure","displayName":"MBG and HbA1c","title":"Relation between mean blood glucose concentrations and glycated hemoglobin (A1C) values","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Relation between mean blood glucose concentrations and glycated hemoglobin (A1C) values</div><div class=\"cntnt\"><img style=\"width:451px; height:272px;\" src=\"images/ENDO/62980_MBG_and_HbA1c.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of quarterly mean blood glucose concentrations with quarterly HbA1c values. The dashed lines represent 95 percent confidence intervals for individual values. The observed relationship applies only to the Diabetes Control and Complications Trial assay or to assays which have been standardized to it. To convert blood glucose values to mmol/L, multiply by 0.056.</div><div class=\"graphic_reference\">Data from: The Diabetes Control and Complications Trial Research Group, Diabetes Care 1987; 10:1.</div><div id=\"graphicVersion\">Graphic 62980 Version 2.0</div></div></div>"},"62981":{"type":"graphic_picture","displayName":"Early repair in osteomyelitis","title":"Early repair in acute osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early repair in acute osteomyelitis</div><div class=\"cntnt\"><img style=\"width:308px; height:227px;\" src=\"images/ID/62981_Early_repair_in_osteomyelit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in acute osteomyelitis of the tibial articular apparatus. The presence of whorls of chondrocytes (blue arrows) indicates early tissue repair in which multinucleated osteoclasts (black arrows) are actively remodeling the subchondral region. Bone (white arrow) has replaced the mature lamellar structure and the medullary spaces are largely filled with inflammatory cells and fibrin.</div><div class=\"graphic_reference\">Courtesy of Jon Mader, MD.</div><div id=\"graphicVersion\">Graphic 62981 Version 1.0</div></div></div>"},"62985":{"type":"graphic_form","displayName":"Areas for injury prevention","title":"Matrix of areas for injury prevention","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Matrix of areas for injury prevention</div><div class=\"cntnt\"><img style=\"width:504px; height:345px;\" src=\"images/PEDS/62985_Areas_for_injury_prevention.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 62985 Version 2.0</div></div></div>"},"62986":{"type":"graphic_table","displayName":"Risk stratification KD","title":"Guidelines for risk stratification of myocardial infarction in the long-term follow-up of children with Kawasaki disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for risk stratification of myocardial infarction in the long-term follow-up of children with Kawasaki disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk level</td> <td class=\"subtitle1\">Medical therapy</td> <td class=\"subtitle1\">Physical activity</td> <td class=\"subtitle1\">Follow-up schedule</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">I</td> </tr> <tr> <td class=\"indent1\">No CA changes at any stage of illness</td> <td>None after first&nbsp;six&nbsp;to&nbsp;eight weeks</td> <td>No restrictions after first&nbsp;six&nbsp;to&nbsp;eight weeks</td> <td>CV risk assessment, counseling at five-year intervals</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">II</td> </tr> <tr> <td class=\"indent1\">Transient CA ectasia (resolves within&nbsp;eight weeks)</td> <td>None after first&nbsp;six&nbsp;to&nbsp;eight weeks</td> <td>No restrictions after first&nbsp;six&nbsp;to&nbsp;eight weeks</td> <td>CV risk assessment, counseling at&nbsp;three- to five-year intervals</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">III</td> </tr> <tr> <td class=\"indent1\">One&nbsp;small-medium CA aneurysm in&nbsp;one major coronary artery</td> <td>Low-dose aspirin (3&nbsp;to 5 mg/kg per day) until documented regression of aneurysm</td> <td> <p><strong>Age &#60;11 years</strong>:</p> <p>No restrictions after first&nbsp;six&nbsp;to&nbsp;eight weeks</p> <p><strong>Age 11&nbsp;to 20 years</strong>:</p> <p>Restriction guided by results of cardiac testing</p> </td> <td>Annual cardiology follow-up; invasive testing at discretion of cardiologist</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">IV</td> </tr> <tr> <td class=\"indent1\">&#8805;1 large or giant CA aneurysm, or multiple or complex aneurysms in same CA without obstruction</td> <td>Long-term antiplatelet therapy AND warfarin or low molecular weight heparin for those with giant aneurysms</td> <td> <p>Contact and high-risk sports should be avoided because of the risk of bleeding</p> <p>Other restrictions guided by results of cardiac testing</p> </td> <td>Cardiology follow-up twice per year; invasive testing at discretion of cardiologist</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">V</td> </tr> <tr> <td class=\"indent1\">CA obstruction</td> <td> <p>Long-term low-dose aspirin</p> <p>Warfarin or low molecular weight heparin if giant aneurysm persists</p> </td> <td> <p>Contact and high-risk sports should be avoided because of the risk of bleeding</p> <p>Other restrictions guided by results of cardiac testing</p> </td> <td>Cardiology follow-up twice per year; invasive testing at discretion of cardiologist</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CA: coronary artery; CV: cardiovascular.</div><div class=\"graphic_reference\">Adapted from Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114:1708.</div><div id=\"graphicVersion\">Graphic 62986 Version 5.0</div></div></div>"},"62988":{"type":"graphic_picture","displayName":"Low grade CIN","title":"Low grade cervical intraepithelial lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Low grade cervical intraepithelial lesion</div><div class=\"cntnt\"><img style=\"width:325px; height:316px;\" src=\"images/OBGYN/62988_Low_grade_cervical_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lesion represents a geographic map-like, low-grade dysplasia. The lesion itself is irregular, and it extends to the posterior cervical portio.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin MM, Barbo DM. Colposcopic assessment system. In: Colposcopy Principles and Practice, Apgar BS, Brotzman GL, Spitzer M (Eds), W.B. Saunders Company, Philadelphia 2002. p. 216. Copyright Â© 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 62988 Version 3.0</div></div></div>"},"62989":{"type":"graphic_picture","displayName":"Liver cirrhosis with iron overload","title":"Micronodular cirrhosis in sideroblastic anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micronodular cirrhosis in sideroblastic anemia</div><div class=\"cntnt\"><img style=\"width:387px; height:531px;\" src=\"images/HEME/62989_Severe_cirrhosis_iron_overl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver sections from a 45-year-old man with pyridoxine-responsive sideroblastic anemia and micronodular cirrhosis resulting from iron overload. Top panel: hematoxylin and eosin stain. Bottom panel: Prussian blue (iron) stain.</div><div class=\"graphic_reference\">Courtesy of Sylvia Bottomley, MD.</div><div id=\"graphicVersion\">Graphic 62989 Version 2.0</div></div></div>"},"62990":{"type":"graphic_diagnosticimage","displayName":"Metaphyseal transverse bands congenital syphilis","title":"Congenital syphilis: Transverse metaphyseal bands and diaphyseal destruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Transverse metaphyseal bands and diaphyseal destruction</div><div class=\"cntnt\"><img style=\"width:186px; height:504px;\" src=\"images/PEDS/62990_Meta_trans_bands_cong_syph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse bands of increased density across the metaphyses (small arrows) associated with patchy areas of bone destruction in the diaphyses. There is solid periosteal new bone formation (large arrow), which is best seen about the distal humerus.</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg RL. An Atlas of Differential Diagnosis, 4th ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 62990 Version 3.0</div></div></div>"},"62991":{"type":"graphic_table","displayName":"Medications and dyspareunia","title":"Medications associated with dyspareunia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications associated with dyspareunia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category or mechanism</td> <td class=\"subtitle1\">Specific medications or classes of medications</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Medications that may induce vulvovaginal atrophy</td> <td> <ul> <li>Aromatase inhibitors </li> <li>Gonadotropin-releasing hormone agonists or antagonists </li> <li>Some chemotherapeutic agents </li> <li>Tamoxifen </li> <li>Depot medroxyprogesterone acetate </li> </ul> </td> <td> <p>If menopause is induced, vaginal atrophy will result. If the effect is temporary, these changes will reverse when the medication is discontinued.</p> <p>Some chemotherapeutic agents result in premature ovarian failure.</p> <p>In premenopausal women, tamoxifen has an anti-estrogenic effect on the vaginal epithelium, resulting in atrophy<sup>[1]</sup>. In contrast, in postmenopausal women, tamoxifen has an estrogenic effect on the vaginal epithelium. This results in increased vaginal discharge. Some postmenopausal women who are taking tamoxifen develop recurrent candidal vulvovaginitis, with resultant dyspareunia.</p> <p>Depot medroxyprogesterone acetate suppresses the hypothalamic-pituitary axis, which induces hypoestrogenism and vaginal atrophy.</p> </td> </tr> <tr> <td>Oral contraceptives</td> <td>&nbsp;</td> <td>Some data suggest that oral contraceptives are associated with vestibulodynia. The mechanism of this is unclear<sup>[2]</sup>. These findings have not been investigated for other formulations of estrogen-progestin contraceptives (patch, vaginal ring).</td> </tr> <tr> <td>Anticholinergics</td> <td> <ul> <li>Anti-histamines (eg, diphenhydramine, chlorpheniramine) </li> <li>Amitriptyline </li> </ul> </td> <td>May result in vaginal dryness and dyspareunia.</td> </tr> <tr> <td>Medications that increase the risk of recurrent candidal vulvovaginitis</td> <td> <ul> <li>Immunosuppressants (eg, glucocorticoids, TNF-alpha inhibitors) </li> <li>Antibiotics </li> </ul> </td> <td>Candidal vulvovaginitis is associated with the development of vulvodynia.</td> </tr> <tr> <td>Topical agents that cause irritant or allergic reactions</td> <td> <ul> <li>Spermicides </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td>Medications that may result in painful clitoral tumescence<sup>[3-9]</sup></td> <td> <ul> <li>Serotonergic agents (Citalopram, Nefazodone, Trazodone) </li> <li>Dopaminergic agents (Bupropion, Bromocriptine, Olanzapine) </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td>Antihypertensives</td> <td>&nbsp;</td> <td>Sexual dysfunction appears to occur more frequently in hypertensive women. It is unclear whether this is associated with the hypertension itself or with antihypertensive medications.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Mourits MJ, De Vries EG, Willemse PH, et al. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001; 97:855. </LI>&#xD;&#xA;<LI>Goldstein A,&nbsp;Burrows L, Goldstein I. Can oral contraceptives cause vestibulodynia? J Sex Med 2010; 7:1585. </LI>&#xD;&#xA;<LI>Berk M, Acton M. Citalopram-associated clitoral priapism: a case series. Int Clin Psychopharmacol 1997; 12:121. </LI>&#xD;&#xA;<LI>Brodie-Meijer CC, Diemont WL, Buijs PJ. Nefazodone-induced clitoral priapism.&nbsp;Int Clin Psychopharmacol 1999; 14:257. </LI>&#xD;&#xA;<LI>Battaglia C, Venturoli S. Persistent genital arousal disorder and trazodone. Morphometric and vascular modifications of the clitoris. A case report. J Sex Med 2009; 6:2896. </LI>&#xD;&#xA;<LI>Pescatori ES, Engelman JC, Davis G, Goldstein I. Priapism of the clitoris: a case report following trazodone use. J Urol 1993; 149:1557. </LI>&#xD;&#xA;<LI>Levenson JL. Priapism associated with bupropion treatment. Am J Psychiatry 1995; 152:813. </LI>&#xD;&#xA;<LI>Blin O, Schwertschlag US, Serratrice G. Painful clitoral tumescence during bromocriptine therapy. Lancet 1991; 18:1231. </LI>&#xD;&#xA;<LI>Bucur M, Mahmood T. Olanzapine-induced clitoral priapism. J Clin Psychopharmacol 2004; 24:572. </LI></OL></div><div id=\"graphicVersion\">Graphic 62991 Version 3.0</div></div></div>"},"62992":{"type":"graphic_table","displayName":"Signs and symptoms of neutropenia","title":"Important clinical signs and symptoms of neutropenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important clinical signs and symptoms of neutropenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indicator</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Fever</td> <td>Determines need to consider immediate treatment. Periodic fever may suggest cyclic neutropenia. Recurrent fevers suggest more serious type of neutropenia, underlying autoimmune disease, or malignancy.</td> </tr> <tr> <td>Gingivitis*</td> <td>Often overlooked and frequently present in untreated clinically significant chronic neutropenia. Normal gingiva argues for normal marrow reserve. Gingivitis can be seen with vasculitis independent of neutropenia.</td> </tr> <tr> <td>Mucosal ulcers*<sup>&#182;</sup></td> <td>Suggests neutropenia with decreased marrow reserve, especially ulcers with no evidence of exudate. May be seen with vasculitis independent of neutropenia.</td> </tr> <tr> <td>Abdominal pain<sup>&#182;</sup></td> <td>Cramping abdominal pain or discomfort, even of a minor nature, can indicate intestinal mucosal ulcerations that can serve as a dangerous portal of entry for enteric bacteria.</td> </tr> <tr> <td>Abscess<sup>&#916;</sup></td> <td>Clear, purulent material anywhere (ear drum, pharyngeal exudate, boil, other abscess) in the presence of significant neutropenia is strong evidence for adequate marrow reserve and ability to deliver neutrophils to tissue.</td> </tr> <tr> <td>Splenomegaly</td> <td>Indicates a chronic inflammatory state and suggests that neutropenia is not benign. May be the only sign of chronic inflammation in some disorders such as systemic rheumatoid arthritis or large granular lymphocyte-related neutropenia.</td> </tr> <tr> <td>Erythrocyte sedimentation rate (ESR)</td> <td>Suggests deep tissue inflammation. ESR can be very helpful in the evaluation of neutropenia and monitoring severe forms of chronic neutropenia.</td> </tr> <tr> <td>C-reactive protein (CRP)</td> <td>Indicates monocyte activation. CRP suggests inflammation and changes faster than the ESR. The interpretation of CRP and ESR elevation overlap but are not the same. Either can be significantly elevated when the other is normal.</td> </tr> <tr> <td>Monocytosis</td> <td>Significant monocytosis (30 to 50 percent) is often seen with congenital neutropenia (cyclic neutropenia, severe congenital neutropenia).</td> </tr> <tr> <td>Past history</td> <td>Unusual or frequent major infections, chronic diarrhea, failure to thrive.</td> </tr> <tr> <td>Dysmorphia</td> <td>Dysmorphic features raise issue of primary marrow failure syndromes.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Note that gingivitis, oral, and mucosal ulcerations can also be seen with vasculitis in the presence or absence of neutropenia. Marrow examination in this case is the only way to infer marrow reserve status.<br />Â¶ Symptoms and signs suggesting low marrow reserve.<br />Î Symptoms and signs suggesting adequate marrow reserve.</div><div id=\"graphicVersion\">Graphic 62992 Version 3.0</div></div></div>"},"62993":{"type":"graphic_picture","displayName":"Widow spider B","title":"Redback spider 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Redback spider 2</div><div class=\"cntnt\"><img style=\"width:430px; height:351px;\" src=\"images/EM/62993_Redback_spider_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Julian White, MD.</div><div id=\"graphicVersion\">Graphic 62993 Version 2.0</div></div></div>"},"62994":{"type":"graphic_table","displayName":"T cell co-stimulator molecules","title":"Co-stimulator molecules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Co-stimulator molecules</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>CD28 and B7</td> <td>&nbsp;</td> </tr> <tr> <td>B7-1 &#62; B7-2 (CD80)</td> <td>eg, dendritic cells</td> </tr> <tr> <td>B7h (GL50, ICOS-L)</td> <td>eg, fibroblasts</td> </tr> <tr> <td>CD40 and CD40L</td> <td>eg, B cells, fibroblasts, thyroid cells</td> </tr> <tr> <td>ICAM and LFA-1</td> <td>eg, thyroid cells</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 62994 Version 4.0</div></div></div>"}};